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Abstract 
Selectins, namely E-, P-, and L-selectin, are carbohydrate-recognizing proteins that mediate 
the initial step of leukocyte recruitment to sites of inflammation. This vital process can turn 
deleterious in case of acute and chronic states of inflammation like stroke, reperfusion injury, 
and psoriasis or rheumatoid arthritis, respectively. In addition, cancer cells have been shown 
to exploit this selectin mediated pathway to metastasize. Blocking of the selectins is 
consequently considered a promising therapeutic approach. 
The tetrasaccharide sialyl Lewisx (sLex) was identified as the minimum binding epitope of all 
three selectins and became the lead structure for various drug discovery programs. SLex itself 
suffers from the typical downsides of carbohydrate leads, namely complex structure and 
synthesis, and poor pharmacokinetic and pharmacodynamic properties, which impede the 
development of selectin antagonists. The rational design of antagonists is furthermore 
hampered by the lack of information on the thermodynamics of the selectin-ligand 
interactions. However, these information are of vital importance for successful lead 
optimization.  
Inter alia, this thesis addresses these major issues in the design of glycomimetic selectin 
antagonists. 
• A fast and efficient synthetic route to the D-GlcNAc mimic (1R,2R,3S)-3-
methylcyclohexane-1,2-diol was developed, which allows the multigram scale synthesis 
of this key intermediate (chapter 2.2.).  
• Similarities and differences between E- and P-selectin were exploited to develop less 
polar, structurally simplified P- and E-selectin antagonists with increased binding affinity 
compared to sLex (chapter 2.3.). 
• A series of glycomimetic amides and sulfonamides was developed to target a hitherto 
unexplored binding pocket of P-selectin. The structurally simplified, and non-charged 
mimetics exhibited up to threefold higher binding affinities than sLex (chapter 2.4.). 
• A synthetic route to derivatives of 2,2-dialkyl-2-O-glycosyl glycolic acid was developed 
and the resulting glycomimetics were tested as E-selectin antagonists (chapter 2.5). 
• Thermodynamic binding parameters of sLex and E-selectin antagonists were analyzed. It 
was found that a combination of reduced polarity of weakly binding residues and 
enhanced pre-organization is the key to overcome enthalpy entropy compensation 
(chapter 2.6.). 
• Literature known antagonists were synthesized to evaluate their potential in established 
in-house assays (chapter 2.7.). 
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1 Introduction 
1.1 Structure and function of selectins 
1.1.1 Structure of selectins 
The selectins, namely E-, P-, and L-selectin,a are cell adhesion molecules that mediate the 
adhesion of leukocytes and platelets to vascular surfaces. They are classified as C-type 
lectins, since they recognize carbohydrate ligands in a Ca2+-dependent manner. Overall, 
selectins share about 50% sequence homology. They are composed of a N-terminal 
carbohydrate recognition domain (CRD), also called lectin domain, an epidermal growth 
factor like domain (EGF), several short consensus repeats (SCR), a transmembrane domain 
and a cytoplasmic tail (Figure 1.1.1).[1] 
 
 
Figure 1.1.1 Schematic presentation of the selectins. 
The lectin domain hosts the binding epitope for physiological carbohydrate ligands. It is 
conformationally stabilized by a Ca2+ ion, which is required for recognition.[1] Though the 
exact function of the EGF domain is not completely clear yet, it is essential for the binding 
process and is involved in binding either directly, or by allosteric modulation of the CRD.[2] 
Recent discussions also propose its role in the catch bond behavior of selectins (see section 
                                                
a The selectins have alternative names: E-selectin: CD62E, ELAM-1, LECAM-2; P-selectin: CD62P, 
LECAM-3; L-selectin: CD62L, LAM-1, LECAM-1. 
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1.2.2). SCRs serve as a spacer between the lectin domain and the cell membrane to reach 
through the glycocalix and allow cell-cell interactions. Their number differ between the 
selectins and different species. Human L-selectin contains two, E-selectin six, and P-selectin 
nine SCRs.[3] The transmembrane domain anchors the selectins to the cell membrane.[4,5] The 
final cytoplasmic tail is involved in signal transduction.[6]  
1.1.2 Natural selectin ligands 
The natural selectin ligands are glycoproteins and glycolipids with typically sialylated and 
fucosylated glycan epitopes. The tetrasaccharides sialyl Lewisx (sLex) and sialyl Lewisa 
(sLea) were identified as common carbohydrate motifs recognized by all three selectins 
(Figure 1.1.2).[7,8] Furthermore, sulfated analogs of sLex were reported to act as selectin 
ligands.[9] 
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Figure 1.1.2 Common carbohydrate motifs recognized by all three selectins. 
Although all selectins share common carbohydrate binding motifs, they differ in their ligand 
specificity (Figure 1.1.3).  
The most important ligand to P-selectin is the 250 kDa, homodimeric type-I transmembrane 
P-selectin glycoprotein ligand 1 (PSGL-1),[10] which also binds to E- and L-selectin, but with 
different affinity and kinetics.[11] Besides the sLex moiety which is essential for recognition, 
PSGL-1 bears three sulfated tyrosine residues which ensure high binding affinity to P-
selectin (see section 1.3.).  
Glycoproteins identified as ligands to L-selectin comprise MadCAM-1,a [12] CD34,b [13] 
endomucin,[14] endoglycan,[15] podocalyxin-like protein,[16] PSGL-1,[15] and the sialo-mucin 
GlyCAM-1,c [17] which is the best characterized L-selectin ligand to date. GlyCAM-1 is 
                                                
a Mucosal vascular addressin cell adhesion molecule 1 
b Cluster of differentiation molecule 34 
c Glycosylation-dependent cell adhesion molecule-1 
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described as regulatory protein involved in the recruitment of lymphocytes into peripheral 
lymphnodes.[3]  
In contrast to P- and L-selectin, E-selectin does not require sulfation of ligands.[7,18] E-
selectin ligand-1 (ESL-1), is a non-sulfated glycoprotein, which lacks binding to P- and L-
selectin.[19] Furthermore, E-selectin binds to PSGL-1 and to carbohydrate structures on L-
selectin of human neutrophils.[20] 
Besides these glycoproteins, P- and L-selectin, but not E-selectin, recognize various 
polyanions like sulfatides, fucoidan and heparin. These are bound in a Ca2+ independent 
manner by a second binding site rich in positively charged amino acids (see section 1.3). 
 
 
Figure 1.1.3 The selectins and their natural glycoprotein ligands (adapted from [3]). 
1.1.3 Physiological role of selectins 
Inflammation is a vital defense and protection mechanism in case of tissue injury and 
invasion of pathogens, which is characterized by the invasion of leukocytes from the 
bloodstream to the site of inflammation. Selectins are key players of this multistep process, 
which is described by the inflammatory cascade (Figure 1.1.4).[21]  
Upon an inflammatory stimulus, pro-inflammatory mediators are released which stimulate 
endothelial cells of post-capillary venules to display E- and P-selectin on their surface. 
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Circulating leukocytes interact with the endothelium via selectin ligands like PSGL-1 and 
ESL-1, and are slowed down. The resulting rolling of leukocytes along the endothelial layer 
allows for the cytokine mediated activation of "2-integrins on the leukocytes.[22] Integrins 
interact with endothelial ligands from the IgG superfamily like ICAM-1a and VCAM-1b, 
which leads to firm adhesion and finally to extravasation and migration of the leukocytes to 
the site of inflammation.[22] 
 
 
Figure 1.1.4 Schematic presentation of the inflammatory cascade (by courtesy of A. Vögtli). 
Though all three selectins have been shown to mediate rolling of leukocytes,[3] they differ in 
their function and in their spatial and temporal expression.[21,23] 
L-selectin is constitutively expressed on most leukocytes and primarily serves as lymphocyte 
homing receptor, i.e. it mediates the attachment of lymphocytes to high endothelial venules 
(HEV) of peripheral lymph nodes, and thereby allows lymphocyte recirculation.[23] Besides, 
L-selectin is involved in the “secondary tethering” of free-flowing leukocytes to already 
adherent ones, which allows the recruitment of further leukocytes to sites of inflammation. 
This process is mediated by the L-selectin-PSGL-1 interaction.[24] 
E-selectin is exclusively expressed on stimulated endothelial cells after de novo synthesis, 
three to four hours after activation. Its expression is stimulated by transcription factors such 
                                                
a Intercellular cell adhesion molecule 1 
b Vascular cell adhesion molecule 1 
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as tumor necrosis factor ! (TNF-!), interleukin-1 (IL-1) and lipopolysaccharides (LPS).[25] It 
mediates slow rolling of leukocytes, which is the prerequisite for further activation of 
leukocytes by chemo-attractants.[26] 
P-selectin is constitutively stored in !-granules of platelets and Weibel-Palade bodies of 
endothelial cells. Upon stimulation by thrombin, histamine, or other agonists, it is 
translocated to the cell surface within minutes.[27] In addition, LPS, TNF-!, and IL-1 can 
induce de novo synthesis of P-selectin, which leads to its expression on the cell surface two to 
four hours later.[28] P-selectin is thought to initiate the capturing of leukocytes and to mediate 
the fast rolling of leukocytes. 
The physiological relevance of selectins has been confirmed by several knockout 
experiments. L-selectin deficient mice show reduced leukocyte rolling and defects in 
lymphocyte homing.[29] Mice deficient in P-selectin[30] and mice deficient in P- as well as E-
selectin[31] exhibit elevated levels of neutrophils in the blood. Even more, P- and / or E-
selectin deficient mice suffered from increased mortality after infection with Streptococcus 
pneumoniae.[32] The relevance of selectins for the human immune system was first evidenced 
by cases of the leukocyte adhesion deficiency syndrome type 2 (LAD-2). This rare genetic 
disorder is caused by a mutation in the GDP-fucose transporter gene, leading to a lack of 
fucosylation in glycoconjugates, which goes along with reduced rolling of leukocytes. LAD-2 
is characterized by recurrent infections, mental retardation, and the Bombay Blood group.[33]  
1.1.4 Pathophysiological role of selectins 
Besides their fundamental role in physiological processes, selectins are also involved in a 
plethora of severe disease states. In these cases, the actions of leukocytes are misdirected, as 
they no longer only fight bacteria and decompose damaged tissue, but also cause injury and 
breakdown of healthy cells.[34] A hallmark of many acute and chronic inflammatory diseases 
is the excessive recruitment of leukocytes to inflamed tissue. Examples of these diseases 
include asthma,[35] rheumatoid arthritis,[36] reperfusion injury,[37] and host versus graft 
disease[38]. Using antibodies, recombinant selectin counter-receptors or low molecular weight 
antagonists, selectins have been evaluated as promising pharmacological targets to tackle 
theses diseases.[39] 
Furthermore, there is growing evidence that cancer cells, coated with sLex and sLea exploit 
the selectin mediated inflammatory pathway to escape the bloodstream and metastasize.[40,41] 
The pathophysiological role of selectins and their relevance as pharmacological targets is 
covered by several excellent reviews: [34,39,41-43] 
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1.2 Binding properties of selectins 
1.2.1 Kinetic properties 
Given the physiological role of selectins, namely the transient tethering of fast flowing 
leukocytes to endothelial cells, relatively weak binding and fast binding kinetics are to be 
expected. Indeed, surface plasmon resonance (SPR) experiments revealed fast association 
and dissociation kinetics for all three selectins. 
For the interaction of E-selectin and ESL-1, Vestweber and coworkers found a dissociation 
rate constant koff of 4.6 s-1 and calculated an association rate constant kon of 7.4 ·104 M-1s-1. 
The dissociation constant KD was determined to be 62 µM. Given the temperature 
independence of the binding affinity, they concluded that the interaction between ESL-1 and 
E-selectin must be entropy driven.[44] With a KD of 0.3 µM, the P-selectin-PSGL-1 
interaction displays the highest affinity of the measured selectin-ligand interactions. 
Association was very fast with a kon of 4.4 ·106 M-1s-1. The koff was 1.4 s-1.[45] The kinetics of 
the L-selectin-GlyCAM-1 interaction were too rapid for precise measurements. Nevertheless, 
it was shown that the koff was # 10 s-1 and the kon was # 105 M-1s-1, with a KD of 108 µM.[46]  
The lower kon of the E-selectin-ESL-1 interaction compared to the kon of the P-selectin-
PSGL-1 interaction points to different roles of the two selectins. It is assumed that P-selectin 
mediates the initial capturing of leukocytes, while E-selectin probably serves to further 
strengthen the contact with the endothelium.[44] This reasoning is supported by the relatively 
poor ability of E-selectin to capture free-flowing leukocytes.[23] 
1.2.2 Catch bond behavior of selectins 
It has been observed that rolling of all three selectins requires a minimum shear threshold to 
become efficient.[47] With increasing shear, higher numbers of leukocytes tether and roll until 
a peak is reached beyond which the rolling of leukocytes decreases again. This observation 
was rationalized by increased formation of bonds between leukocytes and endothelial cells 
with increasing shear[48] and a catch bond behavior of selectins. In contrast to slip bonds, 
catch bonds initially get stronger with increasing tensile force before they break, a finding 
that was demonstrated for the P-selectin/PSGL-1 interaction using atomic force 
microscopy.[49] Two models have been developed to explain this counterintuitive binding 
behavior, an allosteric model and a sliding rebinding model. 
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The allosteric model proposes a single binding site that can adopt a high affinity and a low 
affinity state which can be modulated allosterically by the lectin-EGF interface.[50] This 
model is based on the two different conformations of P-selectin observed in crystal 
structures. Apo P-selectin (pdb code 1g1q) and P-selectin soaked with sLex (1g1r) favor a 
bent conformation while P-selectin cocrystallized with a PSGL-1 fragment (1g1s) adopts an 
extended conformation.[51] These two conformations do not only differ in the orientation of 
the EGF domain relative to the lectin domain, but also in the lectin domain itself (Figure 
1.2.1; more detailed information is given in section 1.2.4).  
 
Figure 1.2.1 Bent conformation of apo-P-selectin (left) and extended conformation of P-selectin 
cocrystallized with a PSGL-1 fragment (right). Figure adapted from [50] 
Binding studies with a glycan wedge at the interface of the lectin- and the EGF-domain, 
which stabilizes the extended conformation of P-selectin, revealed a 5 fold increased affinity 
towards PSGL-1.[52] The same effect on binding affinity was observed upon mutation of an 
amino acid in the lectin domain intended to favor the extended, high affinity conformation.[50] 
The authors concluded that the high and low affinity state are in an equilibrium, which is 
shifted to the high affinity state upon directional force.[50]  
In contrast, in the sliding rebinding model, ligand binding does not induce a conformational 
change in the lectin domain. Instead, it is proposed that force favors the extended 
conformation which enables alignment of ligand and selectin parallel to the applied force, 
and thereby allows the ligand to slide along the selectin surface from one binding site to the 
next.[53] 
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Although more data is needed to verify the allosteric model, allosteric modulation of selectin 
affinity might become a powerful tool for the design of selectin antagonists that overcome the 
typical drawbacks of competitive selectin antagonists.  
1.2.3 Binding of sLex to E- and P-selectin  
SLex was identified as the minimum binding epitope of all three selectins[54] and consequently 
was the lead for most small molecule selectin antagonists developed to date.[55] Towards both 
E- and P-selectin, it exhibits only weak binding of 0.3 to 1.1 mM and 7 to 9 mM, 
respectively.[56]  
Initial structure activity relationship (SAR) studies mainly focused on E-selectin and allowed 
for the identification of the pharmacophoric groups described in Figure 1.2.2. Various studies 
suggested that the D-GlcNAc moiety is not directly involved in binding,[57] but rather acts as a 
spacer ensuring the right spatial orientation of L-fucose (L-Fuc) relative to D-galactose (D-
Gal).[58] The saturation transfer difference NMR (STD-NMR) pattern of sLex on E-selectin 
agreed with the identified pharmacophoric groups, giving strong signals for groups involved 
in binding and only weak signals for protons of N-acetyl-D-glucosamine (D-GlcNAc) and 
sialic acid.[59] 
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Figure 1.2.2  Pharmacophoric groups of sLex identified by SAR studies: hydroxyl of L-
fucose,[51,60,61] hydroxyl groups in 4- and 6- position of D-galactose,[62-64] and the carboxylic acid 
residue of sialic acid[61].  
Only limited SAR data is available for the P-selectin-sLex interaction. Brandley et al. 
reported that the 3-hydroxyl group of L-Fuc is essential, while either the 2- or the 4-hydroxyl 
group can be removed without loss in affinity. He further reported, that the carboxylate of 
sialic acid could be replaced by different charged groups resulting in comparable affinities.[61] 
Hasegawa and coworkers studied the binding of various deoxy sLex gangliosides to P-
selectin and found, that the 6-hydroxyl group of D-Gal is essential, while the 4-hydroxyl 
group of D-Gal was dispensable.[64]  
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The conformation of sLex bound to E- and P-selectin, and consequently the pharmacophore 
of sLex, was deduced from several NMR studies.[56,65,66] The conformation of sLex bound to 
E-selectin found by Scheffler et al.[65,67] was confirmed subsequently by the crystal structures 
of E- and P-selectin in complex with sLex.[51] These crystal structures, solved by Somers and 
Camphausen in 2000, were also in excellent agreement with the pharmacophoric groups 
identified earlier and finally gave a precise picture of the interactions at molecular level 
(Figure 1.2.3 and Figure 1.2.4).  
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Figure 1.2.3 Schematic presentation of interactions between sLex and E-selectin (left) and sLex 
and P-selectin (right) as observed in the crystal structures.[51] sc = side chain; bb = backbone. 
The contacts observed in the crystal structures can be summarized as follows. 
E-selectin: The hydroxyl groups 3 and 4 of L-Fuc directly coordinate to Ca2+ and are 
involved in further hydrogen bonding with protein side chains coordinating to Ca2+. The 
hydroxyl group 2 of L-Fuc forms water mediated hydrogen bonds to the side chains of Asn83 
and Glu107. The hydroxyl groups 4 and 6 of D-Gal bind to the side chains of Tyr94 and 
Glu92, respectively. The carboxylate of the sialic acid moiety forms a hydrogen bond to the 
side chain of Tyr48 and a salt bridge to the side chain of Arg97. The guanidinium moiety of 
Arg97 furthermore binds to the oxygen of the glycosidic bond between D-Gal and sialic acid. 
P-selectin: The hydroxyl groups 3 and 4 of L-Fuc directly coordinate to Ca2+ and are 
involved in further hydrogen bonding with protein side chains coordinating to Ca2+. In 
contrast to E-selectin, Asn83 does not coordinate to Ca2+, and does not mediate the hydrogen 
bond network between water, Glu107, and L-Fuc. Identically to E-selectin, the hydroxyl 
groups 4 and 6 of D-Gal bind to the side chains of Tyr94 and Glu92, respectively. One of the 
major differences between the two proteins is the mutation of Arg97 in E-selectin to Ser97 in 
P-selectin, which goes along with the loss of a charge-charge interaction and a favorable 
hydrogen bond. It is assumed that this mutation is one of the major reasons for the 
approximately tenfold lower binding affinity to P-selectin compared to E-selectin. 
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Furthermore, a hydrogen bond between Ser99 and the 4-hydroxyl group of sialic acid is 
postulated for the P-selectin-sLex complex.  
 
Figure 1.2.4 SLex bound to E-selectin (left) and sLex bound to P-selectin (right).[51] 
Overall, the core of sLex (Gal("1-4)[Fuc(!1-3)]GlcNAc) is coordinated almost identically by 
both proteins, which can be rationalized by the highly conserved amino acid sequence in this 
part of the binding site (Figure 1.2.4).[68] The high degree of similarity is also reflected in the 
nearly identical conformation of sLex bound to P- and E-selectin. Differences, however, exist 
in the protein epitopes near sialic acid. The side chains of Arg97, Glu98, Lys99, and Asp100 
in E-selectin form a rather wide pocket, which is stabilized by the guanidine moiety of Arg97 
stacking against Tyr94 and interacting with Asp100. Ser97, Pro98, Ser99, and Ala100 of P-
selectin in contrast form a binding pocket stabilized by a highly ordered H-bond network. 
Comment on the crystal structures: 
Apo-E-selectin had already been crystallized by Graves et al. in 1994.[69] The crystal 
structure solved by Somers et al. is nearly identical with this earlier one.[51] It is important to 
note that the sLex-P-selectin complex and the sLex-E-selectin complex were both formed by 
soaking sLex into preformed crystals of E- and P-selectin. 
1.2.4 Binding of PSGL-1 to P-selectin  
The physiological ligand to P-selectin, PSGL-1 binds to P-selectin with a KD of 
approximately 0.3 µM,[45] which is about 20 000 fold stronger than the binding affinity of 
sLex alone.[56] While various publications point out the importance of tyrosine sulfation for 
high affinity binding,[70] Somers et al. found that non-sulfated PSGL-1 binds already 200 fold 
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stronger than sLex,[51] suggesting that the protein part of PSGL-1 significantly contributes to 
the increase in binding affinity.  
A highly truncated form of PSGL-1, SGP-3, was used for crystallization with P-selectin, 
since PSGL-1 itself was considered too complex for co-crystallisation.[51] The SGP-3 
construct comprises the 19 N-terminal aminoacids of mature PSGL-1 including sLex 
modified Thr16 and the three tyrosine sulfates (Tys6, Tys8, Tys11) essential for high affinity 
binding. In SPR experiments with SGP-3 and P-selectin kinetics almost identical to the one 
of a soluble recombinant form of PSGL-1 were observed, providing evidence that SGP-3 is a 
functional mimetic of full-length PSGL-1. [51]  
The crystal structure of SGP-3 and P-selectin revealed a combination of hydrophobic and 
electrostatic interactions for the protein part of SGP-3 and P-selectin. Tyrosine sulfates were 
found to bind in a region of positive electrostatic potential, while the sLex part bound to the 
same epitope as in the sLex-P-selectin complex. Nevertheless, striking differences were found 
when comparing the overall conformations of P-selectin bound to SGP-3 with the ones of 
apo-P-selectin and sLex-P-selectin (Figure 1.2.5 and Figure 1.2.6). 
Firstly, the loop formed by Asn83 to Asp89 is moved near the Ca2+ site upon binding of 
PSGL-1, and thereby allows additional interactions. Glu107 now forms a hydrogen bond to 
the 2-hydroxyl group of L-Fuc, and Glu88 simultaneously coordinates Ca2+ and binds to L-
Fuc (Figure 1.2.5). Furthermore, Arg85 is now involved in hydrogen bonds to Tys10 and 
Pro14 of SGP-3. Secondly, the Arg54-Glu74 loop is moved. Thirdly, the orientation of the 
lectin domain relative to the EGF domain is changed. This last observation supports the 
allosteric model for the catch bond behavior of selectins (see section 1.2.2).[50] The authors 
concluded that P-selectin exists in two conformational states, a high-affinity state and a low 
affinity state.[51] However, one should take into consideration that the observed 
conformational changes might be an artifact caused by the crystallisation conditions.[51] 
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Figure 1.2.5 Schematic representation of the interactions between sLex and P-selectin (left) and 
sLex-SGP-3 and P-selectin (right) as observed in the crystal structures.[51] sc = side chain; bb = 
backbone. 
    
Figure 1.2.6 Left: superposition of apo-P-selectin (blue) and P-selectin in complex with SGP-3 
(purple and orange). Right: zoom into the shift of the Asn83-Asp89 loop. Adapted from Somers et 
al.[51] 
Comment on the crystal structures: 
In their publication describing the crystal structures of E- and P-selectin, Somers and 
Camphausen claim that the movement of the loop defined by Asn83 to Asp89 enables Asn83 
to coordinate to Ca2+ and L-Fuc simultaneously (Figure 1.2.6). A closer look at the crystal 
structure submitted at the RCSB protein data bank (1g1s) in contrast reveals that Asn83 does 
not form this claimed interaction, but rather stabilizes the loop via a hydrogen bond to the 
backbone of Glu88 (Figure 1.2.7). 
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Figure 1.2.7 Conformation and interaction of Asn83 as observed in the crystal structure 1g1s.
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1.3 E- and P-selectin: differences, similarities and implications for the 
design of P-selectin antagonists 
A review on selectin antagonists was published in CHIMIA. The main focus of this article is 
set on P-selectin antagonists and how their development is influenced by structural 
differences and similarities between E- and P-selectin. 
 
Binder, F.P.C.; Ernst, B. CHIMIA 2011, 65, 210-213. 
 
Copyright © Swiss Chemical Society: CHIMIA 
 
  15 
 
  16 
  17 
 
  18 
 
  19 
1.4 Ligand pre-organization and rational design of E-selectin antagonists 
Pre-organization describes the correlation between solution conformation and bioactive, i.e. 
bound conformation of a molecule. The closer the solution conformation resembles the 
bioactive conformation, the higher is the degree of pre-organization. A high degree of pre-
organization is expected to reduce the loss of conformational entropy upon binding and 
consequently to increase the binding affinity. Carbohydrates are mostly flexible,[71] which is 
reflected in the unfavorable conformational entropies reported for a broad range of lectin-
carbohydrate interactions[71] and accounts for their weak binding affinities. Carver 
consequently suggested to increase the binding affinity of carbohydrates by increasing their 
pre-organization.[72] Interestingly, carbohydrate ligands that were pre-organized by covalent 
means showed no increase in binding affinity, which could be traced back to 
enthalpy/entropy compensation.[73] Even more, ligands that were covalently pre-organized in 
the wrong conformation suffered from significant loss in affinity.[74] 
In the case of E-selectin antagonists, progress was made by successively replacing 
carbohydrate moieties with mimics that were tuned to improve the pre-organization of the 
ligand and thereby its binding affinity. 
1.4.1 Pre-organization of sLex  
SLex mediates the recognition of physiological selectin ligands by selectins. As this process 
takes place under flow conditions, it requires fast binding kinetics and consequently a high 
degree of pre-organization is expected to be beneficial.  
The solution conformation and the conformation of sLex bound to E-selectin have extensively 
been studied by NMR spectroscopy and molecular dynamics (MD) simulations.[5,56,65-67,75] 
Overall, the data suggest a high degree of pre-organization of the LewisX core, while 
conformational changes of the sialic acid residue upon binding to E-selectin are discussed 
controversially. However, the conformation of sLex bound to E-selectin was identified as one 
of two low energy solution conformations of sLex, and molecular modeling studies predicted 
a high degree of pre-organization for sLex.[76,77] Moreover, recently published crystal 
structures of the staphylococcal toxins SSL5 and SSL11 revealed that these lectins bind 
essentially the same conformation of sLex as E- and P-selectin,[78] again pointing to a strong 
similarity between solution conformation and bound conformation of sLex. 
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1.4.2 Rational design of E-selectin antagonists 
Carbohydrate leads typically suffer from low affinities, high polarity, and complex structure, 
which strongly limits their direct application as drugs. A common strategy to overcome these 
limitations is to eliminate unnecessary polar groups and carbohydrate moiety or to replace 
them with less polar mimics. [43] 
This concept was also applied to the development of E-selectin antagonists based on sLex. D-
GlcNAc, known to act as a spacer between L-Fuc and D-Gal, was replaced with numerous 
linkers.[58,79] Ernst and coworkers showed that the affinity of the resulting mimetics correlated 
with the ability of the linker to pre-organize the Lewisx core.[58] Conformationally restricted 
linkers like (R,R)-cyclohexane-1,2-diol were better suited than more flexible ones like 
ethane-1,2-diol. Sialic acid was typically replaced by glycolic acid, lactic acid, or derivatives 
thereof.[80] Pre-organization also turned out to be essential for the carboxy group of sialic 
acid, i.e. (S)-lactic acid derivatives were superior to (R)-lactic acid derivatives. Efforts to 
replace both D-GlcNAc and sialic acid culminated in the substitution with (R,R)-cyclohexane-
1,2-diol and (S)-cyclohexyllactic acid, respectively, resulting in the lead CGP69669, which 
was 15-fold more potent than sLex (Figure 1.4.1).[81]  
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Figure 1.4.1 Systematic replacement of carbohydrate moieties of sLex resulted in the lead 
CGP69669. 
To easily compare the conformational preferences of different ligands, Ernst and Kolb 
defined two internal dihedral angles. The core conformation, i.e. the orientation of D-Gal 
relative to L-Fuc, and the acid orientation, i.e. the tilting angle of the sialic acid C1-C2 bond 
relative to the core (Figure 1.4.2). Furthermore, they developed a molecular modeling tool 
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that allowed to assess the conformational preference of a ligand in solution based on a Monte 
Carlo (jumping between wells)/stochastic dynamics [MC(JBW)/SD] simulation.[76,77] 
Calculated conformations were weighed with their probability and plotted in an internal 
coordinate system (Figure 1.4.3). The conformational preference found for sLex closely 
resembled the conformation determined by tr-NOE NMR,[65,67] which was used to define the 
bioactive window. Ligands populating this window were predicted to have a high degree of 
pre-organization and consequently superior binding affinity compared to ligands outside the 
window. Indeed, it was shown for a set of E-selectin ligands, that the predicted degree of pre-
organization correlates with relative affinities measured in bioactivity assays.  
 
 
Figure 1.4.2 Graphical representation of the internal dihedral angles that define core orientation and 
acid conformation. 
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Figure 1.4.3 Left: conformation of sLex bound to E-selectin as determined by tr-NOE NMR; right 
conformational preference calculated for sLex: the highest probability for the core conformation and 
the acid orientation were calculated as -20° to -50° and 110° to 140°, respectively; the red square 
indicates the bioactive window (adapted from [76]). 
Based on the lead CGP69669, numerous E-selectin antagonists have been synthesized. To 
date, cyclohexyllactic acid was identified as the best mimic of sialic acid,[82,83] and several 
attempts to improve the affinity via additional lipophilic interactions at the sLex binding site 
failed.[63,83,84] However, it was found that various substituents in 2-position of D-Gal enhance 
the binding affinity (Table 1.1).[85,86] STD NMR experiments indicated direct contact of these 
substituents to the protein,[86] while the crystal structure of sLex bound to E-selectin 
suggested no contact at all. To unambiguously identify the binding mode of these antagonists, 
a crystal structure is required. 
Significant improvements were made by enhancing the pre-organization of the core and 
thereby the affinity of E-selectin antagonists.[58,87] Most importantly, it was found that D-
GlcNAc mimics bearing substituents vicinal to L-Fuc enhance the pre-organization via steric 
compression of the core.[58] Ernst, Wagner, and Schwizer systematically studied the influence 
of various alkyl groups and identified (1R,2R,3S)-3-methyl-1,2-cyclohexanediol and 
(1R,2R,3S)-3-ethyl-1,2-cyclohexanediol as superior mimics of D-GlcNAc (Table 1.1).[87] A 
beneficial effect was also reported for substituents at the former ring oxygen position of D-
GlcNAc. Since these should not directly bind to E-selectin according to the crystal structure 
of sLex bound to E-selectin, stabilization of the chair conformation was discussed.[87]  
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Table 1.1 SAR studies of E-selectin antagonists.[84] 
O
O
O
HO
OH
OR2
CO2R1
R3
O
HO
OH
OH
O
R4
 
 
Compound R1 R2 R3 R4 rIC50a) 
CGP69669 Na H H H 0.080 
BW408-0 
DS4115 H H Me H 0.013 
DS226h Na H Et H 0.009 
LT2_036 H Bz H H 0.040 
GMI 1077 
DS226a 
Na Bz Me H 0.005 
DS226e Na Bz Et H 0.007 
DS226b Na Bz nBu H 0.009 
DS226c Na Bz cPr H 0.032 
DS244 H Bz Me CO2Me 0.002 
a) rIC50 values are referenced to sLex (IC50 = 1 mM, rIC50 = 1.0) 
 
Finally, Jonas Egger and Céline Weckerle used a fragment based drug discovery (FBDD) 
approach to identify nanomolar E-selectin antagonists.[86,88] 
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2 Results and discussion 
2.1 General strategy for the synthesis of sLex, sLex mimetics and key 
building blocks 
Depending on the target molecule and site of modification, different synthetic strategies were 
applied. In general, synthetic routes were designed convergent to require a minimum number 
of building blocks and steps, as well as to introduce modifications at the latest stage possible. 
The following section gives an overview on synthetic strategies and key building blocks used 
throughout this work. The synthesis of building blocks and final compounds is covered by the 
corresponding chapters. 
Nomenclature: Each compound number is composed of the chapter number and a 
consecutive number (left). Compounds that appear in paper draft sections are given simple 
consecutive numbers in this section (middle). If paper draft compounds are referred to in 
another chapter, they are complemented by the chapter number and marked with an asterisk 
(right). A formula index is provided in chapter 4. 
 
2.3
compound number
chapter  
2.3*
compound number
chapter
2.3
compound number
chapter
=
  
2.1.1 Synthesis of sLex and sLex mimetics with sialic acid or cyclohexyllactic acid 
For the synthesis of sLex mimetics with sialic acid (Scheme 2.1.1) or cyclohexyllactic acid 
(Scheme 2.1.2), as well as for the synthesis of sLex (Scheme 2.1.3), a 2+2 strategy was 
applied. This strategy is ideally suited to introduce different derivatives and mimics of D-
GlcNAc with a minimum number of steps and building blocks.  
SLex mimetics with sialic acid were dissected into sialylgalactoside 1.2 and 
pseudodisaccharides 1.3a-c (Scheme 2.1.1). Disaccharide 1.2 was further cleaved into sialic 
acid donor 1.4 and galactoside 1.5, while the pseudodisaccharides were dissected into 
thiofucoside 1.6 and the four D-GlcNAc mimics 1.7a-d.  
SLex mimetic 1.8 was synthesized form galactoside 1.9 and the disaccharides 1.10. The latter 
ones were available from thiofucoside 1.6 and the corresponding N-acetyl-D-glucosamine 
building block 1.11. 
Trimethylsilylethyl (TMSE) protected sLex (1.12) was dissected into donor 1.2 and acceptor 
1.10a (Scheme 2.1.3).  
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Scheme 2.1.1 Retrosynthesis of sLex mimetics with sialic acid.  
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Scheme 2.1.2 Retrosynthesis of a sLex mimetic with (S)-cyclohexyllactic 
acid. 
 
 
 
 
 
 
 
 
 
 
Scheme 2.1.3 Retrosynthesis of TMSE-sLex 1.12. 
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2.1.2 Synthesis of sLex mimetics with novel sialic acid mimics 
Mimetics of sLex with novel sialic acid replacements were derived from one of the three key building blocks 1.13, 1.14, or 1.15, applying a 1+3 
strategy (Scheme 2.1.4). These building blocks only differ in the D-galactose part and were obtained from 1.3b and the corresponding galactosides 
1.16, 1.17 and 1.18. 
1.13
O
HO
HO
OH
R3
R2 O
O
HOOH
OH
O
O
R1O
O
HO
BnO
OH
HO
O
BnOOBn
OBn
O
O
O
HO
HO
OH
O
O
HOOH
OH
O
O
O
R
1.14
O
OH
HO
O
BnOOBn
OBn
O
O
O
O
Ph
1.3b
O
BnOOBn
OBn
O
HO
O
BzO
OBz
BzO
SEt
1.16 1.3b
O
BnOOBn
OBn
O
HO
O
BzO
OBz
O
O
Ph
SEt
1.17
OBn
1.15
O
HO
HO
OH
N
H
O
HOOH
OH
O
O
O
OH
H2N
O
BnOOBn
OBn
O
O
S
O
R
O
O
Ph
O
O
HO
HO
OH
N
H
O
HOOH
OH
O
O
O
R
1.3b
O
BnOOBn
OBn
O
HO
O
N3
OAc
O
O
Ph
SEt
1.18  
Scheme 2.1.4 Retrosynthesis of sLex mimetics with novel sialic acid mimics. 
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2.2 Fast and efficient route to [(1R,2R,3S)-1-hydroxy-3-methyl-cyclohex-
2-yl] 2,3,4-tri-O-benzyl-!-L-fucopyranoside 1.3b – a key building 
block in the synthesis of glycomimetic selectin antagonists 
2.2.1 Exploratory synthetic route to 1.3b 
In his PhD thesis, Daniel Schwizer studied the influence of various substituents in 3-position 
of D-GlcNAc mimics on the binding affinity of E-selectin antagonists (section 1.4.2.). He 
found, that a simple methyl group is best suited to improve the affinity. The corresponding 
building block 1.3b consequently became the standard for the design of novel selectin 
antagonists and was therefore needed in gram amounts (Figure 2.2.1). 
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Figure 2.2.1 (1R,2R,3S)-3-methyl-cyclohexane-1,2-diol was identified as potent mimic of D-
GlcNAc and made 1.3b the standard building block for the synthesis of novel selectin antagonists. 
The synthetic route originally developed by Daniel Schwizer was designed to introduce 
substituents at the latest stage possible, in this case via epoxide opening (Scheme 2.2.1, step 
f). Although perfectly suited for the exploration of the best alkyl substituent, the route turned 
out to be quite unpractical for the large-scale synthesis of disaccharide mimic 1.3b. 
Especially the costly enantioselective Corey-Bakshi-Shibata reduction[1] and the low 
temperature epoxide opening with the higher order cyanocuprate Me2Cu(CN)Li2[2] impeded 
the scale up. Besides, the bulky trityl group, which is needed to ensure regio- and 
stereoselectivity of epoxide formation and opening, hampered effective fucosylation. Steric 
hindrance and lack of stability under acidic conditions of the trityl group led to various side 
products and decreased yields substantially. Finally, in larger scale, detritylation with zinc 
bromide as Lewis acid and triethylsilane as hydride donor led to silylation of 1.3b and made 
an additional deprotection step necessary. 
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Scheme 2.2.1 a) i. Br2, CH2Cl2, 0°C, 2.5 h; ii. Et3N, CH2Cl2, r.t., 2 h (60%); b) (S)-!,!-
diphenylprolinol, B(OMe)3, BH3·N,N-diethylaniline, THF, -10°C to 0°C, 3 h, 93%; c) i. t-BuLi, Et2O, 
-78°C to -20°C, 3 h; ii. aq. NaHCO3, -20°C to r.t., 1 h (79%); d) Ph3CCl, CH2Cl2, DBU, r.t., 14 h 
(91%); e) m-CPBA, NaHCO3, CH2Cl2, 0°C to r.t., 5 h (72%); f) MeLi, CuCN, BF3·Et2O, THF, -78°C 
to -30°C, 2 h (91%); g) i. Br2, CH2Cl2, 0°C, 1h; ii. Et4NBr, MS 3 Å, CH2Cl2, DMF, r.t. 16 h, 30% to 
43%; h) ZnBr2, TES, CH2Cl2, r.t., 32 h, 66%. 
Without the need to introduce different substituents in 3-position of the D-GlcNAc mimic, we 
were able to develop a more efficient route to 1.3b, which is described in the following 
section. 
 
[1] N. Holub, J. Neidhofer, S. Blechert, Org. Lett. 2005, 7, 1227-1229. 
[2] A. Alexakis, D. Jachiet, J. F. Normant, Tetrahedron 1986, 42, 5607-5619; A. Ghribi, 
A. Alexakis, J. F. Normant, Tetrahedron Lett. 1984, 25, 3075-3078. 
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2.2.2 Fast and efficient synthesis of a carbocyclic D-GlcNAc mimic, a key building 
block for the synthesis selectin antagonists 
 
Author contributions: F.P.C. Binder: synthetic route, all experiments except determination 
of enantiomeric excess using chiral HPLC; Dr. E. Francotte (Novartis): determination of the 
enantiomeric excess using chiral HPLC. 
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Abstract  
For the synthesis of selectin antagonists, a fast and efficient approach to a D-GlcNAc mimic 
was developed. Starting from racemic seudenol, it permits the gram-scale synthesis of 
(1R,2R,3S)-1-[(tert-butyldimethylsilyl)oxy]-3-methyl-cyclohexan-2-ol in 4 steps with only 
two chromatographic purifications.  
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Introduction  
Lectins, such as selectins,1 galectins,2 or siglecs3 have gained increasing attention as drug 
targets. Although valuable leads for the development of new drugs, carbohydrates themselves 
rarely find therapeutic application, as they typically suffer from complex synthesis and poor 
pharmacokinetic and pharmacodynamic properties. As a consequence, small molecules 
mimicking the carbohydrate epitope, e.g. the sialidase inhibitor oseltamivir,4 have been 
developed to overcome these unfavorable properties. A common strategy for the design of 
glycomimetics is the substitution of a carbohydrate moiety with a carbocyclic scaffold, which 
offers increased hydrolytic and metabolic stability and reduced polarity. In addition, the 
facile synthetic accessibility of the mimetic structures, which as a consequence of the 
chirality of the parent carbohydrate compound include stereochemical challenges, is of 
cardinal importance. 
In the case of selectin antagonists, stepwise modification of the natural ligand sialyl LewisX 
(sLeX, 1, Figure 1) led to the new lead structure CGP69669 (2),5 where N-acetyl-D-
neuraminic acid (Neu5Ac) was replaced with (S)-cyclohexyl lactic acid and the N-acetyl-D-
glucosamine (D-GlcNAc) unit with (R,R)-cyclohexane-1,2-diol. When (R,R)-cyclohexane-
1,2-diol, on its part, was replaced by (1R,2R,3S)-3-methylcyclohexane-1,2-diol (! 3),6 
affinity could be further improved. The reported synthetic route for D-GlcNAc mimetic 46 
allows the introduction of different alkyl substituents R via epoxide opening with higher 
order cyanocuprates. However, this route is not feasible for the gram scale synthesis of 4. 
Since larger amounts of building block 4 were required for a broad exploration of its potential 
for a new class of selectin antagonists, a more convenient synthetic route had to be 
developed. 
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Figure 1. Selectin antagonists 1-3: The natural carbohydrate epitope sLeX (1), selectin antagonists 2 
(CGP69669)5 and 36, and the D-GlcNAc mimetic 4. 
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Results and discussion 
Starting from commercially available racemic seudenol (3-methyl-2-cyclohexenol, 5) the 
stereoselective enzymatic acylation (! 6) and the subsequent hydrolysis with aqueous 
sodium hydroxide leading to enantiomerically pure (R)-seudenol (7) is described by ter Halle 
et al.7 Using optimized conditions for the butanoylation with immobilized Candida 
antarctica lipase C (Novozym 435),7 we could easily isolate (R)-seudenolester (6) in 46% 
yield in 10 g scale.8 Subsequent saponification afforded (R)-seudenol in 84% yield and 97.5% 
enantiomeric excess (ee) as determined by HPLC using a Chiracel OD-H column. Since the 
protection group of the hydroxy group in 7 has to be stable under strongly basic and acidic 
conditions, should not hamper fucosylation by steric bulk, and finally allow cleavage under 
mild conditions orthogonal to benzyl protecting groups, a tert-butyldimethylsilyl (TBS) ether 
(! 8) was chosen. Hydroboration followed by oxidation yielded all-trans 9 in 81% over two 
steps. Starting from racemic seudenol, this short sequence allowed the gram scale synthesis 
of 9 in 31% overall yield, requiring only two chromatographic purifications.  
Fucosylation of 9 under in situ anomerisation conditions9 gave 11, which was smoothly 
deprotected with tetrabutylammonium fluoride (TBAF), affording pseudodisaccharide 126 in 
excellent yield over two steps. Galactosylation with donor 1310 promoted by 
dimethyl(methylthio)sulfonium triflate (DMTST) afforded 14 "-selectively.6 Debenzylation 
by hydrogenolysis followed by saponification with lithium hydroxide and ion exchange 
chromatography finally gave 3.6 
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Scheme 2. a) Novozyme 435, vinylbutyrate, heptane, 23°C, 200 rpm, 2 h 25 min, 46%; b) aqueous 
NaOH, MeOH, 0°C, 5 h, 84%; c) TBSCl, imidazol, DMAP, CH2Cl2, r.t., 15 h; d) i. BH3!THF, THF, 
0°C to r.t., 2 h; ii. H2O2, aqueous NaOH, 0°C to r.t., 1 h, 81% from 7; e) CuBr2, DTBMP, TBAB, 
CH2Cl2, DMF, MS 4 Å, r.t., 10 h, 87%; f) TBAF, THF, r.t., 20 h, quant. g) DMTST, MS 3Å, CH2Cl2, 
r.t., 43 h, 59%;6 h) i. Pd/C, H2, EtOH, cat. AcOH, r.t., ii. LiOH, MeOH/H2O, r.t., 2 d, iii. Dowex 
(Na+), Sephadex-G15, 74%.6 
Overall, we developed a fast and efficient route to (1R,2R,3S)-1-[(tert-
butyldimethylsilyl)oxy]-3-methylcyclohexan-2-ol (9) starting from racemic seudenol. By 
subsequent fucosylation and galactosylation, a novel class of selectin antagonists can easily 
be explored.  
 
Experimental Part 
NMR spectra were recorded on a Bruker Avance DMX-500 (500 MHz) spectrometer. The 
assignment of 1H and 13C NMR spectra was achieved using 2D methods (COSY, HSQC). 
Chemical shifts are given in ppm and were assigned in relation to the solvent signals on the 
!-scale11 or to tetramethylsilane (0 ppm) as internal standard. Coupling constants J are given 
in Hertz (Hz). Multiplicities were specified as follows: s (singlet), d (doublet), dd (doublet of 
a doublet), t (triplet), q (quartet), m (multiplet). Optical rotations were measured using a 
Perkin-Elmer Polarimeter 341. Electron spray ionization mass spectra (ESI-MS) were 
obtained on a Waters Micromass ZQ. HRMS analysis were carried out using a Agilent 1100 
LC equipped with a photodiode array detector and a Micromass QTOF I equipped with a 4 
GHz digital-time converter. The elemental analysis was performed at the Institute of Organic 
Chemistry at the University of Basel, Switzerland. Reactions were monitored by TLC using 
glass plates coated with silica gel 60 F254 (Merck) and visualized by using UV light and/or by 
charring with a molybdate solution (a 0.02 M solution of ammonium cerium sulfate dihydrate 
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and ammonium molybdate tetrahydrate in aqueous 10% H2SO4). Column chromatography 
was performed on silica gel (Fluka, 40-60 mesh). Tetrahydrofurane (THF) was freshly 
distilled under argon over sodium and benzophenone. Dichloromethane (CH2Cl2) was dried 
by filtration over Al2O3 (Fluka, type 5016 A basic). Enantiomeric excess (ee) was determined 
by HPLC: Agilent 1200 instrument with DAD detection equipped with a Chiralcel OD-H 
column (250 mm x 4.6 mm); Eluent: hexane/isopropanol (99/1 vol); flow rate 1.0 mL/min; 
temperature 23°C; detection, signals measured at 210 nm. Typical retention times: 12.9 (S)-
seudenol, 14.1 (R)-seudenol. 
 
(R)-3-Methylcyclohex-2-en-1-yl butyrate (6). 
Immobilized Novozyme 435 (222 mg, 444 U, EC 232-619-9) was added to a solution of 5 
(10.0 g, 89 mmol) and vinyl butyrate (22.6 mL, 20.3 g, 178 mmol) in heptane (90 mL). The 
mixture was stirred at 23°C and 200 rpm. After 2 h 25 min the mixture was filtered and 
volatiles were evaporated at 60°C and 10 mbar to give 12 g of a clear oil. Column 
chromatography on silica (CH2Cl2) yielded pure 6 (7.50 g, 41 mmol, 46%). 
1H NMR (500.1 MHz, CDCl3): !  5.44 (m, 1H, H-2), 5.23 (m, 1H, H-1), 2.24 (t, 3J = 7.4Hz, 
2H, COCH2CH2CH3), 2.02-1.84 (m, 2H, H-4a, H-4b), 1.81-1.56 (m, 9H, H-5a, H-5b, H6-a, 
H6-b, -CH3, COCH2CH2CH3), 0.92 (t, 3J = 7.4Hz, 3H, COCH2CH2CH3); 13C NMR (125.8 
MHz, CDCl3): ! 173.5 (COCH2CH2CH3), 141.0 (C-3), 120.2 (C-2), 68.6 (C-1), 36.7 
(COCH2CH2CH3), 30.0 (C-4), 28.1 (C-6), 23.8 (-CH3), 19.1, 18.7 (2C, C-5, 
COCH2CH2CH3), 13.7 (COCH2CH2CH3); ["]D +168.7 (c 9.28, CHCl3); MS (ESI) m/z: calcd 
for C11H18NaO2+ [M+Na]+: 205.12; found: 204.83; elemental analysis calcd (%) for C11H18O2 
(182.26): C 72.49, H 9.95; found: C 72.87, H 9.65. 
 
(R)-seudenol (7). A solution of NaOH in H2O (10.3 mL, 4N) was slowly added to a solution 
of seudenol butyrate 6 (3.50 g, 19 mmol) in MeOH (30 mL) at 0°C and stirred at 0°C for 5 h. 
The mixture was diluted with H2O (25 mL) and extracted with CH2Cl2 (25 mL + 20 mL + 15 
mL). The combined organic layers were washed with brine (25 mL) and dried over Na2SO4. 
Filtration and evaporation of volatiles (200 mbar, 40°C) gave spectroscopically pure (R)-
seudenol (7) (1.81 g, 16 mmol, 84%) as a clear oil, which was directly used in the next step. 
["]D +91.7 (c 0.74, CHCl3); HPLC: 97.5% ee, 98% purity; NMR data were in accordance 
with literature.7 
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(R)-1-[(tert-butyldimethylsilyl)oxy]-3-methylcyclohex-2-en (8). Imidazol (4.40 g, 65 
mmol) was added to a solution of (R)-seudenol 7 (3.50 g, 31 mmol), DMAP (cat.), and 
TBSCl (7.31 g, 48 mmol) in anhydrous CH2Cl2 (65 mL) at r.t. under argon. After stirring for 
15 h, the reaction mixture was quenched with satd. aqueous NaHCO3 (50 mL) and extracted 
with CH2Cl2 (20 mL). The organic layer was washed with aqueous HCl (20 mL, 0.01 N), 
satd. aqueous NaHCO3 (20 mL), and brine (20 mL) and dried over Na2SO4. Filtration and 
evaporation of volatiles (200 mbar, 40°C) gave the TBS ether 8 as clear oil.  
 
(1R,2R,3S)-1-[(tert-butyldimethylsilyl)oxy]-3-methylcyclohexan-2-ol (9). A solution of 
BH3!THF (60 mL, 1M in THF) was slowly added to a solution of the crude TBS ether (8) in 
anhydrous THF (60 mL) under argon at 0°C. After stirring for 2 h at r.t., the reaction mixture 
was cooled to 0°C again and aqueous NaOH (180 mL, 3N) followed by aqueous H2O2 (180 
mL, 30%) were slowly added via dropping funnel (CAUTION: strong gas development). 
The mixture was stirred at 0°C for 1 h, subsequently acidified to pH 3 by slow addition of 
10% aqueous HCl via dropping funnel (CAUTION: strong gas development) and extracted 
with CH2Cl2 (2 · 300 mL). The extracts were dried over Na2SO4, filtered, concentrated (100 
mbar, 40°C) and purified by column chromatography (PE/Et2O 98.5/1.5) to yield pure 9 (6.20 
g, 25 mmol, 81%) as clear oil. 
1H NMR (500.1 MHz, CDCl3): " 3.34 (m, 1H, H-1), 2.92 (dd, 3J = 8.5 Hz, 10.0 Hz, 1H, H-
2), 2.47 (s, 1H, OH), 1.81 (m, 1H, H-6a), 1.63-1.56 (m, 2H, H-4a, H-5a), 1.41 (m, 1H, H-3), 
1.34-1.99 (m, 2H, H-5b, H-6b), 1.04-0.92 (m, 4H, H-4b, -CH3), 0.91-0.83 (m, 9H, 
SiC(CH3)3), 0.07 (s, 3H, SiCH3), 0.05 (s, 3H, SiCH3); 13C NMR (125.8 MHz, CDCl3): " 81.0 
(C-2), 77.0 (C-1), 37.0 (C-3), 33.4, 33.9 (2C, C-4, C-6), 25.9 (3C, SiC(CH3)3), 23.6 (C-5), 
18.5 (-CH3), 18.1 (SiC(CH3)3), -3.9, -4.6 (SiCH3); [#]D - 13.7 (c 3.14, CHCl3); HR-MS (ESI) 
m/z: calcd for C13H28NaO2Si+ [M+Na]+: 267.1751; found: 267.1752. 
 
[(1R,2R,3S)-1-((tert-Butyldimethylsilyl)oxy)-3-methyl-cyclohex-2-yl] 2,3,4-tri-O- 
benzyl-# -L-fucopyranoside (11). Ethylthio fucoside 1012 (3.90 g, 8.15 mmol) and TBAB 
(4.00 g, 12.41 mmol) were dried at high vacuum overnight. Powdered activated molecular 
sieves 4 Å (5.0 g), compound 9 (1.00 g, 4.09 mmol), 2,6-di-tert-butyl-4-methylpyridine (2.50 
g, 12.17 mmol), anhydrous CH2Cl2 (35 ml) and DMF (5 ml) were added and the mixture was 
stirred for 4 h at r.t. under argon. CuBr2 (2.70 g, 12.09 mmol), dried under high vacuum 
overnight at 70°C, was added and the resulting dark mixture was stirred at r.t. under argon. 
After completion of the reaction (17 h), the solution was filtered through a pad of celite and 
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the filtrate was washed with a solution of satd. aqueous NH4Cl and aqueous NH3 (9/1 (v/v), 2 
x 200 mL) and brine (100 mL). The aqueous layers were extracted with CH2Cl2 (2 x 200 mL) 
and the combined organic layers were dried (Na2SO4) and concentrated. Column 
chromatography on silica (PE/EtOAc 98/2 to 97/3) gave the pseudodisaccharide 11 as clear 
oil (2.34 g, 3.54 mmol, 87%). 
1H NMR (500.1 MHz, CDCl3): ! 7.47-7.27 (m, 15H, 3 C6H5), 5.16 (d, 3J = 3.4 Hz, 1H, Fuc 
H-1), 5.03 (A of AB, 2J = 11.6Hz, 1H, CH2Ph), 4.89, 4.85, 4.78, 4.76 (4d, 2J = 11.8Hz, 4H, 
CH2Ph), 4.70 (B of AB, 2J = 11.6Hz, 1H, CH2Ph), 4.26 (q, 3J = 6.4 Hz, 1H, Fuc H-5), 4.10 
(dd, 3J = 3.4, 10.2 Hz, 1H, Fuc H-2), 4.05 (dd, 3J = 2.6, 10.2 Hz, 1H, Fuc H-3), 3.75 (m, 1H, 
H-1), 3.70 (m, 1H, Fuc H-4), 3.36 (t, 3J = 6.4 Hz, H-2), 1.88-1.77 (m, 2H, H-3, H-6a), 1.76-
1.68 (m, 2H, H-4a, H-5a), 1.43 (m, 1H, H-6b), 1.34-1.11 (m, 8H, Fuc-H6, -CH3, H-4b, H-
5b), 0.93 (s, 9H, SiC(CH3)3), 0.09 (s, 3H, SiCH3), 0.06 (s, 3H, SiCH3); 13C NMR (125.8 
MHz, CDCl3): ! 139.1, 138.9, 138.8, 128.4, 128.3, 128.2, 127.6, 127.5 (18C, 3 C6H5), 96.8 
(Fuc C-1), 81.5 (C-2), 79.3 (Fuc C-3), 78.2 (Fuc C-4), 76.7 (Fuc C-2), 74.9 (CH2Ph), 73.6 
(CH2Ph), 73.3 (C-1), 73.0 (CH2Ph), 66.4 (Fuc C-5), 35.6 (C-3), 33.2 (C-6), 31.1 (C-5), 26.1 
(3C, SiC(CH3)3), 19.8 (C-4), 18.9 (Fuc C-6), 18.2 (SiC(CH3)3), 17.0 (CH3), -3.9, -5.0 (2C, 
SiCH3); ["]D - 53.7 (c 2.1, CHCl3); HR-MS (ESI) m/z: calcd for C40H56NaO6Si+ [M+Na]+: 
683.3738; found: 683.3740. 
 
[(1R,2R,3S)-1-Hydroxy-3-methyl-cyclohex-2-yl] 2,3,4-tri-O-benzyl-" -L- 
fucopyranoside (12). Compound 11 (2.10 g, 3.18 mmol) was dissolved in a solution of 
TBAF in THF (20 mL, 1M) and stirred for 24 h at r.t.. The solution was diluted with CH2Cl2 
(50 mL) and washed with H2O (100 mL). The aqueous layer was extracted with CH2Cl2 (2 x 
50 mL) and the combined organic layers were dried (Na2SO4) and concentrated. Column 
chromatography on silica (PE/EtOAc 80/20) gave 12 as white solid (1.74 g, 3.18 mmol, 
quant.); ["]D - 42.0 (c 0.45, CHCl3); NMR data were in accordance with literature.6 
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2.3 Development of selectin antagonists based on differences and 
similarities between E- and P-selectin 
2.3.1 E- and P-selectin: Differences and similarities guide the way to selectin 
antagonists 
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Abstract 
Selectins are key players in the inflammatory cascade as they initiate the migration of 
leukocytes to sites of inflammation. However, excessive invasion of leukocytes can cause 
acute and chronic inflammatory diseases. Consequently, blocking of selectins is regarded as a 
potential therapeutic approach. Based on the common binding epitope of all selectins, sialyl 
Lewisx (sLex), we developed potent selectin antagonists, which exploit similarities and 
differences in the binding of sLex to P- and E-selectin. The nearly identical core conformation 
of sLex bound to P- and E-selectin allowed to introduce the D-GlcNAc mimic (1R,2R,3S)-3-
methylcyclohexane-1,2-diol to the design of P-selectin antagonists. Replacement of the 
carboxy group of sialic acid with a methylamide moiety was found to significantly reduce the 
affinity to E-selectin, while affinity to P-selectin was conserved. Finally, sialic acid was 
successfully replaced with small mimics resulting in structurally simplified E- and P-selectin 
antagonists with up to 20-fold improved binding affinity compared to the lead sLex. 
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Introduction 
The selectin family consists of E, P-, and L-selectin. All members contain a Ca2+-dependent 
carbohydrate recognition domain (CRD). Upon an inflammatory stimulus, two of these key 
components of our immune system, namely P- and E- selectin are up-regulated on endothelial 
cells and platelets. They mediate the rolling of leukocytes on the endothelial surface, which is 
followed by firm adhesion via integrins and extravasation to the site of the inflammatory 
stimulus. However, this important defense mechanism becomes harmful in acute and chronic 
inflammatory diseases like stroke, reperfusion injury, psoriasis, or rheumatoid arthritis, since 
in these states, the excessive extravasation of leukocytes leads to the destruction of tissues.[1] 
Inhibiting the interaction of selectins with their physiological ligands and thereby disabling 
the whole inflammatory cascade is considered a promising therapeutic approach.[2]  
Most of the small molecule antagonists developed to date were derived from the 
tetrasaccharide sialyl Lewisx (sLex, Neu5Ac(!2-3)Gal("1-4)[Fuc(!1-3)]GlcNAc, (1), Figure 
1),[3,4] which is the minimum binding epitope of all three selectins. Since sLex (1) itself 
exhibits only weak binding (0.3-1.1 mM E-selectin, 7-9 mM P-selectin),[5] poor 
pharmacokinetics and complex synthesis, efforts were directed to identify drug-like 
glycomimetics, i.e. mimetics with appropriate pharmacodynamic and pharmacokinetic 
properties, especially with high affinity and oral availability. Although numerous high 
affinity antagonists have been reported,[3,6] none of them has been successful in therapeutic 
applications to date.[7] 
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Figure 1. The tetrasaccharide sialyl Lewisx (1) and its pharmacophoric groups: hydroxyl groups of L-
fucose[8-10], hydroxyl groups in 4- and 6- position of D-galactose[11] and the carboxylic acid residue of 
sialic acid[10,12]. 
Results and discussion 
1. Similarities: Same core, same effect 
In a rational approach towards selectin antagonists, carbohydrate residues were subsequently 
replaced with mimics conserving the pharmacophoric groups.[4,13] In the case of E-selectin 
antagonists, sialic acid (N-acetyl-D-neuraminic acid, D-Neu5Ac) was successfully replaced 
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with (S)-cyclohexyllactic acid for instance, which significantly improved binding affinity to 
E-selectin, but abrogated binding to P-selectin. N-Acetyl-D-glucoseamine (D-GlcNAc) 
obviously does not contain pharmacophoric groups and was replaced by various mimics. It 
turned out, that it serves as a spacer to ensure the right core conformation, i.e. the right spatial 
orientation of L-fucose (L -Fuc) relative to D-galactose (D-Gal).[10,12,14-16] In fact, Ernst et al. 
showed, that mimics of D-GlcNAc can increase the binding affinity by pre-organizing the 
core of E-selectin antagonists, forcing the molecule in a conformation closer to the bioactive 
conformation.[17,18] Following this concept, introduction of a methyl group vicinal to L-fucose 
afforded 3, which is six-fold more potent than the lead 2 (Figure 2).[19]  
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Figure 2. Selectin antagonists 2, 3, 5, 6, and 7 and the reference TMSE-sLex 4. IC50 values are given 
as relative IC50 values (rIC50) scaled on 4 (rIC50= 1.0). 
As a starting point for the development of novel selectin antagonists, we chose 5 (Figure 2), 
which is known to bind to both P- and E-selectin.[20] Since the core conformation of sLex 
bound to P-selectin is almost identical to the one of sLex bound to E-selectin,[5,9] we reasoned 
that introduction of a methyl group vicinal to L-fucose should be beneficial for P-selectin 
antagonists as well. The rIC50 values determined for 5 nicely reproduced the relative affinities 
reported by Toepfer et al.[20] The additional methyl group in 6 improved binding to E-selectin 
by factor ten, which is consistent with the improved binding of 3 compared to 2. Towards P-
selectin, binding affinity was improved by factor six, which demonstrates that the concept of 
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pre-organization works for P-selectin antagonists as well. Overall, 6 exhibited a 20-fold 
higher binding affinity to P-selectin than sLex (1), making it a solid starting point for further 
modifications. 
2. Differences: The sialic acid binding domain 
2.1. The carboxy group of sialic acid 
Structure activity relationship (SAR) studies suggest that the carboxylic acid moiety is the 
most important functional group of D-Neu5Ac contributing to P- and E-selectin binding[10,12] 
and various models have been developed to rationalize the importance of the carboxylate. For 
E-selectin, a salt bridge with the guanidinium moiety of Arg97 was predicted.[5,21] For P-
selectin, data were more conflicting[22] and either a salt bridge with the side chain of 
Lys113[14,23] or a hydrogen bond to Tyr48[5] were predicted. In 2000, Somers et al. published 
the crystal structures of E- and P-selectin in complex with sLex, which gave a precise picture 
of the interactions at molecular level.[9] For E-selectin, the crystal structure (pdb code 1g1t) 
confirmed the predicted salt bridge between the guanidinium moiety of Arg97 and the 
carboxylate of D-Neu5Ac and revealed an additional hydrogen bond to Tyr48 (Figure 3). 
However, in the case of P-selectin (pdb code 1g1r), the carboxylate of D-Neu5Ac was found 
not to be involved in a salt bridge but rather in a water mediated hydrogen bond to Ser97 and 
a hydrogen bond to Tyr48 (Figure 3).  
We reasoned that this significant difference in interaction should allow the design of selective 
and less polar P-selectin antagonists, e.g. replacement of the carboxylate of D-Neu5Ac with a 
non-charged isosteric amide should result in loss of affinity to E-selectin, while affinity to P-
selectin should be conserved. To test this hypothesis, we synthesized and tested the 
methylamide analogue of 6, antagonist 7 (Figure 2). Indeed, binding affinity to P-selectin was 
conserved, while binding to E-selectin was reduced by factor ten. Interestingly, this relative 
change in affinity nicely correlates with the different binding affinities of sLex to P-selectin 
and sLex to E-selectin, indicating that the different type of interaction of the carboxylate is 
the major course for the different binding affinities for sLex to E- and P-selectin. 
Our findings underline the importance of the charge-charge interaction for E-selectin 
antagonists and are in strong contrast to the computational modeling studies of Pichierri and 
Matsuo,[24] who reported that the carboxylic acid moiety of D-Neu5Ac was binding in the 
protonated state. Finally, we could demonstrate that negative charge is no prerequisite for P-
selectin antagonists mimicking sLex (1), which is an important step towards selective and less 
polar P-selectin antagonists. 
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Figure 3. SLex bound to E-selectin (left) and sLex bound to P-selectin (right).[9] 
2.2. Mimics of sialic acid 
An obvious step for the design of sLex mimetics as selectin antagonists is the replacement of 
D-Neu5Ac, as it is expensive, polar, and apparently contributes to binding with the 
carboxylate only. Exclusively anionic groups like sulfates,[12,25] phosphates,[3,26] glycolic 
acid,[15,27] lactic acid,[17,28] and derivatives thereof were used for its replacement. Although 
effective -it is known that sulfates for example can fully replace sialic acid[12]- the 
replacement with sulfates and phosphates goes along with various drawbacks. First, the 
binding mode or even the binding site can change, which impedes the rational design of 
antagonists. It was demonstrated that 3-sulfo Lewisx binds to P-selectin Ca2+ 
independently,[12] clearly pointing to a binding mode different from the one observed in the 
crystal structure. Second, introduction of highly polar residues counteracts the optimization 
of the pharmacokinetic properties. Consequently, we decided to replace D-Neu5Ac with 
derivatives of lactic acid, as lactic acid itself already proved successful in the development of 
potent E-selectin antagonists.[17,28,29] With the results of section 2.1 in mind, we reasoned that 
amide analogues might pave the way to structurally simplified, non-charged P-selectin 
antagonists.  
Besides the importance of the carboxylic acid residue of D-Neu5Ac, it is known that 
modifications of the glycerol side chain and the N-acetyl group of D-Neu5Ac have no 
influence on binding affinity.[12,30] While no SAR information is available for the 4-hydroxy 
group, the crystal structure of sLex (1) bound to P-selectin suggests a hydrogen bond to 
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Ser99, a hydrogen bond not available in the complex of E-selectin and sLex (1). 
Consequently, we developed antagonist 8, which comprises a hydroxyl group to mimic the 4-
hydroxyl group of D-Neu5Ac (Figure 4). Antagonist 8 had the same relative binding affinity 
to P- and E-selectin as 7, providing evidence that the sialic acid mimic can fully replace sialic 
acid in E- and P-selectin antagonists. Replacement of the methylamide of 8 with a carboxylic 
acid residue once more enhanced binding affinity to E-selectin (10). Compound 9 served to 
explore the scope of further modifications that might increase binding affinity via additional 
lipophilic interactions. It turned out, that the bulky benzyl group is well tolerated by E-
selectin, but does not enhance binding. Deletion of the hydroxyl group in the sialic acid 
mimic of 10 went along with a small drop in binding affinity for E-selectin (11). 
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Figure 4. Relative IC50 values (rIC50) of selectin antagonists 8 to 11. IC50 values are scaled on sLex 4 
(rIC50=1); n.d. = binding affinity not determined. 
3. Synthesis 
As it is known that minor amounts of ion exchange resin can lead to false positive results in 
selectin assays,[31] no ion exchange resin was used throughout the synthesis.  
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3.1. Synthesis of TMSE-sLex 4  
Thio fucoside 12[18] and D-GlcNAc acceptor 13[32] were coupled under in situ anomerisation 
conditions[33] to give disaccharide 14, which upon regioselective opening of the benzylidene 
acetal[34] yielded acceptor 15. SLex precursor 17 was synthesized via DMTST[35] promoted 
coupling of 16[36] and 15. Hydrogenolytic debenzylation and saponification finally afforded 
TMSE protected sLex 4. 
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Scheme 1. a) Br2, Bu4NBr, CH2Cl2, MS 4 Å, 0°C to r.t., 12 h, 55%; b) Me3N·BH3, AlCl3, H2O, THF, 
r.t., 5 h, 78%; c) DMTST, CH2Cl2, MS 4 Å, r.t., 5 d, 20%; d) H2, Pd(OH)2/C, dioxane, H2O, r.t., 24 h; 
e) aq. NaOH, MeOH, r.t., 20 h, 43% from 17. 
3.2. Synthesis of sLex mimetics 5 - 7  
Pseudodisaccharides 18 and 19, synthesized as reported recently,[15,37] were coupled to donor 
16 using DMTST as promotor (Scheme 2). Hydrogenolytic debenzylation followed by 
saponification with sodium hydroxide afforded 5 and 6 in good to excellent yields. 
Aminolysis of the benzyl ester of 6 afforded methylamide 7 quantitatively.  
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Scheme 2. a) DMTST, CH2Cl2, MS 4 Å, r.t., 3 d (20: 85%, 21: 55%); b) H2, Pd(OH)2/C, dioxane, 
H2O, r.t., 12 h; c) aq. NaOH, MeOH, r.t. (5: 79% from 20, 6: 81% from 21); d) BnBr, KF, DMF, r.t., 
2 d; e) MeNH2, THF, EtOH, r.t., 12 h, quant. from 6. 
3.2. Synthesis of sLex mimetics 8 - 11  
Mimetics 8-11 were synthesized by alkylation of the core building block 28 with triflates 23 
and 25[38] (Scheme 4), which were available from lactone 22 and ester 24, respectively 
(Scheme 3). 
 
22
OH
O O
OTf
O O
23
O
OTf
O
25
O
OH
O
24  
Scheme 3. Tf2O, DTBMP, CH2Cl2, -18°C to r.t., 3 h, (23: 74%, 25: 66%). 
Building block 28 was synthesized in two steps from 19 and galactoside 26[39] via DMTST 
promoted coupling and debenzoylation under Zemplén conditions (Scheme 4). 
Regioselective alkylation of the 3-position of the D-Gal moiety in 28 with triflates 23 and 25 
was achieved via tin acetal formation of 28 with Bu2SnO. Alkylation with 23 afforded 
lactone 29, which was deprotected and subsequently opened with benzylamine or sodium 
hydroxide to yield antagonists 9 and 10, respectively. Compound 11 was synthesized 
analogously, using 25 instead of 23. Finally, for 8, alkylation with 23 and lactone opening 
with methylamine were combined to a one-pot reaction yielding 31 in 51% and allowing 
recovery of unreacted starting material 28 in 33%. Hydrogenolytic debenzylation finally 
afforded 8. 
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Scheme 4. a) DMTST, CH2Cl2, MS 4 Å, r.t., 16 h, 67%; b) NaOMe, MeOH, r.t., 22 h, 87%; c) 
Bu2SnO, toluene, MeOH, 60°C, 4 h; d) CsF, DME, r.t., 24 h, (29: 52%, 28: 17%); e) H2, Pd(OH)2/C, 
dioxane, H2O, r.t., 21 h; f) BnNH2, THF, 20 h, (9: 76% from 29) or aq. NaOH, dioxane, (10: 69% 
from 29); g) Bu2SnO, toluene, MeOH, 60°C, 4 h; h) CsF, DME, r.t., 24 h, 75%; i) H2, Pd(OH)2/C, 
dioxane, H2O, r.t., 17 h; j) aqueous NaOH, dioxane, 14% from 30; k) Bu2SnO, toluene, MeOH, 50°C, 
4 h; l) CsF, DME, MeNH2, r.t., (31: 51%, 28: 33%); m) H2, Pd(OH)2/C, dioxane, H2O, r.t., 5 h, 37%. 
 
4. Biological Evaluation 
The affinity of selectin antagonists to E- and P-selectin was evaluated in a competitive 
binding assay, utilizing a polyacrylamide-type glycoconjugate as synthetic ligand for 
immobilized E-/P-selectin.[40] Briefly, microtiter plates were coated with either E-
selectin/IgG, or P-selectin/IgG, blocked with BSA, and incubated with a fixed concentration 
of sLea-polyacrylamide (sLea-PAA) either in presence or absence of the antagonists. The 
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binding reaction was revealed by the addition of TMB substrate reagent and quantified 
spectrophotometrically at 450 nm. The IC50 defines the molar concentration of the test 
compound that reduces the maximal specific binding of sLea-PAA polymer to E-selectin/P-
selectin by 50%. To ensure comparability of different antagonists, the reference compounds 2 
(E-selectin)/5 (P-selectin) were tested in parallel on each individual microtiter plate. The 
affinities are reported relative to 4 as rIC50. The relative IC50 (rIC50) is the ratio of the IC50 of 
the test compound to the IC50 of 4. 
 
Conclusion  
Taking advantage of the similar binding mode of the sLex core to P- and E-selectin, the 
concept of pre-organization was applied successfully to the design of P-selectin antagonists. 
The D-GlcNAc mimic (1R,2R,3S)-3-methylcyclohexane-1,2-diol improved the binding 
affinity 20-fold for P- and 30-fold for E-selectin. The isosteric exchange of the negatively 
charged carboxylate of D-Neu5Ac with the methylamide had no effect on P-selectin binding, 
while binding to E-selectin was weakened ten-fold. These results clearly demonstrate that 
negative charge is not essential for P-selectin antagonists mimicking sLex (1) and provide the 
opportunity to design selective and less polar P-selectin antagonists. Finally, D-Neu5Ac was 
successfully replaced with (S)-2,4-dihydroxybutyric acid and its methylamide analogue, 
resulting in the potent and structurally less complex selectin antagonists 8 and 10.  
 
Experimental part 
NMR spectra were recorded on a Bruker Avance DMX-500 (500 MHz) spectrometer. 
Assignment of 1H and 13C NMR spectra was achieved using 2D methods (COSY, HSQC, 
HMQC, HMBC). Chemical shifts are given in ppm and were assigned in relation to the 
solvent signals on the !-scale[41] or to tetramethylsilane (0 ppm) as internal standard. 
Coupling constants J are given in Hertz (Hz). Multiplicities were specified as follows: s 
(singlet), d (doublet), dd (doublet of a doublet), t (triplet), q (quartet), m (multiplet). For 
assignment of resonance signals to the appropriate nuclei the following abbreviations were 
used: Cy (cyclohexyl), Fuc (fucose), Gal (galactose), GlcNAc (N-acetylglucosamine), Lac 
(lactone), MeCy (3-methylcyclohexane-1,2-diol), Sia (sialic acid). Reactions were monitored 
by TLC using glass plates coated with silica gel 60 F254 (Merck) and visualized by using UV 
light and/or by charring with a molybdate solution (a 0.02 M solution of ammonium cerium 
sulfate dihydrate and ammonium molybdate tetrahydrate in aqueous 10% H2SO4. Column 
chromatography was performed manually using silica gel 60 (40-63 "m) from Fluka or using 
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automated systems (RediSep Companion or RediSep Rf) from Teledyne Isco with normal 
phase RediSep columns from the same manufacturer or reversed-phase columns containing 
LiChroprep RP-18 (40-63 !m) from Merck KGaA, Darmstadt, Germany. LC-MS separations 
were carried out using Sunfire C18 columns (19 x 150 mm, 5.0 !m) on a Waters 2525 LC, 
equipped with Waters 2996 photodiode array and Waters micromass ZQ MS for detection. 
Size exclusion chromatography was performed with Bio-Gel® P-2 Gel (45-90 mm) from Bio-
Rad. 
Solvents were purchased from Sigma-Aldrich or Acros. Solvents were dried prior to use 
where indicated. Tetrahydrofurane (THF) was dried by refluxing with sodium/benzophenone 
and distilled immediately before use. Dichloromethane (CH2Cl2) and dimethoxyethane 
(DME) were dried by filtration over Al2O3 (Fluka, type 5016 A basic). Methanol was dried 
by distillation from sodium methoxide, DMF by distillation from calcium hydride. Optical 
rotations were measured using a Perkin-Elmer Polarimeter 341. Electron spray ionization 
mass spectra (ESI-MS) were obtained on a Waters micromass ZQ. HRMS analysis were 
carried out using a Agilent 1100 LC equipped with a photodiode array detector and a 
Micromass QTOF I equipped with a 4 GHz digital-time converter. Microanalysis was 
performed at the Institute of Organic Chemistry at the University of Basel, Switzerland. 
Purity of final compounds was determined on an Agilent 1100 HPLC; detector ELS, Waters 
2420; column: Waters Atlantis dC18, 3 µm, 4.6 x 75 mm; eluents: A: water + 0.1% TFA; B: 
90% acetonitrile + 10% water + 0.1% TFA; linear gradient: 0 - 1 min 5% B; 1 - 20 min 5 to 
70% B; flow: 0.5 mL/min. 
 
2-(Trimethylsilyl)ethyl (2,3,4-tri-O-benzyl-! -L-fucopyranosyl)-(1"3)-2-acetamido- 
4,6-O-benzylidene-2-deoxy-#-D-glucopyranoside (14). 
Bromine (0.180 mL, 3.50 mmol) was slowly added to a stirred solution of fucose donor 12 
(1.52 g, 3.18 mmol) in anhydrous CH2Cl2 (90 mL) at 0°C under argon. After 10 min, excess 
bromine was quenched by addition of cyclohexene. Powdered activated molecular sieves 4 Å 
(9 g), TBAB (1.54 g, 4.78 mmol) and 13[32] (0.65 g, 1.59 mmol) were added and the mixture 
was stirred at 0°C for 2 h before warming to r.t. and stirring at r.t. overnight. The reaction 
mixture was filtered (celite) and washed with water (100 mL) and brine (100 mL). The 
organic layer was dried over Na2SO4, filtered, and concentrated under reduced pressure. 
Column chromatography on silica (PE/Et2O) afforded 14 as white foam (0.72 g, 0.87 mmol, 
55%). 
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1H NMR (500.1 MHz, CDCl3): ! 7.51-7.23 (m, 20H, Ar-H), 5.59 (d, 3J = 6.7Hz, 1H, 
NHCOCH3), 5.49 (s, CHPh), 5.04 (d, 3J = 3.2Hz, Fuc-H1), 4.99 (d, 3J = 8.3Hz, GlcNAc-
H1), 4.96-4.88 (m, 2H, CH2Ph), 4.75 (s, 2H, CH2Ph), 4.65 (B of AB, J = 11.7Hz, CH2Ph), 
4.58 (B’ of A’B’, J = 11.5Hz, CH2Ph), 4.39-4.31 (m, 2H, GlcNAc-H3, GlcNAc-H6a), 4.12-
4.04 (m, 2H, Fuc-H2, Fuc-H5), 3.98-3.86 (m, 2H, Fuc-H3, CH2CH2Si(CH3)3), 3.76 (dd, 3J = 
2J = 10.0Hz, GlcNAc-H6b), 3.63-3.45 (m, 4H, Fuc-H4, GlcNAc-H4, GlcNAc-H5, 
CH2CH2Si(CH3)3), 3.28 (m, 1H, GlcNAc-H2), 1.62 (s, 3H, COCH3), 1.01-0.82 (m, 2H, 
CH2CH2Si(CH3)3), 0.80 (d, 3J = 6.4Hz, Fuc-H6), 0.01 (s, 9H, CH2CH2Si(CH3)3); 13C NMR 
(125.8 MHz, CDCl3): ! 170.6 (COCH3), 138.9, 138.8, 138.7, 129.2, 128.8, 128.5, 128.4, 
128.3, 128.0, 127.9, 127.7, 127.5, 126.4 (24C, C6H5), 101.8 (CHPh), 100.1 (GlcNAc-C1), 
98.5 (Fuc-C1), 81.0 (GlcNAc-C4), 80.0 (Fuc-C3), 77.7, 77.4 (Fuc-C2, Fuc-C4), 75.0 
(CH2Ph), 74.9 (GlcNAc-C3), 74.3, 72.6 (CH2Ph), 69.1 (GlcNAc-C6), 67.5 
(CH2CH2Si(CH3)3), 66.9 (Fuc-C5), 66.3 (GlcNAc-C5), 59.1 (GlcNAc-C2), 23.4 (COCH3), 
18.2 (CH2CH2Si(CH3)3), 16.4 (Fuc-C6), -1.3 (3C, CH2CH2Si(CH3)3); ["]D -73.3° (c 0.96, 
CHCl3); MS (ESI) m/z: calcd for C47H59NNaO10Si [M+Na]+: 848.4; found: 848.4; Elemental 
analysis calcd (%) for C47H59NO10Si: C 68.34, H 7.20, N 1.70; found: C 68.46, H 7.27, N 
1.66. 
 
2-(Trimethylsilyl)ethyl (2,3,4-tri-O-benzyl-" -L-fucopyranosyl)-(1!3)-2-acetamido- 
6-O-benzyl-2-deoxy-"-D-glucopyranoside (15). 
To a solution of benzylidene acetal 14 (600 mg, 0.73 mmol) in anhydrous THF (14 mL) were 
added Me3N#BH3 (212 mg, 2.91 mmol) and anhydrous AlCl3 (580 mg, 4.35 mmol) with 
stirring under argon at r.t. Once all reagents were dissolved, H2O (26 µL) was added and the 
mixture was stirred for 5 h. The reaction was quenched by addition of H2O (12 mL) and 1 N 
aq HCl (12 mL) and extracted with CH2Cl2 (3 · 30 mL). The organic layers were washed with 
brine (30 mL), dried over Na2SO4, and concentrated. Column chromatography on silica gel 
(PE/EtOAc 7/3 to 1/1) afforded 15 as white foam (470 mg, 0.57 mmol, 78%). 
1H NMR (500.1 MHz, CDCl3): ! 7.43-7.23 (m, 20H, Ar-H), 5.51 (d, 3J = 7.1Hz, 1H, 
NHCOCH3), 4.96 (m, 2H, Fuc-H1, CH2Ph), 4.91 (d, 3J = 8.2Hz, GlcNAc-H1), 4.86-4.57 (m, 
7H, CH2Ph), 4.13-4.04 (m, 2H, Fuc-H2, Fuc-H5), 4.02-3.89 (m, 3H, Fuc-H3, GlcNAc-H3, 
CH2CH2Si(CH3)3), 3.83 (m, 1H, GlcNAc-H6a), 3.73-3.66 (m, 2H, Fuc-H4, GlcNAc-H6b), 
3.59-3.47 (m, 2H, GlcNAc-H5, CH2CH2Si(CH3)3), 3.43 (dd, 3J = 8.8Hz, 1H, GlcNAc-H4), 
3.26 (m, GlcNAc-H2), 1.60 (s, 3H, COCH3), 1.15 (d, 3J = 6.3Hz, Fuc-H6), 1.02-0.84 (m, 2H, 
CH2CH2Si(CH3)3), -0.01 (s, 9H, CH2CH2Si(CH3)3); 13C NMR (125.8 MHz, CDCl3): ! 170.9 
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(COCH3), 138.6, 138.4, 128.7, 128.6, 128.5, 128.4, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6 
(24C, C6H5), 99.4, 99.3 (Fuc-C1, GlcNAc-C1), 84.1 (GlcNAc-C3), 79.3 (Fuc-C3), 77.4 (Fuc-
C4), 76.0 (Fuc-C2), 75.1 (CH2Ph), 75.0 (GlcNAc-C5), 74.1, 73.6, 73.0 (CH2Ph), 70.7 
(GlcNAc-C4), 69.8 (GlcNAc-C6), 68.1 (Fuc-C5), 67.0 (CH2CH2Si(CH3)3), 56.7 (GlcNAc-
C2), 23.4 (COCH3), 18.2 (CH2CH2Si(CH3)3), 16.8 (Fuc-C6), -1.3 (3C, CH2CH2Si(CH3)3); 
[!]D -36.7° (c 0.55, CHCl3); MS (ESI) m/z: calcd for C47H61NNaO10Si [M+Na]+: 850.4; 
found: 850.5. 
 
2-(Trimethylsilyl)ethyl (benzyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D- 
glycero-!-D-galacto-2-nonulopyranosynate)-(2!3)-2,4-di-O-acetyl-6-O-benzoyl-"-D-
galactopyranosyl-(1!4)-[2,3,4-tri-O-benzyl-! -L-fucopyranosyl-(1!3)]-2-acetamido-6-
O-benzyl-2-deoxy-"-D-glucopyranoside (17). 
16 (300 mg, 0.31 mmol) and 15 (380 mg, 0.46 mmol) were dissolved in anhydrous CH2Cl2 (8 
mL). Powdered activated molecular sieves 4 Å (0.8 g) were added and the mixture was 
stirred at r.t. under argon. After 3.5 h, a solution of DMTST (200 mg, 0.77 mmol) in 
anhydrous CH2Cl2 (2.0 mL) that had been stirred with molecular sieves 4 Å (0.2 g) for 3.5 h, 
was added. After stirring for 5 d, the solution was diluted with CH2Cl2 (10 mL), filtered and 
successively washed with satd aq NaHCO3 (20 mL) and brine (20 mL). The aqueous layers 
were extracted with CH2Cl2 (3 · 20 mL) and the combined organic layers were dried over 
Na2SO4 and concentrated under reduced pressure. Column chromatography on silica 
(PE/EtOAc/MeOH 8/5/0.5 to 8/5/0.9) afforded 17 as white solid (110 mg, 0.06 mmol, 20%). 
1H NMR (500.1 MHz, CDCl3): # 8.09-721 (m, 30H, Ar-H), 6.22 (d, 3J = 8.1Hz, 1H, 
GlcNAc-NH), 5.62 (ddd, 3J = 2.5, 5.9, 8.7Hz, 1H, Sia-H8), 5.43-5.32 (m, 2H, Sia-H7, 
PhCH2), 5.22 (d, 3J = 3.5Hz, 1H, Fuc-H1), 5.20 (d, 3J = 3.5Hz, 1H, Gal-H4), 5.07-4.95 (m, 
3H, Gal-H2, PhCH2), 4.92 (m, 1H, Sia-H4), 4.88-4.72 (m, 7H, Gal-H1, Gal-H3, GlcNAc-H1, 
PhCH2), 4.68 (B of AB, J = 11.8Hz, 1H, PhCH2), 4.61 (A of AB, J = 12.0Hz, 1H, PhCH2), 
4.61 (B of AB, J = 12.0Hz, 1H, PhCH2), 4.41-4.29 (m, 2H, Gal-H6a, Sia-H9a), 4.23 (dd, 3J 
= 7.0Hz, 2J = 11.0Hz, 1H, Gal-H6b), 4.20-3.96 (m, 8H, Fuc-H2, Fuc-H5, Gal-H5, GlcNAc-
H3, GlcNAc-H4, GlcNAc-H6a, Sia-H5, Sia-H9b), 3.93-3.78 (m, 5H, Fuc-H3, GlcNAc-H2, 
GlcNAc-H5, GlcNAc-H6b, CH2CH2Si(CH3)3), 3.56-3.47 (m, 3H, Fuc-H4, Sia-H6, 
CH2CH2Si(CH3)3), 2.64 (dd, 3J = 4.5, 2J = 12.6Hz, 1H, Sia-H3eq), 2.27, 2.15, 2.11, 2.03, 
2.00, 1.94, 1.88, (7s, 24H, 8 COCH3), 1.75 (dd, 3J =2J = 12.4Hz, 1H, Sia-H3ax) 1.13 (d, 3J = 
6.5Hz, 3H, Fuc-H6), 1.06-0.77 (m, 2H, CH2CH2Si(CH3)3), 0.00 (s, 9H, CH2CH2Si(CH3)3); 
13C NMR (125.8 MHz, CDCl3): # 170.7, 170.6, 170.5, 170.4, 170.1, 169.8 (8C, COCH3), 
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167.5 (Sia-C1), 165.8 (ArCO), 139.2, 139.1, 138.8, 138.6, 134.8, 133.4, 129.8, 129.0, 128.8, 
128.6, 128.5, 128.4, 128.3, 127.8, 127.7, 127.6, 127.5, 127.3 (36C, Ar-C), 99.2, 99.1 (Gal-
C1, GlcNAc-C1), 97.0 (Sia-C2), 96.5 (Fuc-C1), 79.5 (Fuc-C3), 77.7 (Fuc-C4), 76.6 (Fuc-
C2), 74.6 (PhCH2), 74.2, 73.5, 73.4 (3C, GlcNAc-C3, GlcNAc-C4, GlcNAc-C5), 73.0, 72.9 
(3C, CH2Ph), 72.2 (Sia-C6), 71.2, 70.7, 70.4, (3C, Gal-C2, Gal-C3, Gal-C5), 69.5 (GlcNAc-
C6), 69.4 (Sia-C4), 68.5 (PhCH2), 67.8, 67.7, 67.2 66.9 (4C, Fuc-C5, Gal-C4, Sia-C7, Sia 
C8), 66.6 (CH2CH2Si(CH3)3), 62.6 (Sia-C9), 61.7 (Gal-C6), 53.4 (GlcNAc-C2), 49.0 (Sia-
C5), 37.6 (Sia-C3), 23.3, 23.2, 21.5, 21.0, 20.9, 20.8, 20.7 (8C, COCH3), 18.0 
(CH2CH2Si(CH3)3), 16.8 (Fuc-C6), -1.3 (3C, CH2CH2Si(CH3)3); [!]D -24.3° (c 0.58, CHCl3); 
MS (ESI) m/z: calcd for C90H110N2NaO30Si [M+Na]+: 1749.7; found: 1749.8. 
 
2-(Trimethylsilyl)ethyl (sodium 5-acetamido-3,5-dideoxy-D-glycero-!-D-galacto-2- 
nonulopyranosynate)-(2!3)-"-D-galactopyranosyl-(1!4)-[! -L-fucopyranosyl-(1!3)]-2-
acetamido-2-deoxy-"-D-glucopyranoside (4). 
Compound 17 (90 mg, 0.052 mmol) was dissolved in dioxane/water (4/1, 10 mL) under 
argon. Pd(OH)2/C (20 mg, 10% Pd(OH)2) was added and the resulting mixture was 
hydrogenated (4 bar H2) at r.t. After 24 h, the mixture was filtered and the solvent was 
removed under reduced pressure. The residue was redissolved in 1 N aq NaOH (10 mL) and 
MeOH (2 mL) and stirred at r.t. After 20 h the mixture was neutralized with 1 N HCl, 
volatiles were removed under reduced pressure, and crude product was purified via SEC and 
RP chromatography (H2O/MeOH). Lyophilization from water afforded 4 as white fluffy solid 
(21 mg, 0.022 mmol, 43%). 
1H NMR (500.1 MHz, D2O, CD3OD): # #5.09 (d, 3J = 4.0Hz, 1H, FucH-1), 4.86-4.74 (m, 
Fuc-H5), 4.56 (d, 3J = 8.1Hz, 1H, GlcNAc-H1), 4.52 (d, 3J = 7.8Hz, 1H, Gal-H1), 4.08 (dd, 
3J = 3.1, 9.8Hz, 1H, Gal-H3), 4.06-3.55 (m, 22H, (CH2CH2Si(CH3)3), Fuc-H2, Fuc-H3, Fuc-
H4, Gal-H4, Gal-H5, Gal-H6a, Gal-H6b, GlcNAc-H2, GlcNAc-H3, GlcNAc-H4, GlcNAc-
H5, GlcNAc-H6a, GlcNAc-H6b, Sia-H4, Sia-H5, Sia-H6, Sia-H7, Sia-H8, Sia-H9a, Sia-
H9b), 3.52 (dd, 3J = 7.8, 9.8Hz, Gal-H2), 2.76 (dd, 3J = 4.6Hz, 2J = 12.1Hz, 1H, Sia-H3eq), 
2.03, 2.01 (2s, 6H, COCH3), 1.79 (t, 2J =3J = 12.1Hz, 1H, Sia-H3ax), 1.17 (d, 3J = 6.6Hz, 3H, 
Fuc-H6), 1.05-0.80 (m, 2H, (CH2CH2Si(CH3)3), 0.00 (s, 9H, (CH2CH2Si(CH3)3); 13C NMR 
(125.8 MHz, D2O, CD3OD): # 176.0, 175.1, 174.8 (3C, NHCOCH3, Sia-C1) 102.6 (Gal-C1), 
101.2, 100.6 (2C, GlcNAc-C1, Sia-C2), 100.6 (Fuc-C1), 99.6, 76.6, 76.3, 76.0, 75.9, 74.4, 
73.9, 72.9, 72.8, 70.2, 69.3, 69.1, 68.7, 68.3, 67.7, 63.6, 62.4, 60.6, 56.7, 52.7, 40.8 (Sia-C3), 
23.3, 23.0 (2C, NHCOCH3) 18.1 (CH2CH2Si(CH3)3), 16.2 (Fuc-C6), -1.5 (3C, 
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CH2CH2Si(CH3)3); [!]D -43.9° (c 0.70, MeOH); HR-MS (ESI) m/z: calcd for 
C36H64N2NaO23Si+ [M+H]+: 943.3561; found: 943.3553; HPLC purity: > 99.5 %. 
 
(Benzyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-!-D-galacto-2- 
nonulopyranosynate)-(2!3)-2,4-di-O-acetyl-6-O-benzoyl-"-D-galactopyranosyl-(1!1)-
[2,3,4-tri-O-benzyl-! -L-fucopyranosyl-(1!2)]-(R,R)-cyclohexane-1,2-diol (20). 
Compound 16 (720 mg, 0.75 mmol) and 18 (460 mg, 0.86 mmol) were dissolved in 
anhydrous CH2Cl2 (12 mL). Powdered activated molecular sieves 4 Å (1.2 g) were added and 
the mixture was stirred at r.t. under argon. After 3.5 h a solution of DMTST (510 mg, 1.97 
mmol) in anhydrous CH2Cl2 (8 mL) that had been stirred with molecular sieves 4 Å (0.8 g) 
for 3.5 h was added. After stirring for 60 h, the solution was diluted with CH2Cl2 (40 mL), 
filtered and successively washed with satd aq NaHCO3 (60 mL) and brine (60 mL). The 
aqueous layers were extracted with CH2Cl2 (2 · 60 mL) and the combined organic layers were 
dried over Na2SO4 and concentrated under reduced pressure. Column chromatography on 
silica (PE/EtOAc/MeOH 8/5/0.3 to 8/5/0.7) afforded 20 as white foam (912 mg, 0.64 mmol, 
85%). 
1H NMR (500.1 MHz, CDCl3): # 8.05-7.11 (m, 25H, Ar-H), 5.47 (ddd, 3J = 2.6, 6.1, 9.0Hz, 
1H, Sia-H8), 5.25-5.18 (m, 2H, Sia-H7, PhCH2), 5.02 (d, 3J = 3.2Hz, 1H, Gal-H4), 4.90 (A’ 
of AB, J = 11.9Hz, 1H, PhCH2), 4.87-4.78 (m, 5H, Fuc-H1, Gal-H2, SiaNH, PhCH2), 4.75 
(m, 1H, Sia-H4), 4.71-4.58 (m, 5H, Gal-C1, PhCH2), 4.50 (dd, 3J = 3.4, 10.2Hz, 1H, Gal-
H3), 4.46 (m, 1H, Fuc-H5), 4.26 (dd, 3J = 2.6, 2J = 12.4Hz, 1H, Sia-H9a), 4.22 (dd, 3J = 
6.3Hz, 2J = 10.8Hz, 1H, Gal-H6a), 4.08-3.83 (m, 6H, Fuc-H2, Fuc-H3, Gal-H6b, Sia-H5, 
Sia-H9b), 3.60 (m, 1H, Cy), 3.57 (m, 1H, Fuc-H4), 3.52 (m, 1H, Cy), 3.39 (dd, 1H, 3J = 2.7, 
10.7Hz, Sia-H6), 2.52 (dd, 3J = 4.6, 2J = 12.6Hz, 1H, Sia-H3eq), 2.10, 2.04, 1.99, 1.94, 1.90, 
1.82, 1.75, (7s, 21H, COCH3), 2.13-1.11 (8H, Cy), 1.62 (m, 1H, Sia-H3ax) 1.07 (d, 3J = 
6.5Hz, 3H, Fuc-H6); 13C NMR (125.8 MHz, CDCl3): # 170.7, 170.6, 170.4, 170.0, 169.9, 
169.6 (7C, COCH3), 167.5 (Sia-C1), 165.8 (ArCO), 139.5, 139.0, 134.9, 133.3, 130.0, 129.9, 
128.9, 128.8, 128.7, 128.5, 128.4, 128.3, 128.1, 127.6, 127.4, (30C, Ar-CH), 99.2 (Gal-C1), 
96.8 (Sia-C2), 94.8 (Fuc-C1), 80.1 (Fuc-C3), 78.9 (Cy), 78.0 (Fuc-C4), 76.8 (Fuc-C2), 75.6 
(Cy), 74.5, 73.2, (3C, PhCH2), 72.1, 71.8 (Gal-C3, Sia-C6), 70.1 (2C, Gal-C2, Gal-C5), 69.4 
(Sia-C4), 68.4 (PhCH2), 67.8, 67.7, 67.2 (Gal-C4, Sia-C7, Sia-C8), 66.2 (Fuc-C5), 62.8 (Sia-
C9), 61.6 (Gal-C6), 49.0 (Sia-C5), 37.5 (Sia-C3), 29.5, 29.0 23.2, 23.1 (4C, Cy), 23.3, 21.5, 
21.0, 20.9, 20.8 (7C, COCH3), 16.8 (Fuc-C6); [!]D -24.4° (c 0.89, CHCl3); MS (ESI) m/z: 
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calcd for C76H89NNaO26 [M+Na]+: 1454.6; found: 1454.7; elemental analysis calcd (%) for 
C76H89NO26 + H2O (1450.53): C 62.93, H 6.32, N 0.97; found: C 63.09, H 6.20, N 0.81.  
 
(Benzyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-!-D-galacto-2- 
nonulopyranosynate)-(2!3)-2,4-di-O-acetyl-6-O-benzoyl-"-D-galactopyranosyl-(1!1)-
[2,3,4-tri-O-benzyl-! -L-fucopyranosyl-(1!2)]-(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol 
(21). 
Compound 16 (300 mg, 0.31 mmol) and 19 (256 mg, 0.47 mmol) were dissolved in 
anhydrous CH2Cl2 (6.0 mL). Powdered activated molecular sieves 4 Å (0.6 g) were added 
and the mixture was stirred at r.t. under argon. After 3.5 h a solution of DMTST (246 mg, 
0.95 mmol) in anhydrous CH2Cl2 (1.9 mL) that had been stirred with molecular sieves 4 Å 
(0.19 g) for 3.5 h, was added. After stirring for 3 d, the solution was diluted with CH2Cl2 (40 
mL), filtered, and successively washed with satd aq NaHCO3 (50 mL) and brine (50 mL). 
The aqueous layers were extracted with CH2Cl2 (2 · 50 mL) and the combined organic layers 
were dried over Na2SO4 and concentrated under reduced pressure. Column chromatography 
on silica (PE/EtOAc/MeOH 8/5/0.5 to 8/5/0.7) afforded 21 as white foam (248 mg, 0.17 
mmol, 55%). 
1H NMR (500.1 MHz, CDCl3): # 8.04-7.14 (m, 25H, Ar-H), 5.48 (ddd, 3J = 2.6, 6.2, 9.1Hz, 
1H, Sia-H8), 5.21 (A of AB, 2J = 12.0Hz, 1H, PhCH2), 5.20 (dd, 3J = 2.8, 9.4Hz, 1H, Sia-
H7), 5.01 (d, 3J = 3.7Hz, 2H, Fuc-H1, Gal-H4), 4.90 (A’ of A’B’, J = 12.0Hz, 1H, PhCH2), 
4.88-4.64 (m, 10H, Fuc-H5, Gal-H2, SiaNH, Sia-H4, 3 PhCH2), 4.56 (d, 3J = 8.0Hz, 1H, Gal-
H1), 4.48 (dd, 3J = 3.3, 10.2Hz, 1H, Gal-H3), 4.25 (dd, 3J = 2.6Hz, 2J = 12.4Hz, 1H, Sia-
H9a), 4.17 (dd, 3J = 6.4Hz, 2J = 10.8Hz, 1H, Gal-H6a), 4.05 (dd, 3J = 3.7, 10.3Hz, 2H, Fuc-
H2), 4.02-3.93 (m, 3H, Fuc-H3, Gal-H6b, Sia-H5), 3.90-3.83 (m, 2H, Gal-H5, Sia-H9b), 3.59 
(m, 1H, Fuc-H4), 3.50 (m, 1H, MeCy-H1), 3.37 (dd, 1H, 3J = 2.7, 10.8Hz, Sia-H6), 3.18 (t, 
3J = 9.2Hz, MeCy-H2), 2.50 (dd, 3J = 4.6Hz, 2J =12.7Hz, 1H, Sia-H3eq), 2.09, 2.05 (2s, 6H, 
2 COCH3), 1.99 (m,1H, MeCy), 1.99, 1.94, 1.90, 1.74, 1.72 (5s, 15H, 5 COCH3), 1.65-1.47 
(m, 4H, Sia-H3ax, MeCy) 1.21-1.11 (m, 5H, Fuc-H6, MeCy), 1.03 (d, 3J = 6.4Hz, 3H, MeCy-
CH3), 0.98 (m, 1H, MeCy); 13C NMR (125.8 MHz, CDCl3): # 170.8, 170.7, 170.6, 170.4, 
169.9, 169.5 (7C, COCH3), 167.5 (Sia-C1), 165.8 (ArCO), 139.3, 139.1, 138.7, 134.9, 133.3, 
128.9, 128.7, 128.6, 128.5, 128.4, 128.3, 127.6, 127.4, 127.3 (30C, Ar-C), 99.4 (Gal-C1), 
98.3 (Fuc-C1), 96.9 (Sia-C2), 82.2 (MeCy-C2), 80.6, 80.5 (Fuc-C3, MeCy-C1), 77.8 (Fuc-
C4), 76.7 (Fuc-C2), 74.6, 74.3, 72.7 (3C, PhCH2), 72.0, 71.9 (Gal-C3, Sia-C6), 70.0, 69.8 
(Gal-C2, Gal-C5), 69.4 (Sia-C4), 68.4 (PhCH2), 67.8 (2C, Gal-C4, Sia-C8), 67.1 (Sia C7), 
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66.3 (Fuc-C5), 62.8 (Sia-C9), 61.5 (Gal-C6), 49.0 (Sia-C5), 39.2 (MeCy-C3) 37.5 (Sia-C3), 
33.6 (MeCy-C4), 30.9 (MeCy-C6), 23.3 (CH3CO), 23.1 (MeCy-C5), 21.5, 21.0, 20.9, 20.8 
(6C, COCH3), 18.9 (MeCy-CH3), 17.1 (Fuc-C6); [!]D -18.9° (c 1.01, CHCl3); MS (ESI) m/z: 
calcd for C77H91NNaO26 [M+Na]+: 1468.6; found: 1468.6; elemental analysis calcd (%) for 
C77H91NO26 + 0.5 H2O (1455.55): C 63.54, H 6.37, N 0.96; found: C 63.58, H 6.35, N 0.80. 
 
(Sodium 5-acetamido-3,5-dideoxy-D-glycero-!-D-galacto-2-nonulopyranosynate)- 
(2!3)-"-D-galactopyranosyl-(1!1)-[! -L-fucopyranosyl-(1!2)]-(R,R)-cyclohexane-1,2-
diol (5). 
Compound 20 (912 mg, 0.64 mmol) was dissolved in dioxane/water (4/1, 50 mL) under 
argon. Pd(OH)2/C (100 mg, 10% Pd(OH)2) was added and the resulting mixture was 
hydrogenated (4 bar H2) at r.t. After 24 h, the mixture was filtered and the solvent was 
removed under reduced pressure. The residue was redissolved in 1 N aq NaOH (9 mL) and 9 
mL MeOH and stirred at r.t. After 3 h the mixture was neutralized with aqueous 1 N HCl, 
volatiles were removed under reduced pressure, and the crude product was purified via SEC 
and RP chromatography (H2O/MeOH). Lyophilization from water afforded 5 as a white 
fluffy solid (371 mg, 0.50 mmol, 79%). Analytical data were in accordance with literature[20]; 
HR-MS (ESI) m/z: calcd for C29H48NNa2O19 [M+Na]+: 760.2610; found: 760.2608; HPLC-
purity: > 99.5 %. 
 
(Sodium 5-acetamido-3,5-dideoxy-D-glycero-!-D-galacto-2-nonulopyranosynate)- 
(2!3)-"-D-galactopyranosyl-(1!1)-[! -L-fucopyranosyl-(1!2)]-(1R,2R,3S)-3-methyl-
cyclohexane-1,2-diol (6). 
Compound 21 (310 mg, 0.21 mmol) was dissolved in dioxane/water (4/1, 10 mL) under 
argon. Pd(OH)2/C (40 mg, 10% Pd(OH)2) was added and the resulting mixture was 
hydrogenated (4 bar H2) at r.t. After 24 h, the mixture was filtered and the solvent removed 
under reduced pressure yielding 220 mg of a white solid, which was directly used for 
saponification. The crude product (75 mg) was stirred in aqueous NaOH (1 N, 1.5 mL) for 24 
h at r.t., lyophilized and purified via SEC and RP chromatography (H2O/MeOH). 
Lyophilization from water afforded 6 as white fluffy solid (42 mg, 0.056 mmol, 81%). 
1H NMR (500.1 MHz, D2O): # "5.07 (d, 3J = 3.6Hz, 1H, Fuc-H1), 5.05-4.71 (m, Fuc-H5), 
4.53 (d, 3J = 7.8Hz, 1H, Gal-H1), 4.05 (dd, 3J = 2.4, 9.6Hz, 1H, Gal-H3), 3.92 (m, Gal-H4), 
3.90-3.50 (m, 15H, Fuc-H2, Fuc-H3, Fuc-H4, Gal-H2, Gal-H5, Gal-H6a, Gal-H6b, MeCy-
H1, Sia-H4, Sia-H5, Sia-H6, Sia-H7, Sia-H8, Sia-H9a, Sia-H9b), 3.20 (t, 3J = 9.6Hz, 1H, 
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MeCy-H2), 2.73 (dd, 3J = 4.4Hz, 2J = 12.1Hz, 1H, Sia-H3eq), 2.13 (m, 1H, MeCy-H6a), 2.00 
(s, 3H, COCH3), 1.78 (t, 3J =2J = 12.1Hz, 1H, Sia-H3ax) 1.69-1.52 (m, 3H, MeCy-H3, 
MeCy-H4a, MeCy-H5a), 1.33-1.17 (m, 2H, MeCy-H5b, MeCy-H6b), 1.15 (d, 3J = 6.4Hz, 
1H, Fuc-H6), 1.11-0.99 (m, 4H, MeCy-CH3, MeCy-H4b); 13C NMR (125.8 MHz, D2O, 
CD3OD): ! 176.0 (COCH3), 175.0 (Sia-C1), 100.8 (Sia-C2), 100.5 (Gal-C1), 99.8 (Fuc-C1), 
85.0 (MeCy-C2), 79.4 (MeCy-C1), 76.9 (Gal-C3), 75.5 (Gal-C5), 73.8 (Sia-C6), 73.0 (Fuc-
C4), 72.7 (Sia-C8), 70.2 (Fuc-C3), 69.9 (Gal-C2), 69.4, 69.2, 69.1 (3C, Fuc-C2, Sia-C4, Sia-
C7), 68.5 (Gal-C4), 67.5 (Fuc-C5), 63.6 (Sia-C9), 62.6 (Gal-C6), 52.7 (Sia-C5), 40.6 (Sia-
C3), 39.8 (MeCy-C3), 34.2 (MeCy-C4), 31.1 (MeCy-C6), 23.6 (MeCy-C5), 23.0 (COCH3), 
19.2 (MeCy-CH3), 16.4 (Fuc-C6); ["]D -47.4° (c 0.89, MeOH); HR-MS (ESI) m/z: calcd for 
C30H50NNa2O19 [M+Na]+: 774.2767; found: 774.2768; HPLC-purity: > 99.5 %. 
 
(5-Acetamido-3,5-dideoxy-N-methyl-D-glycero-"-D-galacto-2-nonulopyranosynylamide)-
(2!3)-#-D-galactopyranosyl-(1!1)-[" -L-fucopyranosyl-(1!2)]-(1R,2R,3S)-3-methyl-
cyclohexane-1,2-diol (7).  
A solution of 6 (40 mg, 0.053 mmol), BnBr (0.019 mL, 0.160 mmol) and KF (8 mg, 0.138 
mmol) in anhydrous DMF (3.0 mL) was stirred at r.t. under argon for 2 d. Water (3 mL) was 
added and the mixture was lyophilized to yield the crude benzyl ester as white solid (80 mg), 
which was directly used in the next step. The crude ester (20 mg) was dissolved in MeNH2 in 
THF (2 M, 4 mL) and MeNH2 in EtOH (8 M, 3 mL) and stirred at r.t. under argon for 12 h. 
Volatiles were removed under reduced pressure and purification via RP chromatography 
(H2O/MeOH) and lyophilization from water afforded 7 as white fluffy solid (10 mg, 0.013 
mmol, quant.). 
1H NMR (500.1 MHz, D2O): !  5.04 (d, 3J = 3.7Hz, 1H, Fuc-H1), 4.97-4.70 (m, Fuc-H5), 
4.50 (d, 3J = 7.9Hz, 1H, Gal-H1), 3.97 (dd, 3J = 2.8, 9.7Hz, 1H, Gal-H3), 3.87-3.53 (m, 15H, 
Fuc-H2, Fuc-H3, Fuc-H4, Gal-H4, Gal-H5, Gal-H6a, Gal-H6b, MeCy-H1, Sia-H4, Sia-H5, 
Sia-H6, Sia-H7, Sia-H8, Sia-H9a, Sia-H9b), 3.49 (m, 1H, Gal-H2), 3.17 (t, 3J = 9.6Hz, 1H, 
MeCy-H2), 2.74 (s, 3H, CONHCH3), 2.70 (dd, 3J = 4.4Hz, 2J = 12.3Hz, 1H, Sia-H3eq), 2.08 
(m, 1H, MeCy-H6a), 1.98 (s, 3H, COCH3), 1.87 (t, 3J = 2J = 12.3Hz, 1H, Sia-H3ax) 1.66-1.47 
(m, 3H, MeCy-H3, MeCy-H4a, MeCy-H5a), 1.27-1.14 (m, 2H, MeCy-H5b, MeCy-H6b), 
1.11 (d, 3J = 6.5Hz, 1H, Fuc-H6), 1.07-0.96 (m, 4H, MeCy-CH3, MeCy-H4b); 13C NMR 
(125.8 MHz, D2O, CD3OD): ! 176.1 (COCH3), 170.8 (Sia-C1), 100.8 (Sia-C2), 100.4 (Gal-
C1), 99.8 (Fuc-C1), 84.9 (MeCy-C2), 79.6 (MeCy-C1), 76.7 (Gal-C3), 75.3 (Gal-C5), 74.5 
(Sia-C6), 73.0 (Fuc-C4), 72.0 (Sia-C8), 70.2 (Fuc-C3), 69.8 (Gal-C2), 69.2 (2C, Fuc-C2, 
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Gal-C4), 68.5 (Sia-C7), 68.2 (Sia-C4), 67.4 (Fuc-C5), 64.0 (Sia-C9), 62.3 (Gal-C6), 52.5 
(Sia-C5), 39.8 (MeCy-C3), 38.4 (Sia-C3), 34.1 (MeCy-C4), 31.2 (MeCy-C6), 26.7 
(CONHCH3), 23.6 (MeCy-C5), 23.0 (COCH3), 19.1 (MeCy-CH3), 16.4 (Fuc-C6); [!]D -
52.0° (c 0.66, MeOH); HR-MS (ESI) m/z: calcd for C31H54N2NaO18 [M+Na]+: 765.3264 ; 
found: 765.3260; HPLC-purity: > 99.5 %. 
 
(R)-2-Oxotetrahydrofuran-3-yl trifluoromethanesulfonate (23). 
 (R)-3-Hydroxydihydrofuran-2(3H)-one (150 mg, 1.47 mmol) and 2,6-di-tert-butyl-4-
methylpyridine (512 mg, 2.49 mmol) were dissolved in anhydrous CH2Cl2 (7.0 mL) under 
argon. The solution was cooled to -18°C and triflic anhydride (0.37 mL, 0.62 mmol) was 
added slowly. The solution was stirred at -18°C for 3 h, warmed to r.t., diluted with CH2Cl2 
(13 mL), and washed with aqueous KH2PO4 (2 M, 20 mL). The aqueous layer was extracted 
with CH2Cl2 (2 · 20 mL) and the combined organic layers were dried over Na2SO4, filtered, 
and concentrated under reduced pressure. Column chromatography on silica (PE/EtOAc) 
afforded the triflate as slightly orange solid (255 mg, 1.09 mmol, 74%), which was directly 
used in the next step. 
1H NMR (500.1 MHz, CDCl3):  " 5.42 (t, 3J = 8.8Hz, H-3), 4.56 (ddd, 2J = 3J = 9.5Hz, 3J = 
2.8 Hz, H-5a), 4.36 (ddd, 2J = 3J = 9.5Hz, 3J = 6.4Hz, H-5b), 2.85 (m, 1H, H-4a), 2.62 (m, 
1H, H-4b); 13C NMR (125.8 MHz, CDCl3): " 168.6 (CO), 118.5 (q, J = 320Hz, CF3), 77.7 
(C3), 64.8 (C5), 29.4 (C4); MS (ESI) m/z: calcd for C5H5F3NaO5S+ [M+Na]+: 257.0; found: 
256.8. 
 
(R)-Methyl 2-(((trifluoromethyl)sulfonyl)oxy)butanoate (25). 
In analogy to 23, (R)-methyl 2-hydroxybutanoate (200 mg, 1.69 mmol) was reacted with 
triflic anhydride (0.430 mL, 2.56 mmol) and DTBMP (560 mg, 2.72 mmol) in anhydrous 
CH2Cl2 (8.0 mL) under argon. Workup and column chromatography on silica (PE/EtOAc) 
afforded the triflate as clear oil (280 mg, 1.12 mmol, 66%), which was directly used in the 
next step. Analytical data were in accordance with literature.[38] 
 
2,3,4-Tri-O-benzoyl-6-O-benzyl-!-D-galactopyranosyl-(1"1)-[2,3,4-tri-O-benzyl-! -L-
fucopyranosyl-(1"2)]-(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol (27) 
Powdered activated molecular sieves 4 Å (3.0 g) were added to a solution of 19 (1.50 g, 2.74 
mmol) and galactoside 26[39] (2.60 g, 4.15 mmol) in anhydrous CH2Cl2 (20 ml) and the 
mixture was stirred at r.t. under argon for 4 h. DMTST (2.12 g, 8.21 mmol) was dissolved in 
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anhydrous CH2Cl2 (6.0 ml), powdered activated molecular sieves 4 Å (0.6 g) were added and 
the suspension was stirred at r.t. under argon for 4 h as well. Subsequently, the two 
suspensions were combined and stirred at r.t. under argon for 16 h. The mixture was diluted 
with CH2Cl2 (30 mL), filtered (celite), and washed with satd. aqueous NaHCO3 (100 mL) and 
brine (100 mL). The aqueous layers were extracted with CH2Cl2 (3 · 50 mL) and the 
combined organic layers were dried over Na2SO4 and concentrated. Column chromatography 
on silica (PE/EtOAc 5/1) afforded 27 as white foam (2.03 g, 1.83 mmol, 67%). 
1H NMR (500.1 MHz, CDCl3): !   7.98, 7.94, 7.80 (3m, 6H, Ar-H), 7.56-7.07 (m, 29H, Ar-
H), 5.97 (d, 3J = 3.4Hz, Gal-H-4), 5.71 (dd, 3J = 8.2, 10.3Hz, Gal-H2), 5.52 (dd, 3J = 3.5, 
10.3Hz, Gal-H3), 5.12 (d, 3J = 3.3Hz, 1H, Fuc-H1), 4.94 (A of AB, 2J = 11.5Hz, 1H, 
CH2Ph), 4.90 (q, 3J = 6.5, 6.4Hz, 1H, Fuc-H5), 4.84-4.79 (m, 2H, CH2Ph, Gal-H1), 4.74 (B’ 
of A’B’, 2J = 11.5Hz, 1H, CH2Ph), 4.70 (A of AB, 2J = 11.5Hz, 1H, CH2Ph), 4.94 (A of AB, 
2J = 11.5Hz, 1H, CH2Ph), 4.58-4.53 (m, 2H, CH2Ph), 4.48 (A of AB, 2J = 11.9Hz, 1H, 
CH2Ph), 4.35 (B of AB, 2J = 11.9Hz, 1H, CH2Ph), 4.12-4.03 (m, 3H, Fuc-H2, Fuc-H3, Gal-
H5), 3.75-3.64 (m, 3H, Fuc-H4, Gal-H6a, MeCy-H1), 3.60 (m, 1H, Gal-H6b), 3.29 (t, 3J = 
9.2Hz, 1H, MeCy), 2.03 (m, 1H, MeCy), 1.70-1.49 (m, 3H, MeCy), 1.43 (d, 3J = 6.5Hz, 3H, 
Fuc-H6), 1.29-1.10 (m, 2H, MeCy), 1.07 (d, 3J = 6.6Hz, 3H, MeCy-CH3), 0.92 (m, 1H, 
MeCy); 13C NMR (125.8 MHz, CDCl3): ! 165.8, 165.7, 165.1 (3C, COC6H5), 139.3, 139.1, 
138.6, 137.6133.6, 133.3, 129.9, 129.8, 129.7, 129.1, 128.7, 128.5, 128.4, 128.3, 127.9, 
127.8, 127.7, 127.5, 127.3 (42 C, Ar-C), 100.0 (Gal-C1), 97.9 (Fuc-C1), 81.3 (MeCy-C2), 
81.0, (MeCy-C1), 80.4 (Fuc-C3), 79.6 (Fuc-C4), 76.4 (Fuc-C2), 75.2, 74.4, 73.8 (3C, 
CH2Ph), 72.8 (2C, CH2Ph, Gal-C5), 72.4 (Gal-C3), 69.8 (Gal-C2), 68.8 (Gal-C4), 67.8 (Gal-
C6), 66.6 (Fuc-C5), 39.0 (MeCy-C3), 33.0 (MeCy-C4), 30.9 (MeCy-C6), 22.8 (MeCy-C5), 
18.9 (MeCy-CH3), 17.1 (Fuc-C6); ["]D +1.22° (c 1.28, CHCl3); MS (ESI) m/z: calcd for 
C68H70NaO14+ [M+Na]+: 1133.5; found: 1133.5; elemental analysis calcd (%) for C68H70O14 + 
0.5 H2O: C 72.90, H 6.39; found: C 73.03, H 6.59. 
 
6-O-Benzyl-!-D-galactopyranosyl-(1"1)-[2,3,4-tri-O-benzyl-" -L-fucopyranosyl-(1"2)]-
(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol (28). 
A freshly prepared solution of NaOMe in MeOH (3 N, 0.18 mL) was slowly added to a 
solution of 27 (500 mg, 0.45 mmol) in anhydrous MeOH (7.0 mL) under argon at r.t. After 
22 h, the mixture was neutralized with aqueous 1 N HCl and concentrated under reduced 
pressure. Column chromatography on silica (CH2Cl2/MeOH 35/1) afforded 28 as white foam 
(311 mg, 0.39 mmol, 87%). 
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1H NMR (500.1 MHz, CDCl3): ! 7.31-7.14 (m, 20H, Ar-H), 5.03 (d, 3J = 3.6Hz, 1H, Fuc-
H1), 4.86 (A of AB, 2J = 11.5Hz, 1H, CH2Ph), 4.74 (A of AB, 2J = 11.5Hz, 1H, CH2Ph), 
4.71-4.64 (m, 2H, CH2Ph), 4.60 (B of AB, 2J = 11.5Hz, 1H, CH2Ph), 4.54-4.43 (m, 4H, Fuc-
H5, CH2Ph), 4.25 (1H, 3J = 6.8Hz, Gal-H1), 4.00 (dd, 3J = 3.6, 10.3Hz, 1H, Fuc-H2), 3.96-
3.90 (m, 2H, Fuc-H3, Gal-H4), 3.75-3.57 (m, 4H, Fuc-H4, Gal-H6a,b, MeCy-H1), 3.55-3.45 
(m, 3H, Gal-H2, Gal-H3, Gal-H5), 3.17 (t, 3J = 9.4Hz, 1H, MeCy-H2), 2.06 (m, 1H, MeCy), 
1.64-1.47 (m, 3H, MeCy), 1.29-1.08 (m, 2H, MeCy), 1.06 (d, 3J = 6.5Hz, 3H, Fuc-H6), 1.02 
(d, 3J = 6.3Hz, 3H, MeCy-CH3), 0.94 (m, 1H, MeCy); 13C NMR (125.8 MHz, CDCl3): ! ! 
139.0, 138.5, 137.9, 128.7, 128.5, 128.3, 128.0, 127.7, 127.6, 127.5, 127.4 (24C, Ar-C), 99.7 
(Gal-C1), 98.0 (Fuc-C1), 84.1 (MeCy-C2), 79.9 (Fuc-C3), 78.7 (MeCy-C1), 78.3 (Fuc-C4), 
76.5 (Fuc-C2), 75.0, 74.4, 73.6 (3C, CH2Ph), 73.6 73.1, 71.5 (Gal-C2, Gal-C3, Gal-C5), 72.7 
(CH2Ph ), 69.5 (Gal-C6), 68.7 (Gal-C4), 66.7 (Fuc-C5), 38.8 (MeCy-C3), 33.7 (MeCy-C4), 
31.1 (MeCy-C6), 23.2 (MeCy-C5), 19.1 (MeCy-CH3), 17.0 (Fuc-C6); ["]D - 56.1° (c 0.94, 
CHCl3); MS (ESI) m/z: calcd for C47H58NaO11+ [M+Na]+: 821.4; found: 821.5; elemental 
analysis calcd (%) for C47H58O11: C 70.66, H 7.32; found: C 70.50, H 7.56. 
 
6-O-Benzyl-3-O-((S)-2-oxotetrahydrofuran-3-yl)-#-D-galactopyranosyl-(1"1)-[2,3,4-tri-
O-benzyl-" -L-fucopyranosyl-(1"2)]-(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol (29). 
Compound 28 (600 mg, 0.75 mmol) and Bu2SnO (300 mg, 1.21 mmol) were suspended in 
anhydrous toluene (5.3 mL) and anhydrous MeOH (2.7 mL) and stirred at 60°C under argon 
for 4 h. Volatiles were evaporated under reduced pressure and the resulting white solid was 
dried in high vacuum overnight. The residue was dissolved in anhydrous DME (10 mL) 
under argon, and extensively dried CsF (345 mg, 2.27 mmol) and 23 (530 mg, 2.26 mmol) 
were added. After 24 h, the solution was diluted with CH2Cl2 (100 mL) and washed with a 
20% aqueous solution of KF (2 · 100 mL) and brine (100 mL). The aqueous layers were 
extracted with CH2Cl2 (2 · 100 mL) and the combined organic layers were dried over Na2SO4 
and concentrated under reduced pressure. Column chromatography on silica (CH2Cl2/i-
propanol) afforded 29 (360 mg, 0.39 mmol, 52%) as white fluffy solid. 28 was recovered in 
17% (100 mg, 0.13 mmol). 
1H NMR (500.1 MHz, CDCl3): ! 7.30-7.13 (m, 20H, Ar-H), 5.00 (d, 3J = 3.4Hz, 1H, Fuc-
H1), 4.86 (A of AB, 2J = 11.4Hz, 1H, CH2Ph), 4.74 (A’ of A’B’, 2J = 11.7Hz, 1H, CH2Ph), 
4.70-4.59 (m, 3H, CH2Ph), 4.55 (dd, 3J = 6.5Hz, 1H, Fuc-H5), 4.51 (B of AB, 2J = 11.4Hz, 
CH2Ph), 4.48-4.43 (m, 3H, CH2Ph, Lac-H-2), 4.34 (m, 1H, Lac-H-4a), 4.24 (d, 3J = 7.7Hz, 
1H, Gal-H1), 4.12 (m, 1H, lac-H-4b), 4.07 (d, 3J = 2.6Hz, 1H, Gal-H4), 3.99 (dd, 3J = 3.4, 
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10.3Hz, 1H, Fuc-H2), 3.95 (dd, 3J = 2.6, 10.3Hz, 1H, Fuc-H3), 3.74 (dd, 3J = 6.4Hz, 2J = 
9.5Hz, 1H, Gal-H6a), 3.71-3.60 (m, 4H, Gal-H2, Gal-H6b, MeCy-H1, Fuc-H4), 3.58 (dd, 3J 
= 2.6, 9.3Hz, 1H, Gal-H3), 3.51 (q, 3J = 6.4Hz, 1H, Gal-H5), 3.16 (t, 3J = 9.4Hz, 1H, MeCy-
H2), 2.53 (m, 1H, lac-H-3a), 2.32 (m, 1H, lac-H-3b), 2.04 (m, 1H, MeCy), 1.61-1.49 (m, 3H, 
MeCy), 1.29-1.08 (m, 2H, MeCy), 1.06 (d, 3J = 6.4Hz, 3H, Fuc-H6), 1.03 (d, 3J = 6.3Hz, 3H, 
MeCy-CH3), 0.93 (m, 1H, MeCy); 13C NMR (125.8 MHz, CDCl3): !  176.8 (CO), 139.1, 
138.6, 138.0, 128.6, 128.5, 128.4, 128.3, 127.9, 127.8, 127.6, 127.5, 127.4 (24C, Ar-C), 
100.1 (Gal-C1), 98.3 (Fuc-C1), 83.8 (MeCy-C2), 82.9 (Gal-C3), 80.0 (Fuc-C3), 79.0 (MeCy-
C1), 78.3 (Fuc-C4), 76.3 (Fuc-C2), 75.1, 74.5, 74.3 (3C, CH2Ph), 73.8 (lac-C2), 73.1 (Gal-
C5), 72.6 (CH2Ph), 70.8 (Gal-C2), 69.2 (Gal-C6), 67.3 (Gal-C4), 66.6 (Fuc-C5), 65.4 (lac-C-
4), 39.0 (MeCy-C3), 33.7 (MeCy-C4), 31.2 (MeCy-C6), 30.1 (lac-C3), 23.2 (MeCy-C5), 19.1 
(MeCy-CH3), 16.9 (Fuc-C6); ["]D -56.5 (c 0.90, CHCl3); MS (ESI) m/z: calcd for 
C51H62NaO13+ [M+Na]+: 905.41; found: 605.64; elemental analysis calcd (%) for C51H62O13 
(883.03): C 69.37, H 7.08; found: C 69.14, H 6.93. 
 
3-O-(Sodium (S)-1-carboxy-3-hydroxypropyl)-#-D-galactopyranosyl-(1"1)- 
[" -L-fucopyranosyl-(1"2)]-(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol (10) 
and 
3-O-((S)-4-Hydroxy-1-(benzylamino)-1-oxobutan-2-yl)-#-D-galactopyranosyl-(1"1)-[" -
L-fucopyranosyl-(1"2)]-(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol (9). 
Compound 29 (270 mg, 0.31 mmol) was dissolved in dioxane/water (4/1, 3.5 mL) under 
argon. Pd(OH)2/C (30 mg, 10% Pd(OH)2) was added and the resulting mixture was 
hydrogenated (1 bar H2) at r.t. After 21 h, the mixture was filtered and the solvent removed 
under reduced pressure to give the debenzylated intermediate as white foam, which was 
directly used in the next step (160 mg, 0.31 mmol). 
10: The intermediate (23 mg, 0.044 mmol) was stirred in dioxane (0.5 mL) and aqueous 
NaOH (1 N, 0.5 mL) for 24 h. Dioxane was removed under reduced pressure and the residue 
was purified via RP chromatography (H2O/MeOH) and lyophilized from water to afford 10 
as white fluffy solid (17 mg, 0.03 mmol, 69%). 
1H NMR (500.1 MHz, CD3OD): !  5.00 (d, 3J = 4.0Hz, 1H, Fuc-H1), 4.93-4.85 (m, 1H, Fuc-
H5), 4.30 (d, 3J = 7.9Hz, 1H, Gal-H1), 3.93 (dd, 3J = 3.3, 9.9Hz, 1H, COCHCH2CH2OH), 
3.89-3.79 (m, 3H, COCHCH2CH2OH, Fuc-H3, Gal-H4), 3.78-3.61 (m, 7H, 
COCHCH2CH2OH, Fuc-H2, Fuc-H4, Gal-H2, Gal-H6a,b, MeCy-H1), 3.44 (m, 1H, Gal-H5), 
3.27 (t, 3J = 3.1, 9.5Hz, 1H, Gal-H3), 3.21 (t, 3J = 9.3Hz, 1H, MeCy), 2.14-2.02 (m, 2H, 
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COCHCH2CH2OH, MeCy), 1.88 (m, 1H, COCHCH2CH2OH), 1.71-1.58 (m, 3H, MeCy), 
1.39-1.22 (m, 2H, MeCy), 1.19 (d, 3J = 6.6Hz, 3H, Fuc-H6), 1.13 (d, 3J = 6.3Hz, 3H, MeCy-
CH3), 1.06 (m, 1H, MeCy); 13C NMR (125.8 MHz, CD3OD): ! 182.0 (COCHCH2CH2OH), 
102.2 (Gal-C1), 100.3 (Fuc-C1), 85.6 (Gal-C3), 84.5 (MeCy-C2), 81.4 (COCHCH2CH2OH), 
79.8 (MeCy-C1), 75.9 (Gal-C5), 73.8 (Fuc-C4), 71.3, 71.1 (Fuc-C3, Gal-C2), 70.3 (Fuc-C2), 
67.6 (Fuc-C5, Gal-C4), 63.2 (Gal-C6), 61.0 (COCHCH2CH2OH), 40.4 (MeCy-C3), 37.7 
(COCHCH2CH2OH), 35.0 (MeCy-C4), 31.9 (MeCy-C6), 24.2 (MeCy-C5), 19.6 (MeCy-
CH3), 16.7 (Fuc-C6); ["]D -89.0 (c 0.67, MeOH); HR-MS (ESI) m/z: calcd for C23H39Na2O14+ 
[M+Na]+: 585.2130 ; found: 585.2127; HPLC-purity: > 99.5 %. 
 
9: Benzyl amine (0.063 mL, 0.577 mmol) was added to a stirred solution of the intermediate 
(25 mg, 0.048 mmol) in anhydrous THF (1.0 mL) at r.t. under argon. After 20 h, volatiles 
were evaporated under reduced pressure, the residue was purified via RP chromatography 
(H2O/MeOH) and lyophilized from water to afford 9 as white fluffy solid (23 mg, 0.037 
mmol, 76%). 
1H NMR (500.1 MHz, CD3OD):  ! 7.35-7.23 (m, 5H, C6H5), 5.00 (d, 3J = 4.0Hz, 1H, Fuc-
H1), 4.93-4.83 (m, 1H, Fuc-H5), 4.45 (A of AB, 2J = 14.8Hz, 1H, CH2Ph), 4.38 (B of AB, 2J 
= 14.8Hz, 1H, CH2Ph), 4.28 (d, 3J = 7.7Hz, 1H, Gal-H1), 4.25 (dd, 3J = 3.8, 8.9Hz, 1H, 
COCHCH2CH2OH), 3.88-3.79 (m, 3H, COCHCH2CH2OH, Fuc-H3, Gal-H4), 3.78-3.61 (m, 
6H, COCHCH2CH2OH, Fuc-H2, Fuc-H4, Gal-H2, Gal-H6a, MeCy-H1), 3.58 (dd, 3J = 4.8, 
11.4Hz, Gal-H6b), 3.38-3.32 (m, 2H, Gal-H3, Gal-H5), 3.20 (t, 3J = 9.3Hz, 1H, MeCy), 2.09 
(m, 1H, MeCy), 2.03 (m, 1H, COCHCH2CH2OH), 1.88 (m, 1H, COCHCH2CH2OH), 1.72-
1.55 (m, 3H, MeCy), 1.40-1.21 (m, 2H, MeCy), 1.17 (d, 3J = 6.6Hz, 3H, Fuc-H6), 1.13 (d, 3J 
= 6.3Hz, 3H, MeCy-CH3), 1.07 (m, 1H, MeCy); 13C NMR (125.8 MHz, CD3OD): ! 176.0 
(COCHCH2CH2OH), 139.8, 129.6, 128.6, 128.4 (6C, C6H5), 102.2 (Gal-C1), 100.4 (Fuc-C1), 
84.8, 84.6 (Gal-C3, MeCy-C2), 80.3, 79.9 (COCHCH2CH2OH, MeCy-C1), 75.9 (Gal-C5), 
73.8 (Fuc-C4), 71.5, 71.4 (Fuc-C3, Gal-C2), 70.3 (Fuc-C2), 68.3 (Gal-C4), 67.5 (Fuc-C5), 
62.9 (Gal-C6), 59.4 (COCHCH2CH2OH), 43.8 (CH2Ph), 40.4 (MeCy-C3), 37.3 
(COCHCH2CH2OH), 34.9 (MeCy-C4), 31.8 (MeCy-C6), 24.2 (MeCy-C5), 19.6 (MeCy-
CH3), 16.7 (Fuc-C6); ["]D -77.6 (c 0.86, MeOH); HR-MS (ESI) m/z: calcd for 
C30H47NNaO13+ [M+Na]+: 652.2945 ; found: 652.2940; HPLC-purity: > 99.5 %. 
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6-O-Benzyl-3-O-((S)-1-methoxy-1-oxobutan-2-yl)-!-D-galactopyranosyl-(1!1)-[2,3,4-tri-
O-benzyl-" -L-fucopyranosyl-(1!2)]-(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol (30). 
Compound 28 (150 mg, 0.19 mmol) and Bu2SnO (70 mg, 0.28 mmol) were suspended in 
anhydrous toluene (1.4 mL) and anhydrous MeOH (0.6 mL) and stirred at 60°C under argon 
for 4 h. Volatiles were evaporated under reduced pressure and the resulting white solid was 
dried in high vacuum overnight. The residue was dissolved in anhydrous DME (3.0 mL) 
under argon, and extensively dried CsF (90 mg, 0.59 mmol) and 25 (130 mg, 0.52 mmol) 
were added. The reaction was monitored by TLC (CH2Cl2/i-propanol 95/5) and after 18 h, the 
solution was diluted with CH2Cl2 (30 mL) and washed with a 20% aqueous solution of KF (2 
· 30 mL) and brine (30 mL). The aqueous layers were extracted with CH2Cl2 (2 · 30 mL) and 
the combined organic layers were dried over Na2SO4 and concentrated under reduced 
pressure. Column chromatography on silica (CH2Cl2/i-propanol) afforded 30 (126 mg, 0.14 
mmol, 75%) as white fluffy solid. 
1H NMR (500.1 MHz, CDCl3): # 7.31-7.13 (m, 20H, Ar-H), 5.01 (d, 3J = 3.3Hz, 1H, Fuc-
H1), 4.87 (A of AB, 2J = 11.5Hz, 1H, CH2Ph), 4.74 (A’ of A’B’, 2J = 11.7Hz, 1H, CH2Ph), 
4.70-4.64 (m, 2H, CH2Ph), 4.64-4.56 (m, 2H, CH2Ph, Fuc-H5), 4.53 (B of AB, 2J = 11.5Hz, 
CH2Ph), 4.49-4.41 (m, 2H, CH2Ph), 4.22 (d, 3J = 7.8Hz, 1H, Gal-H1), 4.06 (dd, 3J = 4.1, 
8.2Hz, COCHCH2CH3), 3.99 (dd, 3J = 3.3, 10.3Hz, 1H, Fuc-H2), 3.95 (dd, 3J = 2.4, 10.3Hz, 
1H, Fuc-H3), 3.86 (d, 3J = 2.9Hz, 1H, Gal-H4), 3.76-3.58 (m, 8H, Fuc-H4, Gal-H2, Gal-
H6a,b, MeCy-H1, COCH3), 3.47 (t, 3J = 6.1Hz, 1H, Gal-H5), 3.23 (dd, 3J = 3.2, 9.3Hz, 1H, 
Gal-H3), 3.17 (t, 3J = 9.3Hz, 1H, MeCy-H2), 2.03 (m, 1H, MeCy), 1.86-1.64 (m, 2H, 
COCHCH2CH3), 1.60-1.48 (m, 3H, MeCy), 1.29-1.10 (m, 2H, MeCy), 1.07 (d, 3J = 6.5Hz, 
3H, Fuc-H6), 1.02 (d, 3J = 6.3Hz, 3H, MeCy-CH3), 0.96 (t, 3J = 7.4Hz, 3H, COCHCH2CH3), 
0.91 (m, 1H, MeCy); 13C NMR (125.8 MHz, CDCl3):  # 174.7 (CO2CH3), 139.2, 138.6, 
138.2, 128.6, 128.5, 128.4, 128.3, 128.2, 127.8, 127.7, 127.6, 127.5, 127.4 (24C, Ar-C), 
100.2 (Gal-C1), 98.1 (Fuc-C1), 83.5 (MeCy-C2), 82.9 (Gal-C3), 80.2 (COCHCH2CH3), 80.0 
(Fuc-C3), 78.8 (MeCy-C1), 78.5 (Fuc-C4), 76.2 (Fuc-C2), 75.1, 74.3, 73.7 (3C, CH2Ph), 73.2 
(Gal-C5), 72.7 (CH2Ph), 70.9 (Gal-C2), 69.2 (Gal-C6), 66.8, 66.7 (Fuc-C5, Gal-C4), 52.3 
(CO2CH3), 38.9 (MeCy-C3), 33.7 (MeCy-C4), 31.2 (MeCy-C6), 26.9 (COCHCH2CH3) 23.2 
(MeCy-C5), 19.1 (MeCy-CH3), 16.9 (Fuc-C6), 10.0 (COCHCH2CH3); ["]D -59.1 (c 1.44, 
CHCl3); MS (ESI) m/z: calcd for C52H66NaO13+ [M+Na]+: 921.44; found: 921.50; elemental 
analysis calcd (%) for C52H66O13 (899.07): C 69.47, H 7.40; found: C 69.38 , H 7.38. 
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3-O-(Sodium (S)-1-carboxypropyl)-!-D-galactopyranosyl-(1"1)-[! -L- 
fucopyranosyl-(1"2)]-(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol (11). 
Compound 30 (95 mg, 0.11 mmol) was dissolved in dioxane/water (4/1, 5 mL) under argon. 
Pd(OH)2/C (30 mg, 10% Pd(OH)2) was added and the resulting mixture was hydrogenated (1 
bar H2) at r.t. After 17 h, the mixture was filtered and the solvent removed under reduced 
pressure yielding 57 mg of a white solid, which was directly used for saponification. The 
crude product was stirred in a solution of aqueous NaOH (1 N, 0.5 mL) and dioxane (1.5 mL) 
at r.t. for 24 h, lyophilized from water and purified via HPLC. Lyophilization from water 
afforded 11 as white fluffy solid (8 mg, 0.015 mmol, 14%). 
1H NMR (500.1 MHz, CD3OD):  "  5.00 (d, 3J = 3.9Hz, 1H, Fuc-H1), 4.93-4.77 (m, 1H, Fuc-
H5), 4.27 (d, 3J = 7.7Hz, 1H, Gal-H1), 4.16 (dd, 3J = 4.3, 7.7Hz, 1H, COCHCH2CH3), 3.91 
(d, 3J = 2.2Hz, 1H, Gal-H4), 3.84 (dd, 3J = 3.2, 10.2Hz, 1H, Fuc-H3), 3.78-3.60 (m, 6H, Fuc-
H2, Fuc-H4, Gal-H2, Gal-H6a,b, MeCy-H1), 3.41 (t, 3J = 5.8Hz, 1H, Gal-H5), 3.34-3.26 (m, 
1H, Gal-H3), 3.20 (t, 3J = 9.3Hz, 1H, MeCy-H2), 2.10 (m, 1H, MeCy), 1.90, 1.77 (2m, 2H, 
COCHCH2CH3), 1.71-1.55 (m, 3H, MeCy), 1.38-1.22 (m, 2H, MeCy), 1.19 (d, 3J = 6.5Hz, 
3H, Fuc-H6), 1.13 (d, 3J = 6.3Hz, 3H, MeCy-CH3), 1.11-1.01 (m, 4H, COCHCH2CH3, 
MeCy); 13C NMR (125.8 MHz, CD3OD): " 102.4 (Gal-C1), 100.4 (Fuc-C1), 84.6, 84.4 (Gal-
C3, MeCy-C2), 80.0 (MeCy-C1), 75.9 (Gal-C5), 73.8 (Fuc-C4), 71.8, 71.4 (Fuc-C3, Gal-C2), 
70.3 (Fuc-C2), 68.1 (Gal-C4), 67.5 (Fuc-C5), 62.9 (Gal-C6), 40.4 (MeCy-C3), 34.9 (MeCy-
C4), 31.9 (MeCy-C6), 27.6 (COCHCH2CH3), 24.2 (MeCy-C5), 19.6 (MeCy-CH3), 16.7 
(Fuc-C6), 10.1 (COCHCH2CH3); [!]D -79.1 (c 0.62, MeOH); HR-MS (ESI) m/z: calcd for 
C23H40NaO13+ [M+Na]+: 547.2361 ; found: 547.2363; HPLC-purity: > 99.5 %. 
 
6-O-Benzyl-3-O-((S)-4-hydroxy-1-(methylamino)-1-oxobutan-2-yl)-#-D-
galactopyranosyl-(1!1)-[2,3,4-tri-O-benzyl-! -L-fucopyranosyl-(1!2)]-(1R,2R,3S)-3-
methyl-cyclohexane-1,2-diol (31). 
Compound 28 (60 mg, 0.075 mmol) and Bu2SnO (28 mg, 0.112 mmol) were suspended in 
anhydrous toluene (1.4 mL) and anhydrous MeOH (0.6 mL) and stirred at 50°C under argon 
for 4 h. Volatiles were evaporated under reduced pressure and the resulting white solid was 
dried in high vacuum overnight. The residue was dissolved in anhydrous DME (1.0 mL) 
under argon, and extensively dried CsF (35 mg, 0.23 mmol) and 23 (53 mg, 0.226 mmol) 
were added. The reaction was monitored by TLC (CH2Cl2/i-propanol 95/5) and upon 
completion NH2Me in THF (2 M, 4 mL) was added. The solution was stirred for 30 min, 
diluted with CH2Cl2 (30 mL) and washed with a 20% aqueous solution of KF (2 ·30 mL) and 
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brine (30 mL). The aqueous layers were extracted with CH2Cl2 (3 · 30 mL) and the combined 
organic layers were dried over Na2SO4 and concentrated under reduced pressure. Column 
chromatography on silica (CH2Cl2/i-propanol) afforded 31 (35 mg, 0.038 mmol, 51%) as 
white fluffy solid. Starting material 28 was recovered in 33% (20 mg, 0.025 mmol). 
1H NMR (500.1 MHz, CDCl3): ! 7.49 (d, 3J = 4.1Hz, CONHCH3), 7.29-7.14 (m, 20H, Ar-
H), 5.01 (d, 3J = 3.6Hz, 1H, Fuc-H1), 4.56 (A of AB, 2J = 11.5Hz, 1H, CH2Ph), 4.76-4.63 
(m, 3H, CH2Ph), 4.56 (B of AB, 2J = 11.5Hz, 1H, CH2Ph), 4.52-4.45 (m, 3H, Fuc-H5, 
CH2Ph), 4.40 (B of AB, 2J = 11.9Hz, 1H, CH2Ph), 4.26 (1H, 3J = 7.7Hz, Gal-H1), 4.04 (m, 
1H, COCHCH2CH2OH), 3.99 (dd, 3J =3.6, 10.3Hz, 1H, Fuc-H2), 3.95-3.89 (m, 2H, Fuc-H3, 
Gal-H4), 3.84-3.61 (m, 6H, Gal-H2, Gal-H6a,b, MeCy-H1, COCHCH2CH2OH), 3.57 (m, 1H, 
Fuc-H4), 3.38 (m, 1H, Gal-H5), 3.16 (t, 3J = 9.3Hz, 1H, MeCy-H2), 2.75 (d, 3J = 4.1Hz, 3H, 
CONHCH3), 2.11-2.01 (m, 2H, MeCy, COCHCH2CH2OH), 1.84 (m, 1H, 
COCHCH2CH2OH), 1.61-1.49 (m, 3H, MeCy), 1.30-1.10 (m, 2H, MeCy), 1.08 (d, 3J = 
6.4Hz, 3H, Fuc-H6), 1.01 (d, 3J = 6.2Hz, 3H, MeCy-CH3), 0.92 (m, 1H, MeCy); 13C NMR 
(125.8 MHz, CDCl3): !  174.0 (CONHCH3), 139.0, 138.4, 137.4, 128.7, 128.5, 128.4, 128.3, 
128.2, 127.7, 127.6, 127.5, 127.3 (24C, Ar-C), 100.1 (Gal-C1), 97.9 (Fuc-C1), 84.1, 83.9 
(Gal-C3, MeCy-C2), 81.1 (COCHCH2CH2OH), 79.9 (Fuc-C3), 78.8 (MeCy-C1), 78.4 (Fuc-
C4), 76.4 (Fuc-C2), 75.0, 74.3, 73.9 (3C, CH2Ph), 72.8 (CH2Ph ), 72.5 (Gal-C5), 70.3 (Gal-
C6), 69.7 (Gal-C2), 67.8 (Gal-C4), 66.8 (Fuc-C5), 59.9 (COCHCH2CH2OH), 38.6 (MeCy-
C3), 35.7 (COCHCH2CH2OH), 33.7 (MeCy-C4), 31.0 (MeCy-C6), 26.0 (CONHCH3), 23.2 
(MeCy-C5), 19.0 (MeCy-CH3), 17.0 (Fuc-C6); ["]D -50.9 (c 0.66, CHCl3); MS (ESI) m/z: 
calcd for C52H67NaNO13+ [M+Na]+: 936.45; found: 936.63; elemental analysis calcd (%) for 
C52H67NO13 + 0.5 H2O (923.10): C 67.66, H 7.43, N 1.52; found: C 67.65, H 7.43, N 1.68. 
 
3-O-((S)-4-hydroxy-1-(methylamino)-1-oxobutan-2-yl)-#-D-galactopyranosyl-(1"1)-[" -
L-fucopyranosyl-(1"2)]-(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol (8). 
Compound 31 (90 mg, 0.098 mmol) was dissolved in dioxane/water (4/1, 3.5 mL) under 
argon. Pd(OH)2/C (5 mg, Pd(OH)2) was added and the resulting mixture was hydrogenated (1 
bar H2) at r.t. After 5 h the mixture was filtered and the solvent removed under reduced 
pressure. Purification via HPLC and lyophilization from water afforded 8 as white fluffy 
solid (20 mg, 0.036 mmol, 37%). 
1H NMR (500.1 MHz, CD3OD): !  5.00 (d, 3J = 4.0Hz, 1H, Fuc-H1), 4.93-4.84 (m, 1H, Fuc-
H5), 4.30 (d, 3J = 7.7Hz, 1H, Gal-H1), 4.19 (dd, 3J = 3.8, 8.7Hz, 1H, COCHCH2CH2OH), 
3.88 (d, 3J = 2.8Hz, Gal-H4), 3.86-3.80 (m, 2H, COCHCH2CH2OH, Fuc-H3), 3.77-3.63 (m, 
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7H, COCHCH2CH2OH, Fuc-H2, Fuc-H4, Gal-H2, Gal-H6a,b, MeCy-H1), 3.40 (m, 1H, Gal-
H5), 3.37-3.27 (m, 1H, Gal-H3), 3.20 (t, 3J = 9.3Hz, 1H, MeCy), 2.78 (s, 3H, NHCH3), 2.11 
(m, 1H, MeCy), 2.02 (m, 1H, COCHCH2CH2OH ), 1.87 (m, 1H, COCHCH2CH2OH), 1.73-
1.55 (m, 3H, MeCy), 1.40-1.23 (m, 2H, MeCy), 1.19 (d, 3J = 6.6Hz, 3H, Fuc-H6), 1.13 (d, 3J 
= 6.3Hz, 3H, MeCy-CH3), 1.06 (m, 1H, MeCy); 13C NMR (125.8 MHz, CD3OD): ! 176.7 
(COCHCH2CH2OH), 102.3 (Gal-C1), 100.4 (Fuc-C1), 84.8, 84.6 (Gal-C3, MeCy-C2), 80.0 
(COCHCH2CH2OH, MeCy-C1), 76.0 (Gal-C5), 73.9 (Fuc-C4), 71.5 (Fuc-C3, Gal-C2), 70.3 
(Fuc-C2), 68.0 (Gal-C4), 67.5 (Fuc-C5), 62.8 (Gal-C6), 59.5 (COCHCH2CH2OH), 40.4 
(MeCy-C3), 37.2 (COCHCH2CH2OH), 34.9 (MeCy-C4), 31.9 (MeCy-C6), 26.1 (NHCH3), 
24.2 (MeCy-C5), 19.6 (MeCy-CH3), 16.8 (Fuc-C6); ["]D -73.0 (c 0.70, MeOH); HR-MS 
(ESI) m/z: calcd for C24H45NNaO13 [M+Na]+: 576.2627; found: 576.2627; HPLC-purity: > 
99.5 %. 
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2.3.2 Further selectin antagonists and synthesis of building blocks 
In the course of our studies on selectin antagonists presented in the previous section, further 
antagonists were developed that have not been described to date. In this section, the rational 
for their development, biological data, and synthesis are discussed. Furthermore, the 
synthesis of building blocks used in, but not covered by section 2.3.1 is outlined.  
2.3.2.1 Rational and biological data 
Table 2.3.1 Relative IC50 values (rIC50) of selectin antagonists. IC50 values were measured by 
Katrin Lemme and GMI using 1.1a (P-sel) and CGP69669 (E-sel) as reference compounds on each 
microtiter plate; n.d. = binding affinity not determined. 
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Entry Compound R1 R2 R3 
rIC50 
(E)  
rIC50 
(P)  
1 1.12 - - - 1.0 1.0 
2 1.1b ONa H H 0.08 0.05 
3 3.7* NHCH3 H H 0.25 0.07 
4 3.1 NH2 H H 0.27 0.22 
5 3.2 ONa COCH3 H 0.03 0.03 
6 3.3 ONa H CO2Na 0.06 0.06 
7 3.4 ONa COCH3 CO2CH3 n.d. n.d. 
8 3.5 ONa H CO2NH(CH2)2NHCOCH2(O(CH2)2)2NH2 n.d. n.d. 
 
All IC50 values of selectin antagonists are referenced to TMSE protected sLex (1.12, entry 1 
in Table 2.3.1). To evaluate the impact of the different modifications, affinity data is also 
provided for 1.1b. 
Compound 3.7*: Design and synthesis of 3.7* are described in section 2.3.1. 
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Compound 3.1: To study the influence of the methyl group in methylamide 3.7*, amide 3.1 
was synthesized. While binding affinity to E-selectin was identical, three-fold weaker binding 
was observed for P-selectin. This difference might result from the higher quality of the 
hydrogen bond formed by the methylamide compared to the amide. 
Compound 3.2: Various esters and amides in 2-position of D-Gal were found to exert a 
positive effect on binding affinity to E-selectin (see section: 1.4.2.). However, this effect was 
only observed for cyclohexyllactic acid derivatives of sLex. We wondered if it can also be 
observed for antagonists containing sialic acid and if it can be found for P-selectin 
antagonists as well. Consequently, mimetic 3.2 was synthesized and tested. Affinity to both 
E- and P-selectin was increased approximately two fold, which is in the same range as 
observed for E-selectin antagonists containing cyclohexyllactic acid. These results suggest, 
that modifications of the 2-position of D-Gal which are beneficial for E-selectin antagonists, 
can be transferred to P-selectin antagonists as well. 
Compound 3.3: Structure activity relationship studies revealed that a methyl ester at the 
position of the former ring oxygen of D-GlcNAc could significantly improve the binding 
affinity of E-selectin antagonists (see section 1.4.2.). According to the crystal structure of 
sLex bound to E-selectin, this part of the mimic has no contact to the protein. Therefore, it 
was reasoned that the gain in affinity is due to stabilization of the ring conformation. To 
explore the effect of an additional substituent on the binding affinity to E- and P-selectin, 3.3 
was synthesized. However, 3.3 did not exhibit a significant improvement in affinity for both 
selectins. Possible explanations might be the compensation of favorable conformational 
stabilization by unfavorable changes in the solvation properties, or a change in the binding 
mode.  
Compound 3.4: No data was available for 3.4, which combines the acetyl ester in position 2 
of D-Gal and the methyl ester at the former ring oxygen position of D-GlcNAc. 
Compound 3.5: Linker modified 3.5 was synthesized for the preparation of an affinity 
column, as well as for immobilization on a Biacore chip (inverse experiment, see thesis of 
Céline Weckerle[1]). The linker was attached to the D-GlcNAc mimic, since SAR studies of 
similarly modified selectin ligands had revealed no negative influence on the binding affinity 
compared to unmodified ligands.[1] 
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2.3.2.2 Synthesis 
2.3.2.2.1 Synthesis of (5-Acetamido-3,5-dideoxy-D-glycero-! -D-galacto-2-
nonulopyranosynylamide)-(2!3)-"-D-galactopyranosyl-[! -L-fucopyranosyl-(1!2)]-
(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol (3.1). 
Amide 3.1 was obtained from the benzyl ester of 1.1b (Scheme 2.3.1). Ester formation 
proceeded chemoselectively with benzyl bromide in presence of KF and aminolysis with NH3 
afforded 3.1 in 95% over two steps. 
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Scheme 2.3.1 a) BnBr, KF, DMF, r.t., 2 d; b) NH3, dioxane, MeOH, r.t., 12 h, 95% from 1.1b. 
2.3.2.2.2 Synthesis of (Sodium 5-acetamido-3,5-dideoxy-D-glycero-! -D-galacto-2-
nonulopyranosynate)-(2!3)-2-O-acetyl-" -D-galactopyranosyl-(1!1)-[! -L-
fucopyranosyl-(1!2)]-(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol (3.2). 
Debenzylation by hydrogenolysis of 3.21* followed by mild transesterification with NaOMe 
in methanol afforded monoacetylated 3.2 in 44% yield over two steps (Scheme 2.3.2). 
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Scheme 2.3.2 a) H2, Pd(OH)2/C, dioxane, H2O, r.t., 24 h; b) NaOMe, MeOH, r.t., 4.5 h, 44%. 
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2.3.2.2.3 Synthesis of (Sodium 5-acetamido-3,5-dideoxy-D-glycero-!-D-galacto-2-
nonulopyranosynate)-(2"3)-#-D-galactopyranosyl-(1"3)-[a-L-fucopyranosyl-(1"4)]-
(1R,3R,4R,5S)-1-sodium carboxylate-5-methyl-cyclohexane-3,4-diol (3.3) and (Sodium 
5-acetamido-3,5-dideoxy-D-glycero-!-D-galacto-2-nonulopyranosynate)-(2"3)-2-O-
acetyl-#-D-galactopyranosyl-(1"3)-[! -L-fucopyranosyl-(1"4)]-(1R,3R,4R,5S)-1-
methoxycarbonyl-5-methyl-cyclohexane-3,4-diol (3.4). 
DMTST promoted coupling of 1.2 with 1.3c afforded 3.7 in 65% yield (Scheme 2.3.3). 
Debenzylation by hydrogenolysis of 3.7 was either followed by saponification with aqueous 
sodium hydroxide to yield 3.3, or by mild transesterification to give 3.4. 
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Scheme 2.3.3 a) DMTST, CH2Cl2, MS 4 Å, r.t., 42 h, 65%; b) H2, Pd(OH)2/C, dioxane, water, 24 h; 
c) NaOH, H2O, r.t., 8 h, 85% 3.3 from 3.7; d) H2, Pd(OH)2/C, dioxane, water, 2 d; e) NaOMe, MeOH, 
r.t., 2 h, 84% 3.4 from 3.7. 
2.3.2.2.4 Synthesis of (5-Acetamido-3,5-dideoxy-D-glycero-!-D-galacto-2-
nonulopyranosidonic acid)-(2"3)-#-D-galactopyranosyl-(1"3)-[a-L-fucopyranosyl-
(1"4)]-(1R,3R,4R,5S)-1((2-(2-(2-(2-aminoethoxy)ethoxy)acetamido)ethyl)carbamoyl)-5-
methyl-cyclohexane-3,4-diol (3.5). 
In analogy to the synthesis of GMI1070,[2] 3.4 was first reacted with 1,2-diaminoethane at 
80°C to cleave the acetyl ester and to introduce an amino side chain at the D-GlcNAc mimic 
(Scheme 2.3.4). To remove side products that might hamper coupling of 3.8 to the linker, 3.8 
was purified via size exclusion chromatography before coupling to Fmoc protected 
succinimidyl ester 3.11 (Scheme 2.3.5) in 26% over two steps. Finally, Fmoc was cleaved 
with piperidine to give 3.5, which was directly used for coupling. 
 80 
 
O
HO
HO
OR1
O
CO2Na
OH
AcHN
HO
OH
OH
O
O
HOOH
OH
O
O
O
R2
O
HO
HO
OH
O
CO2Na
OH
AcHN
HO
OH
OH
O
O
HOOH
OH
O
O
O
H
N NH
O
O
O
R3HN
b)
3.4 R1= Ac; R2= OMe
3.8 R1= H; R2= NH(CH2)2NH2
a)
3.9 R3= Fmoc
3.5 R3= H
c)
 
Scheme 2.3.4 a) 1,2-diaminoethane, 80°C, 5 h; b) 3.11, aq. NaHCO3, MeCN, r.t., 5 h, 26% from 
3.4; c) piperidine, MeCN, r.t., 2 h. 
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Scheme 2.3.5 NHS, DIC, THF, r.t., 14 h, 97%. 
2.3.2.2.5 Synthesis of ethyl (benzyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-
D-glycero-! -D-galacto-2-nonulopyranosynate)-(2!3)-2,4-di-O-acetyl-6-O-benzoyl-1-
thio-"-D-galactopyranoside (1.2). 
In analogy to the synthesis of methyl (methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-
dideoxy-D-glycero-!-D-galacto-2-nonulopyranosylonate)-(2"3)-2,4,6-tri-O-benzoyl-1-thio-
#-D-galactopyranoside,[3,4] building block 1.2[5] was synthesized from sialic acid donor 1.4 
and galactoside 1.5 (Scheme 2.3.6). Using NIS-TfOH as promoter, the glycosyl donor 1.4 
was successfully introduced in 3-position of 1.5. Cumbersome purification was avoided by 
direct acetylation of roughly purified 3.12, giving 3.13 in 28% yield. Cleavage of the TMSE 
group with BF3·Et2O in presence of acetic anhydride afforded 3.14, which was further 
transformed to the title compound 1.2 using BF3·Et2O as promoter. 
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Scheme 2.3.6 a) NIS, TfOH, MeCN, CH2Cl2, MS 3 Å, -70 to -30°C, 12 h; b) Ac2O, DMAP, 
pyridine, r.t., 24 h, 28% from 1.4; c) Ac2O, toluene, MS 3 Å, BF3·Et2O, r.t., 16 h, quant.; d) EtSH, 
BF3·Et2O, CH2Cl2, r.t., 2 h, 88%. 
2.3.2.2.6 Synthesis of O-Ethyl S-(benzyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-
dideoxy-D-glycero-! -D-galacto-2-nonulopyranosynate)dithiocarbonate (1.4). 
Following a procedure developed by Gan-Pang Gao,[6] sialyl 2-xanthate 1.4 was synthesized 
in four steps starting from sialic acid 3.15 (Scheme 2.3.7). DMAP catalyzed acetylation with 
acetic anhydride in pyridine followed by esterification with benzyl bromide in presence of 
KF afforded fully protected 3.17 in good yield. Treatment with acetyl chloride and conc. 
hydrochloric acid afforded the 2-!-chloro derivative 3.18, which was promoted to 1.4 using 
tetrabutylammonium hydrogensulfate (TBAHS) in aqueous NaHCO3 and ethyl acetate. 
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Scheme 2.3.7 a) Ac2O, DMAP, pyridine, 0°C to r.t., 16 h; b) BnBr, KF, DMF, r.t., 21 h, 72% from 
3.15; c) AcCl, HCl (conc.), CH2Cl2, -20°C to r.t., 27 h; d) K-xanthogenate, TBAHS, NaHCO3 (aq., 
satd.), EtOAc, r.t., 3 h, 60% from 3.17. 
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2.3.2.2.7 Synthesis of 2-(trimethylsilyl)ethyl 6-O-benzoyl-! -D-galactopyranoside 
(1.5). 
Starting from per acetylated D-galactose 3.19, the TMSE group was introduced via galactosyl 
bromide 3.20 using Helferich conditions (Scheme 2.3.8). Deprotection of 3.21 under 
Zemplén conditions afforded 3.22. Following a procedure published by Murase et al,[3] 
selective benzoylation in 6-position of 3.22 was done in a three step sequence. Regioselective 
benzylation in 3-position via the tin-acetal (" 3.23) was followed by low temperature 
benzoylation (" 3.24) and subsequent hydrogenolytic debenzylation to afford 1.5. 
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Scheme 2.3.8 a) HBr, AcOH, CH2Cl2, 0°C to r.t., 2.5 h, 92%; b) 2-(Trimethylsilyl)ethanol, HgO, 
HgBr2, CaSO4, CH2Cl2, r.t., 12 h, 85%; c) NaOMe, MeOH, r.t., 1 h, quant.; d) BnBr, Bu2SnO, 
Bu4NBr, toluene, 80°C to 60°C, 8 h, 82%; e) BzCl, pyridine, CH2Cl2, -50°C to -20°C, 1.5 h, 60%; f) 
H2, Pd(OH)2/C, dioxane, H2O, 12 h, quant. 
2.3.2.2.8 Synthesis of 2,3,4-Tri-O-benzyl-# -L-fucopyranosyl-(1!2)-(R,R)-
cyclohexane-1,2-diol (1.3a). 
Thio fucoside 1.6[7] was reacted with commercially available (R,R)-cyclohexane-1,2-diol 1.7a 
under Lemieux in situ anomerisation conditions affording 1.3a[8] #-selectively in 67% yield 
(Scheme 2.3.9). 
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Scheme 2.3.9 Br2, CH2Cl2, DMF, Bu4NBr, 0°C to r.t., 12 h, 67%. 
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2.3.2.2.9 Synthesis of [(1R,3R,4R,5S)-1-methoxycarbonyl-5-methyl-cyclohex-4-yl] 
2,3,4-tri-O-benzyl-! -L-fucopyranosid (1.3c). 
Pseudodisaccharide 1.3c was synthesized from in-house building block 3.25 following 
literature procedures (Scheme 2.3.10).[9] Epoxidation of 3.25, followed by Lewis acid 
catalyzed epoxide opening with the higher-order cyanocuprate Me2Cu(CN)Li2 afforded 
compound 1.7c, which was fucosylated with 1.6[7] under in situ anomerisation conditions. 
Cleavage of the TBS protecting group with tetrabutylammonium fluoride finally afforded 
1.3c.  
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Scheme 2.3.10 a) m-CPBA, CH2Cl2, 10°C to r.t., 2 h (81%); b) MeLi, CuCN, BF3·Et2O, THF, -78°C, 
5 h (52%); c) Bu4NBr, DTBMP, MS 4 Å, CuBr2, DMF, CH2Cl2, r.t., 20 h (56%); d) TBAF, THF, r.t., 
24 h (88%). 
2.3.2.3 Experimental 
General experimental conditions are described in section 2.3.1. 
 
(5-Acetamido-3,5-dideoxy-D-glycero-!-D-galacto-2-nonulopyranosynylamide)-(2!3)-"-
D-galactopyranosyl-[! -L-fucopyranosyl-(1!2)]-(1R,2R,3S)-3-methyl-cyclohexane-1,2-
diol (3.1). 
A solution of 1.1b (40 mg, 0.053 mmol), BnBr (0.019 mL, 0.160 mmol) and KF (8 mg, 0.138 
mmol) in anhydrous DMF (3.0 mL) was stirred at r.t. under argon for 2 d. Water (3 mL) was 
added and the mixture was lyophilized to yield the crude benzyl ester as white solid (80 mg), 
which was directly used in the next step. The crude ester 3.6 (20 mg) was dissolved in NH3 in 
dioxane (0.5 M, 2 mL) and NH3 in MeOH (7 M, 2 mL) and stirred at r.t. under argon. 
Volatiles were evaporated under reduced pressure and purification via SEC and 
lyophilization from water afforded 3.1 as white fluffy solid (9.2 mg, 0.013 mmol, 95%). 
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1H NMR (500.1 MHz, D2O): !  5.05 (d, 3J = 3.6Hz, 1H, Fuc-H1), 5.01-4.72 (m, Fuc-H5), 
4.51 (d, 3J = 7.9Hz, 1H, Gal-H1), 4.02 (dd, 3J = 2.8, 9.7Hz, 1H, Gal-H3), 3.93 (m, Gal-H4), 
3.89-3.54 (m, 14H, Fuc-H2, Fuc-H3, Fuc-H4, Gal-H5, Gal-H6a, Gal-H6b, MeCy-H1, Sia-
H4, Sia-H5, Sia-H6, Sia-H7, Sia-H8, Sia-H9a, Sia-H9b), 3.51 (m, 1H, Gal-H2), 3.18 (t, 3J = 
9.6Hz, 1H, MeCy-H2), 2.68 (dd, 3J = 4.4Hz, 2J = 12.4Hz, 1H, Sia-H3eq), 2.09 (m, 1H, 
MeCy), 1.99 (s, 3H, COCH3), 1.87 (t, 3J = 2J = 12.4Hz, 1H, Sia-H3ax) 1.70-1.46 (m, 3H, 
MeCy), 1.31-1.13 (m, 2H, MeCy), 1.11 (d, 3J = 6.5Hz, 1H, Fuc-H6), 1.04 (m, 4H, MeCy-
CH3, MeCy); 13C NMR (125.8 MHz, D2O, CD3OD): ! 176.0 (COCH3), 173.1 (Sia-C1), 
100.7 (Sia-C2), 100.4 (Gal-C1), 99.8 (Fuc-C1), 84.9 (MeCy-C2), 79.6 (MeCy-C1), 76.8 
(Gal-C3), 75.3 (Gal-C5), 74.6 (Sia-C6), 73.0 (Fuc-C4), 72.0 (Sia-C8), 70.2 (Fuc-C3), 69.9 
(Gal-C2), 69.2 (2C, Fuc-C2, Gal-C4), 68.6 (Sia-C7), 68.3 (Sia-C4), 67.4 (Fuc-C5), 64.0 (Sia-
C9), 62.4 (Gal-C6), 52.5 (Sia-C5), 39.8 (MeCy-C3), 38.4 (Sia-C3), 34.1 (MeCy-C4), 31.2 
(MeCy-C6), 23.6 (MeCy-C5), 23.0 (CH3CO), 19.1 (MeCy-CH3), 16.4 (Fuc-C6); ["]D -49.6° 
(c 0.61, MeOH); HR-MS (ESI) m/z: calcd for C30H52N2NaO18 [M+Na]+: 751.3107 ; found: 
751.3105; HPLC-purity: > 99.5 % (B). 
 
(Sodium 5-acetamido-3,5-dideoxy-D-glycero-"-D-galacto-2-nonulopyranosynate)- 
(2!3)-2-O-acetyl-#-D-galactopyranosyl-(1!1)-[" -L-fucopyranosyl-(1!2)]-(1R,2R,3S)-
3-methyl-cyclohexane-3,4-diol (3.2). 
3.21* (310 mg, 0.21 mmol) was dissolved in dioxane/water (4/1, 10 mL) under argon. 
Pd(OH)2/C (40 mg, 10% Pd(OH)2) was added and the resulting mixture was hydrogenated (4 
bar H2) at r.t. After 24 h, the mixture was filtered and the solvent removed under reduced 
pressure yielding 220 mg of a white solid. 50 mg of this residue were dissolved in anhydrous 
MeOH (5 mL) under argon. A solution of NaOMe in anhydrous MeOH (1 N, 125 mL) was 
added under stirring. After 4.5 h, the solution was neutralized with 1 N HAc in MeOH. 
Volatiles were evaporated under reduced and the crude product was purified via SEC. 
Lyophilization from water afforded 3.2 as white fluffy solid (17 mg, 0.021 mmol, 44%). 
1H NMR (500.1 MHz, D2O): "! 5.02 (d, 3J = 3.9Hz, 1H, Fuc-H1), 4.95-4.76 (m, 2H, Fuc-H5, 
Gal-H2), 4.71 (d, 3J = 8.1Hz, 1H, Gal-H1), 4.25 (dd, 3J = 2.9, 10.1Hz, 1H, Gal-H3), 3.94-
3.81 (m, 4H, Fuc-H3, Gal-H4, Sia-H8, Sia-H9a), 3.79-3.55 (m, 10H, Fuc-H2, Fuc-H4, Gal-
H5, Gal-H6a, Gal-H6b, MeCy-H1, Sia-H4, Sia-H5, Sia-H7, Sia-H9b), 3.40 (dd, 3J = 1.8, 
10.3Hz, 1H, Sia-H6), 3.13 (t, 3J = 9.5Hz, 1H, MeCy-H2), 2.65 (t, 3J = 4.6Hz, 2J = 12.4Hz, 
1H, Sia-H3eq), 2.19 (s, 3H, COCH3), 2.09 (m, 1H), 2.00 (s, 3H, COCH3), 1.66-1.61 (m, 4H, 
MeCy, Sia-H3ax), 1.25-1.10 (m, 3H, Fuc-H6, MeCy), 1.08-0.95 (m, 4H, MeCy-CH3, MeCy); 
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13C NMR (125.8 MHz, D2O, CD3OD): ! 176.3, 175.0 (2C, COCH3), 174.9 (Sia-C1), 100.4 
(Sia-C2), 99.8 (Fuc-C1), 99.5 (Gal-C1), 84.5 (MeCy-C2), 80.7 (MeCy-C1), 75.6 (Gal-C5), 
74.5 (Gal-C3), 73.9 (Sia-C6), 73.1 (Fuc-C4), 72.8 (Sia-C8), 71.8 (Gal-C2), 70.3 (Fuc-C3), 
69.2 (3C, Fuc-C2, Sia-C4, Sia-C7), 68.7 (Gal-C4), 67.5 (Fuc-C5), 63.6 (Sia-C9), 62.6 (Gal-
C6), 52.9 (Sia-C5), 40.7 (Sia-C3), 39.7 (MeCy-C3), 34.1 (MeCy-C4), 31.7 (MeCy-C6), 23.5 
(MeCy-C5), 22.9, 21.8 (CH3CO), 19.1 (MeCy-CH3), 16.4 (Fuc-C6); ["]D -58.82 (c 0.91, 
MeOH); HR-MS (ESI) m/z: calcd for C32H52NNa2O20 [M+Na]+: 816.2873 ; found: 816.2874; 
HPLC-purity: > 99.5 % (B). 
 
(Benzyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-"-D-galacto-2- 
nonulopyranosynate)-(2!3)-2,4-di-O-acetyl-6-O-benzoyl-#-D-galactopyranosyl-(1!3)-
[2,3,4-tri-O-benzyl-" -L-fucopyranosyl-(1!4)]-(1R,3R,4R,5S)-1-methoxycarbonyl-5-
methyl-cyclohexane-3,4-diol (3.7). 
1.2 (160 mg, 0.17 mmol) and 1.3c (200 mg, 0.33 mmol) were dissolved in anhydrous CH2Cl2 
(14 mL). Powdered activated molecular sieves 4 Å (1.4 g) were added and the mixture was 
stirred at r.t. under argon. After 3.5 h, a solution of DMTST (130 mg, 0.50 mmol) in 
anhydrous CH2Cl2 (1.0 mL) that had been stirred over powdered activated molecular sieves 4 
Å (0.1 g) for 3.5 h was added. After stirring for 42 h, the solution was diluted with CH2Cl2 
(30 mL), filtered and successively washed with satd aq NaHCO3 (50 mL) and brine (50 mL). 
The aqueous layers were extracted with CH2Cl2 (2 · 50 mL) and the combined organic layers 
were dried over Na2SO4 and concentrated under reduced pressure. Column chromatography 
on silica (MTBE) afforded 3.7 as white foam (167 mg, 0.11 mmol, 65%). 
1H NMR (500.1 MHz, CDCl3): ! 8.10-7.20 (m, 25H, Ar-H), 5.52 (ddd, 3J = 2.9, 5.6, 8.8Hz, 
1H, Sia-H8), 5.32-5.25 (m, 2H, PhCH2, SiaH-7), 5.10 (d, 3J = 3.1Hz, 1H, Gal-H4), 5.06 (d, 
3J = 3.8Hz, 1H, Fuc-H1), 5.00-4.70 (m, 11H, Fuc-H5, Gal-H2, SiaNH, Sia-H4, 4 PhCH2), 
4.64 (d, 3J = 8.0Hz, 1H, Gal-H1), 4.58 (dd, J = 3.3, 10.1Hz, 1H, Gal-H3), 4.31 (dd, 3J = 
2.8Hz, 3J = 12.4Hz, 1H, Sia-H9a), 4.24 (dd, 3J = 6.3Hz, 3J =10.8Hz, 1H, Gal-H6a), 4.13 (dd, 
3J = 3.7, 10.3Hz, 1H, Fuc-H2), 4.08-4.00 (m, 3H, Fuc-H3, Gal-H6b, Sia-H5), 4.00-3.92 (m, 
2H, Gal-H5, Sia-H9b), 3.69-3.59 (m, 5H, CO2CH3, Fuc-H4, MeCy-H3), 3.45 (dd, 1H, 3J = 
2.7, 10.7Hz, Sia-H6), 3.27 (t, 3J = 9.6Hz, MeCy-H4), 2.57 (dd, 3J = 4.6Hz, 3J = 12.7Hz, 1H, 
Sia-H3eq), 2.39-2.28 (m, 2H, MeCy), 2.18, 2.12, 2.07, 2.01, 1.97, 1.85, 1.81 (7s, 21H, 
COCH3), 1.85 (m, 1H, MeCy) 1.72-1.63 (m, 2H, Sia-H3ax, MeCy), 1.45 (m, 1H, MeCy) 1.23-
1.19 (m, 4H, Fuc-H6, MeCy), 1.12 (d, 3J = 6.5Hz, 3H, MeCy-CH3); 13C NMR (125.8 MHz, 
CDCl3): ! 174.8, 170.8, 170.7, 170.5, 170.4, 169.9, (8C, 7 COCH3, CO2Me), 167.5 (Sia-C1), 
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165.8 (ArCO), 139.3, 139.1, 138.6, 134.9, 133.4, 130.0, 129.9, 128.9, 128.8, 128.7, 128.6, 
128.5, 128.4, 128.3, 127.7, 127.6, 127.4, 127.3 (30C, Ar-C), 99.5 (Gal-C1), 98.5 (Fuc-C1), 
96.9 (Sia-C2), 81.6 (MeCy-C4), 80.6 (Fuc-C3), 79.4 (MeCy-C3), 77.7 (Fuc-C4), 76.5 (Fuc-
C2), 74.8, 74.3, 72.7 (3C, PhCH2), 72.1 (Sia-C6), 71.8 (Gal-C3), 70.1, 69.8, 69.4 (Gal-C2, 
Gal-C5, Sia-C4), 68.5 (PhCH2), 67.8, 67.7 (Gal-C4, Sia-C8), 67.1 (Sia C7), 66.4 (Fuc-C5), 
62.4 (Sia-C9), 61.5 (Gal-C6), 51.9 (CO2CH3), 49.0 (Sia-C5), 40.5 (MeCy), 38.4, 37.5, (2C, 
MeCy, Sia-C3), 36.4, 33.2 (2C, MeCy), 23.3, 21.5, 21.0, 20.9, 20.8 (7C, COCH3), 18.7 
(MeCy-CH3), 17.0 (Fuc-C6); [!]D -7.7 (c 0.75, CHCl3); MS (ESI) m/z: calcd for 
C79H93NNaO28 [M+Na]+: 1526.6 ; found: 1526.6; elemental analysis calcd (%) for 
C79H93NO28 + H2O (1522.59): C 62.32, H 6.29, N 0.92; found: C 62.12, H 6.31, N 0.83. 
 
(Sodium 5-acetamido-3,5-dideoxy-D-glycero-!-D-galacto-2-nonulopyranosynate)- 
(2!3)-"-D-galactopyranosyl-(1!3)-[! -L-fucopyranosyl-(1!4)]-(1R,3R,4R,5S)-1-sodium 
carboxylate-5-methyl-cyclohexane-3,4-diol (3.3). 
3.7 (80 mg, 0.053 mmol) was dissolved in dioxane/water (4/1, 5 mL) under argon. 
Pd(OH)2/C (30 mg, 10% Pd(OH)2) was added and the resulting mixture was hydrogenated (4 
bar H2) at r.t. After 24 h, the mixture was filtered and the solvent was removed under reduced 
pressure. The residue was redissolved in 1 N aq NaOH (2 mL) and stirred at r.t. for 8 h. The 
mixture was lyophilized and the resulting solid was dissolved in 1.0 mL water. The pH was 
adjusted to 9.0 with 1 N aq HAc and the crude product purified via SEC. Lyophilization from 
water afforded 3.3 as white fluffy solid (37 mg, 0.045 mmol, 85%). 
1H NMR (500.1 MHz, D2O): #  4.97 (d, 3J = 4.0Hz, 1H, Fuc-H1), 4.79-4.64 (m, Fuc-H5), 
4.45 (d, 3J = 7.9Hz, 1H, Gal-H1), 3.96 (dd, 3J = 3.0, 9.8Hz, 1H, Gal-H3), 3.82 (d, 3J = 
3.0Hz, 1H, Gal-H4), 3.80-3.62 (m, 7H, Cy-H3, Fuc-H3, Fuc-H4, Sia-H4, Sia-H5, Sia-H8, 
Sia-H9a), 3.61-3.40 (m, 8H, Fuc-H2, Gal-H2, Gal-H5, Gal-H6a,b, Sia-H-6, Sia-H7, Sia-
H9b), 3.14 (t, 3J = 9.7Hz, 1H, Cy-H4), 2.62 (dd, 3J = 4.6Hz, 2J = 12.4Hz, 1H, Sia-H3eq), 
2.16 (m, 2H, Cy-H2a, Cy-H6a), 1.90 (s, 3H, COCH3), 1.69 (m, 2H, Cy-H1, Sia-H3ax), 1.56 
(m, 1H, Cy-H5), 1.30 (q, J = 12.4Hz, 1H, Cy-H2b), 1.11 (q, J = 12.8Hz, 1H, Cy-H6b), 1.05 
(d, 3J = 6.6Hz, 1H, Fuc-C6), 0.99 (d, 3J = 6.5Hz, 1H, MeCy-CH3); 13C NMR (125.8 MHz, 
D2O): # 184.7 (Cy-CO2Na), 175.9 (COCH3), 175.1 (Sia-C1), 100.8 (Sia-C2), 100.4 (Gal-C1), 
99.8 (Fuc-C1), 84.4 (Cy-C4), 78.4 (Cy-C3), 76.7 (Gal-C3), 75.4 (Gal-C5), 73.7 (Sia-C6), 
73.0 (Fuc-C4), 72.7 (Sia-C8), 70.2 (Fuc-C3), 69.9 (Gal-C2), 69.4, 69.2, 69.1 (3C, Fuc-C2, 
Sia-C4, Sia-C7), 68.5 (Gal-C4), 67.5 (Fuc-C5), 63.5 (Sia-C9), 62.5 (Gal-C6), 52.6 (Sia-C5), 
40.5 (Sia-C3), 38.7 (Cy-C5), 37.7 (Cy-C6), 34.4 (Cy-C2), 23.0 (COCH3), 19.0 (Cy-CH3), 
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16.4 (Fuc-C6); [!]D -58.3 (c 0.94, MeOH); HR-MS (ESI) m/z: calcd for C31H50NNa2O21 
[M+H]+: 818.2665; found: 818.2664; HPLC-purity: > 99.5 % (E). 
 
(Sodium 5-acetamido-3,5-dideoxy-D-glycero-!-D-galacto-2-nonulopyranosynate)- 
(2!3)-2-O-acetyl-"-D-galactopyranosyl-(1!3)-[! -L-fucopyranosyl-(1!4)]-
(1R,3R,4R,5S)-1-methoxycarbonyl-5-methyl-cyclohexane-3,4-diol (3.4). 
Pd(OH)2/C (5 mg, 10% Pd(OH)2/C) was added to a solution of 3.7 (40 mg, 0.027 mmol) in 
dioxane/H2O (4/1, 10 mL) and the resulting mixture was hydrogenated (4 bar H2) at r.t. After 
2 d, the reaction mixture was filtered, concentrated, and dried at high vacuum 12 h The 
residue was redissolved in absolute MeOH (4.0 mL) and a freshly prepared solution of 
NaOMe in MeOH (1M, 0.160 mL) was added. The solution was stirred under argon for 2 h, 
neutralized with HCl in MeOH (1 M, 0.160 mL), and concentrated under reduced pressure. 
Purification via RP chromatography (H2O/MeOH) afforded 3.4 (19 mg, 0.022 mmol, 84%) as 
white fluffy solid. 
1H NMR (500.1 MHz, CD3OD): #  5.03 (dd, 3J = 8.0, 9.8Hz, Gal-H2), 4.97 (d, 3J = 4.0Hz, 
1H, Fuc-H1), 4.95-4.85 (m, Fuc-H5), 4.51 (d, 3J = 8.0Hz, 1H, Gal-H1), 4.19 (dd, 3J = 3.0, 
9.8Hz, 1H, Gal-H3), 3.98 (m, 1H, Sia-H8), 3.90 (d, 3J = 3.0Hz, 1H, Gal-H4), 3.89-3.83 (m, 
2H, Fuc-H3, Sia-H9a), 3.78-3.58 (m, 11H, Fuc-H2, Fuc-H4, Gal-H6a,b, Cy-H3, Cy-CO2CH3, 
Sia-H4, Sia-H5, Sia-H9b), 3.51-3.43 (2H, Gal-H5, Sia-H7), 3.39 (dd, 3J = 2.0, 10.3Hz, Sia-
H6), 3.17 (t, 3J = 9.6Hz, 1H, Cy-H4), 2.78 (dd, 3J = 4.8Hz, 2J = 12.3Hz, 1H, Sia-H3eq), 2.46 
(m, 1H, Cy-H1), 2.29 (m, 1H, Cy-H2a), 2.17 (s, 3H, COCH3), 2.01 (s, 3H, COCH3), 1.84 (m, 
1H, Cy-H6a), 1.69 (m, 1H, Cy-H5), 1.55 (t, 3J = 12.3Hz, 1H, Sia-H3ax), 1.33 (m, 1H, Cy-
H2b), 1.26-1.21 (m, 2H, Cy-H6b, Fuc-H6), 1.14 (d, 3J = 6.5Hz, 1H, Cy-CH3); 13C NMR 
(125.8 MHz, CD3OD): # 176.5 (Cy-CO2CH3) 175.7, 175.4 (2C, CH3CO, Sia-C1), 172.7 
(COCH3), 100.6, 100.5, 100.4 (3C, Fuc-C1, Gal-C1, Sia-C2), 83.0 (Cy-C4), 79.4 (Cy-C3), 
76.3 (Gal-C5), 75.5 (Gal-C3), 74.8 (Sia-C6), 73.9 (Fuc-C4), 72.9 (Sia-C8), 71.9 (Gal-C2), 
71.3 (Fuc-C3), 70.3, 69.4 (3C, Fuc-C2, Sia-C4, Sia-C7), 68.8 (Gal-C4), 67.7 (Fuc-C5), 64.7 
(Sia-C9), 63.3 (Gal-C6), 54.1 (Sia-C5), 52.3 (CyCO2CH3), 42.3 (Sia-C3), 41.4 (Cy-C1), 39.3 
(Cy-C5), 37.3 (Cy-C6), 34.5 (Cy-C2), 22.5, 21.6 (2C, COCH3), 19.3 (Cy-CH3), 16.7 (Fuc-
C6); [!]D -13.9 (c 0.47, MeOH); HR-MS (ESI) m/z: calcd for C34H54NNa2O22+ [M+Na+]+: 
874.2927; found: 874.2929; HPLC purity: 99% (B). 
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(5-Acetamido-3,5-dideoxy-D-glycero-!-D-galacto-2-nonulopyranosidonic acid)- 
(2!3)-"-D-galactopyranosyl-(1!3)-[! -L-fucopyranosyl-(1!4)]-(1R,3R,4R,5S)-1-((1-
(9H-fluoren-9-yl)-3,12-dioxo-2,7,10-trioxa-4,13-diazapentadecan-15-yl)carbamoyl)-5-
methyl-cyclohexane-3,4-diol (3.9). 
A solution of 3.4 (13 mg, 15.7 µmol) in 1,2-diaminoethane (2.0 mL, 30 mmol) was stirred in 
a sealed vessel under argon at 80°C for 5 h. The solution was concentrated under reduced 
pressure, roughly purified via SEC, and lyophilized from water to give still impure amine 3.8 
(7.0 mg), which was directly used in the next step. The residue was dissolved in aqueous 
NaHCO3 (50 mM, 2.0 mL) and MeCN (1.0 mL) and a solution of 3.11 (4.0 mg, 8.3 µmol) in 
MeCN (1.0 mL) was added. The reaction mixture was stirred at r.t. for 5 h, lyophilized and 
purified via RP chromatography (H2O/MeOH) to give 3.9 (4.9 mg, 4.1 µmol, 26%) as white 
fluffy solid. 
1H NMR (500.1 MHz, CD3OD): #  7.80, 7.65, 7.40, 7.31 (4m, 8H, Ar-H), 4.98 (d, 3J = 
3.9Hz, 1H, Fuc-H1), 4.96-4.85 (m, 1H, Fuc-H5), 4.40-4.32 (m, 3H, Gal-H1, 2H linker), 4.21 
(t, 3J = 6.7Hz, 1H, Fmoc-H2), 4.02-3.96 (m, 3H, Gal-H3, 2H linker), 3.92-3.26 (12H linker), 
3.92-3.52 (Fuc-H2, Fuc-H3, Fuc-H4, Gal-H2, Gal-H4, Gal-H6a, Gal-H6b, Cy-H3, Sia-H4, 
Sia-H5, Sia-H6, Sia-H8, Sia-H9a, Sia-H9b), 3.48 (m, 1H, Sia-H7), 3.41 (m, 1H, Gal-H5), 
3.23 (t, 3J = 9.5Hz, 1H, Cy-H4), 2.85 (m, 1H, Sia-H3eq), 2.24 (m, 2H, Cy-H2a, Cy-H6a), 
2.00 (s, 3H, COCH3), 1.79-1.63 (m, 3H, Cy, Sia-H3ax), 1.53 (q, J = 12.3Hz, 1H, Cy), 1.31 
(m, 1H, Cy), 1.17 (d, 3J = 6.5Hz, 1H, Fuc-C6), 1.13 (d, 3J = 6.2Hz, 1H, MeCy-CH3); 13C 
NMR (125.8 MHz, CD3OD): # 177.6, 127.5, 175.2, 173.2 (4C, Cy-CONH, 2 CONH, Sia-
C1), 159.0 (NHCO2CH2), 145.3, 142.6 (4C, Ar-Ci), 128.8, 128.2, 126.2, 121.0 (8C, Ar-CH), 
102.2, 101.0, 100.4 (Fuc-C1, Gal-C1, Sia-C2), 83.6 (Cy-C4), 78.7 (Cy-C3), 77.9 (Gal-C3), 
76.3 (Gal-C5), 74.8, 73.8, 73.0, 72.0, 71.2, 71.0, 70.4, 70.3, 70.1, 69.5, 68.9 (13C, Fuc-C2, 
Fuc-C3, Fuc-C4, Gal-C2, Gal-C4, Sia-C4, Sia-C6, Sia-C7, Sia-C8, 4C linker), 67.7 (Fmoc-
C1), 67.5 (Fuc-C5), 64.6 (Sia-C9), 63.3 (Gal-C6), 53.9 (Sia-C5), 48.4 (Fmoc-C2), 43.2 (Cy-
C1), 42.1 (Sia-C3), 41.7, 39.8, (3C, linker), 39.2 (Cy-C5), 37.6 (Cy-C6), 34.9 (Cy-C2), 22.6 
(COCH3), 19.4 (Cy-CH3), 16.7 (Fuc-C6); MS (ESI) m/z: calcd for C54H78N4NaO25 [M+Na]+: 
1205.48; found: 1205.46. 
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(5-Acetamido-3,5-dideoxy-D-glycero-!-D-galacto-2-nonulopyranosidonic acid)- 
(2!3)-"-D-galactopyranosyl-(1!3)-[! -L-fucopyranosyl-(1!4)]-(1R,3R,4R,5S)-1((2-(2-
(2-(2-aminoethoxy)ethoxy)acetamido)ethyl)carbamoyl)-5-methyl-cyclohexane-3,4-diol 
(3.5). 
A solution of 3.9 (1.0 mg, 0.85 µmol) in MeCN/piperidine (20% v/v piperidine, 0.5 mL) was 
stirred at r.t. for 2 h. Volatiles were evaporated under reduced pressure and the residue was 
redissolved in H2O (4 mL) and washed with CH2Cl2 (2 · 4 mL). Lyophilization of the 
aqueous layer afforded 3.5, which was directly used.  
MS (ESI) m/z: calcd for C39H69N4O23 [M+H]+: 961.43; found: 961.51. 
 
2,5-Dioxopyrrolidin-1-yl 1-(9H-fluoren-9-yl)-3-oxo-2,7,10-trioxa-4-azadodecan-12-oate 
(3.11). 
A solution of 8-(Fmoc-amino)-3,6-dioxaoctanoic acid 3.10 (60 mg, 0.156 mmol), NHS (24 
mg, 0.208 mmol) and DIC (40 µL, 0.258 mmol) in anhydrous THF (3.0 mL) was stirred 
under argon at r.t. for 16 h. The solution was diluted with THF (5 mL) and washed with satd. 
aq NaHCO3 (10 mL) and brine (10 mL). The aqueous layers were extracted with Et2O (3 · 10 
mL), dried over Na2SO4 and the organic layers were concentrated under reduced pressure. 
The residue was dissolved in MeCN (4 mL) to precipitate diisopropyl urea, filtered and the 
filtrate was concentrated under reduced pressure to give 3.11 (73 mg, 0.151 mmol, 97%), 
which was directly used in the next step. 
MS (ESI) m/z: calcd. for C25H26N2NaO8 [M+Na]+: 505.16; found: 505.11 
 
2-(Trimethylsilyl)ethyl (benzyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D- 
glycero-"-D-galacto-2-nonulopyranosynate)-(2!3)-2,4-di-O-acetyl-6-O-benzoyl-#-D-
galactopyranoside (3.13). 
1.4 (5.00 g, 7.44 mmol) and 1.5 (3.00 g, 7.80 mmol) were dissolved in anhydrous 
MeCN/CH2Cl2 (3/2, 150 mL). Powdered activated molecular sieves 3 Å (15 g) were added 
and the mixture was stirred under argon at r.t. for 3 h. The mixture was then cooled to -70°C 
and NIS (3.20 g, 14.22 mmol) in MeCN was added. Within 20 min, 5.7 mL of a 0.4 N 
solution of trifluormethanesulfonic acid in MeCN was added dropwise and the solution was 
stirred at -70°C for 20 min. After stirring overnight at -30°C the mixture was diluted with 
CH2Cl2, filtered and successively washed with 20% aq Na2S2O3, satd aq NaHCO3, and brine. 
The organic layer was dried over Na2SO4 and concentrated under reduced pressure. Column 
chromatography on silica (CH2Cl2/i-propanol 30/1) afforded still impure 3.12 (2.92 g), which 
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was directly used in the next step. The residue (2.50 g) and Ac2O (3.0 mL, 31.7 mmol) were 
dissolved in anhydrous pyridine (6.0 mL) and catalytic amounts of DMAP were added. After 
stirring for 24 h at r.t., volatiles were evaporated under reduced pressure. The residue was 
dissolved in EtOAc and washed with water, aqueous HCl (1M), satd. aqueous NaHCO3 and 
brine. The aqueous layers were extracted with CH2Cl2 (2 ·50 mL), the combined organic 
layers were dried with Na2SO4 and concentrated under reduced pressure. Column 
chromatography on silica (MTBE) afforded 3.13 (1.80 g, 2.47 mmol, 28% over 2 steps) as 
white foam. 
1H NMR (500.1 MHz, CDCl3): ! 8.08-7.28 (m, 10H, Ar-H), 5.51 (ddd, 3J = 2.6, 5.4, 8.4Hz, 
1H, Sia-H8), 5.32-5.26 (m, 2H, PhCH2, Sia-H7), 5.15 (d, 3J = 10.3Hz, 1H, Sia-NH), 5.13 (d, 
3J = 3.0Hz, 1H, Gal-H4), 5.03 (dd, 3J = 8.1, 10.0Hz, 1H, Gal-H2), 4.94 (B of AB, J = 
12.1Hz, 1H, PhCH2), 4.81 (td, 3J = 4.6, 11.9Hz, 1H, Sia-H4), 4.61 (d, 3J = 8.1Hz, 1H, Gal-
H1), 4.60 (dd, 3J = 3.0, 10.0Hz, 1H, Gal-H3), 4.42 (dd, 3J = 6.8Hz, 2J = 11.1Hz, 1H, Gal-
H6a), 4.30 (dd, 3J = 2.4Hz, 2J = 12.4Hz, 1H, Sia-H9a), 4.21 (dd, 3J = 6.8Hz, 2J = 11.1Hz, 
1H, Gal-H6b), 4.05-3.94 (m, 4H, Gal-H5, Sia-H5, Sia-H9b, OCH2CH2), 3.58 (td, J = 4.6, 
12.6Hz, 1H, OCH2CH2), 3.47 (dd, 1H, 3J = 2.6, 10.8Hz, Sia-H6), 2.59 (dd, 3J = 4.6Hz, 2J = 
12.4Hz, 1H, Sia-H3eq), 2.18, 2.09, 2.06, 2.03, 2.00, 1.94, 1.79 (7s, 21H, 7 COCH3), 1.66 (dd, 
2J =3J = 12.4Hz, 1H, Sia-H3ax), 1.06-0.86 (m, 2H, OCH2CH2), -0.03 (s, 9H, Me3Si); 13C 
NMR (125.8 MHz, CDCl3): ! 170.6, 170.6, 170.4, 170.3, 169.7, 169.7 (7C, CH3CO), 167.4 
(Sia-C1), 165.8 (ArCO), 134.8 (Bn, Ar-Ci), 133.2 (Ar-CH), 129.8 (Ar-Ci), 129.7, 128.8, 
128.6, 128.4 (9C, Ar-CH), 100.6 (Gal-C1), 96.8 (Sia-C2), 72.0 (Sia-C6), 71.7 (Gal-C3), 70.3 
(Gal-C5), 70.0 (Gal-C2), 69.3 (Sia-C4), 68.4 (PhCH2), 67.8, 67.6 (Gal-C4, Sia-C8), 67.5 
(OCH2CH2Si), 67.0 (Sia C7), 62.4 (Sia-C9), 61.9 (Gal-C6), 48.9 (Sia-C5), 37.5 (Sia-C3), 
23.1, 21.4, 21.1, 20.8, 20.8 (7C, CH3CO), 18.0 (OCH2CH2), -1.4 (3C, Si(CH3)3); ["]D -0.5° (c 
1.08, CHCl3); MS (ESI) m/z: calcd for C48H63NNaO21Si [M+Na]+: 1040.4; found: 1040.5; 
elemental analysis calcd (%) for C48H63NO21Si (1018.10): C 56.63, H 6.24, N 1.38; found: C 
56.58, H 6.32, N 1.26.  
 
(Benzyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-"-D-galacto-2- 
nonulopyranosynate)-(2!3)-1,2,4-tri-O-acetyl-6-O-benzoyl-"-D-galactopyranoside 
(3.14). 
3.13 (1.00 g, 0.98 mmol) and Ac2O (1.39 mL, 14.7 mmol) were dissolved in anhydrous 
toluene (16 mL). Powdered activated molecular sieves 4 Å (2.0 g) were added and the 
mixture was stirred at r.t. under argon for 30 min. Freshly distilled BF3·Et2O (0.50 mL, 3.98 
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mmol) was added dropwise and stirring was continued for 16 h. After dilution with CH2Cl2 
(30 mL), the reaction mixture was filtered and the filtrate was washed with satd. aqueous 
NaHCO3 (30 mL) and brine (30 mL). The aqueous layers were extracted with CH2Cl2 (2 ·30 
mL) and the combined organic layers were dried over Na2SO4 and concentrated. Column 
chromatography on silica (MTBE/acetone 4/1) afforded 3.14 as white foam (0.94 g, quant.). 
1H NMR (500.1 MHz, CDCl3): ! 8.09-7.32 (m, 10H, Ar-H), 5.87 (d, 3J = 8.3Hz, 1H, Gal-
H1), 5.52 (ddd, 3J = 2.4, 6.4, 8.8Hz, 1H, Sia-H8), 5.34 (A of AB, J = 12.0Hz, 1H, PhCH2), 
5.30 (dd, 3J = 2.4, 8.7Hz, 1H, Sia-H7), 5.23-5.17 (m, 2H, Gal-H2, Gal-H4), 4.98 (m, 2H, Sia-
NH, PhCH2), 4.88-4.79 (m, 2H, Gal-H3, Sia-H4), 4.45-4.36 (m, 2H, Gal-H6a, Sia-H9a), 
4.27-4.19 (m, 2H, Gal-H5, Gal-H6b), 4.05 (dd, 3J =3J = 10.5Hz, 1H, Sia-H5), 3.94 (dd, 3J = 
6.4Hz, 2J =12.4Hz, 1H, Sia-H9b), 3.49 (dd, 1H, 3J = 2.4, 10.5Hz, Sia-H6), 2.63 (dd, 3J = 
4.6Hz, 2J =12.6Hz, 1H, Sia-H3eq), 2.22, 2.14, 2.12, 2.11, 2.06, 2.05, 1.98, 1.82 (8s, 24H, 8 
COCH3), 1.69 (m, 1H, Sia-H3ax); 13C NMR (125.8 MHz, CDCl3): ! 170.9, 170.8, 170.6, 
170.5, 170.2, 169.9, 169.8, 169.1 (8C, COCH3), 167.4 (Sia-C1), 165.9 (ArCO), 134.8, 129.9, 
129.8, 129.1, 128.8, 128.5 (12C, Ar-C), 97.0 (Sia-C2), 92.3 (Gal-C1), 72.4 (Sia-C6), 71.5, 
71.4 (Gal-C3, Gal-C5), 69.3 (Sia-C4), 68.9 (Gal-C2), 68.6 (PhCH2), 68.2 (Sia-C8), 67.5, 67.3 
(Gal-C4, Sia-C7), 62.7 (Sia-C9), 61.8 (Gal-C6), 49.0 (Sia-C5), 37.6 (Sia-C3), 23.3, 21.6, 
21.1, 21.0, 20.9 (8C, COCH3); ["]D 13.4° (c 1.27, CHCl3); MS (ESI) m/z: calcd for 
C45H53NNaO22 [M+Na]+: 982.3; found: 982.6; elemental analysis calcd (%) for C45H53NO22 
(959.90): C 56.31, H 5.57, N 1.46; found: C 56.15, H 5.68, N 1.41. 
 
Ethyl (benzyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-"-D-galacto-2-
nonulopyranosynate)-(2!3)-2,4-di-O-acetyl-6-O-benzoyl-1-thio-#-D-galacto 
pyranoside (1.2). 
3.14 (1.71 g, 1.78 mmol) and ethanethiol (0.20 mL, 2.70 mmol) were dissolved in anhydrous 
CH2Cl2 (40 mL) under argon. Freshly distilled BF3·Et2O (0.47 mL, 3.74 mmol) was added 
dropwise and the reaction was stirred at r.t. for 2 h. After dilution with CH2Cl2 (60 mL), the 
reaction mixture was washed with satd. aqueous NaHCO3 (100 mL) and brine (100 mL). The 
aqueous layers were extracted with CH2Cl2 (2 ·100 mL) and the combined organic layers 
were dried over Na2SO4 and concentrated under reduced pressure. Column chromatography 
on silica (MTBE) afforded 1.2 as white foam (1.51 g, 1.57 mmol, 88%). 
1H NMR (500.1 MHz, CDCl3): ! 8.10-7.32 (m, 10H, Ar-H), 5.52 (ddd, 3J = 2.7, 5.4, 8.5Hz, 
1H, Sia-H8), 5.36-5.31 (m, 2H, Sia-H7, PhCH2), 5.20 (d, 3J = 3.0Hz, 1H, Gal-H4), 5.11 (dd, 
3J =3J = 9.9Hz, 1H, Gal-H2), 4.97 (B of AB, J = 11.4Hz, 1H, PhCH2), 4.94 (d, 3J = 10.4Hz, 
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1H, Sia-NH) 4.84 (ddd, 3J = 4.6, 12.4Hz, 1H, Sia-H4), 4.71 (d, 3J = 7.6Hz, 1H, Gal-H1), 
4.69 (dd, 3J = 3.0, 9.9Hz, 1H, Gal-H3), 4.43 (dd, 3J = 6.8Hz, 2J = 11.2Hz, 1H, Gal-H6a), 
4.33 (dd, 3J = 2.7Hz, 2J =12.5Hz, 1H, Sia-H9a), 4.22 (dd, 3J = 6.8, 2J =11.2Hz, 1H, Gal-
H6b), 4.09-4.03 (m, 2H, Gal-H5, Sia-H5), 3.99 (dd, 3J = 5.4Hz, 2J =12.5Hz, 1H, Sia-H9b), 
3.48 (dd, 1H, 3J = 2.7, 10.8Hz, Sia-H6), 2.83-2.68 (m, 2H, SCH2CH3), 2.62 (dd, 3J = 4.6Hz, 
2J =12.4Hz, 1H, Sia-H3eq), 2.22, 2.13, 2.10, 2.06, 2.04, 1.98, 1.83 (7s, 21H, 7 COCH3), 1.70 
(dd, 2J =3J =12.4Hz, 1H, Sia-H3ax), 1.30 (t, 3J = 7.4Hz, 3H, SCH2CH3); 13C NMR (125.8 
MHz, CDCl3): ! 170.7, 170.6, 170.4, 170.0, 169.8 (7C, COCH3), 167.5 (Sia-C1), 166.0 
(ArCO), 134.9, 133.4, 129.9, 129.0, 128.8, 128.8, 128.5 (12C, Ar-C), 96.7 (Sia-C2), 83.9 
(Gal-C1), 74.3 (Gal-C5), 72.5 (Gal-C3), 72.2 (Sia-C6), 69.4 (Sia-C4), 68.5 (PhCH2), 68.4 
(Gal-C2), 68.0 (Gal-C4, Sia-C8), 67.1 (Sia C7), 62.5 (Sia-C9), 62.2 (Gal-C6), 49.1 (Sia-C5), 
37.6 (Sia-C3), 24.7 (S-CH2CH3), 23.3, 21.6, 21.1, 20.9, (7C, COCH3), 15.2 (S-CH2CH3); 
["]D 1.2° (c 0.70, CHCl3); MS (ESI) m/z: calcd for C45H55NNaO20S [M+Na]+: 984.3; found: 
984.6; elemental analysis calcd (%) for C45H55NO20S (961.98): C 56.19, H 5.76, N 1.46; 
found: C 56.14, H 5.79, N 1.33.  
 
Benzyl 5-acetamido-2,4,7,8,9-penta-O-acetyl-3,5-dideoxy-D-glycero-# -D-galacto-2- 
nonulopyranosynate (3.17). 
N-Acetyl neuraminic acid 3.15 (2.00 g, 6.5 mmol) and DMAP (cat.) were dissolved in 
anhydrous pyridine (10 mL) under argon at 0°C. Acetic anhydride (5.0 mL, 6.2 mmol) was 
added slowly and the mixture was stirred at r.t. for 16 h. After completion of the reaction 
(TLC: CH2Cl2/MeOH/H2O 13:7:1.6), it was quenched with MeOH (4 mL) and stirred for 1 h. 
Evaporation of volatiles yielded crude 3.16 (3.91 g), which was used without further 
purification.  
The crude product was dissolved in anhydrous DMF (35 mL) and KF (932 mg, 16.0 mmol) 
and BnBr (1.14 mL, 9.6 mmol) were added. After stirring for 21 h, DMF was evaporated 
under reduced pressure, the residue was dissolved in CH2Cl2, filtered and washed with water. 
Column chromatography on silica (CH2Cl2/MeOH) yielded 3.17 as a white foam (72%). 
Analytical data were in accordance with literature.[10] 
 
O-Ethyl S-(benzyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-"-D-  
galacto-2-nonulopyranosynate)dithiocarbonate (1.4). 
3.17 (2.0 g, 3.28 mmol) was dissolved in anhydrous CH2Cl2 (12 mL) in a sealed vessel and 
cooled to -20°C. Acetyl chloride (4.0 mL, 56.3 mmol) and concentrated HCl (0.50 mL) were 
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added dropwise under stirring. After stirring at r.t. for 27 h, the mixture was cooled to -20°C 
again, diluted with CH2Cl2 and washed with water, satd. aq NaHCO3, and brine. The organic 
layer was dried (Na2SO4), filtered and concentrated under reduced pressure to yield the 
chloro derivative 3.18 as white foam (1.92 g, 3.28 mmol, quant.), which was directly used in 
the next step.  
A solution of satd. aqueous NaHCO3 (10 ml) was slowly added to a stirred solution of the 
chloro intermediate (1.0 g, 1.71 mmol), potassium ethyl xanthogenate (0.33 g, 2.06 mmol) 
and TBAHS (0.58 g, 1.71 mmol) in EtOAc (10 mL). The resulting mixture was stirred at r.t. 
for 3 h, diluted with EtOAc and washed with water and brine. The organic layer was dried 
(Na2SO4), filtered and concentrated under reduced pressure. Column chromatography on 
silica (PE/EtOAc 1/1 to 0/1) afforded 1.4 as white foam (0.96 g, 1.03 mmol, 60%). Analytical 
data were in accordance with literature.[6] 
 
2,3,4,6-Tetra-O-acetyl-!-D-galactopyranosyl bromide (3.20). 
HBr in acetic acid (33% solution, 90 mL) was added to a stirred solution of pentaacetyl-"-D-
galactose 3.19 (10.0 g, 25.6 mmol) in anhydrous CH2Cl2 (40 mL) at 0°C over the course of 1 
h. The mixture was stirred at 0°C for another 1.5 h and subsequently poured on an ice/water 
mixture. The aqueous layer was extracted with CH2Cl2 and the organic layers were washed 
with satd. aqueous NaHCO3 and brine. The combined organic layers were dried over Na2SO4, 
filtered and concentrated. Column chromatography on silica (PE/EtOAc) afforded 3.20 as 
white solid (9.66 g, 23.5 mmol, 92%). Analytical data were in accordance with literature.[11] 
 
2-(Trimethylsilyl)ethyl 2,3,4,6-tetra-O-acetyl-"-D-galactopyranoside (3.21). 
A suspension of 3.20 (9.18 g, 22.3 mmol), HgO (4.84 g, 22.3 mmol), HgBr2 (40mg, 0.11 
mmol), powdered activated molecular sieves 3 Å (10 g) and 2-(trimethylsilyl)ethanol (6.50 
mL, 45.0 mmol) in CH2Cl2 was stirred with light exclusion at r.t. for 12 h. The mixture was 
filtered (Celite) and the Celite was washed with CH2Cl2. The filtrate was concentrated and 
the resulting residue was purified by column chromatography on silica (PE/EtOAc 1/0 to 1/1) 
to afford 3.21 as white foam (8.50 g, 19.0 mmol, 85%). Analytical data were in accordance 
with literature.[12] 
 
2-(Trimethylsilyl)ethyl "-D-galactopyranoside (3.22). 
To a stirred solution of 3.21 (1.34 g, 2.99 mmol) in anhydrous MeOH (14 mL) was added a 
freshly prepared solution of NaOMe in MeOH (1M, 1.4 mL) under argon at r.t. The mixture 
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was stirred for 2 h, neutralized with Amberlyst 15 ion exchange resin and filtered (Celite). 
Celite was washed with MeOH and the combined filtrates were concentrated to afford 3.22 
(0.836 g, 2.98 mmol, quant.) as white foam, which was used in the next step without further 
purification. Analytical data were in accordance with literature.[13] 
 
2-(Trimethylsilyl)ethyl 3-O-benzyl-!-D-galactopyranoside (3.23). 
A suspension of 3.22 (0.62 g, 2.21 mmol) and Bu2SnO (0.83 g, 3.33 mmol) in anhydrous 
toluene (15 mL) was stirred under argon at 80°C for 4 h. TBAB (0.36 g, 1.12 mmol) and 
BnBr (3.20 mL, 26.90 mmol) were added and the solution was stirred at 60°C for 4 h. 
Concentration under reduced pressure followed by column chromatography on silica 
(PE/EtOAc 1/1 to 0/1) afforded 3.23 as sticky white solid (0.67 g, 1.81 mmol, 82%). 
Analytical data were in accordance with literature.[14] 
 
2-(Trimethylsilyl)ethyl 6-O-benzoyl-3-O-benzyl-!-D-galactopyranoside (3.24). 
A solution of benzoyl chloride (0.088 mL, 0.76 mmol) in anhydrous CH2Cl2 (10 mL) was 
slowly added to a stirred solution of 3.23 (0.20 g, 0.54 mmol) in anhydrous pyridine (2 mL) 
and anhydrous CH2Cl2 (8 mL) at -50°C under argon. After 1 h, the reaction mixture was 
warmed to -20°C, quenched with MeOH (0.5 mL) and stirred at -20°C for 0.5 h. The reaction 
was warmed to r.t., volatiles were evaporated, the mixture was redissolved in CH2Cl2 and 
washed with water. The organic layer was dried (Na2SO4), filtered, and concentrated. 
Column chromatography on silica (PE/EtOAc) afforded 3.24 (0.154 g, 0.32 mmol, 60%) as 
white crystalline solid. Analytical data were in accordance with literature.[14] 
 
2-(Trimethylsilyl)ethyl 6-O-benzoyl-!-D-galactopyranoside (1.5). 
A suspension of 3.24 (5.0 g, 10.5 mmol) and Pd(OH)2/C (0.20 g, 10% Pd(OH)2) in 
dioxane/water (4/1, 50 mL) was hydrogenated at (4 bar H2) at r.t. After 12 h, the mixture was 
filtered (Celite) and concentrated to afford 1.5 (4.05 g, 10.5 mmol, quant.) as white foam. 
Analytical data were in accordance with literature.[14] 
 
2,3,4-Tri-O-benzyl-" -L-fucopyranosyl-(1"2)-(R,R)-cyclohexane-1,2-diol (1.3a). 
Bromine (0.113 mL, 2.20 mmol), was slowly added to a stirred solution of fucose donor 
1.6[18] (0.96 g, 2.00 mmol) in anhydrous CH2Cl2 (70 mL) and DMF (3 mL) at 0°C under 
argon. After 10 min, excess bromine was quenched by addition of cyclohexene. Powdered 
activated molecular sieves 4 Å (6.0 g), TBAB (1.93 g, 5.99 mmol), and (R,R)-cyclohexane-
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1,2-diol (0.70 g, 6.03 mmol) were added and the mixture was stirred at 0°C for 2 h before 
warming to r.t. and stirring at r.t. for 12 h The reaction mixture was filtered (celite) and 
washed with water and brine. The organic layer was dried over Na2SO4, filtered, and 
concentrated under reduced pressure. Column chromatography on silica (CH2Cl2/MTBE 
40/1) afforded 1.3a as clear oil (0.716 g, 1.34 mmol, 67%). Analytical data were in 
accordance with literature.[18] 
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Abstract 
A small series of amides and sulfonamides was synthesized to target a hitherto unexplored 
binding pocket of P-selectin. The structurally simplified and non-charged mimetics of the 
lead sialyl Lewisx (sLex) exhibited up to threefold higher binding affinities than sLex. 
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Introduction 
Numerous chronic and acute inflammatory diseases like asthma, psoriasis, and rheumatoid 
arthritis are characterized by an excessive influx of leukocytes into inflamed tissue.[1] 
Selectins are lectins that mediate the initial step of leukocyte recruitment to sites of 
inflammation and consequently became attractive targets for the development of anti-
inflammatory agents.[2] The minimum carbohydrate motif recognized by all selectins is the 
tetrasaccharide sialyl Lewisx (sLex, 1, Figure 1),[3] which has been the lead structure for the 
design of most selectin antagonists.  
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Figure 1. Left: the tetrasaccharide sialyl Lewisx (1) and its pharmacophoric groups: hydroxyl groups 
of L-fucose[4,5], hydroxyl groups in 4- and 6- position of D-galactose[6] and the carboxylic acid residue 
of sialic acid[7]. Right: Exchange of GlcNAc by (1R,2R,3S)-3-methyl-cyclohexane-1,2-diol enhances 
binding affinity on E- and P-selectin 30- and 20-fold, respectively. 
Since sLex itself is binding only weakly to the selectins and suffers from poor 
pharmacokinetic properties as well as complex synthesis, huge efforts were made both by 
academic and industrial research groups to improve the drug-likeness of sLex.[8] A common 
and successful strategy is the stepwise replacement of single or several carbohydrate residues 
by mimics.[9] The replacement of N-acetyl-D-glucosamine (D-GlcNAc), which merely serves 
as a spacer between L-fucose (L-Fuc) and D-galactose (D-Gal),[5,10] with (1R,2R,3S)-3-
methyl-cyclohexane-1,2-diol for instance enhanced binding affinity towards E- and P-selectin 
30-fold and 20-fold, respectively (2, Figure 1).[11] The comparable effect of this modification 
on the affinity to both selectins was rationalized by the almost identical conformation of the 
Lewisx core upon binding to P- and E-selectin and the high degree of similarity of the core 
binding sites of both selectins. A major difference however exists in the sialic acid (N-acetyl-
D-neuraminic acid, D-Neu5Ac) binding site formed by the loop of amino acids 94 to 100 
(Figure 2).[12] In the complex with E-selectin, the carboxylate of sLex forms a salt bridge with 
Arg97 and a hydrogen bond with Tyr48, interactions of utmost importance for the affinity of 
the antagonists. In P-selectin, Arg97 is replaced with Ser97 and the salt bridge is no longer 
possible. Instead, a water-mediated hydrogen bond with Ser97 is formed. The additional H-
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bond to Tyr48 contributes similarly to binding as in E-selectin. In line with this binding 
mode, we could recently show that the negative charge of the carboxylic acid residue of sialic 
acid is no prerequisite for affinity to P-selectin, while it is essential for binding to E-
selectin.[11] 
The side chains of Glu98, Lys99 and Asp100 in E-selectin form a rather wide and lipophilic 
binding pocket, which is partially occluded by the guanidinium moiety of Arg97 (Figure 2). 
In contrast, Ser97, Pro98, Ser99, and Ala100 of P-selectin form a rigid groove, stabilized by a 
highly ordered H-bond network. As this well defined binding pocket is only occupied by 
water, we reasoned that D-Neu5Ac could be replaced with appropriate mimics to directly 
target the pocket and gain additional interactions.  
 
              
Figure 2. Sialic acid residue of sLex binding to E-selectin (left) and to P-selectin (right).[5] 
Results and discussion 
1. Design 
A closer look at the crystal structures of apo-P-selectin (1g1q) and P-selectin co-crystallized 
with a fragment of the physiological P-selectin ligand PSGL-1 (SGP-3, pdb-code: 1g1s) 
reveals that a water molecule positioned above Tyr94 is present in both crystal structures.[5] 
In apo-P-selectin, it binds to Ser97, in the P-selectin SGP-3 complex, it mediates a hydrogen 
bond between Ser97 and the carboxy group of D-Neu5Ac. Replacement of this structure 
water with a properly positioned heteroatom consequently offers the possibility to increase 
the affinity of P-selectin antagonists, especially since this water molecule is only weakly 
anchored in the binding pocket. Additional affinity might also result from lipophilic 
interactions with the aromatic side chain of Tyr94. Based on the core of 2, two small series of 
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mimetics were designed to target the D-Neu5Ac binding pocket of P-selectin (Table 1). 
Amides 12 and 13 were designed to replace the water molecule with the side chain oxygen, 
while amide 16 served to evaluate the effect of the amide moiety itself. Since molecular 
modeling studies indicated that sulfonamides were better suited to target the aromatic moiety 
of Tyr48, sulfonamide 15 was synthesized as well. Finally, sulfonamides 18 to 20 were 
designed to target both Tyr94 and Ser97 (Figure 3). Methyl sulfonamide 14 served as a 
control to study the effect of the sulfonamide moiety itself. 
 
Figure 3. Predicted binding mode of sulfonamide 19 designed to occupy the pocket formed by Tyr48, 
Tyr94, Ser97, Pro98, and Ser99. 
2. Synthesis 
Azide 7 was obtained from 3 in analogy to a double inversion route developed by Öberg et 
al. (Scheme 1).[13] The 4,6-benzylidene acetal of ethyl thio-!-D-galactoside (3) was 
successively treated with triflic anhydride in pyridine/CH2Cl2 and acetyl chloride to yield 
triflate 4. Nitrite mediated inversion of 4 afforded guloside 5 in 55% yield, which was again 
activated as triflate 6. A second inversion using tetrabutylammonium azide under microwave 
conditions afforded 3-azido-3-deoxy-!-D-galactoside 7, which upon DMTST[14] promoted 
coupling to pseudo disaccharide 8 provided 9. Subsequent hydrolysation of the acetate 
followed by reduction of azide 10 to amine 11 proceeded in excellent yields.  
Pseudotrisaccharide 11 was coupled to carboxylic acids using standard coupling conditions. 
Subsequent debenzylation by hydrogenolysis afforded 12 and a 1:1 diastereomeric mixture of 
13. Sulfonylation of 11 with methansulfonyl chloride and furan-3-sulfonyl chloride at 0°C 
yielded the corresponding sulfonamides, which were directly deprotected under reducing 
conditions to afford 14 and a diastereomeric mixture (58 : 42) of 15. 
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Scheme 1. a) i. Tf2O, pyridine, CH2Cl2, -20°C, ii. AcCl; b) n-Bu4NNO2, DMF, 50°C, 55% from 3; c) 
Tf2O, pyridine, CH2Cl2, -20°C; d) n-Bu4NN3, DMF, mw 80°C, 46% from 5; e) DMTST, CH2Cl2, MS 
4 Å, r.t., 81%; f) aq. NaOH, dioxane, r.t., 94%; g) Pd(OH)2/C, H2, dioxane, H2O, r.t., 92%; h) RCO2H, 
HBtU, HOBt, DIPEA, CH2Cl2, r.t.; i) Pd(OH)2/C, H2, CH2Cl2/MeOH/H2O/ HAc, r.t., (12: 51%, 13: 
51% from 11); j) RSO2Cl, DIPEA, DCE, 0°C to r.t.; k) Pd(OH)2/C, H2, CH2Cl2/MeOH/H2O/HAc, r.t., 
(14: 56%, 15: 28% from 11); l) Pd(OH)2/C, H2, CH2Cl2/MeOH/H2O/HAc, r.t., 26%; m) Pd(OH)2/C, 
H2, CH2Cl2/MeOH/H2O/HAc, r.t., 93%; n) RSO2Cl, DIPEA, DCE, DMF, -78°C to r.t., 18: 39% ; or 
RSO2Cl, MgO, DIPEA, THF/H2O, r.t., (19: 30%, 20: 31%). 
Initially, we planned to study the influence of an acetyl ester in 2-O position of D-galactose in 
addition to modifications in 3-O position. The reaction conditions for the combined 
reduction/debenzylation of 9 however caused acetyl group migration and directly provided 
acetamide 16. 
The aromatic sulfonamides 18, 19, and 20 were obtained from deprotected 17, as the applied 
conditions for debenzylation were considered to be incompatible with furan and thiophene 
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moieties. Chemoselective sulfonylation of 17 was achieved either by low temperature 
reaction with the sulfonyl chlorides in presence of DIPEA in a CH2Cl2/DMF mixture or by a 
modified version of the magnesium oxide mediated procedure reported by Kang et al.[15]. 
 
3. Biological Evaluation 
The affinity of selectin antagonists to E- and P-selectin was evaluated in a competitive 
binding assay, utilizing a polyacrylamide-type glycoconjugate as synthetic ligand for 
immobilized E-/P-selectin.[16] Briefly, microtiter plates were coated with either E-
selectin/IgG, or P-selectin/IgG, blocked with BSA, and incubated with a fixed concentration 
of sLea-polyacrylamide (sLea-PAA) either in presence or absence of the antagonists. The 
binding reaction was revealed by the addition of TMB substrate reagent and quantified 
spectrophotometrically at 450 nm. The IC50 defines the molar concentration of the test 
compound that reduces the maximal specific binding of sLea-PAA polymer to E-selectin/P-
selectin by 50%. To ensure comparability of different antagonists, the reference compounds 
22 (P-selectin) / 23 (E-selectin) were tested in parallel on each individual microtiter plate. 
The affinities are reported relative to 21 as rIC50 in Table 1. The relative IC50 (rIC50) is the 
ratio of the IC50 of the test compound to the IC50 of 21. 
 
The biological results can nicely be correlated to the modeling studies. As expected, none of 
the compounds bound to E-selectin up to 15 mM (Table 1). Neither the free amine in 17 
(entry 4), nor the amide or sulfonamide moiety alone (14 entry 8, 16 entry 5) supported 
binding up to 15 mM on P-selectin. This is in accordance with the expected binding mode for 
14 (entry 8) and 16 (entry 5), which predicts no direct interaction of these moieties with the 
protein. In contrast, compound 12 (entry 6), which bears an oxygen atom in the side chain to 
replace the water molecule, was four-fold more potent than sLex. Its rigid analogues 13 (entry 
7), a 1:1 mixture of diastereomers, bound slightly worse than 12 (entry 6), which can be 
explained by the unfavorable configuration of one of the two diastereomers. The same holds 
true for sulfonamide analogue 15 (entry 9), a 6:4 mixture of diastereomers. Thiophene 
derivatives 19 (entry 11) and 20 (entry 12) bound in the same range as 12 (entry 6). The 
weaker hydrogen bond between the thiophene sulfur and a hydroxyl group was obviously 
compensated by packing of the thiophene sulfur against Tyr94. 
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Table 1. Relative IC50 values (rIC50) of P-selectin antagonists 12 to 20. IC50 values were measured 
using 22 (P-sel) and 23 (E-sel) as reference compounds on each microtiter plate and are scaled on 
TMSE-sLex 21 (rIC50= 1.0); n.b. = no binding observed up to 15 mM; n.d. = binding affinity not 
determined. 
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Entry Compound R1 R2 rIC50 (P-sel) rIC50 (E-sel) 
1 22 
 
H 0.3 0.4 
2 
23 
(CGP69669) 
 
H n.b. 0.08 
3 2 
 
Me 0.05 0.03 
4 17  Me n.b. n.b. 
5 16  Me n.b. n.b. 
6 12  Me 0.3 n.b. 
7 13  Me 1.1 n.b. 
8 14  Me n.b. n.b. 
9 15 
 
Me 1.0 n.d. 
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Me n.d. n.d. 
11 19 
 
Me 0.3 n.b. 
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Conclusion 
A small series of amides and sulfonamides, designed to target a potential binding pocket of 
P-selectin, was synthesized and evaluated in a competitive binding assay. Though it was not 
possible to fully replace sialic acid, the affinity of these structurally simplified and non-
charged antagonists was improved up to three-fold compared to sLex. 
 
Experimental Part 
NMR spectra were recorded on a Bruker Avance DMX-500 (500 MHz) spectrometer. 
Assignment of 1H and 13C NMR spectra was achieved using 2D methods (COSY, HSQC, 
HMQC, HMBC). Chemical shifts are given in ppm and were assigned in relation to the 
solvent signals on the !-scale[17] or to tetramethylsilane (0 ppm) as internal standard. 
Coupling constants J are given in Hertz (Hz). Multiplicities were specified as follows: s 
(singlet), d (doublet), dd (doublet of a doublet), t (triplet), q (quartet), m (multiplet). For 
assignment of resonance signals to the appropriate nuclei the following abbreviations were 
used: Fuc (fucose), Gal (galactose), MeCy (3-methylcyclohexane-1,2-diol), THF 
(tetrahydrofuran), Thio (thiophene), Fur (furan). Reactions were monitored by TLC using 
glass plates coated with silica gel 60 F254 (Merck) and visualized by using UV light and/or by 
charring with a molybdate solution (a 0.02 M solution of ammonium cerium sulfate dihydrate 
and ammonium molybdate tetrahydrate in aqueous 10% H2SO4). Column chromatography 
was performed manually using silica gel 60 (40-63 "m) from Fluka or using automated 
systems (RediSep Companion or RediSep Rf) from Teledyne Isco with normal phase 
RediSep columns from the same manufacturer or reversed-phase columns containing 
LiChroprep RP-18 (40-63 "m) from Merck KGaA, Darmstadt, Germany. LC-MS separations 
were carried out using Sunfire C18 columns (19 x 150 mm, 5.0 "m) on a Waters 2525 LC, 
equipped with Waters 2996 photodiode array and Waters micromass ZQ MS for detection. 
HRMS analysis were carried out using a Agilent 1100 LC equipped with a photodiode array 
detector and a Micromass QTOF I equipped with a 4 GHz digital-time converter. Size 
exclusion chromatography was performed with Bio-Gel® P-2 Gel (45-90 mm) from Bio-Rad. 
Solvents were purchased from Sigma-Aldrich or Acros. Solvents were dried prior to use 
where indicated. Dichloromethane (CH2Cl2) and dichlorethane (DCE) were dried by filtration 
over Al2O3 (Fluka, type 5016 A basic). DMF was dried by distillation from calcium hydride. 
Optical rotations were measured using a Perkin-Elmer Polarimeter 341. Electron spray 
ionization mass spectra (ESI-MS) were obtained on a Waters micromass ZQ. IR spectra were 
recorded on a Perkin Elmer Spectrum One FT-IR spectrometer as KBr pellets. Microanalysis 
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was performed at the Institute of Organic Chemistry at the University of Basel, Switzerland. 
Compound purity was determined on an Agilent 1100 HPLC; detector ELS, Waters 2420; 
column: Waters Atlantis dC18, 3 µm, 4.6 x 75 mm; eluents: A: water + 0.1% TFA; B: 90% 
acetonitrile + 10% water + 0.1% TFA; depending on the polarity of analytes, gradients were 
applied as indicated. A) linear gradient: 0 - 1 min 5% B; 1 - 20 min 5 to 70% B; flow: 0.5 
mL/min; B) linear gradient: 0 - 1 min 5% B; 1-20 min 5 to 50% B; flow: 0.5 mL/min; C) linear 
gradient: 0 - 1 min 5% B; 1 - 20 min 5 to 40% B; flow: 0.5 mL/min. 
 
Ethyl 2-O-acetyl-4,6-O-benzylidene-3-O-trifluoromethansulfonyl-1-thio-!-D- 
galactopyranoside 4. 
Ethyl 4,6-O-benzylidene-1-thio-!-D-galactopyranoside 3 (9.00 g, 28.8 mmol) was dissolved 
in anhydrous CH2Cl2 (140 mL) and anhydrous pyridine (4.7 mL, 58.1 mmol) under argon. 
The solution was cooled to -20°C and Tf2O (5.60 mL, 33.2 mmol) was slowly added. After 
2.5 h, AcCl (2.25 mL, 31.7 mmol) was added and the reaction was slowly warmed to r.t. 
Additional pyridine (2.33 mL, 28.8 mmol) and AcCl (1.64 mL, 23.1 mmol) were added after 
1 h and stirring was continued for another 1 h. The solution was diluted with CH2Cl2 (150 
mL) and washed with aqueous HCl (5%, 200 mL), aqueous satd. NaHCO3 (200 mL) and 
brine (200 mL). The organic layer was dried over Na2SO4, filtered, and concentrated under 
reduced pressure to give crude 4 as orange sticky solid, which was directly used in the next 
step. 
 
Ethyl 2-O-acetyl-4,6-O-benzylidene-1-thio-!-D-gulopyranoside 5. 
To a stirred solution of crude 4 (! 28.8 mmol) in anhydrous DMF (100 mL) at 50°C under 
argon was added tetrabutylammonium nitrite (25.0 g, 86.7 mmol). After 24 h, volatiles were 
evaporated and the residue was dissolved in CH2Cl2 (350 mL) and washed with aqueous HCl 
(5%, 350 mL), aqueous satd. NaHCO3 (350 mL) and brine (350 mL). The organic layer was 
dried over Na2SO4, filtered, and concentrated under reduced pressure. Column 
chromatography on silica (PE/EtOAc) afforded 5 as white foam (5.69 g, 16.1 mmol, 56%). 
1H NMR (500.1 MHz, CDCl3): " 7.53-7.33 (m, 5H, Ar-H), 5.53 (s, 1H, CHPh), 5.31 (dd, 3J 
= 3.0, 10.2Hz, 1H, H-2), 4.89 (d, 3J = 10.2Hz, 1H, H-1), 4.34 (d, 2J = 12.5, 1H, H-6a), 4.20 
(dd, 3J = 3.0Hz, 1H, H-3), 4.13 (d, 3J = 3.0Hz, 1H, H-4), 4.03 (dd, 3J = 1.5, 2J =12.5Hz, 1H, 
H6b), 3.83 (s, 1H, H-5), 2.85-2.71 (m, 2H, SCH2CH3), 2.14 (s, 3H, COCH3), 1.29 (t, 3J = 
7.5Hz, 3H, SCH2CH3); 13C NMR (125.8 MHz, CDCl3): " 169.2 (CH3CO), 137.8 (Ar-Ci), 
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129.4, 128.5, 126.5 (5C, Ar-CH), 101.5 (PhCH), 79.0 (C1), 76.1 (C4), 69.6 (C6), 68.7 (C3), 
68.4 (C2), 67.6 (C5), 23.0 (SCH2CH3), 21.2 (COCH3), 15.0 (SCH2CH3); [!]D -76.4 (c 1.44, 
CHCl3); MS (ESI) m/z: calcd for C17H22NaO6S [M+Na]+: 377.1 ; found: 377.1; elemental 
analysis calcd (%) for C17H22O6S (354.42): C 57.61, H 6.26; found: C 57.75, H 6.38. 
 
Ethyl 2-O-acetyl-4,6-O-benzylidene-3-O-trifluoromethansulfonyl-1-thio-"-D- 
gulopyranoside 6. 
To a stirred solution of 5 (2.37 g, 6.72 mmol) in anhydrous CH2Cl2 (30 mL) and anhydrous 
pyridine (1.08 mL, 13.3 mmol) at -20°C under argon was slowly added Tf2O (1.35 mL, 8.02 
mmol). After 6 h, the solution was warmed to r.t., diluted with CH2Cl2 (60 mL) and washed 
with aqueous HCl (5%, 100 mL), aqueous satd. NaHCO3 (100 mL) and brine (100 mL). The 
organic layer was dried over Na2SO4, filtered, and concentrated under reduced pressure to 
afford crude 6 as slightly orange foam (2.93 g), which was directly used in the next step. 
 
Ethyl 2-O-acetyl-3-azido-4,6-O-benzylidene-3-deoxy-1-thio-"-D-galactopyranoside 7. 
Crude 6 (1.00 g, 2.06 mmol) and tetrabutylammonium azide (1.17 g, 4.71 mmol) were 
dissolved in anhydrous DMF (6.0 mL) under argon in a sealed microwave vial. After 
microwave irradiation at 200W and 80°C for 1 h, volatiles were removed under reduced 
pressure. Column chromatography on silica (PE/EtOAc) afforded 7 as white foam (0.40 g, 
1.05 mmol, 46%). 
1H NMR (500.1 MHz, CDCl3): 7.54-7.31 (m, 5H, Ar-H), 5.59 (s, 1H, CHPh), 5.46 (dd, 3J = 
9.9Hz, 1H, H-2), 4.44 (dd, 3J = 9.9Hz, 1H, H-1), 4.38-4.33 (m, 2H, H-4, H-6a), 4.06 (m, 1H, 
H6b), 3.52 (s, 1H, H-5), 3.40 (dd, 3J = 3.2, 9.9Hz, H-3), 2.91-2.67 (m, 2H, SCH2CH3), 2.15 
(s, 3H, COCH3), 1.28 (t, 3J = 7.5Hz, 3H, SCH2CH3); 13C NMR (125.8 MHz, CDCl3): # 169.6 
(CH3CO), 137.3 (Ar-Ci), 129.3, 128.4, 126.3 (5C, Ar-CH), 101.4 (PhCH), 83.2 (C1), 75.6 
(C4), 70.5 (C5), 69.4 (C6), 67.1 (C2), 62.7 (C3), 23.0 (SCH2CH3), 21.1 (COCH3), 14.9 
(SCH2CH3); [!]D + 2.6 (c 0.88, CHCl3); IR (KBr): 2111 (s, N3), 1730 (s, C=O) cm-1; MS 
(ESI) m/z: calcd for C17H21N3NaO5S [M+Na]+: 402.11; found: 402.06; elemental analysis 
calcd (%) for C17H21N3O5S (379.43): C 53.81, H 5.58, N 11.07; found: C 54.00, H 5.66, N 
10.88. 
 
2-O-Acetyl-3-azido-4,6-O-benzylidene-3-deoxy-"-D-galactopyranosyl-(1!1)-[2,3,4-tri-O-
benzyl-! -L-fucopyranosyl-(1!2)]-(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol 9. 
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Compounds 9 (533 mg, 1.40 mmol) and 8 (640 mg, 1.17 mmol) were dissolved in anhydrous 
CH2Cl2 (25 mL). Powdered activated molecular sieves 4 Å (2.5 g) were added and the 
mixture was stirred at r.t. under argon. After 3.5 h a solution of DMTST (725 mg, 2.81 
mmol) in anhydrous CH2Cl2 (15 mL) that had been stirred with molecular sieves 4 Å (1.5 g) 
for 3.5 h, was added. After stirring for 26 h, the solution was filtered and the filtrate was 
concentrated under reduced pressure. Column chromatography on silica (PE/EtOAc) afforded 
9 as white foam (820 mg, 0.95 mmol, 81%). 
1H NMR (500.1 MHz, CDCl3): ! 7.56-7.07 (m, 20H, Ar-H), 5.63 (s, 1H, CHPh), 5.28 (dd, 3J 
= 7.8, 10.8Hz, 1H, Gal-H2), 4.89 (d, 3J = 3.3Hz, 1H, Fuc-H1), 4.82 (q, 3J = 6.5Hz, 1H, Fuc-
H5), 4.74 (A of AB, J = 11.6Hz, 1H, PhCH2), 4.63 (B of AB, J = 11.6Hz, 1H, PhCH2), 4.56-
4.49 (m, 2H, PhCH2), 4.44 (d, 3J = 7.8Hz, 1H, Gal-H1), 4.29 (d, 2J = 12.2Hz, 1H, Gal-H6a), 
4.25 (d, 3J = 3.2Hz, 1H, Gal-H4), 4.13 (A of AB , J = 11.3Hz, 1H, PhCH2), 4.05 (d, 2J = 
12.2Hz, 1H, Gal-H6b), 3.91-3.82 (m, 2H, Fuc-H2, Fuc-H3), 3.53 (B of AB , J = 11.3Hz, 1H, 
PhCH2), 3.50 (m, 1H, MeCy-H1), 3.36 (s, 1H, Gal-H5), 3.20-3.11 (m, 3H, Fuc-H4, Gal-H3, 
MeCy-H2), 2.05 (s, 3H, COCH3), 1.90 (m, 1H, MeCy), 1.60-1.50 (m, 3H, MeCy), 1.21-1.13 
(m, 2H, MeCy), 1.09 (d, 3J = 6.5Hz, 3H, Fuc-H6), 1.00 (d, 3J = 6.4Hz, 3H, MeCy-CH3), 0.94 
(m, 1H, MeCy); 13C NMR (125.8 MHz, CDCl3): ! 168.1 (CH3CO), 138.6, 138.5, 137.7, 
136.4 (4C, Ar-Ci), 127.9, 127.6, 127.2, 127.1, 126.8, 126.5, 126.4, 126.1, 125.8, 124.8 (20C, 
Ar-CH), 99.4 (PhCH), 98.6 (Gal-C1), 97.4 (Fuc-C1), 80.6 (MeCy-C2), 79.6 (MeCy-C1), 78.7 
(Fuc-C3), 78.0 (Fuc-C4), 75.0 (Gal-C4), 74.6 (Fuc-C2), 73.9, 73.5, 70.3 (3C, PhCH2), 68.4 
(Gal-C6), 67.5 (Gal-C2), 65.8 (Gal-C5), 65.2 (Fuc-C5), 60.6 (Gal-C3), 38.5 (MeCy-C3), 32.6 
(MeCy-C4), 30.2 (MeCy-C6), 22.3 (MeCy-C5), 19.8 (CH3CO), 17.7 (MeCy-CH3), 15.2 
(Fuc-C6); ["]D -71.3 (c 1.20, CHCl3); IR (KBr): 2102 (s, N3), 1756 (s, C=O) cm-1; MS (ESI) 
m/z: calcd for C49H57N3NaO11 [M+Na]+: 886.4; found: 886.5; elemental analysis calcd (%) 
for C49H57N3O11 (863.99): C 68.12, H 6.65, N 4.86; found: C 68.03, H 6.85, N 4.79. 
 
3-Azido-4,6-O-benzylidene-3-deoxy-#-D-galactopyranosyl-(1!1)-[2,3,4-tri-O-benzyl-" -
L-fucopyranosyl-(1!2)]-(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol 10. 
A solution of 9 (600 mg, 0.69 mmol) in aqueous NaOH (1 M, 7.0 mL) and dioxane (14 mL) 
was stirred at r.t. for 16 h. Dioxane was evaporated under reduced pressure, the mixture was 
diluted with CH2Cl2 (30 mL), and washed with brine (30 mL). The aqueous layer was 
extracted with CH2Cl2 (2 · 25 mL) and the combined organic layers were dried over Na2SO4, 
filtered and concentrated under reduced pressure. Column chromatography on silica 
(PE/EtOAc) afforded 10 as white foam (540 mg, 0.66 mmol, 95%). 
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1H NMR (500.1 MHz, CDCl3): ! 7.70-7.13 (m, 20H, Ar-H), 5.66 (s, 1H, CHPh), 4.97 (d, 3J 
= 2.2Hz, 1H, Fuc-H1), 4.85-4.79 (m, 2H, Fuc-H5, PhCH2), 4.71 (B of AB, J = 11.6Hz, 1H, 
PhCH2), 4.63-4.58 (m, 2H, PhCH2), 4.38 (d, 3J = 7.6Hz, 1H, Gal-H1), 4.34 (dd, 3J = 1.0Hz, 
2J = 12.2Hz, 1H, Gal-H6a), 4.23 (d, 3J = 3.2Hz, 1H, Gal-H4), 4.11 (dd, 3J = 1.5, 2J = 
12.2Hz, 1H, Gal-H6b), 4.01 (dd, 3J = 7.6, 10.5Hz, Gal-H2), 3.98-3.92 (m, 2H, Fuc-H2, Fuc-
H3), 3.70-3.62 (m, 2H, MeCy-H1, PhCH2), 3.45 (s, 1H, Gal-H5), 3.32 (dd, 3J = 3.2, 10.5Hz, 
Gal-H3), 3.26-3.16 (m, 2H, Fuc-H4, MeCy-H2), 2.07 (m, 1H, MeCy), 1.71-1.54 (m, 3H, 
MeCy), 1.39-1.16 (m, 2H, MeCy), 1.09 (d, 3J = 6.5Hz, 3H, MeCy-CH3), 1.08-0.97 (m, 4H, 
Fuc-H6, MeCy); 13C NMR (125.8 MHz, CDCl3): ! 139.7, 139.5, 138.7, 137.8 (4C, Ar-Ci), 
129.0, 128.8, 128.4, 128.3, 128.2, 128.1, 127.7, 127.6, 127.5, 127.3, 127.1, 125.9 (20C, Ar-
CH), 101.2 (Gal-C1), 100.4 (PhCH), 98.7 (Fuc-C1), 82.6 (MeCy-C2), 80.0, 79.8 (MeCy-C1, 
Fuc-C3), 78.8 (Fuc-C4), 75.6, 75.5 (Fuc-C2, Gal-C4), 75.0, 74.7, 71.6 (3C, PhCH2), 69.6 
(Gal-C6), 68.4 (Gal-C2), 67.2 (Gal-C5), 66.3 (Fuc-C5), 62.6 (Gal-C3), 39.6 (MeCy-C3), 33.8 
(MeCy-C4), 31.5 (MeCy-C6), 22.4 (MeCy-C5), 18.9 (MeCy-CH3), 16.7 (Fuc-C6); ["]D -94.6 
(c 0.72, CHCl3); MS (ESI) m/z: calcd for C47H55N3NaO10 [M+Na]+: 844.4; found: 844.5; 
elemental analysis calcd (%) for C47H55N3O10 (821.95): C 68.68, H 6.74, N 5.11; found: C 
68.71, H 6.56, N 5.13; 
 
3-Amino-4,6-O-benzylidene-3-deoxy-#-D-galactopyranosyl-(1!1)-[2,3,4-tri-O-benzyl-" -
L-fucopyranosyl-(1!2)]-(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol 11.  
10 (190 mg, 0.23 mmol) was dissolved in dioxane/H2O (4/1, 3.5 mL) under argon. 
Pd(OH)2/C (40 mg, 10% Pd(OH)2) was added and the resulting mixture was hydrogenated (4 
bar H2) at r.t. After 3 h, the mixture was filtered and the solvent removed under reduced 
pressure. The residue was dissolved in CH2Cl2 (25 mL) and washed with satd. aqueous 
NaHCO3 (2 · 25 mL). The organic layer was dried over Na2SO4, filtered and concentrated 
under reduced pressure to give 11 (170 mg) as slightly grey solid, which was directly used in 
the next step. 
 
3-(3-Methoxy-propanamido)-3-deoxy-#-D-galactopyranosyl-(1!1)-[" -L-fucopyranosyl-
(1!2)]-(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol 12. 
To a solution of HOBt (14 mg, 0.10 mmol) and HBtU (33 mg, 0.09 mmol) in anhydrous 
DMF (1.0 mL) under argon was added DIPEA (0.035 mL, 0.02 mmol) and 3-methoxy 
propionic acid (0.010 mL, 0.11 mmol). After 10 min, a solution of 11 (27 mg, 0.034 mmol) 
in CH2Cl2/DMF (1/1, 1.0 mL) was added and the resulting solution was stirred for 1 h. The 
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solution was concentrated under reduced pressure, roughly purified via column 
chromatography (PE/EtOAc) and directly used in the next step. The residue was dissolved in 
CH2Cl2/MeOH/H2O/HAc (1/1/2/2, 2.0 mL) under argon. Pd(OH)2/C (10 mg, 10% Pd(OH)2) 
was added and the resulting mixture was hydrogenated (5 bar H2) at r.t. After 42 h, the 
mixture was filtered and the solvent removed under reduced pressure. Purification via RP 
chromatography (H2O/MeOH) and lyophilization from water afforded 12 as white fluffy 
solid (9.0 mg, 0.017 mmol, 51%).  
1H NMR (500.1 MHz, CD3OD): !  5.00 (d, 3J = 4.0Hz, 1H, Fuc-H1), 4.93-4.86 (m, 1H, Fuc-
H5), 4.62 (s, 1H, NH), 4.35 (d, 3J = 7.6Hz, 1H, Gal-H1), 3.86-3.82 (m, 3H, Fuc-H3, Gal-H3, 
Gal-H4), 3.74 (dd, 3J = 4.0, 10.3Hz, 1H, Fuc-H2), 3.71-3.61 (m, 6H, COCH2CH2OCH3, Fuc-
H4, Gal H6a, Gal-H6b, MeCy-H1), 3.56 (dd, 3J = 7.6, 10.3Hz, 1H, Gal-H2), 3.50 (t, 3J = 
6.0Hz, 1H, Gal-H5), 3.35 (s, 3H, COCH2CH2OCH3), 3.20 (t, 3J = 9.3Hz, 1H, MeCy-H2), 
2.53 (m, 2H, COCH2CH2OCH3), 2.13 (m, 1H, MeCy), 1.72-1.54 (m, 3H, MeCy), 1.39-1.25 
(m, 2H, MeCy), 1.20 (d, 3J = 6.6Hz, 3H, Fuc-H6), 1.13 (d, 3J = 6.3Hz, 3H, MeCy-CH3), 1.07 
(m, 1H, MeCy); 13C NMR (125.8 MHz, CD3OD): ! 174.1 (CONH), 103.0 (Gal-C1), 100.4 
(Fuc-C1), 84.7 (MeCy-C2), 80.0 (MeCy-C1), 77.3 (Gal-C5), 73.9 (Fuc-C4), 71.4 (Fuc-C3), 
70.4 (Fuc-C2), 69.8 (2C, COCH2CH2OCH3, Gal-C2), 68.4 (Gal-C4), 67.5 (Fuc-C5), 63.0 
(Gal-C6), 58.9 (COCH2CH2OCH3), 56.7 (Gal-C3), 40.4 (MeCy-C3), 37.3 (COCH2CH2CH3), 
34.9 (MeCy-C4), 31.9 (MeCy-C6), 24.2 (MeCy-C5), 19.6 (MeCy-CH3), 16.8 (Fuc-C6); ["]D 
-48.5 (c 1.12, MeOH); HR-MS (ESI) m/z: calcd for C23H41NNaO12 [M+Na]+: 546.2521; 
found: 546.2532; HPLC-purity: > 99.5% (A). 
 
3-(Tetrahydrofuran-3-carboxamido)-3-deoxy-#-D-galactopyranosyl-(1!1)-[" -L-
fucopyranosyl-(1!2)]-(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol 13.  
To a solution of HOBt (14 mg, 0.10 mmol) and HBtU (33 mg, 0.09 mmol) in anhydrous 
DMF (1.0 mL) under argon was added DIPEA (0.035 mL, 0.02 mmol) and tetrahydro-3-
furoic acid (0.010 mL, 0.10 mmol). After 10 min, a solution of 11 (27 mg, 0.034 mmol) in 
CH2Cl2/DMF (1/1, 1.0 mL) was added and the resulting solution was stirred for 1 h. The 
solution was concentrated under reduced pressure, roughly purified via column 
chromatography (PE/EtOAc), and directly used in the next step. The residue was dissolved in 
CH2Cl2/MeOH/H2O/HAc (1/1/2/2, 2.0 mL) under argon. Pd(OH)2/C (50 mg, 10% Pd(OH)2) 
was added and the resulting mixture was hydrogenated (1 bar H2) at r.t. After 2 d, the mixture 
was filtered and the solvent removed under reduced pressure. Purification via RP 
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chromatography (H2O/MeOH) and lyophilization from water/acetonitrile afforded 13 as 
white fluffy solid (9.0 mg, 0.017 mmol, 51%). 
1H NMR (500.1 MHz, CD3OD): !  5.00 (d, 3J = 4.0Hz, 1H, Fuc-H1), 4.95-4.85 (m, 1H, Fuc-
H5), 4.62 (s, 1H, NH), 4.35 (2d, 3J = 7.6Hz, 1H, Gal-H1), 3.96 (td, J = 3.9, 8.2Hz, 1H, 
THF), 3.89 (m, 1H, THF), 3.86-3.76 (m, 5H, Fuc-H3, Gal-H3, Gal-H4, THF), 3.74 (dd, 3J = 
4.0, 10.3Hz, 1H, Fuc-H2), 3.71-3.55 (m, 5H, Fuc-H4, Gal-H2, Gal-H6a, Gal-H6b, MeCy-
H1), 3.50 (t, 3J = 5.9Hz, 1H, Gal-H5), 3.21 (t, 3J = 9.3Hz, 1H, MeCy-H2), 3.13 (m, 1H, 
THF), 2.17-2.09 (m, 3H, MeCy, THF), 1.71-1.59 (m, 3H, MeCy), 1.39-1.24 (m, 2H, MeCy), 
1.21 (d, 3J = 6.6Hz, 3H, Fuc-H6), 1.13 (d, 3J = 6.3Hz, 3H, MeCy-CH3), 1.06 (m, 1H, MeCy); 
13C NMR (125.8 MHz, CD3OD): ! 176.3 (CONH), 103.1 (Gal-C1), 100.4 (Fuc-C1), 84.7 
(MeCy-C2), 80.1 (MeCy-C1), 77.4 (Gal-C5), 73.9 (Fuc-C4), 72.1, 72.0 (1C, THF), 71.4 
(Fuc-C3), 70.4 (Fuc-C2), 69.7 (Gal-C2), 69.5 (THF), 68.5, 68.4 (Gal-C4), 67.5 (Fuc-C5), 
63.0 (Gal-C6), 56.7 (Gal-C3), 45.9, 45.8 (1C, THF), 40.3 (MeCy-C3), 34.9 (MeCy-C4), 31.9 
(MeCy-C6), 31.5 (THF), 24.2 (MeCy-C5), 19.6 (MeCy-CH3), 16.8 (Fuc-C6); ["]D -49.5 (c 
0.86, MeOH); HR-MS (ESI) m/z: calcd for C24H41NNaO12 [M+Na]+: 558.2521; found: 
558.2522; HPLC-purity: > 99.5%; diastereomeric ratio: 1:1 (B). 
 
3-(Methylsulfonamido)-3-deoxy-#-D-galactopyranosyl-(1!1)-[" -L-fucopyranosyl-
(1!2)]-(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol 14.  
To a solution of 11 (20 mg, 0.025 mmol) and DIPEA (0.008 mL, 0.046 mmol) in anhydrous 
DCE (0.40 mL) under argon was added a solution of methansulfonyl chloride (0.005 mL, 4.4 
mg, 0.038 mmol) in anhydrous DCE (0.06 mL) at 0°C. After 30 min, the reaction was 
quenched with MeOH (2 mL) and concentrated under reduced pressure to yield a white foam, 
which was directly used in the next step. The residue was dissolved in 
CH2Cl2/MeOH/H2O/HAc (1/1/2/2, 2.5 mL) under argon. Pd(OH)2/C (30 mg, 10% Pd(OH)2) 
was added and the resulting mixture was hydrogenated (5 bar H2) at r.t. After 48 h, the 
mixture was filtered and the solvent removed under reduced pressure. Purification via HPLC 
and lyophilization afforded 14 as white solid (7.2 mg, 0.014 mmol, 56%). 
1H NMR (500.1 MHz, CD3OD): ! 5.00 (d, 3J = 4.0Hz, 1H, Fuc-H1), 4.95-4.83 (m, 1H, Fuc-
H5), 4.63 (s, 1H, NH), 4.32 (d, 3J = 7.6Hz, 1H, Gal-H1), 3.83 (dd, 3J = 3.3, 10.4Hz, 1H, Fuc-
H3), 3.81 (d, 3J = 2.8Hz, 1H, Gal-H4), 3.73 (dd, 3J = 4.0, 10.4Hz, 1H, Fuc-H2), 3.71-3.66 
(m, 3H, Fuc-H4, Gal H6a, MeCy-H1), 3.64 (dd, 3J = 5.1Hz, 2J = 11.3Hz, 1H, Gal-H6b), 
3.52-3.46 (m, 2H, Gal-H2, Gal-H5), 3.31 (m, 1H, Gal-H3), 3.20 (t, 3J = 9.3Hz, 1H, MeCy-
H2), 3.06 (s, 3H, NHSO2CH3), 2.15 (m, 1H, MeCy), 1.73-1.57 (m, 3H, MeCy), 1.41-1.23 (m, 
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2H, MeCy), 1.19 (d, 3J = 6.6Hz, 3H, Fuc-H6), 1.13 (d, 3J = 6.3Hz, 3H, MeCy-CH3), 1.06 (m, 
1H, MeCy); 13C NMR (125.8 MHz, CD3OD): ! 103.1 (Gal-C1), 100.4 (Fuc-C1), 84.7 
(MeCy-C2), 80.0 (MeCy-C1), 77.2 (Gal-C5), 73.9 (Fuc-C4), 71.4 (Fuc-C3), 70.7, 70.5, 70.3 
(Fuc-C2, Gal-C2, Gal-C4), 67.5 (Fuc-C5), 62.9 (Gal-C6), 60.8 (Gal-C3), 41.8 (NHSO2CH3), 
40.4 (MeCy-C3), 34.8 (MeCy-C4), 32.0 (MeCy-C6), 24.2 (MeCy-C5), 19.6 (MeCy-CH3), 
16.8 (Fuc-C6); ["]D -61.9 (c 0.44, MeOH); HR-MS (ESI) m/z: calcd for C20H37NNaO12S 
[M+Na]+: 538.1929 ; found: 538.1936; HPLC-purity: > 99.5% (B). 
 
3-(Tetrahydrofuran-3-sulfonamido)-3-deoxy-#-D-galactopyranosyl-(1!1)-[" -L-
fucopyranosyl-(1!2)]-(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol 15. 
To a solution of 11 (25 mg, 0.031 mmol) and DIPEA (0.006 mL, 0.035 mmol) in anhydrous 
DCE (0.40 mL) under argon was added a solution of furan-3-sulfonyl chloride (5.8 mg, 0.035 
mmol) in anhydrous DCE (0.075 mL) at 0°C. After 30 min, the reaction was quenched with 
MeOH (1.0 mL) and concentrated under reduced pressure to yield a white solid, which was 
directly used in the next step. The residue was dissolved in CH2Cl2/MeOH/H2O/HAc 
(1/1/2/2, 6 mL) under argon. Pd(OH)2/C (25 mg, 10% Pd(OH)2) was added and the resulting 
mixture was hydrogenated (5 bar H2) at r.t. After 2 d, the mixture was filtered and the solvent 
removed under reduced pressure. Purification via HPLC and lyophilization afforded 15 as 
white solid (5.0 mg, 0.009 mmol, 28%). 
1H NMR (500.1 MHz, CD3OD): !  5.00 (d, 3J = 3.9Hz, 1H, Fuc-H1), 4.94-4.84 (m, 1H, Fuc-
H5), 4.63 (s, 1H, NH), 4.30, 4.29 (2d, 3J = 7.5Hz, 1H, Gal-H1), 4.16-3.88 (m, 4H, THF), 
3.86-3.62 (m, 5H, Fuc-H4, Gal-H4, Gal-H6a, MeCy-H1, THF), 3.83 (dd, 3J = 2.9, 10.3Hz, 
1H, Fuc-H3), 3.74 (dd, 3J = 4.0, 10.3Hz, 1H, Fuc-H2), 3.64 (dd, 3J = 5.3Hz, 2J = 11.3Hz, 
1H, Gal-H6b), 3.52-3.44 (m, 2H, Gal-H2, Gal-H5), 3.34-3.24 (m, 1H, Gal-H3), 3.19 (t, 3J = 
9.3Hz, 1H, MeCy-H2), 2.30 (m, 2H, THF), 2.13 (m, 1H, MeCy), 1.74-1.57 (m, 3H, MeCy), 
1.42-1.22 (m, 2H, MeCy), 1.19 (d, 3J = 6.5Hz, 3H, Fuc-H6), 1.13 (d, 3J = 6.3Hz, 3H, MeCy-
CH3), 1.06 (m, 1H, MeCy); 13C NMR (125.8 MHz, CD3OD): ! 103.2 (Gal-C1), 100.4 (Fuc-
C1), 84.7 (MeCy-C2), 80.1 (MeCy-C1), 77.2 (Gal-C5), 73.9 (Fuc-C4), 71.4 (Fuc-C3), 70.7, 
70.3, 70.1, 69.5, 69.2, 69.0 (5C, Fuc-C2, Gal-C2, Gal-C4, THF), 67.5 (Fuc-C5), 62.9 (Gal-
C6), 62.6, 62.1 (1C, THF), 60.7, 60.6 (Gal-C3), 40.4 (MeCy-C3), 34.9 (MeCy-C4), 32.0 
(MeCy-C6), 29.9, 29.1 (1C, THF), 24.2 (MeCy-C5), 19.6 (MeCy-CH3), 16.8 (Fuc-C6); ["]D -
46.5 (c 0.55, MeOH); HR-MS (ESI) m/z: calcd for C23H41NNaO13S [M+Na]+: 594.2191; 
found: 594.2196; HPLC-purity: > 99.5%; diastereomeric ratio 58:42 (C). 
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3-Acetamido-3-deoxy-!-D-galactopyranosyl-(1!1)-[" -L-fucopyranosyl-(1!2)]-
(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol 16. 
9 (68 mg, 0.08 mmol) was dissolved in CH2Cl2/MeOH/H2O/HAc (1/1/2/2, 4 mL) under 
argon. Pd(OH)2/C (80 mg, 10% Pd(OH)2) was added and the resulting mixture was 
hydrogenated (2.5 bar H2) at r.t. After 14 h, the mixture was filtered and the solvent removed 
under reduced pressure. Purification via HPLC and lyophilization from water/acetonitrile 
afforded 16 as white solid (10.0 mg, 0.02 mmol, 26%). 
1H NMR (500.1 MHz, CD3OD): #  5.00 (d, 3J = 3.9Hz, 1H, Fuc-H1), 4.93-4.86 (m, 1H, Fuc-
H5), 4.62 (s, 1H, NH), 4.35 (d, 3J = 7.6Hz, 1H, Gal-H1), 3.86-3.79 (m, 3H, Fuc-H3, Gal-H3, 
Gal-H4), 3.74 (dd, 3J = 3.9, 10.5Hz, 1H, Fuc-H2), 3.71-3.65 (m, 3H, Fuc-H4, Gal H6a, 
MeCy-H1), 3.63 (dd, 3J = 5.9Hz, 2J = 11.4Hz, 1H, Gal-H6b), 3.57 (dd, 3J = 7.6, 10.3Hz, 1H, 
Gal-H2), 3.50 (t, 3J = 5.9Hz, 1H, Gal-H5), 3.21 (t, 3J = 9.3Hz, 1H, MeCy-H2), 2.14 (m, 1H, 
MeCy), 2.00 (s, 3H, COCH3), 1.72-1.57 (m, 3H, MeCy), 1.41-1.23 (m, 2H, MeCy), 1.20 (d, 
3J = 6.5Hz, 3H, Fuc-H6), 1.13 (d, 3J = 6.3Hz, 3H, MeCy-CH3), 1.06 (m, 1H, MeCy); 13C 
NMR (125.8 MHz, CD3OD): # 173.7 (CONH), 103.0 (Gal-C1), 100.3 (Fuc-C1), 84.7 
(MeCy-C2), 80.0 (MeCy-C1), 77.3 (Gal-C5), 73.9 (Fuc-C4), 71.4 (Fuc-C3), 70.3 (Fuc-C2), 
69.7 (Gal-C2), 68.4 (Gal-C4), 67.5 (Fuc-C5), 63.0 (Gal-C6), 56.7 (Gal-C3), 40.3 (MeCy-C3), 
34.9 (MeCy-C4), 31.9 (MeCy-C6), 24.2 (MeCy-C5), 22.6 (COCH3), 19.6 (MeCy-CH3), 16.8 
(Fuc-C6); ["]D -60.4 (c 0.94, MeOH); HR-MS (ESI) m/z: calcd for C21H37NNaO11 [M+Na]+: 
502.2259; found: 502.2260; HPLC-purity: > 99.5% (A). 
 
3-Amino-3-deoxy-!-D-galactopyranosyl-(1!1)-[" -L-fucopyranosyl-(1!2)]-(1R,2R,3S)-
3-methyl-cyclohexane-1,2-diol 17. 
10 (250 mg, 0.30 mmol) was dissolved in CH2Cl2/MeOH/H2O/HAc (1/1/2/2, 6 mL) under 
argon. Pd(OH)2/C (250 mg, 10% Pd(OH)2) was added and the resulting mixture was 
hydrogenated (4 bar H2) at r.t. After 48 h, the mixture was filtered and the solvent removed 
under reduced pressure. Purification via HPLC and lyophilization from water/acetonitrile 
afforded 17 as white solid (123 mg, 0.28 mmol, 93%). 
1H NMR (500.1 MHz, CD3OD): # 4.99 (d, 3J = 3.9Hz, 1H, Fuc-H1), 4.96-4.84 (m, 1H, Fuc-
H5), 4.35 (d, 3J = 7.6Hz, 1H, Gal-H1), 3.98 (d, 3J = 2.8Hz, 1H, Gal-H4) 3.82 (dd, 3J = 3.2, 
10.3Hz, 1H, Fuc-H3), 3.74 (dd, 3J = 3.9, 10.3Hz, 1H, Fuc-H2), 3.72-3.61 (m, 5H, Fuc-H4, 
Gal-H2, Gal H6a, Gal-H6b, MeCy-H1), 3.51 (t, 3J = 6.1Hz, 1H, Gal-H5), 3.23-3.13 (m, 2H, 
Gal-H3, MeCy-H2), 2.12 (m, 1H, MeCy), 1.72-1.57 (m, 3H, MeCy), 1.40-1.23 (m, 2H, 
MeCy), 1.20 (d, 3J = 6.6Hz, 3H, Fuc-H6), 1.14 (d, 3J = 6.3Hz, 3H, MeCy-CH3), 1.06 (m, 1H, 
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MeCy);13C NMR (125.8 MHz, CD3OD): ! 102.5 (Gal-C1), 100.5 (Fuc-C1), 84.7 (MeCy-C2), 
80.4 (MeCy-C1), 76.8 (Gal-C5), 73.9 (Fuc-C4), 71.4 (Fuc-C3), 70.3 (Fuc-C2), 68.7 (Gal-
C2), 67.5 (Gal-C4), 66.5 (Fuc-C5), 62.2 (Gal-C6), 57.0 (Gal-C3), 40.4 (MeCy-C3), 34.9 
(MeCy-C4), 32.0 (MeCy-C6), 24.2 (MeCy-C5), 19.6 (MeCy-CH3), 16.7 (Fuc-C6); ["]D -72.4 
(c 1.04, MeOH); HR-MS (ESI) m/z: calcd for C19H35NNaO10 [M+Na]+: 460.2153; found: 
460.2161; HPLC-purity: > 99.5% (A). 
 
3-(Furan-3-sulfonamido)-3-deoxy-#-D-galactopyranosyl-(1!1)-[" -L-fucopyranosyl-
(1!2)]-(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol 18. 
To a solution of 17 (10 mg, 0.023 mmol) in DIPEA (0.30 mL), THF (0.60 mL) and DMF 
(0.30 mL) was added a solution of furan-3-sulfonyl chloride (5.7 mg, 0.034 mmol) in DCE 
(0.075 mL) at -78°C under argon. The solution was stirred at -78°C for 10 min and slowly 
warmed to r.t. Concentration under reduced pressure and purification via HPLC afforded 18 
as white solid (5.0 mg, 0.009 mmol, 39%). 
1H NMR (500.1 MHz, CD3OD): ! 8.11 (s, 1H, Fur-H2), 7.61 (t, J = 1.7Hz, 1H, fur-H5), 6.75 
(d, J = 1.7Hz, Fur-H4), 4.99 (d, 3J = 3.9Hz, 1H, Fuc-H1), 4.86 (m, 1H, Fuc-H5), 4.63 (s, 1H, 
NH), 4.28 (d, 3J = 7.6Hz, 1H, Gal-H1), 3.82 (dd, 3J = 3.3, 10.3Hz, 1H, Fuc-H3), 3.79 (d, 3J 
= 2.8Hz, 1H, Gal-H4), 3.73 (dd, 3J = 3.9, 10.3Hz, 1H, Fuc-H2), 3.70-3.62 (m, 3H, Fuc-H4, 
Gal H6a, MeCy-H1), 3.60 (dd, 3J = 6.0Hz, 2J = 11.3Hz, 1H, Gal-H6b), 3.46 (dd, 3J = 7.6, 
10.5Hz, 1H, Gal-H2), 3.42 (t, 3J = 6.0Hz, 1H, Gal-H5), 3.22 (dd, 3J = 2.8, 10.5Hz, 1H, Gal-
H3), 3.18 (t, 3J = 9.3Hz, 1H, MeCy-H2), 2.10 (m, 1H, MeCy), 1.70-1.54 (m, 3H, MeCy), 
1.37-1.20 (m, 2H, MeCy), 1.18 (d, 3J = 6.6Hz, 3H, Fuc-H6), 1.12 (d, 3J = 6.3Hz, 3H, MeCy-
CH3), 1.05 (m, 1H, MeCy); 13C NMR (125.8 MHz, CD3OD): ! 146.7 (Fur-C2), 145.8 (fur-
C5), 130.2 (fur-C3), 109.7 (fur-C4), 102.8 (Gal-C1), 100.4 (Fuc-C1), 84.7 (MeCy-C2), 79.9 
(MeCy-C1), 76.9 (Gal-C5), 73.8 (Fuc-C4), 71.4 (Fuc-C3), 70.3 (Fuc-C2), 69.8 (Gal-C2), 
69.5 (Gal-C4), 67.5 (Fuc-C5), 62.9 (Gal-C6), 60.8 (Gal-C3), 40.3 (MeCy-C3), 34.9 (MeCy-
C4), 31.9 (MeCy-C6), 24.2 (MeCy-C5), 19.6 (MeCy-CH3), 16.8 (Fuc-C6); ["]D -51.6 (c 
0.34, MeOH); HR-MS (ESI) m/z: calcd for C23H37NNaO13S [M+Na]+: 590.1878; found: 
590.1885; HPLC-purity: > 99.5% (B). 
 
3-(Thiophene-3-sulfonamido)-3-deoxy-#-D-galactopyranosyl-(1!1)-[" -L-fucopyranosyl-
(1!2)]-(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol 19. 
To a suspension of 17 (10 mg, 0.023 mmol) and MgO (4 mg, 0.10 mmol) in THF/H2O (4/1, 
0.30 mL) that had been stirred at r.t. for 40 min, was added a solution of 3-thiophenesulfonyl 
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chloride (4 mg, 0.022 mmol) in THF (0.04 mL). After 1 h, DIPEA (0.005 mL, 0.03 mmol) 
was added and the mixture was stirred for 22 h. Subsequent filtration (celite), concentration 
under reduced pressure, and purification via HPLC afforded 19 as white solid (4.0 mg, 0.007 
mmol, 30%). 
1H NMR (500.1 MHz, CD3OD): !  8.14 (dd, J = 1.2, 3.0Hz, 1H, Thio-H5), 7.54 (dd, J = 3.0, 
5.1Hz, 1H, Thio-H2), 7.43 (dd, J = 1.2, 5.1Hz, Thio-H3), 4.98 (d, 3J = 3.9Hz, 1H, Fuc-H1), 
4.85 (dd, 3J = 6.6, 13.3Hz, 1H, Fuc-H5), 4.63 (s, 1H, NH), 4.27 (d, 3J = 7.6Hz, 1H, Gal-H1), 
3.81 (dd, 3J = 3.3, 10.3Hz, 1H, Fuc-H3), 3.72 (dd, 3J = 3.9, 10.3Hz, 1H, Fuc-H2), 3.69 (d, 3J 
= 2.8Hz, 1H, Gal-H4), 3.68-3.60 (m, 3H, Fuc-H4, Gal H6a, MeCy-H1), 3.57 (dd, 3J = 6.0Hz, 
2J = 11.3Hz, 1H, Gal-H6b), 3.46 (dd, 3J = 7.6, 10.4Hz, 1H, Gal-H2), 3.39 (t, 3J = 6.0Hz, 1H, 
Gal-H5), 3.22 (dd, 3J = 2.8, 10.4Hz, 1H, Gal-H3), 3.17 (t, 3J = 9.3Hz, 1H, MeCy-H2), 2.09 
(m, 1H, MeCy), 1.71-1.56 (m, 3H, MeCy), 1.37-1.20 (m, 2H, MeCy), 1.17 (d, 3J = 6.6Hz, 
3H, Fuc-H6), 1.12 (d, 3J = 6.3Hz, 3H, MeCy-CH3), 1.05 (m, 1H, MeCy); 13C NMR (125.8 
MHz, CD3OD): ! 143.1 (Thio-C4), 131.0 (Thio-C5), 128.8 (Thio-C3), 126.9 (Thio-C2), 
102.8 (Gal-C1), 100.3 (Fuc-C1), 84.6 (MeCy-C2), 79.9 (MeCy-C1), 76.9 (Gal-C5), 73.8 
(Fuc-C4), 71.4 (Fuc-C3), 70.3 (Fuc-C2), 69.9 (Gal-C2), 69.5 (Gal-C4), 67.5 (Fuc-C5), 62.9 
(Gal-C6), 60.8 (Gal-C3), 40.3 (MeCy-C3), 34.9 (MeCy-C4), 31.9 (MeCy-C6), 24.2 (MeCy-
C5), 19.6 (MeCy-CH3), 16.8 (Fuc-C6); ["]D -44.0 (c 0.22, MeOH); HR-MS (ESI) m/z: calcd 
for C23H37NNaO12S2 [M+Na]+: 606.1649; found: 606.1649; HPLC-purity: > 99.5% (B). 
 
3-(2-(Methoxycarbonyl)thiophene-3-sulfonamido)-3-deoxy-#-D-galactopyranosyl-(1!1)-
[" -L-fucopyranosyl-(1!2)]-(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol 20. 
To a suspension of 17 (15 mg, 0.034 mmol), DIPEA (0.012 mL, 0.07 mmol) and MgO (6 mg, 
0.15 mmol) in THF/H2O (4/1, 0.30 mL) that had been stirred at r.t. for 90 min, was added a 
solution of 2-carboxymethoxy3-thiophenesulfonyl chloride (6 mg, 0.025 mmol) in THF (0.04 
mL). After 5 h, the mixture was filtered (celite), concentrated under reduced pressure and 
purified via HPLC to yield 20 as white solid (5.0 mg, 0.008 mmol, 31%). 
1H NMR (500.1 MHz, CD3OD): ! 7.77 (d, J = 5.2Hz, 1H, Thio-H5), 7.52 (d, J = 5.2Hz, 1H, 
Thio-H4), 4.96 (d, 3J = 3.9Hz, 1H, Fuc-H1), 4.81 (q, 3J = 6.4Hz, 1H, Fuc-H5), 4.63 (s, 1H, 
NH), 4.21 (d, 3J = 7.5Hz, 1H, Gal-H1), 3.92 (s, 3H, CO2CH3), 3.80 (dd, 3J = 3.3, 10.3Hz, 
1H, Fuc-H3), 3.76 (d, 3J = 2.9Hz, 1H, Gal-H4), 3.72 (dd, 3J = 3.9, 10.3Hz, 1H, Fuc-H2), 
3.69-3.55 (m, 4H, Fuc-H4, Gal H6a, Gal-H6b, MeCy-H1), 3.40-3.34 (m, 2H, Gal-H2, Gal-
H5), 3.25 (dd, 3J = 3.1, 10.4Hz, 1H, Gal-H3), 3.13 (t, 3J = 9.3Hz, 1H, MeCy-H2), 2.04 (m, 
1H, MeCy), 1.68-1.53 (m, 3H, MeCy), 1.36-1.18 (m, 2H, MeCy), 1.15 (d, 3J = 6.6Hz, 3H, 
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Fuc-H6), 1.11 (d, 3J = 6.3Hz, 3H, MeCy-CH3), 1.04 (m, 1H, MeCy); 13C NMR (125.8 MHz, 
CD3OD): ! 162.5 (CO2CH3), 147.4 (Thio-C2, Thio-C3), 131.9 (Thio-C5), 131.2 (Thio-C4), 
102.4 (Gal-C1), 100.5 (Fuc-C1), 84.8 (MeCy-C2), 79.6 (MeCy-C1), 76.9 (Gal-C5), 73.8 
(Fuc-C4), 71.4 (Fuc-C3), 70.6, 70.3 (Fuc-C2, Gal-C2), 69.5 (Gal-C4), 67.5 (Fuc-C5), 62.8 
(Gal-C6), 61.0 (Gal-C3), 53.5 (CO2CH3), 40.3 (MeCy-C3), 34.9 (MeCy-C4), 31.7 (MeCy-
C6), 24.2 (MeCy-C5), 19.5 (MeCy-CH3), 16.7 (Fuc-C6); ["]D -8.9 (c 0.08, MeOH); HR-MS 
(ESI) m/z: calcd for C25H39NNaO14S2 [M+Na]+: 664.1704; found: 664.1715; HPLC-purity: > 
99.5% (B). 
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2.4.2 Replacement of sialic acid with esters 
To initially validate the concept of sialic acid free antagonists described in the previous 
section, a small library of carboxylic acid esters was synthesized and tested (Table 2.4.1). In 
contrast to amides and sulfonamides, these esters could be synthesized from readily available 
building blocks and gave a first impression of suitable substituents. 
Table 2.4.1. Relative IC50 values (rIC50) of P-selectin antagonists 4.1a-4.1d (determined by Katrin 
Lemme). IC50 values are scaled on TMSE-sLex 1.12 (rIC50=1); n.b. = no binding observed up to 15 
mM. 
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entry Compound R rIC50 (P-selectin) 
1 1.1b 
 
0.05 
2 4.1a  n.b. 
3 4.1b  2.1 
4 4.1c  0.4 
5 4.1d 
 
1.3 
 
2.4.2.1 Biological evaluation 
The results of this first small library (Table 2.4.1) nicely agreed with the results of molecular 
modeling studies. Compound 4.1a (entry 2), which lacks a heteroatom essential for 
interaction with P-selectin, did not bind up to 15 mM. Introduction of an oxygen atom 
increased the binding affinity dramatically as it allows interaction with either Ser97 or Ser99. 
In addition, affinity depended on the position of the heteroatom. As expected from docking 
studies, 4.1c (entry 4) was more potent than 4.1b (entry 3), since it was better suited to 
properly position the oxygen atom. The cyclic analogue of 4.1b (entry 3), 4.1d (entry 5) 
bound slightly stronger which can be explained by a higher degree of pre-organization, or the 
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O
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reduced number of rotatable bonds. Though it was not possible to fully replace sialic acid (! 
1.1b) with any of the ester side chains, the results obtained for this series strongly supported 
our concept and laid the basis for the P-selectin antagonists presented in the previous section. 
2.4.2.2 Synthesis 
Esters 4.1a to 4.1d were synthesized by acylation of tin acetal activated building blocks 1.13 
or 1.14 with acyl chlorides and subsequent hydrogenolytic debenzylation (Scheme 2.4.2 and 
Scheme 2.4.3). Acyl chlorides not commercially available were synthesized from the 
corresponing acids via DMF catalyzed chlorination with oxalyl dichloride (Scheme 2.4.1).  
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Scheme 2.4.1 (COCl)2, DMF, CH2Cl2, r.t., 0.5 h, (4.3: 57%, 4.5: 43%). 
Acylation of the tin acetal of 1.13 with 3-methylbutyryl chloride repeatedly proceeded with 
poor regioselectivity even at -78°C, leading to very poor yields of 4.1a (Scheme 2.4.2).  
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Scheme 2.4.2 a) i. Bu2SnO, toluene, MS 4 Å, 80°C, 12 h; ii. 3-methylbutyryl chloride, toluene, -
78°C, 2 h, 32%; b) Pd(OH)2/C, H2, dioxane, H2O, 9 h, 45%. 
As it is known, that the tin acetal of 4,6 benzylidene-galactosides can be benzoylated with 
high regioselectivity in 3-position,[1] esters 4.1b to 4.1d were synthesized from building block 
1.14, which was available from 4.3* in three steps (Scheme 2.4.3). Though acylation of tin 
acetal activated 1.14 proceeded quite smoothly then, overall yields were still poor. To 
increase the regioselectivity of the acylation reaction and the stability of the final antagonists, 
as well as to broaden the range of substituents, amide and sulfonamide analogues were 
synthesized (see section 2.4.1). 
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Scheme 2.4.3. a) BzCl, pyridine, r.t., 2 h, 96%; b) DMTST, CH2Cl2, MS 4 Å, r.t., 16 h, (4.7: 76%, 
1.3b: 22%); c) NaOMe, MeOH, r.t., 22 h, 82%; d) i. Bu2SnO, toluene, MS 4 Å, 80°C, 12 h; ii. 
RCOCl, toluene, r.t., (4.8b:77%, 4.8c: 40%, 4.8d: 69%); b) Pd(OH)2/C, H2, dioxane, H2O, (4.1b: 
32%, 4.1c: 25%, 4.1d: 21%). 
2.4.2.3 Experimental 
General experimental conditions are described in section 2.4.1. 
 
3-Methoxypropanoyl chloride 4.3. 
To a stirred solution of 3-methoxypropionic acid (2.0 mL, 21.1 mmol) in anhydrous CH2Cl2 
(30 ml) under argon were added oxalyl dichloride (4.0 mL, 46.6 mmol) and DMF (cat.). The 
solution was stirred at r.t. for 30 min, concentrated and distilled to yield 4.3 (1.47 g, 12.0 
mmol, 57%) as clear oil, which was directly used in the next step. 
 
(R)-Tetrahydrofuran-2-carbonyl chloride 4.5. 
To a stirred solution of (S)-tetrahydrofuroic acid (2.0 mL, 20.7 mmol) in anhydrous CH2Cl2 
(30 ml) under argon were added oxalyl dichloride (4.0 mL, 46.6 mmol) and DMF (cat.). The 
solution was stirred at r.t. for 30 min, concentrated and distilled to yield 4.5 (1.20 g, 8.9 
mmol, 43%) as clear oil, which was directly used in the next step. 
 
6-O-Benzyl-3-O-(3-methylbutanoyl)-!-D-galactopyranosyl-(1!1)-[2,3,4-tri-O-benzyl-" -
L-fucopyranosyl-(1!2)]-(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol 4.6. 
A suspension of 1.13 (120 mg, 0.150 mmol), dibutyltin oxide (56 mg, 0.225 mmol), and 
activated powdered molecular sieves 4 Å (0.2 g) in anhydrous toluene (2.0 mL) was stirred in 
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a sealed vessel under argon at 80°C for 19 h. The mixture was cooled to -78°C and 
isovaleroyl chloride (0.030 mL, 0.244 mmol) was added slowly. After 2 h, the reaction was 
quenched with MeOH, the mixture was filtered (celite) and concentrated under reduced 
pressure. Column chromatography on silica afforded (PE/EtOAc) 4.6 as white solid (43 mg, 
0.049 mmol, 32%), which was directly used in the next step. 
 
General procedure A for the hydrogenolytic debenzylation 
The corresponding intermediate was dissolved in dioxane/water (4/1, 5.0 mL) under argon. 
Pd(OH)2/C (25 mg, 10% Pd(OH)2) was added and the resulting mixture was hydrogenated 
(3.5 bar H2) at r.t. After 9 h, the mixture was filtered and the solvent removed under reduced 
pressure. Purification via HPLC and lyophilization from water/acetonitrile afforded the 
corresponding products. 
 
3-O-(3-methylbutanoyl)-!-D-galactopyranosyl-(1!1)-[" -L-fucopyranosyl-(1!2)]-
(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol 4.1a. 
According to general procedure A, 4.6 (43 mg, 0.049 mmol) was hydrogenated and purified 
to give 4.1a as a white fluffy solid (12 mg, 0.023 mmol, 45% from 1.13). 
1H NMR (500.1 MHz, CD3OD): #  5.00 (d, 3J = 4.0Hz, 1H, Fuc-H1), 4.93-4.86 (m, 1H, Fuc-
H5), 4.72 (dd, 3J = 3.2, 10.2Hz, 1H, Gal-H3), 4.36 (d, 3J = 7.7Hz, 1H, Gal-H1), 3.97 (d, 3J = 
2.9Hz, 1H, Gal-H4), 3.84 (dd, 3J = 3.3, 10.2Hz, 1H, Fuc-H3), 3.77-3.60 (m, 6H, Fuc-H2, 
Fuc-H4, Gal-H2, Gal-H6a, Gal-H6b, MeCy-H1), 3.49 (t, 3J = 6.0Hz, 1H, Gal-H5), 3.20 (t, 3J 
= 9.3Hz, 1H, MeCy-H2), 2.37-2.20 (m, 2H, (CH3)2CHCH2CO), 2.16-2.07 (m, 2H, MeCy, 
(CH3)2CHCH2CO), 1.73-1.57 (m, 3H, MeCy), 1.41-1.23 (m, 2H, MeCy), 1.20 (d, 3J = 6.6Hz, 
3H, Fuc-H6), 1.13 (d, 3J = 6.3Hz, 3H, MeCy-CH3), 1.10-1.03 (m, 1H, MeCy), 0.99, 0.98 (2s, 
6H, (CH3)2CHCH2CO); 13C NMR (125.8 MHz, CD3OD): # 174.5 ((CH3)2CHCH2CO), 102.5 
(Gal-C1), 100.4 (Fuc-C1), 84.6 (MeCy-C2), 80.1 (MeCy-C1), 77.1 (Gal-C3), 76.1 (Gal-C5), 
73.8 (Fuc-C4), 71.4 (Fuc-C3), 70.4 (Fuc-C2), 69.7 (Gal-C2), 67.8 (Gal-C4), 67.5 (Fuc-C5), 
62.7 (Gal-C6), 44.2 ((CH3)2CHCH2CO), 40.4 (MeCy-C3), 34.9 (MeCy-C4), 31.9 (MeCy-
C6), 26.8 ((CH3)2CHCH2CO), 24.2 (MeCy-C5), 22.8 (2C, (CH3)2CHCH2CO), 19.6 (MeCy-
CH3), 16.7 (Fuc-C6); ["]D -57.4 (c 0.87, MeOH); HR-MS (ESI) m/z: calcd for C24H42NaO12 
[M+Na]+: 545.2568 ; found: 545.2569. 
 
Ethyl 2,3-di-O-benzoyl-4,6-O-benzylidene-1-thio-! -D-galactopyranoside 1.17. 
A solution of ethyl 4,6-O-benzylidene-1-thio-!-D-galactopyranoside 4.3* (1.40 g, 4.48 mmol) 
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and benzoyl chloride (1.24 mL, 10.69 mmol) in anhydrous pyridine (15 mL) was stirred for 2 
h at r.t. under argon. The solution was concentrated under reduced pressure and the resulting 
residue was redissolved in CH2Cl2 (50 mL) and washed with cold aqueous HCl (1 N, 50 mL), 
aqueous satd. NaHCO3 (5%, 50 mL) and brine (50 mL). The aqueous layers were extracted 
with CH2Cl2 (3 · 50 mL) and the combined organic layers were dried over Na2SO4, filtered, 
and concentrated. Column chromatography on silica afforded 1.17 as white solid (2.23 g, 
4.28 mmol, 96%). 
1H NMR (500.1 MHz, CDCl3): !   7.97, 7.50, 7.37 (3m, 15H, Ar-H), 5.96 (t, 3J = 9.9Hz, 1H, 
H2), 5.54 (s, 1H, CHPh), 5.40 (dd, 3J = 3.5, 9.9Hz, 1H, H3), 4.74 (d, 3J = 9.9Hz, 1H, H1), 
4.63 (d, 3J = 3.5 Hz, 1H, H-4), 4.42 (d, 2J = 11.3Hz, 1H, H-6a), 4.09 (d, 2J = 11.3Hz, 1H, H-
6b), 3.73 (s, 1H, H-5), 2.95, 2.81 (2m, 2H, SCH2CH3), 1.30 (m, 3H, SCH2CH3); 13C NMR 
(125.8 MHz, CDCl3): ! 166.3, 165.5 (2C, COC6H5), 137.8, 133.5, 133.3, 130.1, 129.9, 129.7, 
129.2, 128.5, 128.3, 126.4 (18C, Ar-C), 101.2 (CHPh), 83.1 (C-1), 74.0 (2C, C-3, C-4), 70.1 
(C-5), 69.4 (C-6), 67.4 (C-2), 23.1 (SCH2CH3), 15.0 (SCH2CH3); ["]D 103.0 (c 0.82, CHCl3); 
MS (ESI) m/z: calcd for C29H28NaO7S+ [M+Na]+: 543.14; found: 543.10; elemental analysis 
calcd (%) for C29H28O7S + 0.25 H2O (525.10): C 66.33, H 5.47; found: C 66.45, H 5.40. 
 
2,3-Di-O-benzoyl-4,6-O-benzylidene-#-D-galactopyranosyl-(1!1)-[2,3,4-tri-O-benzyl-" -
L-fucopyranosyl-(1!2)]-(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol 4.7. 
Powdered activated molecular sieves 4 Å (3.0 g) were added to a solution of 1.3b (0.70 g, 
1.28 mmol) and galactoside 1.17 (0.89 g, 1.71 mmol) in anhydrous CH2Cl2 (30 ml) and the 
mixture was stirred at r.t. under argon for 4 h. DMTST (1.29 g, 5.00 mmol) was dissolved in 
anhydrous CH2Cl2 (10 ml), powdered activated molecular sieves 4 Å (1.0 g) were added, and 
the suspension was stirred at r.t. under argon for 4 h as well. Subsequently, the two 
suspensions were combined and stirred at r.t. under argon for 16 h. The mixture was diluted 
with CH2Cl2 (30 mL), filtered (celite), and washed with satd. aqueous NaHCO3 (100 mL) and 
brine (100 mL). The aqueous layers were extracted with CH2Cl2 (3 · 50 mL) and the 
combined organic layers were dried over Na2SO4 and concentrated. Column chromatography 
on silica (PE/EtOAc 4/1 to 2/1) afforded 4.7 as white foam (0.98 g, 0.98 mmol, 76%). 1.3b 
was recovered in 22% (0.16 g, 0.29 mmol). 
1H NMR (500.1 MHz, CDCl3): !   7.98, 7.91, 7.51, 7.44 (4m, 8H, Ar-H), 7.37-7.04 (m, 22H, 
Ar-H), 5.80 (dd, 3J = 8.1, 10.4Hz, Gal-H2), 5.55 (s, 1H, CHPh), 5.25 (dd, 3J = 3.5, 10.4Hz, 
Gal-H3), 4.96 (q, 3J = 6.4, 6.5Hz, Fuc-H5) 4.90 (d, 3J = 3.8Hz, 1H, Fuc-H1), 4.78-4.70 (m, 
2H, Gal-H1, CH2Ph), 4.63 (B of AB, 2J = 11.7Hz, 1H, CH2Ph), 4.57-4.51 (m, 3H, Gal-H4, 
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CH2Ph), 4.34 (m, 1H, Gal-H6a), 4.17 (A of AB, 2J = 11.3Hz, 1H, CH2Ph), 4.08 (m, 1H, Gal-
H6b), 3.93 (dd, 3J = 2.6, 10.4Hz, Fuc-H3), 3.87 (dd, 3J = 3.8, 10.4Hz, Fuc-H2), 3.61-3.53 
(m, 3H, Gal-H5, MeCy-H1, CH2Ph), 3.23 (m, 1H, Fuc-H4), 3.12 (t, 3J = 9.6Hz, MeCy-H2), 
1.89 (m, 1H, MeCy), 1.67-1.37 (m, 3H, MeCy), 1.24 (d, 3J = 6.5Hz, 3H, Fuc-H6), 1.20-1.01 
(m, 2H, MeCy), 0.97 (d, 3J = 6.5Hz, 3H, MeCy-CH3), 0.84 (m, 1H, MeCy); ! 13C NMR 
(125.8 MHz, CDCl3): ! 166.3, 165.2 (2C, COC6H5), 139.9, 139.7, 138.9, 138.0, 133.6, 133.2, 
130.1, 129.9, 129.8, 129.3, 129.0, 128.8, 128.6, 128.5, 128.3, 128.2, 128.0, 127.7, 127.5, 
127.2, 127.0, 125.9 (36C, Ar-C), 99.8 (CHPh), 99.6 (Gal-C1), 98.5 (Fuc-C1), 81.6 (MeCy-
C2), 80.9, (MeCy-C1), 79.9 (Fuc-C3), 79.2 (Fuc-C4), 75.8 (Fuc-C2), 75.1, 74.6 (2C, CH2Ph), 
73.7 (Gal-C4), 73.2 (Gal-C3), 71.4 (CH2Ph), 69.4 (Gal-C6), 69.1 (Gal-C2), 66.4, 66.3 (2C, 
Fuc-C5, Gal-C5), 39.6 (MeCy-C3), 33.6 (MeCy-C4), 31.3 (MeCy-C6), 23.5 (MeCy-C5), 
18.8 (MeCy-CH3), 16.6 (Fuc-C6); ["]D -40.6 (c 1.50, CHCl3); MS (ESI) m/z: calcd for 
C61H64NaO13+ [M+Na]+: 1027.4; found: 1027.5; elemental analysis calcd (%) for C61H64O13: 
C 72.89, H 6.42; found: C 72.81, H 6.37. 
 
4,6-O-Benzylidene-#-D-galactopyranosyl-(1!1)-[2,3,4-tri-O-benzyl-" -L-fucopyranosyl-
(1!2)]-(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol 1.14. 
A freshly prepared solution of NaOMe in anhydrous MeOH (3 N, 0.47 mL) was slowly 
added to a solution of 4.7 (920 mg, 0.92 mmol) in anhydrous MeOH (20 mL) under argon at 
r.t. After 22 h, the mixture was neutralized with HCl in MeOH (3 N, 0.47 mL) and 
concentrated under reduced pressure. Column chromatography on silica (EtOAc) afforded 
1.14 as white foam (600 mg, 0.75 mmol, 82%). 
1H NMR (500.1 MHz, CDCl3): ! 7.56-6.93 (m, 20H, Ar-H), 5.49 (s, 1H, CHPh), 4.90 (d, 3J 
= 2.6Hz, 1H, Fuc-H1), 4.80 (q, 3J = 6.3Hz, Fuc-H5), 4.74 (A of AB, 2J = 11.6Hz, 1H, 
CH2Ph), 4.63 (B of AB, 2J = 11.6Hz, 1H, CH2Ph), 4.56-4.49 (m, 2H, CH2Ph), 4.62 (A of AB 
, 2J = 11.3Hz, 1H, CH2Ph), 4.22-4.16 (m, 2H, Gal-H1, Gal-H6a), 4.04 (d, 3J = 2.9Hz, 1H, 
Gal-H4), 3.93 (m, 1H, Gal-H6b), 3.96-3.90 (m, 2H, Fuc-H2, Fuc-H3), 3.69-3.59 (m, 3H, 
CH2Ph, Gal-H2, Gal-H3), 3.55 (m, 1H, MeCy-H1), 3.24 (m, 1H, Fuc-H4), 3.21 (m, 1H, Gal-
H5), 3.13 (t, 3J = 9.5Hz, MeCy-H2), 1.96 (m, 1H, MeCy), 1.61-1.42 (m, 3H, MeCy), 1.32-
1.05 (m, 2H, MeCy), 1.04-0.85 (m, 7H Fuc-H6, MeCy); 13C NMR (125.8 MHz, CDCl3): ! " 
139.6, 139.4, 138.7, 138.0, 128.9, 128.7, 128.3, 128.2, 128.1, 128.0, 127.5, 127.4, 127.2, 
125.8 (24C, Ar-C), 101.0 (Gal-C1), 100.0 (CHPh), 98.5 (Fuc-C1), 82.4 (MeCy-C2), 80.1 
(MeCy-C1), 79.7 (Fuc-C3), 78.8 (Fuc-C4), 75.6, 75.5 (2C, Fuc-C2, Gal-C4), 74.9, 74.5 (2C, 
CH2Ph), 72.6 (Gal-C3), 71.4, 71.3 (Gal-C2, CH2Ph), 69.5 (Gal-C6), 66.4, 66.22 (Fuc-C5, 
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Gal-C5), 39.5 (MeCy-C3), 33.7 (MeCy-C4), 31.4 (MeCy-C6), 23.4 (MeCy-C5), 19.9 
(MeCy-CH3), 16.7 (Fuc-C6); [!]D -83.0 (c 1.18, CHCl3); MS (ESI) m/z: calcd for 
C47H56NaO11+ [M+Na]+: 819.4; found: 819.4; elemental analysis calcd (%) for C47H56O11 + 
0.5 H2O (805.95): C 70.04, H 7.13; found: C 69.80, H 7.00. 
 
General procedure B for acylations of 1.14 
A suspension of 1.14, dibutyltin oxide, and activated powdered molecular sieves 4 Å in 
anhydrous toluene was stirred in a sealed vessel under argon at 80°C for 19 h. The mixture 
was cooled to r.t. and the corresponding acyl chloride was added slowly. After 30 min, the 
reaction was quenched with MeOH, the mixture was filtered (celite) and concentrated under 
reduced pressure. Column chromatography on silica afforded the corresponding products 
esters. 
 
4,6-O-Benzylidene-2-O-(2-methoxyacetyl)-"-D-galactopyranosyl-(1!1)-[2,3,4-tri-O-
benzyl-! -L-fucopyranosyl-(1!2)]-(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol 4.8b. 
According to general procedure B, 1.14 (80 mg, 0.100 mmol), dibutyltin oxide (33 mg, 0.133 
mmol) and molecular sieves (0.05 g) were reacted in anhydrous toluene (0.5 mL). 
Methoxyacetyl chloride (17 mg, 0.157 mmol) was added. Column chromatography on silica 
afforded 4.8b as white solid (67 mg, 0.077 mmol, 77%), which was directly used in the next 
step. 
 
4,6-O-Benzylidene-3-O-(3-methoxypropanoyl)-"-D-galactopyranosyl-(1!1)-[2,3,4-tri-O-
benzyl-! -L-fucopyranosyl-(1!2)]-(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol 4.8c. 
According to general procedure B, 1.14 (70 mg, 0.088 mmol), dibutyltin oxide (33 mg, 0.133 
mmol) and molecular sieves (0.05 g) were reacted in anhydrous toluene (0.5 mL). 4.3 (16 
mg, 0.131 mmol) was added. Column chromatography on silica afforded 4.8c as white solid 
(31 mg, 0.035 mmol, 40%).  
1H NMR (500.1 MHz, CDCl3): # 7.57-7.04 (m, 20H, Ar-H), 5.50 (s, 1H, CHPh), 4.92-4.85 
(m, 2H, Fuc-H1, Gal-H3), 4.80 (q, 3J = 6.4Hz, Fuc-H5), 4.75 (A of AB, 2J = 11.6Hz, 1H, 
CH2Ph), 4.64 (B of AB, 2J = 11.6Hz, 1H, CH2Ph), 4.56-4.52 (m, 2H, CH2Ph), 4.33 (d, 3J = 
7.8Hz, 1H, Gal-H1), 4.30 (d, 3J = 3.4Hz, 1H, Gal-H4), 4.28-4.20 (2H, m, Gal-H6a, CH2Ph), 
4.02-3.98 (m, 1H, Gal-H6b), 3.94-3.84 (m, 3H, Fuc-H2, Fuc-H3, Gal-H2), 3.69-3.52 (m, 4H, 
CH2CH2OCH3, MeCy-H1, CH2Ph), 3.40 (s, 1H, Gal-H5), 3.25 (s, 3H, CH2CH2OCH3), 3.18 
(s, 1H, Fuc-H4), 3.14 (t, 3J = 9.5Hz, MeCy-H2), 2.66 (td, J =1.8, 6.2Hz, 2H, CH2CH2OCH3), 
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2.00 (m, 1H, MeCy), 1.65-1.43 (m, 3H, MeCy), 1.20-1.17 (m, 2H, MeCy), 1.06-0.90 (m, 7H 
Fuc-H6, MeCy); 13C NMR (125.8 MHz, CDCl3): ! ! 171.6 (COCH2CH2OCH3), 139.7, 139.5, 
138.7, 138.1, 128.9, 128.8, 128.3, 128.2, 128.0, 127.6, 127.5, 127.2, 127.0, 125.9 (24C, Ar-
C), 101.2 (Gal-C1), 99.7 (CHPh), 98.6 (Fuc-C1), 82.4 (MeCy-C2), 80.2 (MeCy-C1), 79.7 
(Fuc-C3), 78.8 (Fuc-C4), 75.6 (Fuc-C2), 74.9, 74.6 (2C, CH2Ph), 73.9 (Gal-C3), 73.6 (Gal-
C4), 71.4 (CH2Ph), 69.4 (Gal-C6), 68.3 (Gal-C2), 68.1 (CH2CH2OCH3), 66.3, 66.2 (Fuc-C5, 
Gal-C5), 58.9 (CH2CH2OCH3), 39.6 (MeCy-C3), 35.2 (CH2CH2OCH3), 33.8 (MeCy-C4), 
31.5 (MeCy-C6), 23.4 (MeCy-C5), 18.9 (MeCy-CH3), 16.7 (Fuc-C6); MS (ESI) m/z: calcd 
for C51H62NaO13+ [M+Na]+: 905.41; found: 905.47.  
 
4,6-O-Benzylidene-3-O-((R)-tetrahydrofuran-2-carboxyl)-"-D-galactopyranosyl-(1"1)-
[2,3,4-tri-O-benzyl-# -L-fucopyranosyl-(1"2)]-(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol 
4.8d. 
According to general procedure B, 1.14 (70 mg, 0.088 mmol), dibutyltin oxide (33 mg, 0.133 
mmol) and molecular sieves (0.05 g) were reacted in anhydrous toluene (0.5 mL). 4.5 (15 
mg, 0.111 mmol) was added. Column chromatography on silica (CH2Cl2/MeOH) afforded 
4.8d as white foam (54 mg, 0.060 mmol, 69%).  
1H NMR (500.1 MHz, CDCl3): ! 7.56-7.00 (m, 20H, Ar-H), 5.49 (s, 1H, CHPh), 4.93-4.85 
(m, 2H, Fuc-H1, Gal-H3), 4.78 (m, 1H, Fuc-H5), 4.75 (A of AB, 2J = 11.6Hz, 1H, CH2Ph), 
4.64 (B of AB, 2J = 11.6Hz, 1H, CH2Ph), 4.59-4.51 (m, 3H, CH2Ph, THF-H1), 4.33-4.29 (m, 
2H, Gal-H1, Gal-H4), 4.28-4.22 (2H, m, Gal-H6a, CH2Ph), 4.06-3.97 (m, 2H, Gal-H6b, 
THF-H4a), 3.95-3.83 (m, 4H, Fuc-H2, Fuc-H3, Gal-H2, THF-H4b), 3.64-3.54 (m, 2H, 
MeCy-H1, CH2Ph), 3.41 (s, 1H, Gal-H5), 3.19 (s, 1H, Fuc-H4), 3.13 (t, 3J = 9.5Hz, MeCy-
H2), 2.26 (m, 1H, THF-H2a), 2.05 (m, 1H, THF-H2b), 1.99 (m, 1H, MeCy), 1.95-1.80 (m, 
2H, THF-H3a,b), 1.62-1.47 (m, 3H, MeCy), 1.31-1.09 (m, 2H, MeCy), 1.06-0.86 (m, 7H 
Fuc-H6, MeCy); 13C NMR (125.8 MHz, CDCl3): ! ! 173.7 (THF-CO), 139.6, 139.5, 138.7, 
138.1, 128.9, 128.8, 128.3, 128.2, 128.0, 127.6, 127.5, 127.2, 127.0, 125.8 (24C, Ar-C), 
101.2 (Gal-C1), 99.7 (CHPh), 98.6 (Fuc-C1), 82.5 (MeCy-C2), 80.3 (MeCy-C1), 79.7 (Fuc-
C3), 78.8 (Fuc-C4), 76.7 (THF-C1), 75.6 (Fuc-C2), 74.9, 74.6 (2C, CH2Ph), 73.8, 73.6 (2C, 
Gal-C3, Gal-C4), 71.5 (CH2Ph), 69.7 (THF-C4), 69.4 (Gal-C6), 68.4 (Gal-C2), 66.3, 66.2 
(Fuc-C5, Gal-C5), 39.6 (MeCy-C3), 33.7 (MeCy-C4), 31.5 (MeCy-C6), 30.7 (THF-C2), 29.8 
(THF-C3), 23.4 (MeCy-C5), 18.9 (MeCy-CH3), 16.7 (Fuc-C6); MS (ESI) m/z: calcd for 
C52H62NaO13+ [M+Na]+: 917.4; found: 917.5. 
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3-O-(2-methoxyacetyl)-!-D-galactopyranosyl-(1!1)-[" -L-fucopyranosyl-(1!2)]-
(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol 4.1b. 
According to general procedure A, 4.8b (53 mg) was hydrogenated and purified to give 4.1b 
as a white fluffy solid (10 mg, 0.020 mmol, 32%). 
1H NMR (500.1 MHz, CD3OD): # "5.00 (d, 3J = 4.0Hz, 1H, Fuc-H1), 4.94-4.86 (m, 1H, Fuc-
H5), 4.79 (dd, 3J = 2.8, 10.1Hz, 1H, Gal-H3), 4.39 (d, 3J = 7.7Hz, 1H, Gal-H1), 4.16 (s, 2H, 
COCH2OCH3), 4.02 (d, 3J = 2.8Hz, 1H, Gal-H4), 3.84 (dd, 3J = 3.3, 10.3Hz, 1H, Fuc-H3), 
3.77-3.64 (m, 6H, Fuc-H2, Fuc-H4, Gal-H2, Gal H6a, Gal-H6b, MeCy-H1), 3.52 (t, 3J = 
6.0Hz, 1H, Gal-H5), 3.44 (s, 3H, COCH2OCH3), 3.20 (t, 3J = 9.3Hz, 1H, MeCy-H2), 2.14 
(m, 1H, MeCy), 1.72-1.57 (m, 3H, MeCy), 1.40-1.22 (m, 2H, MeCy), 1.19 (d, 3J = 6.6Hz, 
3H, Fuc-H6), 1.14 (d, 3J = 6.3Hz, 3H, MeCy-CH3), 1.11-1.02 (m, 1H, MeCy); 13C NMR 
(125.8 MHz, CD3OD): # 171.9 (COCH2OCH3), 102.3 (Gal-C1), 100.5 (Fuc-C1), 84.6 
(MeCy-C2), 80.1 (MeCy-C1), 78.0 (Gal-C3), 75.9 (Gal-C5), 73.8 (Fuc-C4), 71.4 (Fuc-C3), 
70.3 (2C, COCH2OCH3, Fuc-C2), 69.6 (Gal-C2), 67.7 (Gal-C4), 67.5 (Fuc-C5), 62.6 (Gal-
C6), 59.5 (COCH2OCH3), 40.4 (MeCy-C3), 34.9 (MeCy-C4), 31.9 (MeCy-C6), 24.2 (MeCy-
C5), 19.6 (MeCy-CH3), 16.7 (Fuc-C6); ["]D -62.2 (c 0.60, MeOH); HR-MS (ESI) m/z: calcd 
for C22H38NaO13 [M+Na]+: 533.2205 ; found: 533.2205. 
 
3-O-(3-Methoxypropanoyl)-!-D-galactopyranosyl-(1!1)-[" -L-fucopyranosyl-(1!2)]-
(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol 4.1c. 
According to general procedure A, 4.8c (30 mg, 0.034 mmol) was hydrogenated and purified 
to give 4.1c as a white fluffy solid (4.5 mg, 0.009 mmol, 25%). 
1H NMR (500.1 MHz, CD3OD): # "4.99 (d, 3J = 4.0Hz, 1H, Fuc-H1), 4.97-4.86 (m, 1H, Fuc-
H5), 4.71 (dd, 3J = 3.1, 10.1Hz, 1H, Gal-H3), 4.37 (d, 3J = 7.7Hz, 1H, Gal-H1), 3.99 (d, 3J = 
2.6Hz, 1H, Gal-H4), 3.84 (dd, 3J = 3.3, 10.3Hz, 1H, Fuc-H3), 3.79-3.62 (m, 8H, Fuc-H2, 
Fuc-H4, Gal-H2, Gal H6a, Gal-H6b, MeCy-H1, COCH2CH2OCH3), 3.50 (t, 3J = 6.0Hz, 1H, 
Gal-H5), 3.34 (s, 3H, COCH2CH2OCH3), 3.20 (t, 3J = 9.3Hz, 1H, MeCy-H2), 2.68 (t, 2H, 
COCH2CH2OCH3), 2.12 (m, 1H, MeCy), 1.72-1.57 (m, 3H, MeCy), 1.39-1.22 (m, 2H, 
MeCy), 1.19 (d, 3J = 6.6Hz, 3H, Fuc-H6), 1.13 (d, 3J = 6.3Hz, 3H, MeCy-CH3), 1.06 (m, 1H, 
MeCy); 13C NMR (125.8 MHz, CD3OD): # 172.9 (COCH2CH2OCH3), 102.4 (Gal-C1), 100.5 
(Fuc-C1), 84.6 (MeCy-C2), 80.1 (MeCy-C1), 77.8 (Gal-C3), 76.0 (Gal-C5), 73.9 (Fuc-C4), 
71.4 (Fuc-C3), 70.4, 69.7 (2C, Fuc-C2, Gal-C2), 69.1 (COCH2CH2OCH3), 67.6, 67.5 (2C, 
Fuc-C5, Gal-C4), 62.6 (Gal-C6), 59.0 (COCH2CH2OCH3), 40.4 (MeCy-C3), 35.7 
(COCH2CH2OCH3), 34.9 (MeCy-C4), 31.9 (MeCy-C6), 24.2 (MeCy-C5), 19.6 (MeCy-CH3), 
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16.7 (Fuc-C6); [!]D -63.1 (c 0.76, MeOH); HR-MS (ESI) m/z: calcd for C23H40NaO13 
[M+Na]+: 547.2361; found: 547.2365. 
 
3-O-((R)-tetrahydrofuran-2-carboxyl)-"-D-galactopyranosyl-(1!1)-[! -L-fucopyranosyl-
(1!2)]-(1R,2R,3S)-3-methyl-cyclohexane-1,2-diol 4.1d. 
According to general procedure A, 4.8d (43 mg, 0.048 mmol) was hydrogenated and purified 
to give 4.1d as white fluffy solid (5.4 mg, 0.010 mmol, 21%). 
1H NMR (500.1 MHz, CD3OD): # "4.99 (d, 3J = 4.0Hz, 1H, Fuc-H1), 4.95-4.86 (m, 1H, Fuc-
H5), 4.76 (dd, 3J = 3.2, 10.1Hz, 1H, Gal-H3), 4.57 (dd, 3J = 5.1, 8.6Hz, 1H, THF-H1), 4.37 
(d, 3J = 7.7Hz, 1H, Gal-H1), 4.04-3.95 (m, 2H, Gal-H4, THF-H4a), 3.92-3.86 (m, 1H, THF-
H4b), 3.83 (dd, 3J = 3.3, 10.2Hz, 1H, Fuc-H3), 3.77-3.62 (m, 6H, Fuc-H2, Fuc-H4, Gal-H2, 
Gal H6a, Gal-H6b, MeCy-H1), 3.51 (t, 3J = 6.1Hz, 1H, Gal-H5), 3.20 (t, 3J = 9.3Hz, 1H, 
MeCy-H2), 2.35-2.24 (m, 1H, THF-H2a), 2.19-2.08 (m, 2H, MeCy, THF-H2b), 2.01-1.87 
(m, 2H, THF-H3a,3b), 1.73-1.57 (m, 3H, MeCy), 1.38-1.23 (m, 2H, MeCy), 1.19 (d, 3J = 
6.6Hz, 3H, Fuc-H6), 1.13 (d, 3J = 6.3Hz, 3H, MeCy-CH3), 1.10-1.02 (m, 1H, MeCy); 13C 
NMR (125.8 MHz, CD3OD): # 174.8 (THF-CO), 102.5 (Gal-C1), 100.4 (Fuc-C1), 84.6 
(MeCy-C2), 80.2 (MeCy-C1), 77.8 (2C, Gal-C3, THF-C1), 76.0 (Gal-C5), 73.8 (Fuc-C4), 
71.4 (Fuc-C3), 70.4 (2C, Fuc-C2, THF-C4), 69.8 (Gal-C2), 67.8 (Gal-C4), 67.5 (Fuc-C5), 
62.6 (Gal-C6), 40.4 (MeCy-C3), 34.9 (MeCy-C4), 32.0 (MeCy-C6), 31.2 (THF-C2), 26.0 
(THF-C3), 24.2 (MeCy-C5), 19.6 (MeCy-CH3), 16.7 (Fuc-C6); [!]D -68.7 (c 0.87, MeOH); 
HR-MS (ESI) m/z: calcd for C24H40NaO13 [M+Na]+: 559.2361; found: 559.2365. 
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2.5 Derivatives of 2,2-dialkyl-2-O-glycosyl glycolic acid as E-selectin 
antagonists 
2.5.1 Design, synthesis, and characterization of 2,2-dialkyl-2-O-glycosyl glycolic acid 
derivatives as E-selectin antagonists 
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Abstract 
Selectins have been recognized as promising targets for the development of anti-
inflammatory drugs. Since the carbohydrate lead structure sialyl Lewisx (sLex) exhibits poor 
pharmacokinetic and pharmacodynamic properties and requires a complex synthesis, efforts 
were directed to replace carbohydrate residues with less complex and less polar mimics. For 
E-selectin antagonists, mostly derivatives of (S)-lactic acid were used to replace the sialic 
acid moiety of sLex. As molecular dynamics simulations indicated that derivatives of 2,2-
dialkyl glycolic acid might be suited as replacements as well, two glycomimetic derivatives 
were synthesized and tested for their ability to block E-selectin in a competitive binding 
assay. 
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1. Introduction 
Selectins, namely E-, P-, and L-selectin, are Ca2+-dependent carbohydrate binding proteins 
that mediate the initial step of leukocyte recruitment to sites of inflammation. Blocking the 
interaction of selectins with their physiological ligands is consequently considered a 
promising therapeutic approach to tackle chronic and acute inflammatory diseases like stroke, 
psoriasis or reperfusion injuries.[1] Most drug discovery programs started from the 
tetrasaccharide sialyl Lewisx (1, Figure 1), as it is the common carbohydrate binding epitope 
recognized by all three selectins.[2] However, the development of carbohydrate derived drugs 
is strongly hampered by the intrinsic properties of carbohydrates, as these typically exhibit 
poor pharmacokinetic and pharmacodynamic properties and require complex synthesis. A 
typical strategy to overcome these drawbacks is the stepwise replacement of carbohydrate 
residues with (carbocyclic) mimics. In the ideal case, this leads to glycomimetics of reduced 
complexity, increased affinity, and improved pharmacokinetic properties. This strategy was 
also applied to the rational design of selectin antagonists.[3] 
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Figure 1 Left: the tetrasaccharide sialyl Lewisx (1) and its pharmacophoric groups: hydroxyl groups 
of L-Fuc[4], hydroxyl groups in 4- and 6- position of D-Gal[5] and the carboxylic acid residue of sialic 
acid[6]. Right: E-selectin antagonist 2.[7] 
N-Acetyl-D-glucosamine (D-GlcNAc), which does not bear pharmacophoric groups, but 
rather acts as a spacer between L-fucose (L-Fuc) and D-galactose (D-Gal), was replaced by 
numerous linkers.[8,9] It was shown that the affinity of the resulting mimetics correlated with 
the ability of the linker to pre-organize the Lewisx core.[9] Conformationally restricted linkers 
like (R,R)-cyclohexane-1,2-diol were better suited than more flexible ones like ethane-1,2-
diol. Sialic acid, which contributes to binding mainly with its carboxy group, [6,10] was 
typically replaced by glycolic acid, lactic acid, or derivatives thereof.[11] Pre-organization also 
turned out to be essential for the carboxy group of sialic acid, i.e. derivatives of (S)-lactic acid 
were superior to derivatives of (R)-lactic acid and to glycolic acid. Efforts to replace both D-
GlcNAc and sialic acid simultaneously resulted in antagonist 2 (Figure 1), which showed a 
80-fold improvement of affinity compared to the lead structure sLex (1).[7]  
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Though derivatives of lactic acid have been studied extensively as mimics of sialic acid,[12,13] 
no replacements with 2,2-dialkyl substituted glycolic acid or derivatives thereof have been 
reported. Given the fact that neither the glycerol side chain nor the acetamide moiety of sialic 
acid contribute to binding,[6,10] we wondered if sialic acid could be replaced by a simple 
carbocyclic mimic (! 3, Figure 2) as well. In this short communication, we report on the 
design, synthesis, and biological evaluation of 2,2-dialkyl substituted glycolic acids as 
replacements for sialic acid. 
2. Results and Discussion 
The ability to properly orient the carboxylic acid residue of sialic acid in the bioactive 
conformation is a key prerequisite for novel sialic acid mimics. Consequently, we used a 
molecular modeling tool developed by Ernst and Kolb[13] to assess the degree of pre-
organization of potential sialic acid replacements. 
Based on a Monte Carlo (jumping between wells)/stochastic dynamics [MC(JBW)/SD] 
simulation,[13] this tool allows to compare the calculated conformational preference of the 
mimetic with the experimentally observed conformation of sLex bound to E-selectin,[14] 
which defines the bioactive window. For a graphical presentation, two internal coordinates, 
the acid orientation and the core conformation were defined and the relative population of the 
conformations was indicated with a color code (Figure 2). Mimetics populating the bioactive 
window are predicted to be better selectin ligands than those outside the window.  
To rule out conformational bias caused by a ring flip of 3, we also planned the synthesis of 
non-cyclic 4. According to the conformational preferences found for 3 and 4, both 
compounds should be very well pre-organized (Figure 2).  
 
  133 
                          
   
Figure 2 The conformational preferences calculated for 3 (left) and 4 (right) nicely superimpose with 
the experimentally observed conformation of sLex bound to E-selectin (blue rectangle). Relative 
population of the conformations is indicated with a color code ranging from white to dark red. The 
darker the color, the higher is the population of the conformation. 
Synthesis 
Glycomimetics of type 2 are typically synthesized by SN2-type alkylation of an appropriately 
protected trisaccharide mimic with a lactic acid derivative, activated as triflate. However, this 
strategy could not be applied to the synthesis of compounds 3 and 4, as the sterically 
demanding tertiary triflates are not suited for SN2-type reactions. Since, to the best of our 
knowledge, no method is described for the synthesis of 2,2-dialkyl-2-O-glycosyl-glycolic 
acids, and the harsh conditions usually applied for the ether formation with tert-alcohols were 
considered incompatible with carbohydrate chemistry, an alternative route had to be found 
(Table 1). Alkylation of galactoside 5[15] with spiroepoxide 6[16] was planned to give 7 regio- 
and chemoselectively under acidic conditions. The newly formed primary hydroxy group 
should serve as precursor for the carboxy group. To reduce steric constraints and thereby 
increase the reactivity of the galactoside, the 2-O and 4-O position of galactoside 5 were not 
protected. BF3·Et2O catalyzed alkylation of 5 with spiroepoxide 6 was repeated several times 
with slightly modified conditions (Table 1). Unfortunately, the rate of conversion was rather 
low and several attempts to increase it failed. Higher concentrations of 5 did not affect the 
3 4 
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conversion, and higher temperatures, stronger Lewis acids, or increased concentrations of 6 
led to the enhanced formation of side products (results not shown). Multiple alkylation and 
hemiacetal formation due to hydride shift were observed as main side reactions.  
Table 1 Alkylation of 5 with spiroepoxide 6 using different reaction conditions. 
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Entry c(6) 
[M]   
ratio 
5/6 
T [°C ]  t [min]  Recovered 5 Yield  
7 + 8 
Ratio 7/8 
(NMR) 
A 2.9 2/1 -15 to 0 55 75% 7% 1.0/1.2 
B 2.2 1.7/1 -15  50 84% 7% 1.0/1.4 
C 2.3 1.4/1 -15 55 67% 5% 1.0/1.0 
D 0.4 0.7/1 -18 135 72% 8% 1.0/1.5 
 
Finally, the reaction conditions shown in entry D were successfully applied to the synthesis 
of the tetrasaccharide mimetics 11 and 12 (Scheme 1). Yields and conversion of the 
alkylation reactions were comparable to the alkylation of 5 and proved the general 
applicability of the reaction conditions to the synthesis of more complex glycomimetics. 
TEMPO mediated chemoselective oxidation[17] of 11 and 12 provided lactones 13 and 14. 
The oxidation led to a significant low-field shift of the proton in 2-position of D-Gal (!"= 0.8 
ppm), confirming the identity of 13 and 14. Debenzylation by hydrogenolysis finally yielded 
the lactones 15 and 16, which were hydrolyzed to give 3 and 4. The identity of compounds 3 
and 4 was unambiguously confirmed by HMBC, as a crosspeak between the tertiary carbon 
of the sialic acid mimic and H-3 of D-Gal was observed. 
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O
R
R
6   R= -(CH2)5 
10 R= CH3
  
Scheme 1 a) 6 or 10, BF3·Et2O, CH2Cl2, -18°C, (11: 4%, 9: 74%), (12: 6%, 9: 56%); b) NaOCl, 
TEMPO, NaBr, Bu4NBr, NaHCO3, CH2Cl2, H2O, 0°C to r.t., 45 min to 80 min, (13: 68%, 14: 67%); 
c) H2, Pd(OH)2/C, dioxane, H2O, r.t., 8 h, (15: 81%, 16: 77%); d) NaOH, dioxane, H2O, r.t., 5 h, (3: 
70%, 4: 70%). 
Evaluation of 3 and 4 as E-selectin antagonists 
The affinity of selectin antagonists to E-selectin was evaluated in a competitive binding 
assay, utilizing a polyacrylamide-type glycoconjugate as synthetic ligand for immobilized E-
selectin.[18] Briefly, microtiter plates were coated with E-selectin/IgG, blocked with BSA, and 
incubated with a fixed concentration of sLea-polyacrylamide (sLea-PAA) either in presence 
or absence of the antagonists. The binding reaction was revealed by the addition of TMB 
substrate reagent and quantified spectrophotometrically at 450 nm. The IC50 defines the 
molar concentration of the test compound that reduces the maximal specific binding of sLea-
PAA polymer to E-selectin by 50%. The affinities are reported relative to TMSE protected 
sLex (17) as rIC50 in Table 2. The relative IC50 (rIC50) is the ratio of the IC50 of the test 
compound to the IC50 of 17. To assess the impact of the sialic acid exchange, affinity data is 
also provided for compounds 2 and 18.  
Antagonists 3 (entry C) and 4 (entry D) showed a dramatic loss in affinity compared to 
cyclohexyllactic acid containing analogue 2 (entry A) and sialic acid containing 18 (entry B, 
Table 2). The affinity of 3 was 50 fold weaker than the one of 18. The low affinity of 3 could 
be the consequence of a ring flip of the cyclohexane moiety, resulting in an equatorial 
orientation of the carboxy group. In the bioactive conformation, this orientation leads to a 
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steric clash of the cyclohexane moiety and D-Gal. However, non-cyclic 4 bound in the same 
range as 3, arguing against this hypothesis. Furthermore, both mimetics should be perfectly 
pre-organized and no steric clash of the alkyl substituents with the protein is to be expected 
according to MD simulations. A possible explanation for the unexpectedly poor binding 
affinities might be a binding mode different from the one of sLex, which had been the basis 
for our modeling studies. 
Table 2 Relative IC50 values (rIC50) of compounds 3, 4 and reference compounds 2 and 18. IC50 are 
scaled on TMSE-sLex 17 (rIC50=1; IC50 = 0.88 mM). 
O
HO
HO
OH
O
O
HO
OH
OH
O
OR
O
HO
HO
OH
O
OH
AcHN
HO
OH
OH
O
O
HO
OH
OH
O
NHAc
O
O
ONaO
17
OTMSE
OH
 
 
Entry Compound R rIC50 (E-sel) 
A 2  
O ONa
 
0.01 
B 18 O
OH
AcHN
HO
OH
OH
ONaO
 
0.03 
C 3 
O ONa
 
1.8 
D 4 
O ONa
 
1.2 
 
3. Conclusion 
Two derivatives of glycolic acid were explored as replacements for sialic acid in E-selectin 
antagonists. According to MD simulations, both mimics should be able to properly pre-
organize the carboxylic acid moiety. Nevertheless, a significant drop in affinity was observed 
compared to sialic acid or (S)-cyclohexyllactic acid bearing derivatives. 
 
  137 
Experimental Part 
NMR spectra were recorded on a Bruker Avance DMX-500 (500 MHz) spectrometer. 
Assignment of 1H and 13C NMR spectra was achieved using 2D methods (COSY, HSQC, 
HMQC, HMBC). Chemical shifts are given in ppm and were assigned in relation to the 
solvent signals on the !-scale[19] or to tetramethylsilane (0 ppm) as internal standard. 
Coupling constants J are given in Hertz (Hz). Multiplicities were specified as follows: s 
(singlet), d (doublet), dd (doublet of a doublet), t (triplet), q (quartet), m (multiplet). For 
assignment of resonance signals to the appropriate nuclei the following abbreviations were 
used: Cy (cyclohexyl), Fuc (fucose), Gal (galactose), MeCy (3-methylcyclohexane-1,2-diol).  
Reactions were monitored by TLC using glass plates coated with silica gel 60 F254 (Merck) 
and visualized by using UV light and/or by charring with a molybdate solution (a 0.02 M 
solution of ammonium cerium sulfate dihydrate and ammonium molybdate tetrahydrate in 
aqueous 10% H2SO4.  
Column chromatography was performed using automated systems (RediSep Companion) 
from Teledyne Isco with normal phase RediSep columns from the same manufacturer or 
reversed-phase columns containing LiChroprep RP-18 (40-63 "m) from Merck KGaA, 
Darmstadt, Germany. LC-MS separations were carried out using Sunfire C18 columns (19 x 
150 mm, 5.0 "m) on a Waters 2525 LC, equipped with Waters 2996 photodiode array and 
Waters micromass ZQ MS for detection.  
Solvents were purchased from Sigma-Aldrich or Acros. Solvents were dried prior to use 
where indicated. Tetrahydrofurane (THF) was dried by refluxing with sodium/benzophenone 
and distilled immediately before use. Dichloromethane (CH2Cl2) and dimethoxyethane 
(DME) were dried by filtration over Al2O3 (Fluka, type 5016 A basic). Methanol was dried 
by distillation from sodium methoxide, DMF by distillation from calcium hydride. Optical 
rotations were measured using a Perkin-Elmer Polarimeter 341. Electron spray ionization 
mass spectra (ESI-MS) were obtained on a Waters micromass ZQ. HRMS analysis were 
carried out using a Agilent 1100 LC equipped with a photodiode array detector and a 
Micromass QTOF I equipped with a 4 GHz digital-time converter. Microanalysis was 
performed at the Institute of Organic Chemistry at the University of Basel, Switzerland. 
Purity of final compounds was determined on an Agilent 1100 HPLC; detector ELS, Waters 
2420; column: Waters Atlantis dC18, 3 µm, 4.6 x 75 mm; eluents: A: water + 0.1% TFA; B: 
90% acetonitrile + 10% water + 0.1% TFA; depending on the polarity of analytes, gradients 
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were applied as indicated. A) linear gradient: 0 - 1 min 5% B; 1 - 20 min 5 to 95% B; flow: 0.5 
mL/min; B) linear gradient: 0 - 1 min 5% B; 1 - 20 min 5 to 70% B; flow: 0.5 mL/min. 
 
2-Propen-1-yl 3-O-(1-hydroxymethylcyclohexyl)-6-O-(tert-butyldiphenylsilyl)-! -D- 
galactopyranoside 7  
and  
2-Propen-1-yl 2-O-(1-hydroxymethylcyclohexyl)-6-O-(tert-butyldiphenylsilyl)-! -D- 
galactopyranoside 8 using condition D. 
To a stirred solution of 5 (1.00 g, 2.18 mmol) and 6 (0.150 g, 1.34 mmol) in anhydrous 
CH2Cl2 (5.0 mL) under argon was slowly added freshly distilled BF3 etherate (0.020 mL, 0.16 
mmol) at -18°C. The solution was stirred at -18°C and after 40 min and after 90 min, 
additional 6 (0.100 g, 0.89 mmol) and BF3 etherate (0.020 mL, 0.16 mmol) were added. After 
2 h and 15 min, the reaction was quenched with satd. aqueous NaHCO3 (2.0 mL) and brine 
(30 mL). The aqueous layer was extracted with CH2Cl2 (3 · 30 mL) and the combined organic 
layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. Column 
chromatography on silica (PE/EtOAc) yielded starting material 5 (720 mg, 1.57 mmol, 72%) 
and an impure mixture of 7 and 8 (140 mg), which was purified in a second chromatography 
(PE/MTBE) to give 3-O alkylated 7 (35 mg, 0.06 mmol, 3%) and 2-O alkylated 8 (60 mg, 
0.11 mmol, 5%). 
7: 1H NMR (500.1 MHz, CDCl3): " 7.72-7.64, 7.46-7.34 (2m, 10H, Ar-H), 5.90 (dddd, J = 
5.2, 6.6, 10.4, 17.1Hz, 1H, OCH2CHCH2), 5.27 (m, 1H, OCH2CHCH2), 5.19 (m, 1H, 
OCH2CHCH2), 4.35 (m, 1H, OCH2CHCH2), 4.27 (bd, 3J = 7.8Hz, 2H, Gal-H1, Cy-OH), 4.08 
(m, 1H, OCH2CHCH2), 3.99 (dd, 3J = 6.6Hz, 2J = 10.2Hz, 1H, Gal-H6a), 3.93 (d, 3J = 
3.1Hz, Gal-H4), 3.90 (dd, 3J = 6.0Hz, 2J = 10.2Hz, 1H, Gal-H6b), 3.76-3.66 (m, 2H, Gal-H2, 
Cy-CH2OH), 3.60 (dd, 3J = 3.1, 9.4Hz, 1H, Gal-H3), 3.51 (bt, 3J = 6.3Hz, 1H, Gal-H5), 3.32 
(dd, J = 10.3, 12.3 Hz, 1H, Cy-CH2OH), 3.22 (s, 1H, Gal-C2-OH), 2.71 (s, 1H, Gal-C4-OH), 
1.89 (m, 1H, Cy), 1.65-1.23 (m, 9H, Cy), 1.06 (s, 9H, SiPh2C(CH3)3); 13C NMR (125.8 MHz, 
CDCl3): " 135.7, 133.6, 133.4, 129.9, 127.8 (12C, Ar-C), 133.8 (OCH2CHCH2), 118.2 
(OCH2CHCH2), 101.7 (Gal-C1), 78.9 (Cy-Cq), 75.0 (Gal-C5), 72.2 (Gal-C3), 71.3 (Gal-C2), 
69.9 (OCH2CHCH2), 68.9 (Gal-C4), 65.1 (Cy-CH2OH), 62.6 (Gal-C6), 33.9, 31.3 (2C, Cy), 
26.9 (3C, SiC(CH3)3), 26.0, 22.4, 22.2 (3C, Cy), 19.4 (SiC(CH3)3); [#]D -1.39° (c 0.90, 
CHCl3); HR-MS (ESI) m/z: calcd for C32H46NaO7Si+ [M+Na]+: 593.2905; found: 593.2904.  
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8: 1H NMR (500.1 MHz, CDCl3): ! 7.72-7.64, 7.46-7.34 (2m, 10H, Ar-H), 5.92 (m, 1H, 
OCH2CHCH2), 5.28 (m, 1H, OCH2CHCH2), 5.18 (m, 1H, OCH2CHCH2), 4.36 (m, 1H, 
OCH2CHCH2), 4.23 (d, 3J = 7.5Hz, 1H, Gal-H1), 4.09-3.99 (m, 4H, Cy-OH, Gal-H4, Gal-
C3-OH, OCH2CHCH2), 3.95-3.86 (m, 2H, Gal-H6a, Gal-H6b), 3.70 (dd, 3J = 7.8, 8.9Hz, 1H, 
Gal-H2), 3.64 (d, 2J = 12.4Hz, 1H, Cy-CH2OH), 3.56-3.50 (m, 2H, Cy-CH2OH, Gal-H3), 
3.47 (dd, 3J = 5.6Hz, 2J = 11.3 Hz, 1H, Gal-H5), 3.01 (d, 3J = 4.3Hz, 1H, Gal-C4-OH), 1.76-
1.23 (m, 10H, Cy), 1.05 (s, 9H, SiPh2C(CH3)3); 13C NMR (125.8 MHz, CDCl3): ! 135.7, 
133.2, 133.0, 130.0, 127.9 (12C, Ar-C), 133.8 (OCH2CHCH2), 118.0 (OCH2CHCH2), 102.2 
(Gal-C1), 79.2 (Cq), 74.8 (Gal-C3), 74.2 (Gal-C5), 71.8 (Gal-C2), 70.3 (OCH2CHCH2), 69.5 
(Gal-C4), 64.1 (Cy-CH2OH), 63.4 (Gal-C6), 33.9, 32.3 (2C, Cy), 26.9 (3C, SiC(CH3)3), 26.0, 
23.2, 23.1 (3C, Cy), 19.3 (SiC(CH3)3); ["]D -13.9 (c 2.22, CHCl3); HR-MS (ESI) m/z: calcd 
for C32H46NaO7Si+ [M+Na]+: 593.2905; found: 593.2904. 
 
6-O-Benzyl-3-O-(1-(hydroxymethyl)cyclohexyl)-#-D-galactopyranosyl-(1!1)-[2,3,4-tri-
O-benzyl-" -L-fucopyranosyl-(1!2)]-(1R,2R,3S)-3-methylcyclohexane-1,2-diol 11. 
To a stirred solution of 9 (0.265 g, 0.332 mmol) and 6 (0.022 g, 0.196 mmol) in anhydrous 
CH2Cl2 (0.8 mL) under argon was added BF3 etherate (0.004 mL, 0.032 mmol) at -18°C, and 
the solution was stirred at -18°C. After 40 min, additional 6 (0.022 g, 0.196 mmol) and BF3 
etherate (0.004 mL, 0.032 mmol) were added. After another 60 min, the solution was 
quenched with satd. aqueous NaHCO3 (1.0 mL) and brine (10 mL). The aqueous layer was 
extracted with CH2Cl2 (3 · 10 mL) and the combined organic layers were dried over Na2SO4, 
filtered, and concentrated under reduced pressure. Column chromatography on silica 
(PE/EtOAc) afforded starting material 9 (0.195 g, 0.088 mmol, 74%) and impure 11 (25 mg), 
which was further purified via HPLC to yield pure 11 (13 mg, 0.014 mmol, 4%). 
1H NMR (500.1 MHz, CDCl3): ! 7.33-7.12 (m, 20H, Ar-H), 5.04 (d, 3J = 3.4Hz, 1H, Fuc-
H1), 4.87 (A of AB, 2J = 11.4Hz, 1H, CH2Ph), 4.76-4.64 (m, 4H, CH2Ph), 4.61 (B’’ of 
A’’B’’, 2J = 11.5Hz, 1H, CH2Ph), 4.47 (s, 2H, CH2Ph), 4.42 (q, 2J = 3J = 6.3Hz, 1H, Fuc-
H5), 4.27 (m, 1H, Gal-H1), 3.98 (dd, 3J = 3.4, 10.3Hz, 1H, Fuc-H2), 3.92 (dd, 3J = 2.4, 
10.3Hz, 1H, Fuc-H3), 3.75 (s, 1H, Gal-H4), 3.73-3.64 (m, 2H, Gal-H6a, MeCy-H1), 3.64-
3.56 (m, 3H, Fuc-H4, Gal-H6b, Cy-CH2OH), 3.55-3.51 (m, 2H, Gal-H2, Gal-H3), 3.49 (t, 3J 
= 6.1Hz, Gal-H5), 3.25 (d, 2J = 12.8Hz, Cy-CH2OH), 3.17 (t, 3J = 9.3Hz, 1H, MeCy-H2), 
2.06 (m, 1H, MeCy), 1.76 (m, 1H, MeCy), 1.62-1.08 (14H, MeCy, Cy), 1.06 (d, 3J = 6.4Hz, 
3H, Fuc-H6), 1.02 (d, 3J = 6.2Hz, 3H, MeCy-CH3), 0.91 (m, 1H, MeCy); 13C NMR (125.8 
MHz, CDCl3): ! " 139.1, 138.5, 138.2, 128.6, 128.5, 128.4, 128.3, 127.9, 127.8, 127.6, 127.5 
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(24C, Ar-C), 99.8 (Gal-C1), 97.6 (Fuc-C1), 83.9 (MeCy-C2), 79.8 (Fuc-C3), 79.0 (Cy-Cq), 
78.8, 78.4 (2C, Fuc-C4, MeCy-C1), 76.5 (Fuc-C2), 75.1, 74.2, 73.8 (3C, CH2Ph), 73.4 (Gal-
C5), 72.9 (CH2Ph), 72.1 (Gal-C3), 70.6 (Gal-C2), 69.2 (Gal-C4), 69.1 (Gal-C6), 66.9 (Fuc-
C5), 64.8 (Cy-CH2OH), 38.6 (MeCy-C3), 34.1, 33.8, 31.5, 31.4, 26.0, 23.3, 22.6, 22.4 (8C, 
5C Cy, 3C MeCy), 19.2 (MeCy-CH3), 17.0 (Fuc-C6); [!]D - 36.8 (c 0.50, CHCl3); MS (ESI) 
m/z: calcd for C54H70NaO12+ [M+Na]+: 933.48; found: 933.56; elemental analysis calcd (%) 
for C54H70O12 (911.13): C 71.19 H 7.74; found: C 71.06 , H 7.76. 
 
6-O-Benzyl-3-O-(1-hydroxy-2-methylpropan-2-yl)-"-D-galactopyranosyl-(1!1)-[2,3,4-
tri-O-benzyl-! -L-fucopyranosyl-(1!2)]-(1R,2R,3S)-3-methylcyclohexane-1,2-diol 12. 
To a stirred solution of 9 (0.500 g, 0.626 mmol) and 2,2-dimethyloxirane 10 (0.040 mL, 
0.450 mmol) in anhydrous CH2Cl2 (2.0 mL) under argon was added BF3 etherate (0.009 mL, 
0.072 mmol) at -18°C, and the solution was stirred at -18°C. After 40 min, additional 2,2-
dimethyloxirane (0.040 mL, 0.450 mmol) and BF3 etherate (0.009 mL, 0.072 mmol) were 
added. After another 25 min, the solution was quenched with satd. aqueous NaHCO3 (2.0 
mL) and brine (30 mL). The aqueous layer was extracted with CH2Cl2 (3 · 30 mL) and the 
combined organic layers were dried over Na2SO4, filtered, and concentrated under reduced 
pressure. Column chromatography on silica (PE/MTBE) afforded starting material 9 (0.280 
g, 0.350 mmol, 56%) and impure 12 (70 mg), which was further purified via HPLC to yield 
pure 12 (30 mg, 0.034 mmol, 6%). 
1H NMR (500.1 MHz, CDCl3): # 7.39-7.12 (m, 20H, Ar-H), 5.03 (d, 3J = 3.5 Hz, 1H, Fuc-
H1), 4.87 (A of AB, 2J = 11.5Hz, 1H, CH2Ph), 4.75-4.59 (m, 4H, CH2Ph), 4.53 (B of AB, 2J 
= 11.5Hz, 1H, CH2Ph), 4.49-4.45 (m, 2H, CH2Ph), 4.42 (q, 3J = 6.2Hz, 1H, Fuc-H5), 4.28 
(d, 3J = 7.6Hz, 1H, Gal-H1), 3.98 (dd, 3J = 3.5, 10.3Hz, 1H, Fuc-H2), 3.92 (dd, 3J = 2.6, 
10.3Hz, 1H, Fuc-H3), 3.75-3.46 (m, 9H, Fuc-H4, Gal-H2, Gal-H3, Gal-H4, Gal-H5, Gal-
H6a,b, MeCy-H1, C(CH3)2CH2OH), 3.20-3.13 (m, 2H, MeCy-H2, C(CH3)2CH2OH), 2.06 (m, 
1H, MeCy), 1.61-1.48 (3H, MeCy), 1.30-1.03 (m, 11H, Fuc-H6, MeCy, C(CH3)2CH2OH), 
1.00 (d, 3J = 6.2Hz, 3H, MeCy-CH3), 0.92 (m, 1H, MeCy); 13C NMR (125.8 MHz, CDCl3): #" 
139.1, 138.5, 138.2, 128.6, 128.5, 128.4, 128.3, 127.9, 127.8, 127.7, 127.6, 127.5 (24C, Ar-
C), 99.9 (Gal-C1), 97.7 (Fuc-C1), 83.9 (MeCy-C2), 79.8 (Fuc-C3), 78.5 (MeCy-C1), 78.4 
(Fuc-C4), 77.8 (C(CH3)2CH2OH), 76.5 (Fuc-C2), 75.1, 74.2, 73.8 (3C, CH2Ph), 73.4 (Gal-
C5), 72.9 (2C, CH2Ph, Gal-C3), 70.4 (Gal-C2), 69.5 (Gal-C4), 69.2 (Gal-C6), 66.9 (2C, Fuc-
C5, C(CH3)2CH2OH), 38.6 (MeCy-C3), 33.8 (MeCy-C4), 31.5 (MeCy-C6), 25.9 
(C(CH3)2CH2OH), 23.3 (MeCy-C5), 22.6 (C(CH3)2CH2OH), 19.2 (MeCy-CH3), 17.0 (Fuc-
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C6); [!]D - 66.0 (c 1.28, MeOH); HR-MS (ESI) m/z: calcd for C51H66NaO12 [M+Na]+: 
893.4446; found: 869.4454. 
 
 
6-O-Benzyl-3-O-(carboxycyclohexyl)-2-O-lactone-"-D-galactopyranosyl-(1!1)-[2,3,4-tri-
O-benzyl-! -L-fucopyranosyl-(1!2)]-(1R,2R,3S)-3-methylcyclohexane-1,2-diol 13. 
To a stirred suspension of 11 (100 mg, 0.110 mmol) in CH2Cl2 (3.0 mL) and H2O (0.430 mL) 
at 0°C were added an aqueous solution of NaBr (1 M, 0.070 mL), an aqueous solution of 
Bu4NBr (0.120 mL), TEMPO (5.0 mg, 0.032 mmol), and satd. aq NaHCO3 (0.330 mL). 
Subsequently, an aqueous solution of NaOCl (0.220 mL, 10 to 15% NaOCl) was added and 
the mixture was stirred vigorously at 0°C. After 45 min, the mixture was warmed to r.t., 
diluted with H2O (40 mL), and extracted with CH2Cl2 (2 · 40 mL). The combined organic 
layers were dried over Na2SO4, filtered and concentrated under reduced pressure. Column 
chromatography on silica (PE/EtOAc) afforded 13 (68 mg, 0.075 mmol, 68%) as white fluffy 
solid. 
1H NMR (500.1 MHz, CDCl3): # 7.37-7.10 (m, 20H, Ar-H), 5.00 (d, 3J = 3.6Hz, 1H, Fuc-
H1), 4.87 (A of AB, 2J = 11.5Hz, 1H, CH2Ph), 4.74 (A’ of A’B’, 2J = 11.6Hz, 1H, CH2Ph), 
4.69-4.64 (m, 3H, CH2Ph, Fuc-H5), 4.59 (B’’ of A’’B’’, 2J = 11.4Hz, 1H, CH2Ph), 4.51 (B 
of AB, 2J = 11.5Hz, 1H, CH2Ph), 4.46-4.42 (m, 3H, CH2Ph, Gal-H1), 4.25 (m, 1H, Gal-H2), 
4.09 (d, 3J = 2.7Hz, 1H, Gal-H4), 3.99 (dd, 3J = 3.6, 10.3Hz, 1H, Fuc-H2), 3.94 (dd, 3J = 
2.6, 10.3Hz, 1H, Fuc-H3), 3.71 (dd, 3J = 6.7Hz, 2J = 8.9Hz, 1H, Gal-H6a), 3.65-3.55 (m, 4H, 
Fuc-H4, Gal-H5, Gal-H6b, MeCy-H1), 3.48 (dd, 3J = 3.0, 9.5Hz, 1H, Gal-H3), 3.20 (t, 3J = 
9.2Hz, 1H, MeCy-H2), 1.96 (m, 1H, MeCy), 1.91-0.91 (16H, MeCy, Cy), 1.05 (d, 3J = 
6.5Hz, 3H, Fuc-H6), 1.03 (d, 3J = 6.5Hz, 3H, MeCy-CH3); 13C NMR (125.8 MHz, CDCl3): # " 
172.0 (CO), 139.2, 139.1, 138.6, 137.7, 128.7, 128.5, 128.4, 128.3, 128.2, 128.0, 127.7, 
127.6, 127.5, 127.4, 127.3 (24C, Ar-C), 98.3, 97.8 (Fuc-C1, Gal-C1), 82.8 (MeCy-C2), 80.3 
(Fuc-C3), 79.5 (MeCy-C1), 79.4 (Cy-Cq), 78.4 (Fuc-C4), 76.4 (Fuc-C2), 75.9 (Gal-C2), 75.0, 
74.4, 73.8 (3C, CH2Ph), 73.1 (Gal-C5), 72.6 (CH2Ph), 71.9 (Gal-C3), 68.5 (Gal-C6), 67.0 
(Gal-C4), 66.2 (Fuc-C5), 39.1, 35.6, 33.5, 31.9, 30.7, 24.8, 22.9, 20.7, 20.6 (9C, 5C Cy, 4C 
MeCy), 19.0 (MeCy-CH3), 16.9 (Fuc-C6); [!]D - 77.9 (c 0.76, CHCl3); HR-MS (ESI) m/z: 
calcd for C54H66NaO12+ [M+Na]+: 929.4446; found: 929.4447.  
 
6-O-Benzyl-3-O-(dimethylcarboxy)-2-O-lactone-"-D-galactopyranosyl-(1!1)-[2,3,4-tri-
O-benzyl-! -L-fucopyranosyl-(1!2)]-(1R,2R,3S)-3-methylcyclohexane-1,2-diol 14. 
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To a stirred suspension of 12 (30 mg, 0.034 mmol) in CH2Cl2 (0.8 mL) and H2O (0.130 mL) 
at 0°C were added an aqueous solution of NaBr (1 M, 0.020 mL), an aqueous solution of 
Bu4NBr (0.036 mL), TEMPO (2.0 mg 0.013 mmol), and satd. aq NaHCO3 (0.100 mL). 
Subsequently, an aqueous solution of NaOCl (0.065 mL, 10 to 15% NaOCl) was added and 
the mixture was stirred vigorously at 0°C. After 45 min, the mixture was warmed to r.t., 
diluted with H2O (10 mL), and extracted with CH2Cl2 (2 · 10 mL). The combined organic 
layers were dried over Na2SO4, filtered and concentrated under reduced pressure. Column 
chromatography on silica (PE/EtOAc) afforded 14 (20 mg, 0.023 mmol, 67%) as white fluffy 
solid. 
1H NMR (500.1 MHz, CDCl3): ! 7.33-7.11 (m, 20H, Ar-H), 5.01 (d, 3J = 3.6Hz, 1H, Fuc-
H1), 4.86 (A of AB, 2J = 11.5Hz, 1H, CH2Ph), 4.74 (A’ of A’B’, 2J = 11.6Hz, 1H, CH2Ph), 
4.70-4.62 (m, 3H, CH2Ph, Fuc-H5), 4.59 (B’’ of A’’B’’, 2J = 11.5Hz, 1H, CH2Ph), 4.50 (B 
of AB, 2J = 11.5Hz, 1H, CH2Ph), 4.46 (d, 3J = 7.8Hz, 1H, Gal-H1), 4.43 (m, 2H, CH2Ph), 
4.30 (dd, 3J = 7.9, 9.4Hz, 1H, Gal-H2), 4.06 (d, 3J = 2.1Hz, 1H, Gal-H4), 4.00 (dd, 3J = 3.6, 
10.3Hz, 1H, Fuc-H2), 3.94 (dd, 3J = 2.6, 10.3Hz, 1H, Fuc-H3), 3.71 (dd, 3J = 6.7Hz, 2J = 
9.4Hz, 1H, Gal-H6a), 3.66-3.59 (m, 3H, Fuc-H4, Gal-H6b, MeCy-H1), 3.56 (m, 1H, Gal-
H5), 3.51 (dd, 3J = 3.0, 9.5Hz, 1H, Gal-H3), 3.21 (t, 3J = 9.2Hz, 1H, MeCy-H2), 2.40 (s, 1H, 
Gal-C4OH), 1.98 (m, 1H, MeCy), 1.63-1.47 (6H, MeCy, C(CH3)2CO2), 1.45 (s, 3H, 
C(CH3)2CO2), 1.33 (m, 1H, MeCy), 1.21-0.92 (m, 2H, MeCy), 1.06 (d, 3J = 6.5Hz, 3H, Fuc-
H6), 1.03 (d, 3J = 6.5Hz, 3H, MeCy-CH3); 13C NMR (125.8 MHz, CDCl3): ! ! 172.0 
(C(CH3)2CO2), 139.2, 138.7, 137.7, 128.7, 128.5, 128.4, 128.3, 128.2, 128.1, 127.7, 127.6, 
127.5, 127.4 (24C, Ar-C), 98.4 (Fuc-C1), 97.7 (Gal-C1), 82.9 (MeCy-C2), 80.3 (Fuc-C3), 
79.5 (MeCy-C1), 78.5 (Fuc-C4), 78.2 (C(CH3)2CO2), 76.6, 76.4 (Fuc-C2, Gal-C2), 75.0, 
74.4, 73.8 (3C, CH2Ph), 73.1 (Gal-C5), 72.7 (CH2Ph), 72.3 (Gal-C3), 68.8 (Gal-C6), 67.2 
(Gal-C4), 66.3 (Fuc-C5), 39.1 (MeCy-C3), 33.5 (MeCy-C4), 30.6 (MeCy-C6), 28.0, 25.8 
(2C, C(CH3)2CO2) 22.9 (MeCy-C5), 19.0 (MeCy-CH3), 16.9 (Fuc-C6); ["]D - 75.0 (c 1.08, 
CHCl3); HR-MS (ESI) m/z: calcd for C51H62NaO12+ [M+Na]+: 889.4133; found: 889.4141. 
 
3-O-(Carboxycyclohexyl)-2-O-lactone-#-D-galactopyranosyl-(1"1)-[" -L-fucopyranosyl-
(1"2)]-(1R,2R,3S)-3-methylcyclohexane-1,2-diol 15. 
13 (45 mg, 0.64 mmol) was dissolved in dioxane/water (4/1, 2.0 mL) under argon. 
Pd(OH)2/C (5 mg, 10% Pd(OH)2) was added and the resulting mixture was hydrogenated (1 
bar H2) at r.t. After 15 h, the mixture was filtered and the solvent was removed under reduced 
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pressure. Column chromatography on silica (CH2Cl2/i-propanol) afforded 15 as white fluffy 
solid (22 mg, 0.040 mmol, 81%). 
1H NMR (500.1 MHz, CD3OD): ! 4.99 (d, 3J = 4.0Hz, 1H, Fuc-H1), 4.83 (q, 3J = 6.5Hz, 1H, 
Fuc-H5), 4.64 (d, 3J = 7.9Hz, 1H, Gal-H1), 4.33 (dd, 3J = 7.9, 9.6Hz, 1H, Gal-H2), 4.02 (d, 
3J = 2.4Hz, 1H, Gal-H4), 3.82 (dd, 3J = 3.3, 10.3Hz, 1H, Fuc-H3), 3.78 (dd, 3J = 2.4, 9.6Hz, 
1H, Gal-H3), 3.76-3.67 (m, 5H, Fuc-H2, Fuc-H4, Gal-H6a,b, MeCy-H1), 3.60 (t, 3J = 6.3Hz, 
Gal-H5), 3.22 (t, 3J = 9.3Hz, MeCy-H2), 2.17-1.05 (23H, Cy, MeCy, Fuc-H6); 13C NMR 
(125.8 MHz, CD3OD): ! ! 174.6 (CO), 100.5 (Fuc-C1), 98.7 (Gal-C1), 84.3 (MeCy-C2), 80.0 
(MeCy-C1), 79.9 (Cy, Cq), 78.0 (Gal-C2), 77.0 (Gal-C5), 73.8 (Fuc-C4), 72.7 (Gal-C3), 71.5 
(Fuc-C3), 70.3 (Fuc-C2), 67.9 (Gal-C4), 67.4 (Fuc-C5), 62.4 (Gal-C6), 40.4, 36.8, 34.8, 32.6, 
31.7, 26.1, 21.6, 21.5 (9C, 5C Cy, 4C MeCy), 19.5 (MeCy-CH3), 16.7 (Fuc-C6); ["]D - 99.3 
(c 1.20, MeOH); HR-MS (ESI) m/z: calcd for C26H42NaO12+ [M+Na]+: 569.5268; found: 
569.2570; HPLC-purity: 97% (A). 
 
3-O-(Dimethylcarboxy)-2-O-lactone-#-D-galactopyranosyl-(1"1)-[" -L-fucopyranosyl-
(1"2)]-(1R,2R,3S)-3-methylcyclohexane-1,2-diol 16. 
14 (20 mg, 0.023 mmol) was dissolved in dioxane (2.0 mL) under argon. Pd/C (10 mg, 10% 
Pd) was added and the resulting mixture was hydrogenated (1 bar H2) at r.t. After 29 h, the 
mixture was filtered and the solvent was removed under reduced pressure. Column 
chromatography on silica (CH2Cl2/i-propanol) afforded 16 as white fluffy solid (9.0 mg, 
0.018 mmol, 77%). 
1H NMR (500.1 MHz, CD3OD): ! 5.00 (d, 3J = 4.0Hz, 1H, Fuc-H1), 4.92-4.79 (m, 1H, Fuc-
H5), 4.66 (d, 3J = 7.8Hz, 1H, Gal-H1), 4.36 (dd, 3J = 7.9, 9.5Hz, 1H, Gal-H2), 3.97 (d, 3J = 
2.5Hz, 1H, Gal-H4), 3.84-3.80 (m, 2H, Fuc-H3, Gal-H3), 3.77-3.67 (m, 5H, Fuc-H2, Fuc-H4, 
Gal-H6a,b, MeCy-H1), 3.60 (m, 1H, Gal-H5), 3.22 (t, 3J = 9.3Hz, MeCy-H2), 2.12 (m, 1H, 
MeCy), 1.75-1.58 (m, 3H, MeCy), 1.52 (s, 6H, C(CH3)2CO2), 1.40-1.23 (m, 2H, MeCy), 1.17 
(d, 3J = 6.6Hz, 3H, MeCy-CH3), 1.14 (d, 3J = 6.4Hz, 3H, Fuc-H6), 1.10 (m, 1H, MeCy); 13C 
NMR (125.8 MHz, CD3OD): !! 174.6 (C(CH3)2CO2), 100.5 (Fuc-C1), 98.7 (Gal-C1), 84.4 
(MeCy-C2), 80.0 (MeCy-C1), 78.8 (C(CH3)2CO2), 78.5 (Gal-C2), 76.9 (Gal-C5), 73.8 (Fuc-
C4), 73.0 (Gal-C3), 71.5 (Fuc-C3), 70.3 (Fuc-C2), 67.9 (Gal-C4), 67.4 (Fuc-C5), 62.4 (Gal-
C6), 40.3 (MeCy-C3), 34.8 (MeCy-C4), 31.7 (MeCy-C6), 28.2, 25.8 (2C, C(CH3)2CO2), 24.1 
(MeCy-C5), 19.5 (MeCy-CH3), 16.7 (Fuc-C6); ["]D - 112.9 (c 0.40, MeOH); HR-MS (ESI) 
m/z: calcd for C23H38NaO12+ [M+Na]+: 529.2255; found: 529.2258; HPLC-purity > 99.5 % 
(B). 
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3-O-(Sodium carboxycyclohexyl)-!-D-galactopyranosyl-(1!1)-[2,3,4-tri-O-benzyl- 
" -L-fucopyranosyl-(1!2)]-(1R,2R,3S)-3-methylcyclohexane-1,2-diol 3. 
A solution of 15 (12.0 mg, 0.020 mmol) in dioxane (1.0 mL) and aqueous 1 N NaOH (0.1 ml) 
was stirred at r.t. for 5 h. The solution was concentrated under reduced pressure and the crude 
product was purified via RP chromatography (H2O/MeOH). Lyophilization from water 
afforded 3 as white fluffy solid (9.0 mg, 0.015 mmol, 70%). 
1H NMR (500.1 MHz, CD3OD): # 5.02 (d, 3J = 4.0Hz, 1H, Fuc-H1), 4.95-4.85 m, 1H, Fuc-
H5), 4.31 (d, 3J = 7.8Hz, 1H, Gal-H1), 3.86 (dd, 3J = 3.3, 10.2Hz, 1H, Fuc-H3), 3.83 (d, 3J = 
2.4Hz, 1H, Gal-H4), 3.76-3.62 (m, 6H, Fuc-H2, Fuc-H4, Gal-H2, Gal-H6a,b, MeCy-H1), 
3.52 (dd, 3J = 2.4, 9.7Hz, 1H, Gal-H3), 3.41 (m, 1H, Gal-H5), 3.23 (t, 3J = 9.4Hz, MeCy-
H2), 2.16-1.23 (16H, Cy, MeCy), 1.21 (d, 3J = 6.6Hz, 3H, Fuc-H6), 1.12 (d, 3J = 6.3Hz, 1H, 
MeCy-CH3), 1.08 (m, 1H, MeCy); 13C NMR (125.8 MHz, CD3OD): # 183.4 (CO), 102.9 
(Gal-C1), 100.0 (Fuc-C1), 84.2 (MeCy-C2), 83.4 (Cy-Cq), 79.9 (MeCy-C1), 78.3 (Gal-C3), 
76.0 (Gal-C5), 73.9 (Fuc-C4), 71.4 (Fuc-C3), 70.9, 70.4 (Fuc-C2, Gal-C2), 69.5 (Gal-C4), 
67.5 (Fuc-C5), 63.1 (Gal-C6), 40.3, 35.4, 35.0, 34.4, 31.9, 26.9, 24.2, 23.1, 22.9 (9C, 5C Cy, 
4C MeCy), 19.7 (MeCy-CH3), 16.8 (Fuc-C6); ["]D - 67.7 (c 0.92, MeOH); HR-MS (ESI) 
m/z: calcd forC26H44NaO13+ [M+H]+: 587.2674; found: 587.2670; HPLC-purity > 99.5 % (B). 
 
3-O-(Sodium carboxyprop-2-yl)-!-D-galactopyranosyl-(1!1)-[" -L-fucopyranosyl- 
(1!2)]-(1R,2R,3S)-3-methylcyclohexane-1,2-diol 4. 
A dispersion of 16 (6.0 mg, 0.012 mmol) in aqueous NaOH (0.03 N, 0.45 ml) was stirred at 
r.t. for 1 h. Purification via RP chromatography (H2O/MeOH) and lyophilization from water 
afforded 4 as white fluffy solid (4.5 mg, 0.008 mmol, 70%). 
1H NMR (500.1 MHz, CD3OD): # 5.01 (d, 3J = 4.0Hz, 1H, Fuc-H1), 4.88 (m, 1H, Fuc-H5), 
4.32 (d, 3J = 7.4Hz, 1H, Gal-H1), 3.88-3.83 (m, 2H, Fuc-H3, Gal-H4), 3.76-3.59 (m, 6H, 
Fuc-H2, Fuc-H4, Gal-H2, Gal-H6a,b, MeCy-H1), 3.57 (dd, 3J = 2.9, 9.6Hz, 1H, Gal-H3), 
3.42 (m, 1H, Gal-H5), 3.23 (t, 3J = 9.3Hz, MeCy-H2), 2.11 (m, 1H, MeCy), 1.71-1.57 (m, 
3H, MeCy), 1.46, 1.43 (2s, 6H, C(CH3)2CO2), 1.41-1.22 (m, 2H, MeCy), 1.20 (d, 3J = 6.6Hz, 
3H, MeCy-CH3), 1.12 (d, 3J = 6.4Hz, 3H, Fuc-H6), 1.08 (m, 1H, MeCy); 13C NMR (125.8 
MHz, CD3OD): # " 183.3 (C(CH3)2CO2), 102.8 (Gal-C1), 100.0 (Fuc-C1), 84.2 (MeCy-C2), 
81.5 (C(CH3)2CO2), 79.8 (MeCy-C1), 78.7 (Gal-C3), 76.0 (Gal-C5), 73.9 (Fuc-C4), 71.4 
(Fuc-C3), 70.8, 70.4, 70.1 (Fuc-C2, Gal-C2, Gal-C4), 67.5 (Fuc-C5), 63.1 (Gal-C6), 40.4 
(MeCy-C3), 35.0 (MeCy-C4), 31.8 (MeCy-C6), 28.1, 26.0 (2C, C(CH3)2CO2), 24.2 (MeCy-
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C5), 19.7 (MeCy-CH3), 16.7 (Fuc-C6); [!]D - 60.9 (c 0.62, MeOH); HR-MS (ESI) m/z: calcd 
for C23H40NaO13+ [M+H]+: 547.2361; found: 547.2365; HPLC-purity > 99.5 % (B). 
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2.5.2 Approaches towards the synthesis of 2,2-dialkyl-2-O-glycosyl glycolic acid 
derivatives. 
The synthetic route presented in section 2.5.1 was the result of extensive screening and 
optimization efforts, which are described in section 2.5.2.1. Section 2.5.2.2 comprises 
alternative routes, which were discontinued in favor of the spiroepoxide route. 
2.5.2.1 Spiroepoxide opening with carbohydrate building blocks 
When opening an epoxide, especially with a carbohydrate nucleophile, several aspects should 
be considered. Since positive charge is better stabilized on tertiary carbon atoms than on 
secondary or primary ones, epoxides can be opened regioselectively at the higher substituted 
position under acidic conditions (Figure 2.5.1). A typical side reaction under acidic 
conditions is a 1,2-hydride shift, resulting in aldehyde 5.3, which can form hemiacetal 5.4 
with alcohols.  
 
R1 R2
ROH R
1 R2
O
HO
RR1 R2
H O
R1 R2
HO O
R3 acid
5.1 5.25.35.4
O
1,2 hydride shift
acidR3OH
 
Figure 2.5.1 Reaction of an asymmetric epoxide and an alcohol under acidic conditions. 
To prevent this side reaction, a highly reactive nucleophile is required. The attacking 
galactoside should consequently offer a reactive 3-OH group and little steric bulk. Protecting 
groups should therefore not reduce the reactivity neither by electronic nor by steric factors 
and must be compatible with the reaction conditions. Lewis or Brønstedt acids can be used 
for the activation of the epoxide. The solvent must allow high substrate concentrations, but 
should not be too polar, as this would decrease the nucleophilicity of the hydroxyl group. 
Low temperatures usually increase selectivity, but might also favor hemiacetal formation via 
hydride shift due to the decreased reactivity of the galactoside. To evaluate the protecting 
group pattern and suitable reaction conditions, several D-Gal derivatives were synthesized 
and reacted with spiroepoxide 5.6* under different reaction conditions. The reactions were 
monitored by TLC and mass spectrometry, which did not allow to distinguish regioisomers. 
In case product isolation was possible, NMR was used for further characterization. The 
results are summarized in Tables 2.5.1 and 2.5.2. 
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Table 2.5.1 Reaction of spiroepoxide 5.6* with galactoside 1.5. 
5.6*
+
O
OH
HO OBz
OTMSE
1.5
O
HO
+
O
OH
HO OBz
OTMSE
5.5
O
HO O
O
HO OBz
OTMSE
5.6
HO
OH
O
OH
HO OBz
OTMSE
5.7
O+ HO
ether hemiacetal  
 
Entry c1.5[M]  Ratio 
1.5 
/5.6* 
Catalyst 
(eq.) 
Solvent T  t [h] Observation 
 
A) 0.5 1:1 Hydrazine 
sulfate (0.1) 
THF 60°C 17 
no reaction 
B) 0.5 1:2 (±)CSA (0.1) THF r.t. 17 hemiacetal 
C) 0.5 1:2 SnCl4 (0.1) THF r.t. 17 ether, 
hemiacetal 
D) 1.0 10:1 DDQ  
(1.0) 
CH2Cl2/ 
THF 
r.t. 48 
no reaction 
E) 2.5 2:1 Hydrazine 
sulfate (1.0) 
CH2Cl2 50°C 17 Ether (NMR) 
hemiacetal 
F) 2.5 1:2 (±)CSA (0.1) CH2Cl2 r.t. 17 Ether 
hemiacetal 
G) 0.9 1:10 (±)CSA (1.0) - r.t. 16 Oligomerisation of 
5.6* 
multiple alkylation  
H) 4.2 2.6:1 i. SnCl4 
ii. (±)CSA 
DMF r.t. 68 
no reaction 
I) 0.1 1:1 i. ZnBr2 (0.1) 
ii. TMSOTf 
(0.3) 
CH2Cl2 -78°C 
to r.t. 
12 
hemiacetal 
J) 0.3 1:1 TBSOTf (0.4) CH2Cl2 -15°C 
to r.t. 
0.2 no product 
red solid 
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The initial attempts presented in Table 2.5.1 allowed to identify 5.5, 5.6, and 5.7, which were 
formed with approximately 10%, 5%, and 4%, respectively (entry E). Starting material 1.5 
could be recovered to 41%. Unfortunately, these reaction conditions did not reproducibly 
yield the three products. All reactions (entry A to J) suffered from poor reaction rates, which 
was partially attributed to the electron pulling, and thereby reactivity decreasing effect of the 
benzoyl protecting group. Using 5.6* as solvent to increase the reaction rate led to 
oligomerisation reactions (entry G). Reactions with silyltriflates (entries I and J), thought to 
quench the newly formed primary alcohol, were hard to control and often led to 
polymerization reactions. 
To increase the reaction rate of the alkylation, galactal 5.8 was synthesized (Table 2.5.2). It 
combines a highly reactive allylic hydroxy group, little steric bulk, and good selectivity, since 
only two hydroxyl groups are available. However, the acid lability of 5.8 strongly limited the 
range of catalysts and no product could be isolated. 
Table 2.5.2 Reaction of galactal 5.8 with spiroepoxide 5.6*. 
5.8
O
HO
OH
TBDPSO
5.6*
+
O
5.9
O
HO
O
TBDPSO
OH
 
Entry cgal 
[M]  
Ratio 
5.8 
/5.6* 
Catalyst 
(eq.) 
Solvent T  t [h] Observation 
 
A) 0.1 1:20 CSA (0.1) THF mw 
40°C 
150W 
24 
r.t. 
2 mw 
Ether + multiple 
alkylation (MS) 
Heating destroyed ether 
B) 0.1 1:6 TMSOTf THF 0°C 0.02 Strong reaction 
No starting material 
No ether 
C) 0.03 1:6 TMSOTf THF -78°C to 
r.t. 
2 
3 
No starting material 
Ether (MS) 
 
Finally, 5.6* was reacted with 5.5* (Scheme 2.5.1, see also section 2.5.1). The anomeric allyl 
protecting group allowed to use BF3·Et2O, which was not possible with TMSE protected D-
Gal derivative 1.5. We assumed that BF3·Et2O would lead to reduced hemiacetal formation 
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compared to Brønstedt acid (±)-camphorsulfonic acid ((±)-CSA). The silyl protecting group 
in 6-O position should increase the reactivity compared to e.g. a benzoate. The identified 
reaction conditions were successfully transferred to the synthesis of more complex 
tetrasaccharide mimetics (section 2.5.1). 
 
5.5*
O
HO
OH
O
OTBDPS
+
HO
5.7*
O
O
OH
O
OTBDPSHO
5.8*
O
O
O
OTBDPSHO
HO
OH
HO
O
5.6*
+
 
Scheme 2.5.1 BF3·Et2O, CH2Cl2, -18°C, 135 min, (5.7*: 3 %, 5.8*: 5%, 5.5*: 72%). 
2.5.2.2 Alternative strategies 
2.5.2.2.1 Substitution 
Regioselective alkylations of galactosides are typically performed by reacting a tin acetal 
activated galactoside with the corresponding alkyl triflates in presence of cesium fluoride. 
These SN2-type reactions proceed nicely with secondary triflates. Tertiary triflates, especially 
with an adjacent carboxy group, are very prone to elimination reactions and consequently not 
suited for substitutions. An alternative approach is the substitution of the triflyl guloside 4.4* 
with the corresponding alcoholate (Scheme 2.5.2). 4.4* has already been successfully 
converted to the corresponding 3-azido galactoside (chapter 2.4.1). Although azides are by 
far better nucleophiles than tertiary alcoholates, we tried to react guloside 4.4* with 
alcoholates 5.10 and 5.12 (Scheme 2.5.2). However, no product formation was observed by 
TLC and mass spectrometry. 
4.4*
O
OAc
SEt
5.10
+
OH
O OMe
O
O
Ph
5.11
O
O
OAc
SEt
O
O
Ph
OMeO
5.12 5.13
O
O
OAc
SEt
O
O
Ph
O OH
O
O
O
O
O
O
O
OTf
 
Scheme 2.5.2 NaH, DMF, 0°C to r.t. 
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2.5.2.2.2 Nucleophilic attack of anhydro carbohydrates 
In analogy to nucleophilic substitutions, epoxide opening can be achieved by two different 
strategies; either by opening a spiroepoxide with a galactoside (sections 2.5.1 and 2.5.2.1) or 
a sugar epoxide with an alcohol. Latter strategy will be discussed in the following section. 
According to the Fürst-Plattner rule,[1] epoxide opening on carbohydrates favors the 
formation of two axial hydroxyl groups. Consequently, epoxide 1,6:2,3-dianhydro-!-D-
gulopyranoside 5.14 should be used to ensure the correct stereochemical outcome.  
Since nucleophilic epoxide opening of the 4-O-benzylated derivative of 5.14 was successful 
with NaN3[2] and Et2AlCN[3], modified conditions with an alcohol as nucleophile might be as 
well. To compensate for the low reactivity of the tertiary alcohol 5.15, an intramolecular 
reaction with 5.19 was planned (Scheme 2.5.3). This would favor epoxide opening 
entropically and kinetically and would reduce the need for protecting groups. Although ester 
formation on the 4-OH of 5.14 is known[2] and 5.15 can be transformed into esters without 
protection of the "-hydroxy group,[4] no product 5.16 could be isolated. As the sterically 
demanding CH2 group in position 6 as well as epoxide opening via the carbonyl group in 5.16 
might also hamper the formation of 5.17, this strategy was not further pursued. 
 
O OH
OH
O
O
OH
O
HOO
O
HO
O
5.175.14 5.15
CO2Me
O
O
O
O
5.16
O
OH
b)a)
+
 
Scheme 2.5.3 a) DIC, DMAP, CH2Cl2, DMF, r.t., 12 d; b) i. NaH, THF, 0°C to r.t. ii. MeOH. 
2.5.2.2.3 Acetal formation 
Reaction of 5.18 with 5.19 was planned to yield acetal 5.20, which could then be opened 
regioselectively under reducing conditions, e.g. with Et3SiH and TiCl4, to give 5.22 (Scheme 
2.5.4). Acetyl groups were chosen as protecting groups to reduce the electron density of the 
ring and thereby activate the keto group for acid catalyzed acetal formation. The reaction was 
followed by TLC and mass spectrometry. Various conditions a) to e) did not yield the desired 
acetal, although hemiacetal formation was observed by mass spectrometry in case of a) and 
d). These results indicated that condensation might be the rate-limiting factor, and 5.18 was 
reacted with spiroepoxide 5.6*. Mass spectrometry indicated adduct formation, however it 
did not allow to distinguish between hemiacetal and acetal. Due to the extremely slow 
reaction rate and uncertain stereochemical outcome, this route was discontinued. 
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O
OAc
AcO OAc
OTMSE
5.18
O
O
OAc
AcO OAc
OTMSE
5.20
O
O
O
OAc
AcO OAc
OTMSE
5.22
O
HO
O
OAc
AcO OAc
OTMSE
5.21
O
O
OH
OH
O
5.19
5.6*
a) to e)
f)
 
Scheme 2.5.4 a) (±)CSA, CH2Cl2, r.t., 2 d; b) (±)CSA, toluene 70°C to 110°C, 10 h; c) amberlyst 
15, CaSO4, DCE, 75°C to r.t., 10 h; d) p-TsOH·H2O, CaSO4, DCE, 75°C 2 h, r.t. 8 h; e) amberlyst 15, 
DCE, r.t., 7.5 h; f) amberlyst 15, CH2Cl2, r.t., 2 d. 
2.5.2.3 Synthesis of building blocks 
2.5.2.3.1 Synthesis of building block 5.6* 
Peroxidation of alkene 5.23 with 3-chloroperbenzoic acid afforded spiroepoxide 5.6* in 47% 
yield. 
5.6*5.23
O
 
Scheme 2.5.5 MCPBA, CH2Cl2, 0°C to r.t., 47%. 
2.5.2.3.2 Synthesis of building blocks 5.10 and 5.19 
5.15 was reduced to diol 5.19 via methyl ester 5.10 using LiAlH4. 
 
5.15
a)
O OH
OH
5.10
O OMe
OH
5.19
OH
OH
b)
 
Scheme 2.5.6 a) (CH3)3SiCHN2, Et2O, MeOH, 10 min, r.t., quant.; b) LiAlH4, Et2O, r.t., 54%.[5] 
2.5.2.3.3 Synthesis of building block 5.12 
Lactone 5.12 was readily available from (-)-quinic acid 5.24 via acid catalyzed acetal 
formation/lactonisation.[6] 
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5.24
OH
HO
HO
OH
OHO
5.12
O
O
HO
O
O
 
Scheme 2.5.7 2,2-DMP, (±) CSA, acetone, 70°C, 3.5 h, 65%. 
2.5.2.3.4 Synthesis of building block 5.18 
5.18 was readily available in three steps from intermediate 3.23. Acetylation of 3.23 and 
hydrogenolytic debenzylation afforded 5.26, which was oxidized with pyridinium 
chlorochromate to 5.18 in 48% overall yield. 
 
a)
3.23
O
BnO
OH
OTMSE
OHHO
5.25
O
BnO
OAc
OTMSE
OAcAcO
5.26
O
HO
OAc
OTMSE
OAcAcO
5.18
O
OAc
OTMSE
OAcAcO
O
b) c)
 
Scheme 2.5.8 a) Ac2O, pyridine, DMAP, r.t., quant.; b) H2, Pd(OH)2/C, dioxane, H2O r.t., 81%; c) 
PCC, MS 4 Å, CH2Cl2, r.t., 60%. 
2.5.2.3.5 Synthesis of building block 5.17 
Following a procedure of Grindley and Thangarasa, monotosylation of levoglucosan 5.27 
was achieved via the stannylene intermediate.[7] Tosylate 5.28 was then converted to epoxide 
5.29 using Amberlite IRA 400, a strongly basic ion exchange resin.[8] Epoxide migration 
(5.29 ! 5.14) does not take place under these conditions. A method developed by Mubarak 
and Fraser was applied, since a higher yield of 5.14 is expected when using sodium hydride 
in THF instead of sodium hydroxide in MeOH.[3] Direct conversion of tosylate 5.28 to 
epoxide 5.14 under basic reflux conditions[9] mainly led to the hydrolysis of the epoxide. 
However, epoxide formation and Payne rearrangement can be combined in one step using 
sodium hydride in DMF. This procedure allows the synthesis of 5.14 from inexpensive 5.27 
in two steps (steps a & d) and 42% yield. The developed route might further be explored for 
the efficient synthesis of 3-azido-3-deoxy galactosides. 
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O
O
OH
OH
O
O
HO
O
5.27 5.14
OH
a)
O
O
OH
OH
5.28
OTs
O
O
OH
O
d)
b) c)
5.29  
Scheme 2.5.9 a) i. Bu2SnO, toluene, MeOH, 70°C; ii. TsCl, Et3N, DME, MS 4 Å, r.t., 51%; b) 
Amberlite IRA400-OH, MeOH, r.t., 3 min, 79%; c) NaH, THF, 0°C to r.t., 63%; d) NaOH, EtOH, 
H2O, reflux (epoxide hydrolysation) or NaH, DMF, 82%. 
2.5.2.3.6 Synthesis of building block 5.8 
Tert-butyldiphenylsilyl protected galactal 5.8 was synthesized from 5.30 in 65% over two 
steps.[10] 
 
O
AcO
OAc
AcO
O
TBDPSO
OH
HO
5.85.30
a) b)
 
Scheme 2.5.10 a) NaOMe, MeOH, r.t., 13 h; b) TBDPSCl, Et3N, DMAP, DMF, r.t., 6 d, 65%. 
2.5.2.3.7 Synthesis of building block 5.5* 
5.5* was synthesized in four steps from peracetylated D-galactose 3.19. The anomeric allyl 
protecting group was introduced via the 2,3,4,6-tetra-O-acetyl-!-D-galactopyranosyl bromide 
3.20 using Koenigs-Knorr conditions. Deacetylation under Zemplén conditions provided allyl 
galactoside 5.31. Selective protection of the 6 position of D-galactose was achieved with the 
sterically demanding tert butyldiphenylsilyl group, which was installed in 77% yield. 
 
5.5*
O
HO
OH
O
OTBDPSHO
a)
3.19
O
AcO
OAc
OAc
OAcAcO
3.20
O
AcO
AcO
OAcAcO
Br
5.31
O
AcO
OAc
O
OAcAcO
b)c) a)
 
Scheme 2.5.11  a) HBr, AcOH, CH2Cl2, 0°C to r.t., 2.5 h, 92%; b) allyl alcohol, Ag2CO3, CH2Cl2, 
MS 3 Å, r.t., 3 h; c) NaOMe, MeOH, r.t., 4 h, 86% from 3.20; d) TBDPSCl, Et3N, DMAP, DMF, r.t., 
12 h, 77%. 
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Experimental 
General experimental conditions are given in section 2.5.1.  
 
1-Oxaspiro[2.5]octane 5.6*. 
To a stirred solution of 3-chloroperbenzoic acid (9.00 g, 77%) in anhydrous CH2Cl2 (100 
mL) under argon was slowly added methylene cyclohexene (5.00 g, 52 mmol) at 0°C. The 
solution was stirred at r.t. for 12 h, cooled to 0°C and filtered. The filtrate was washed with 
satd. aqueous Na2S2O3 (100 mL) and satd. aqueous NaHCO3 (100 mL) and checked for 
peroxides. The organic layer was dried over Na2SO4, filtered, and concentrated. Distillation 
afforded 5.6* as clear oil (2.75 g, 24.5 mmol, 47%). Analytical data were in accordance with 
literature.[11] 
 
Methyl 1-hydroxycyclohexanecarboxylate 5.10. 
To a stirred solution of 1-hydroxycyclohexanecarboxylic acid (500 mg, 3.47 mmol) in MeOH 
(10 mL) and Et2O (10 mL) was slowly added a solution of (trimethylsilyl)diazomethane in 
hexanes (2.0 M, 1.80 mL, 3.60 mmol) at r.t. The reaction was monitored by mass 
spectrometry and upon completion volatiles were removed under reduced pressure (40°C, 60 
mbar) to give a slightly yellow oil, which was directly used in the next step (550 mg, 3.48 
mmol).  
1H NMR (500.1 MHz, CDCl3): !  3.77 (s, 3H, CO2CH3), 1.83-1.73 (m, 2H), 1.72-1.54 (m, 
7H), 1.28 (m, 1H); MS (ESI) m/z: calcd for C8H14NaO3+ [M+Na+]+: 181.08; found: 180.81.  
 
1-Hydroxycyclohexylmethanol 5.19. 
To a stirred solution of 5.10 (550 mg, 3.48 mmol) in anhydrous Et2O (3.0 mL) under argon 
was slowly added a suspension of LiAlH4 (79 mg, 2.09 mmol) in anhydrous Et2O (2.0 mL). 
The suspension was heated to reflux for 1 h and stirred at r.t. for 12 h. The reaction mixture 
was diluted with Et2O (50 mL) and washed with satd. aqueous NaHCO3 (2 · 50 mL). The 
aqueous layer was extracted with Et2O (2 · 50 mL) and the combined organic layers were 
dried (Na2SO4), filtered, and concentrated under reduced pressure to give 5.19 as white solid 
(245 mg, 1.88 mmol, 54%). Analytical data were in accordance with literature.[5] 
 
3,4-O-Isopropylidene-1,5-quinic lactone 5.12. 
A solution of (-)-quinic acid (10.0 g, 52 mmol), (±)-camphor sulfonic acid (100 mg, 0.43 
mmol), and 2,2-dimethoxypropane (23.0 mL, 188 mmol) in acetone (50.0 mL) was stirred at 
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70 °C. After 3.5 h, the reaction was quenched with Et3N (1.5 mL), and volatiles were 
evaporated under reduced pressure. Column chromatography on silica afforded 5.12 as white 
solid (7.30 g, 34 mmol, 65%). Analytical data were in accordance with literature.[12] 
 
2-(Trimethylsilyl)ethyl 2,4,6-tri-O-acetyl-3-O-benzyl-! -D-galactopyranoside 5.25.  
To a stirred solution of 3.23 (2.59 g, 6.99 mmol) and DMAP (cat) in pyridine (20 mL) was 
added acetic anhydride (4.0 mL, 42.6 mmol). After stirring at r.t. for 15 h, volatiles were 
evaporated under reduced pressure. Column chromatography on silica (PE/EtOAc) afforded 
5.25 as white solid (3.44 g, 6.93 mmol, 99%). Analytical data were in accordance with 
literature.[13] 
 
2-(Trimethylsilyl)ethyl 2,4,6-tri-O-acetyl-!-D-galactopyranoside 5.26.  
5.25 (3.19 g, 6.42 mmol) was dissolved in dioxane/water (4/1, 35 mL) under argon. 
Pd(OH)2/C (100 mg, 10% Pd(OH)2) was added and the resulting mixture was hydrogenated 
(3 bar H2) at r.t. After 20 h, the mixture was filtered and the solvent removed under reduced 
pressure to give 5.26 as clear crystals (2.11 g, 5.19 mmol, 81%). 
1H NMR (500.1 MHz, CDCl3): "  5.31 (d, 3J = 3.1Hz, 1H, H-4), 4.94 (dd, 3J = 7.9, 10.0Hz, 
H-2), 4.43 (d, 3J = 7.9Hz, 1H, H-1), 4.14 (d, 2J = 6.6Hz, 2H, H-6a,b), 3.98 (m, 1H, 
CH2CH2Si(CH3)3), 3.81 (m, 2H, H-3, H-5), 3.56 (m, 1H, CH2CH2Si(CH3)3), 2.16, 2.11, 2.05 
(3s, 9H, COCH3), 1.03-0.86 (m, 2H, CH2CH2Si(CH3)3), 0.00 (s, 9H, CH2CH2Si(CH3)3); 13C 
NMR (125.8 MHz, CDCl3): 171.4, 171.1, 170.7 (3C, COCH3), 100.5 (C-1), 73.0 (C-2), 71.8, 
71.0 (C-3, C-5), 69.9 (CH2CH2Si(CH3)3), 67.6 (C-4), 62.0 (CH2CH2Si(CH3)3), 21.1, 20.9 
20.8 (3C, COCH3), 18.0 (CH2CH2Si(CH3)3), -1.3 (3C, CH2CH2Si(CH3)3); [#]D -16.0 (c 0.88, 
CHCl3); MS (ESI) m/z: calcd for C17H30NaO9Si [M+Na]+: 429.16; found: 429.08. 
 
2-(Trimethylsilyl)ethyl 2,4,6-tri-O-acetyl-!-D-xylo-hex-3-ulopyranoside 5.18. 
To a stirred suspension of PCC (1.326 g, 6.15 mmol) and powdered activated molecular 
sieves 4 Å (2.5 g) in anhydrous CH2Cl2 (20 mL) was slowly added a solution of 5.26 (1.0 g, 
2.46 mmol) in CH2Cl2 (5.0 mL) at r.t. After stirring for 19 h, the reaction mixture was filtered 
(Celite) and run through a short silica column (EtOAc) to give ketone 5.18 as slightly yellow 
oil (600 mg, 1.48 mmol, 60%), which was directly used in the next step. 
 
1,6-Anhydro-4-O-p-tolylsulfonyl-! -D-glucopyranose 5.28. 
A solution of 1,6-anhydro-!-D-glucopyranose (1.00 g, 6.16 mmol) and dibutyltin oxide (2.30 
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g, 9.24 mmol) in anhydrous toluene (50 mL) and anhydrous methanol (10 mL) was stirred at 
60°C under argon. After 5 h, volatiles were removed under reduced pressure and the resulting 
white residue was dried under high vacuum for 12 h. The tin acetal was dissolved in 
anhydrous 1,2-dimethoxyethane (50 mL) and powdered activated molecular sieves 4 Å (3.0 
g), and a solution of p-toluenesulfonyl chloride (1.29 g, 6.77 mmol) in anhydrous 1,2-
dimethoxyethane (20 mL) was added. After stirring vigorously at r.t. for 14 h, the reaction 
mixture was filtered, the filtrate was diluted with CH2Cl2 ( 50 mL) and washed with brine (2 · 
50 mL). The aqueous layers were extracted with CH2Cl2 (2 · 50 mL) and the combined 
organic layers were dried over Na2SO4, filtered, and concentrated under reduced pressure. 
Column chromatography on silica (PE/EtOAc) afforded 5.28 as white solid (993 mg, 3.14 
mmol, 54%). Analytical data were in accordance with literature.[7] 
 
1,6;3,4-Dianhydro-! -D-galactopyranose 5.29. 
To a solution of 5.28 (100 mg, 0.32 mmol) in anhydrous MeOH (2.0 mL) was added 
Amberlite IRA 400 OH- ® (1.4 mL) and the resulting mixture was shaken at r.t. for 15 min. 
The mixture was filtered, the filter was washed with MeOH, and the combined filtrates were 
concentrated under reduced pressure to give 5.29 as clear oil (36 mg, 0.25 mmol, 79%). 
Analytical data were in accordance with literature.[14] 
 
1,6;2,3-Dianhydro-! -D-gulopyranose 5.14.  
From 1,6;3,4-Dianhydro-!-D-galactopyranose 5.29: A suspension of NaH (56 mg, 60% NaH) 
was washed several times with anhydrous PE under argon. Subsequently, anhydrous THF 
(5.0 mL) was added and the dispersion was cooled to 0°C. A solution of 5.29 (100 mg, 0.69 
mmol) in anhydrous THF (4.0 mL) was added and the reaction mixture was stirred slowly 
warmed to r.t. After stirring for 22 h, the mixture was poured on an ice-water mixture (30 
mL) and the aqueous layer was extracted with EtOAc (30 mL). The organic layer was 
washed with brine (30 mL) and the aqueous layers were extracted with EtOAc (3 · 30 mL). 
The combined organic layers were dried over Na2SO4, filtered, and concentrated under 
reduced pressure. Column chromatography on silica (PE/EtOAc) afforded 5.14 as white solid 
(63 mg, 0.44 mmol, 63%). Analytical data were in accordance with literature.[2] 
From 1,6-Anhydro-4-O-p-tolylsulfonyl-!-D-glucopyranose 5.27: Following the previous 
procedure, 5.28 (40 mg, 0.13 mmol) was reacted with NaH suspension (10 mg) in anhydrous 
THF (2.0 mL) for 14 h to give 5.14 (15 mg, 0.10 mmol, 82%) after workup and column 
chromatography (PE/EtOAc). Analytical data were in accordance with literature.[2] 
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1,5-Anhydro-6-O-(tert-butyl)diphenylsilyl-2-deoxy-D-lyxo-hex-1-enitol 5.8. 
To a freshly prepared solution of NaOMe in MeOH (0.03 M, 50 mL) under argon at r.t. was 
added 3,4,5-tri-O-acetyl-D-galactal 5.30 (4.09 g, 15.0 mmol). The mixture was stirred for 13 
h and subsequently concentrated under reduced pressure to afford the D-galactal as white 
solid (2.20 g, 15.0 mmol, quant.), which was directly used in the next step. The residue (1.0 
g, 6.8 mmol) was dissolved in anhydrous DMF (7.0 mL) under argon at r.t. and DMAP (cat.), 
Et3N (1.90 mL), and tert-butyldiphenylsilyl chloride (1.90 mL, 7.4 mmol) were added. After 
stirring at r.t. for 6 d, the solution was diluted with EtOAc (100 mL) and washed with water 
(4 x 100 mL). The combined organic layers were dried over Na2SO4, filtered, and 
concentrated under reduced pressure. Column chromatography on silica (CH2Cl2/EtOAc) 
afforded 5.9 as clear oil (1.712 g, 4.45 mmol, 65%). Analytical data were in accordance with 
literature.[10] 
 
2-Propen-1-yl ! -D-galactopyranoside 5.31.  
Allyl alcohol (10.0 mL, 146 mmol) and 3.20 (10.0 g, 24.3 mmol) in anhydrous CH2Cl2 (60 
mL) were stirred with powdered activated molecular sieves 3 Å (6.0 g) at r.t. under argon for 
3 h. Ag2CO3 (8.0 g, 29.2 mmol) was added slowly and the mixture was stirred under argon 
for 13 h. The mixture was filtered (celite) and volatiles were evaporated to yield a clear sticky 
solid (9.32 g, 24.0 mmol), which was used in the next step without further purification.  
The crude product was dissolved in anhydrous MeOH (50 mL) under argon and a freshly 
prepared solution of NaOMe in MeOH (1 M, 1.0 mL) was slowly added. After 4 h, the 
solution was neutralized with HCl in MeOH (0.1 M) and concentrated. Column 
chromatography on silica (CH2Cl2/MeOH 9/1 to 8/2) afforded 5.31 as white solid (4.63 g, 
21.0 mmol, 86%). Analytical data were in accordance with literature.[15] 
 
2-Propen-1-yl 6-O-(tert-butyldiphenylsilyl)-! -D-galactopyranoside 5.5*. 
tert-Butyldiphenylsilyl chloride (4.40 mL, 17.2 mmol) was slowly added to a stirred solution 
of 5.31 (3.44 g, 15.5* mmol), Et3N (4.35 mL, 31.0 mmol) and DMAP (cat.) in anhydrous 
DMF (15 mL) under argon. After 12 h, the solution was diluted with EtOAc (100 mL) and 
washed with water (3 ·100 mL). The organic layer was dried (Na2SO4) and concentrated. 
Column chromatography on silica (PE/EtOAc 1/1 to 0/1) yielded 5.5* as white foam (1.50 g, 
12.0 mmol, 77%). Analytical data were in accordance with literature.[16] 
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2.6 Sialyl LewisX: A “Pre-organized Water Oligomer”? 
 
The following article was published as a “very important paper” in Angewandte Chemie: 
Binder, F.P.C.; Lemme, K.; Preston, R.; Ernst, B. Angew. Chem. Int. Ed. 2012, 51, 7327 - 
7331; Angew. Chem. 2012, 142, 7440 - 7444. 
 
Author contributions: F.P.C. Binder: synthesis of selectin antagonists 3, 4, and 5, 
manuscript; K. Lemme: ITC measurements, bioassay, protein expression & purification, 
manuscript; R.C. Preston: generation of the 7A9 antibody column used for the functional 
purification of E-selectin. 
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2.7 Synthesis of literature known small molecule selectin antagonists 
Numerous selectin antagonists have been developed over the past 15 years (see chapter 1.3.). 
To evaluate the potency of some of these small molecule antagonists in our own assays, three 
representative compounds were synthesized (Figure 2.7.1). 
Revotar’s TBC1269 (7.1)[1] is one of the most promising selectin antagonists so far and is 
currently in Phase II clinical trials for the treatment of asthma and psoriasis. Nevertheless, it 
should be noted, that the mechanism of action of TBC1269 (7.1) is controversially discussed. 
Beauharnois et al. for example found Ca2+ independent binding of TBC1269 (7.1) to P-
selectin in a Biacore experiment,[2] and Hicks et al., showed that TBC1269 (7.1) does not 
influence rolling in an intravital microscopy experiment.[3] 
Based on the pharmacophore of TBC1269 (7.1), researchers at Revotar also developed a 
series of polyhydroxyphenols.[4] From this series, 7.2 was selected as it was reported to 
exhibit remarkable IC50 values in a static binding assay (PAA-sLex-TYS) for all three 
selectins (IC50= 0.8 µM E-selectin, IC50 = 1.2 µM P-selectin, and IC50= 1.4 µM L-selectin).[4] 
However, the authors point out that the compound has to be freshly prepared before testing, 
because rapid oxidation by air occurs.  
Wyeth (now Pfizer) developed a series of quinoline salicylic acid derivatives,[5] which led to 
the identification of a clinical candidate which is currently in Phase I clinical trials.[6] 
Compound 7.3 was chosen as representative example of this series.  
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Figure 2.7.1 Small molecule selectin antagonists developed by Revotar and Pfizer. 
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2.7.1 Synthesis of TBC1269 (7.1) 
The published synthesis of TBC1269 (7.1) suffers from an extremely poor overall yield of 
3% starting from 7.7 (Scheme 2.7.1).[1] Compound 7.7 is not commercially available and is 
prepared in two steps in 74% yield. Since the expected overall yield of 2% was considered 
unreasonably low, the synthesis was discontinued after step b) and an alternative route was 
explored (Scheme 2.7.2). 
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Scheme 2.7.1 a) i. TMEDA, n-BuLi, Et2O, -78°C to r.t., ii. B(OMe)3, -10°C to r.t., iii. aq. HCl, r.t.; 
b) CsF, Pd(Ph3)4, DME, mw 100°C; c) adipoyl dichloride, AlCl3, DCE, 0°C to r.t.; d) aq. LiOH, 
MeCN, r.t., then aq. 2N HCl; e) i. N2H4, DMSO, 80°C; ii. KOtBu, DMSO, 80°C, then aq. 2 N HCl; f) 
BBr3, CH2Cl2, -78°C to r.t.; g) H2SO4, MeOH, reflux; h) !-D Man pentaacetate, DCE, BF3·Et2O; i) 
aq. LiOH, MeCN, r.t. 
In contrast to the published route (Scheme 2.7.1), the second route is convergent and allows 
to shift the Suzuki coupling from the beginning of the synthesis to the fourth step (Scheme 
2.7.2). Friedel Crafts acylation of anisole 7.4 ("7.11)[1] followed by reduction ("7.12)[1] 
proceeded in excellent yield. Regiospecific bromination of 7.12 with NBS in acetonitrile[7] 
gave 7.13 ready for Suzuki coupling in 67% yield. Pinacol arylboronate 7.14 was obtained 
from ester 7.6 and bis(pinacolato)diboron in excellent yield using optimized microwave 
conditions[8] of the cross-coupling procedure developed by Miyaura.[9] Subsequent Suzuki 
coupling of 7.13 and 7.14 proceeded quantitatively. Cleavage of the methoxy groups with 
boron tribromide gave diol 7.9. Since dimannosylation with 1,2,3,4,6-penta-O-acetyl-!-D-
mannopyranose and BF3·Et2O proceeded in poor yields, the resulting mixture was reacted 
again with 2,3,4,6-tetra-O-acetyl-!-D-mannopyranosyl trichloroacetimidat to provide 7.10. 
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Final hydrolysation of the ester groups of 7.10 and purification via HPLC afforded 7.1 in 9 % 
overall yield. 
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Scheme 2.7.2 a) adipoyl dichloride, AlCl3, CH2Cl2, -18°C to r.t., 25 min, 98%; b) TFA, TES, 
BF3!Et2O, CH2Cl2, r.t., 2.5 h, quant.; c) NBS, MeCN, r.t., 3 h, 68%; d) bis(pinacolato)diborane, 
KOAc, PdCl2(dppf), dppf, dioxane, mw: 300 W, 120°C, 2 h, 94%; e) Pd(Pph3)4, CsF, dioxane, mw, 
120°C, 3.5 h, quant. ; f) BBr3, CH2Cl2, -78°C to r.t., 2 h, 63%; g) i. 1,2,3,4,6-penta-O-acetyl-"-D-
mannopyranose, BF3·Et2O, CH2Cl2, 0°C to r.t., 12 h; ii. 2,3,4,6-tetra-O-acetyl-"-D-mannopyranosyl 
trichloroacetimidat, TMSOTf, toluene, r.t., 5 h, 68%; h) aq. LiOH, MeCN, r.t., 12 h, 32%.  
2.7.2 Synthesis of compound 7.2 
Compound 7.2 was synthesized in analogy to reference [4] (Scheme 2.7.3). Acid catalyzed 
ester formation of nicotinic acid (7.16) gave 7.17, which was coupled to 7.18 under standard 
coupling conditions. Amide 7.19 was deprotected and transferred to the sodium salt to give 
the title compound 7.2.  
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Scheme 2.7.3 a) H2SO4 (conc.), MeOH, reflux, 2 d, 99%; b) EDC·HCl, Et3N, DMAP, anhyd. 
CH2Cl2, r.t., 24 h, 62%; c) i. BBr3, anhyd. CH2Cl2, -78°C to r.t., ii. H2O, r.t.; iii. ion exchange resin, 
H2O, 27% from 7.19. 
2.7.3 Synthesis of compound 7.3 
Compound 7.3 was synthesized following literature procedures (Scheme 2.7.4).[5] 
Sandmeyer-isatin synthesis with 4-bromo-2-methylaniline 7.20 gave isatin 7.21, which was 
reacted with 7.23 in a Pfitzinger reaction.  
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Scheme 2.7.4 a) i. chloral hydrate, NH2OH!HCl, Na2SO4, 2M HCl (aq), H2O, 55°C, 24 h, ii. H2SO4, 
55°C to 80°C, 81%; b) NaOAc!3H2O, AcOH, H2O, reflux, 2.5 h, 75%; c) 6M KOH (aq), EtOH, 
100°C to reflux, 4 h, 55%. 
Biological evaluation 
Up to date no biological data is available. 
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Experimental 
NMR spectra were recorded on a Bruker Avance DMX-500 (500 MHz) spectrometer. 
Assignment of 1H and 13C NMR spectra was achieved using 2D methods (COSY, HSQC, 
HMQC, HMBC). Reactions were monitored by TLC using glass plates coated with silica gel 
60 F254 (Merck) and visualized by using UV light and/or by charring with a molybdate 
solution (a 0.02 M solution of ammonium cerium sulfate dihydrate and ammonium 
molybdate tetrahydrate in aqueous 10% H2SO4. Column chromatography was performed on 
automated systems (RediSep Companion) from Teledyne Isco with normal phase RediSep 
columns from the same. LC-MS separations were carried out using Sunfire C18 columns (19 x 
150 mm, 5.0 !m) on a Waters 2525 LC, equipped with Waters 2996 photodiode array and 
Waters micromass ZQ MS for detection. Size exclusion chromatography was performed with 
Bio-Gel® P-2 Gel (45-90 mm) from Bio-Rad. Solvents were purchased from Sigma-Aldrich 
or Acros. Solvents were dried prior to use where indicated. Dichloromethane (CH2Cl2) and 
Dichloroethane (DCE) were dried by filtration over Al2O3 (Fluka, type 5016 A basic). 
Methanol was dried by distillation from sodium methoxide, Electron spray ionization mass 
spectra (ESI-MS) were obtained on a Waters micromass ZQ. HRMS analysis were carried 
out using a Agilent 1100 LC equipped with a photodiode array detector and a Micromass 
QTOF I equipped with a 4 GHz digital-time converter. Microanalysis was performed at the 
Institute of Organic Chemistry at the University of Basel, Switzerland.  
 
1,6-Bis(4-methoxyphenyl)hexane-1,6-dione 7.11. 
Adipoyl dichloride (1.46 mL, 10.0 mmol) and anisole (2.63 mL, 24.0 mmol) were dissolved 
in anhydrous DCE (30 mL) under argon and the resulting solution was cooled to -18°C. 
Aluminium chloride (6.67 g, 50 mmol) was added in small portions. After stirring for 25 min 
at -18°C, the reaction was quenched with ice water and extracted with CH2Cl2. The combined 
organic layers were dried over Na2SO4, filtered, and concentrated. Column chromatography 
on silica (CH2Cl2/MeOH) gave 7.11 as white solid (3.19 g, 9.77 mmol, 98%). Analytical data 
were in accordance with literature.[1] 
 
1,6-Bis(4-methoxyphenyl)hexane 7.12. 
To a stirred solution of diketone 7.11 (3.19 g, 9.77 mmol) in CH2Cl2 (70 mL) was slowly 
added TFA (6.0 mL, 78 mmol), BF3!Et2O (9.8 mL, 79 mmol) and Et3SiH (6.3 mL, 39 mmol). 
The mixture was stirred at r.t. for 165 min, cooled to 0°C and mixed with water. The mixture 
was extracted with CH2Cl2 and the combined organic layers were dried over Na2SO4, filtered, 
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and concentrated under reduced pressure. Column chromatography on silica (PE/EtOAc) 
gave 7.12 as white crystals (3.10 g, 10.4 mmol). Analytical data were in accordance with 
literature.[1] 
 
1,6-Bis(3-bromo-4-methoxyphenyl)hexane 7.13. 
A solution of 7.12 (60 mg, 0.20 mmol) and NBS (80 mg, 0.45 mmol) in MeCN (3.0 mL) was 
stirred at r.t. for 4 h. Volatiles were evaporated under reduced pressure and the resulting 
white crystalline residue was washed with CCl4. Column chromatography on silica 
(PE/EtOAc) gave 7.13 as white crystals (62 mg, 0.14 mmol, 68%). Analytical data were in 
accordance with literature.[1] 
 
Methyl 2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetate 7.14. 
A microwave tube was charged with methyl 2-(3-bromophenyl)acetate 7.6 (60 mg, 0.26 
mmol), potassium acetate (77 mg, 0.78 mmol), bis(pinacolato)diborane (80 mg, 0.32 mmol), 
PdCl2(dppf) (6.4 mg, 7.8 µmol), and dppf (4.4 mg, 7.9 µmol) and evacuated at high vacuum. 
After 10 min, the tube was flushed with argon and anhydrous dioxane (1.5 mL) was added 
under vigorous stirring. The solution was degassed in an ultrasonic bath for 15 min and 
subsequently flushed with argon for another 10 min. Microwave irradiation at 120°C (300 W) 
for 2 h gave the crude product as red solution. Dioxane was evaporated under reduced 
pressure and the residue was dissolved in CH2Cl2 (50 mL) and washed with brine (2 x 25 
mL). The organic layer was dried over Na2SO4, filtered and concentrated under reduced 
pressure. Column chromatography on silica (CH2Cl2, short column) gave 7.14 as clear oil (68 
mg, 0.25 mmol, 94%). Analytical data were in accordance with literature.[4] 
 
Dimethyl 2,2'-(hexane-1,6-diylbis(2'-methoxy-[1,1'-biphenyl]-5',3-diyl))diacetate 7.15. 
A microwave tube was charged with 7.13 (36 mg, 0.08 mmol), 7.14 (72 mg, 0.26 mmol), 
Pd(PPh3)4 (4 mg, 3.5 µmol), and CsF (790 mg, 5.2 mmol) and evacuated at high vacuum. 
After 10 min, the tube was flushed with argon and anhydrous dioxane (5.0 mL) was added 
under vigorous stirring. The solution was degassed in an ultrasonic bath for 15 min and 
subsequently flushed with argon for another 10 min. Microwave irradiation at 120°C (300 W) 
for 5 h gave the crude product. Dioxane was evaporated under reduced pressure and the 
residue was dissolved in CH2Cl2 (50 mL) and washed with brine (2 x 25 mL). The organic 
layer was dried over Na2SO4, filtered and concentrated under reduced pressure. Column 
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chromatography on silica gave 7.15 as orange oil, which was directly used in the next step 
(47 mg, 0.08 mmol, quant.).  
 
1,6-Bis[3-(3-carbomethoxymethylphenyl)-4-hydroxyphenyl]hexane 7.9. 
To a solution of 7.15 (62 mg, 0.10 mmol) in anhydrous CH2Cl2 (4.0 mL) under argon at -
78°C was slowly added BBr3 (80 µL, 0.8 µmol). The solution was slowly warmed to -20°C 
and stirred at -20°C for 1h. The reaction was quenched with ice-water and extracted with 
CH2Cl2. The organic layer was washed with brine, dried over Na2SO4, filtered, and 
concentrated under reduced pressure. Column chromatography on silica gave 7.9 (37 mg, 
0.07 mmol, 63%) as slightly yellow oil. Analytical data were in accordance with literature.[1] 
 
1,6-Bis[3-(3-carbomethoxymethylphenyl)-4-(2,3,4,6-tetra-O-acetyl-! -D-manno 
pyranosyloxy)phenyl]hexane 7.10. 
To a stirred solution of 7.9 (25 mg, 0.04 mmol) and 1,2,3,4,6-penta-O-acetyl-!-D-
mannopyranose (52 mg, 0.13 mmol) in anhydrous CH2Cl2 (2.0 mL) under argon at 0°C was 
slowly added BF3"Et2O (65 µL, 0.51 mmol). The solution was stirred at 0°C for 20 min and at 
r.t. overnight. The reaction mixture was diluted with CH2Cl2 and washed with water, satd. aq. 
NaHCO3, and brine. The organic layer was dried over Na2SO4, filtered, and concentrated 
under reduced pressure. Column chromatography on silica gave three still impure fractions. 
The product 7.10 (25 mg, 0.02 mmol), monoglycosylated 7.9, and 7.9. The three fractions 
were combined and reacted again, this time with trichloroacetimidat activated !-D-Man 
tetraacetat. 
To a stirred solution of the three fractions, additional 7.9 (21 mg, 0.04 mmol) and 2,3,4,6-
tetra-O-acetyl-!-D-mannopyranosyl trichloroacetimidat (87 mg, 0.13 mmol) in anhydrous 
toluene (3.0 mL) under argon at r.t. was added TMSOTf (2.6 µL, 0.014 mmol). The solution 
was stirred for 5 h, diluted with toluene (5 mL) and quenched with aq. satd NaHCO3 (5 mL). 
The aq. layer was extracted with toluene and the combined organic layers were dried over 
Na2SO4, filtered, and concentrated under reduced pressure. Column chromatography on silica 
gave 7.10 as slightly yellow foam (68 mg, 0.06 mmol, 68%). Analytical data were in 
accordance with literature.[1] 
 
TBC1269 7.1. 
To a stirred solution of 7.10 (18 mg, 15 µmol) in acetonitrile (0.5 mL) was slowly added a 
solution of LiOH (10 mg, 0.42 mmol) in water (0.5 mL). The mixture was stirred at r.t. for 24 
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h, diluted with water (10 mL), and acidified to pH 3 with conc. HCl. Evaporation of volatiles, 
subsequent purification via HPLC, and lyophilization gave TBC1269 as white powder (4 mg, 
4.6 µmol, 32%). Analytical data were in accordance with literature.[1] 
 
Methyl 3-aminobenzoate 7.17. 
To a stirred solution of 3-aminobenzoic acid 7.16 (296 mg, 2.16 mmol) in MeOH (10.0 mL) 
was added sulfuric acid (0.12 mL) and the reaction mixture was refluxed for 2 d. After 
cooling to r.t., volatiles were removed under reduced pressure, the residue was dissolved in 
EtOAc (50 mL) and washed with satd. aq. NaHCO3 (50 mL). The aq. layer was extracted 
with EtOAc (3 x 50 mL) and the combined organic layers were washed with brine and dried 
over Na2SO4. Solvent was evaporated under reduced pressure to give 7.17 as red oil, which 
was directly used in the next step (320 mg, 2.11 mmol, 98%). 
 
Methyl 3-(2-(3,4,5-trimethoxyphenyl)acetamido)benzoate 7.19. 
To a solution of EDC hydrochloride (604 mg, 3.15 mmol) and Et3N in anhydrous CH2Cl2 
(12.0 mL) was added 3,4,5-trimethoxyphenylacetic acid 7.18 (716 mg, 3.16 mmol) and 
DMAP (cat.). After stirring for 10 min at r.t. under argon, 7.17 (320 mg, 2.11 mmol) was 
added and the reaction mixture was stirred at r.t. overnight. The reaction was quenched by 
addition of a satd. aq. NH4Cl solution (20 mL), which was extracted with CH2Cl2 (3x 20 
mL). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, 
filtered, and concentrated under reduced pressure to afford a brown oil. Column 
chromatography on silica (PE/EtOAc) gave 7.19 as orange sticky solid (476 mg, 1.32 mmol, 
62%). Analytical data were in accordance with literature.[4] 
 
Sodium 3-[2-(3,4,5-trihydroxyphenyl)-acetamido]-benzoate 7.2. 
To a stirred solution of 7.19 (160 mg, 0.45 mmol) in anhydrous CH2Cl2 (2.0 mL) under argon 
at -78°C, was added BBr3 (0.56 mL, 5.8 mmol) within 30 min. The resulting green solution 
was stirred at r.t. for 4 h before it was cooled to 0°C and water (2 mL) was added slowly 
under vigorous stirring. Methanol and CH2Cl2 were added and the mixture was extracted with 
EtOAc (3x). The combined organic layers were dried over Na2SO4, filtered, and concentrated 
under reduced pressure. Purification via HPLC, conversion to the sodium salt via ion 
exchange resin (DOWEX 50X8) and purification via SEC gave the final compound 7.2 (40 
mg, 0.12 mmol, 27%). Analytical data were in accordance with literature.[4] Elemental 
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analysis calcd (%) for C15H13NO6 + 1.1 H2O: C 52.09, H 4.16, N 4.05; found: C 52.02, H 
4.11, N 4.26.  
 
5-Bromo-7-methylindoline-2,3-dione 7.21. 
Chloral hydrate (1.19 g, 7.2 mmol) was added to a stirred suspension of hydroxylamine 
hydrochloride (1.50 g, 21.5 mmol), sodium sulfate (6.80 g, 47.9 mmol), 4-bromo-2-
methylaniline 7.20 (1.12 g, 6.0 mmol) in water (40 mL) and aq. HCl (2N, 2.0 mL). The 
mixture was stirred at 55°C o.n. After cooling to 0°C, the hydroxyiminoacetanilide was 
isolated by filtration, washed with cold water, and dried under high vacuum o.n. The 
cyclisation was carried out by adding the hydroxyiminoacetanilide in small portions to a flask 
containing sulfuric acid (4.0 mL, which had been heated to 55°C. The temperature was 
maintained below 70°C during the addition. After complete addition, the dark solution was 
heated to 80°C for 10 min, cooled to r.t., poured onto crushed ice (20 mL), and allowed to 
stand on the ice for 30 min. The resulting brown precipitate was collected by filtration, 
washed with water (3x 30 mL) and dried under high vacuum over night to give isatin 7.21 as 
brown powder (1.17 g, 4.9 mmol, 81%). Analytical data were in accordance with literature.[5] 
 
2-(4-Chlorophenyl)-2-oxoethyl acetate 7.23. 
To a solution of 2-bromo-4’-chloroacetophenone 7.22 (1.40 g, 6.0 mmol) in ethanol (5.0 mL) 
was added a solution of sodium acetate trihydrate (0.93 g, 6.8 mmol) in water (3.1 mL) and 
acetic acid (0.31 mL). The solution was refluxed for 2.5 h, cooled to r.t. and stored in a 
freezer at -18°C o.n. The white crystalline product was collected by filtration (0.96 g, 4.5 
mmol, 75%). Analytical data were in accordance with literature.[5] 
 
6-Bromo-2-(4-chlorophenyl)-3-hydroxy-8-methylquinoline-4-carboxylic acid 7.3. 
 A suspension of isatin 7.21 (600 mg, 2.50 mmol) in aq. potassium hydroxide (6.0 mL) was 
heated to 100°C. A solution of 7.23 (532 mg, 2.50 mmol) in warm ethanol (4.0 mL) was 
added over the course of 1 h, and upon completion of the addition, the mixture was refluxed 
for 2.5 h. After cooling to r.t., ethanol was removed under reduced pressure, the residue was 
diluted with water (15 mL), treated with charcoal, filtered and the clear solution was acidified 
to pH 1 with aq. HCl (1N). The resulting yellow precipitate was collected by filtration, 
washed with water, and dried under high vacuum. The crude product was purified by column 
chromatography on silica gel (70:2.5 EtOAc/MeCN + 0.5% Et3N) and converted back to the 
free acid by precipitation from an acidic solution of MeCN/H2O (20% MeCN, acidified with 
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HCl) to give the title compound 7.3 as pale yellow solid (537 mg, 1.37 mmol, 55%). 
Analytical data were in accordance with literature.[5] Compound purity was confirmed by 
elemental analysis: calcd (%) for C17H11BrClNO3: C 52.00, H 2.82, N 3.57; found: C 52.13, 
H 2.77, N 3.42. 
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3 Outlook 
Introduction of different amide and ester substituents in position 2 of D-galactose has proven 
beneficial for the design of E-selectin antagonists (see introduction). Since an acetyl ester 
increased binding affinity to P-selectin as well, bulkier substituents like benzoates might be 
used to further enhance the affinity of P-selectin antagonists. 
Lactones between the carboxy group of a sialic acid mimic and the 2-O or 4-O position of D-
galactose could be useful for the development of prodrugs with improved pharmacokinetic 
properties (in analogy to 5.15*, 5.16*). 
Given the unexpectedly poor binding affinity of E-selectin antagonists 5.3* and 5.4*, as well 
as the conflicting data of STD-NMR studies and the crystal structure of sLex in complex with 
E-selectin, crystal structures of E-selectin antagonists in complex with E-selectin are urgently 
needed to overcome roadblocks and promote our understanding in selectin glycomimetic 
interactions. 
The binding of PSGL-1 to P-selectin is associated with conformational changes in both the 
lectin and the EGF domain, shifting P-selectin from a bent to an extended conformation. 
Stabilization of the extended conformation via a glycan wedge between lectin and EGF 
domain was shown to increase the binding affinity towards PSGL-1 (see introduction). These 
information might be used to develop a new class of allosteric selectin antagonists, suited to 
overcome the unfavorable properties of sLex mimetics. 
P-selectin bears a second binding site close to the sLex binding epitope, which ensures the 
high binding affinity of its natural ligand PSGL-1 (see introduction). This second site offers 
promising preconditions for a fragment based drug discovery approach and might be 
explored with small molecules mimicking non-carbohydrate binding epitopes of PSGL-1, e.g. 
tyrosine sulfate. 
Finally, it is well known that the potency of selectin antagonists strongly depends on the 
assay setup. As the natural binding process between selectins and their ligands takes place 
under flow-conditions, a flow assay might prove useful for the characterization of future 
selectin antagonists.  
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